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ABSTRACT 
Malaria control relies heavily on the use of insecticides, especially the pyrethroids, for control 
interventions such as Long Lasting Insecticide Nets (LLINs) and Indoor Residual Spraying (ITNs). 
However, widespread resistance to insecticides in major malaria vectors, such as An. funestus is 
threatening to derail these control tools. To design and implement suitable resistance management 
strategies which will ensure the continued effectiveness of these control tools it is necessary to 
elucidate the molecular basis of the resistance. In An. funestus, resistance is mainly metabolic with 
the duplicated P450s CYP6P9a and CYP6P9b implicated as the major pyrethroid resistance genes. 
Despite the detection of these key resistance genes the detailed molecular mechanisms through 
which they confer pyrethroid resistance remain uncharacterised. Because CYP6P9a and CYP6P9b 
were shown to exhibit significant allelic variation between resistant and susceptible mosquitoes, we 
hypothesised that this allelic variation is potentially a key mechanism conferring pyrethroid 
resistance. Here, I characterised the role of these genes in the resistance to pyrethroids and 
identified other candidate genes which confer cross-resistance to non-pyrethroid insecticides. The 
role of allelic variation in pyrethroid resistance was investigated using polymorphism survery and in 
silico prediction of activity. Metabolic activities and efficiencies of allelic variants of CYP6P9a and 
CYP6P9b were investigated using fluorescent probes, metabolism assays and transgenic expression 
in D. melanogaster system. Pyrethroid resistance causative mutations were detected using the site-
directed mutagenesis. Other candidate P450s that confer cross-resistance to pyrethroids carbamates 
and organochlorines were identified and characterised.  
This study revealed that CYP6P9a and CYP6P9b from resistant populations of An. funestus are 
undergoing directional selection with reduced genetic diversity and beneficial mutations selected, 
compared to the alleles from susceptible strain (FANG), which exhibited high genetic variation. 
Modelling and docking simulations predicted the alleles of CYP6P9a and CYP6P9b from the resistant 
strains all across Africa to metabolise pyrethroids with high efficiency while the susceptible alleles 
FANGCYP6P9a and FANGCYP6P9b were predicted to have low activity toward pyrethroids. Validation 
of the docking predictions with probes and metabolism assays established that the resistant alleles 
of CYP6P9a and CYP6P9b possess high activities toward pyrethroids with kinetic profiles significantly 
different (high affinity and catalytic efficiency) from those obtained from the FANG, indicating that 
allelic variation is playing a major role in pyrethroid resistance. These findings were further 
strengthened by results from transgenic expression with GAL4/UAS technology showing that flies 
expressing the resistant alleles of both genes were significantly more resistant to pyrethroids than 
those expressing the susceptible alleles.  
Using mutagenesis, three key residues (Val109, Asp335 and Asn384) from the resistant allele of 
CYP6P9b were established as the important amino acid changes responsible for resistance with 
impact on substrate channelling, possible enhancement of interaction with redox partners and inter-
molecular hydrogen bonding interactions, respectively conferring high metabolic efficiency. The 
finding of these resistance markers make it possible to design a diagnostic tool that can allow 
detection and tracking of the resistant alleles in the field population of An. funestus across Africa.  
Other up-regulated P450s in multiple resistant populations from southern Africa were also 
characterised, revealing that pyrethroid resistance is mediated by other P450s as well: CYP6M7, 
CYP6Z1, CYP9J11 and CYP6AA4 all of which metabolise pyrethroids. CYP6Z1 and CYP9J11 are cross-
resistance genes which metabolise bendiocarb, while CYP6Z1 metabolise DDT in addition.  
In conclusion, allelic variation is a key mechanism conferring pyrethroid resistance in An. 
funestus s.s. from sub-Saharan Africa. Key amino acid changes control pyrethroid resistance factors 
and these molecular markers can be used to design DNA-based diagnostic tests which will allow 
tracking of the resistance alleles in the field. Pyrethroid resistance is multi-genic in the field 
populations of An. funestus with other P450s involved apart from CYP6P9a and CYP6P9b. The finding 
of cross-resistance P450s is of concern to resistance management and should be taken into account 
when designing resistance management strategies. 
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1. LITERATURE REVIEW 
1.1 Background 
Despite the recent decrease in global rates of mortality (42%) due to malaria (WHO, 2013b),  the 
disease steals 627,000 lives in 2012 alone, mostly children under the age of 5. Malaria is caused by 
infection with protozoan parasites belonging to the genus Plasmodium, which are transmitted by 
female Anopheles mosquitoes (Cox, 2010). The major mosquito vectors in sub-Saharan Africa are An. 
gambiae, An. arabiensis and An. funestus (Ranson et al., 2011).  Impediments to malaria control and 
eradication include the absence of a licensed vaccine (Mwangoka et al., 2013), development of and 
spread of parasite resistance to anti-malarial drugs (Packard, 2014) and the mosquito resistance to 
insecticides used in public health as reviewed (Corbel and N’Guessan, 2013). Control of malarial 
vectors relies heavily on the use of insecticide formulations alone or in combination, for wide-
coverage as in conventional Insecticide Treated Nets (ITNs) (WHO, 2013b), Long-Lasting Insecticide 
Treated Nets (LLINs) and indoor residual spraying (IRS) (Hemingway, 2014). Unfortunately, widespread 
emergence and increasing resistance to insecticides especially pyrethroids- the only class fully 
approved by WHO for LLINs and ITNs (WHO, 2013a), in one of the major malaria vector An. funestus 
(Riveron et al., 2014a, Mulamba et al., 2014b, Coetzee and Koekemoer, 2013) is threatening the 
success of these intervention tools (WHO, 2012).  Within the Funestus complex, An. funestus s.s. is the 
most widely, geographically distributed across African continent (Dia et al., 2013) and the specie with 
high vectorial capacity conferred by its unusually high anthropophilic and endophilic behaviour 
(Coetzee and Fontenille, 2004, Gilles and De Meillon, 1968). To date An. funestus populations from 
different regions of Africa have been established to be resistant to three of the four major classes of 
insecticides: pyrethroids, carbamates and organochlorines widely utilized for control of malaria 
vectors (Brown, 1986, Coetzee and Koekemoer, 2013, Dia et al., 2013, Ranson et al., 2011, Wondji et 
al., 2012, Corbel and N’Guessan, 2013). With the knockdown resistance (kdr) type mutation in the 
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voltage-gated sodium channel not yet selected in An. funestus s.l., (Hemingway, 2014, Djouaka et al., 
2011, Morgan et al., 2010, Wondji et al., 2007b) pyrethroid resistance is mainly metabolic and 
mediated fully or partially by P450 monooxygenases (Coetzee and Koekemoer, 2013, Wondji et al., 
2012, Okoye et al., 2008, Corbel and N’Guessan, 2013). In An. funestus resistance to insecticides is 
heterogeneous across Africa, with populations from different regions showing overlapping or 
contrasting resistance patterns (Djouaka et al., 2011, Morgan et al., 2010, Cuamba et al., 2010, Wondji 
et al., 2012). The duplicated CYP450s CYP6P9a and CYP6P9b and other candidate genes detected 
through genome-wide microarray and transcriptomic analysis have been implicated as the major 
pyrethroid resistance genes in An. funestus across Africa (Amenya et al., 2008, Riveron et al., 2013, 
Wondji et al., 2009, Wondji et al., 2012, Gregory et al., 2011). But, despite the remarkable progress so 
far made in detection of such candidate resistance genes in An. funestus and their functional 
characterisation in some cases (Riveron et al., 2013, Riveron et al., 2014b), the exact mechanisms of 
pyrethroid resistance still remains unknown, factors responsible for multiple resistance to different 
insecticide classes are yet to be elucidated and molecular markers are lacking to track resistance in the 
field. Therefore this study was carried out to attempt to fill these gaps. Here, I dissected and assessed 
the impact of allelic variation in two major pyrethroid resistance genes CYP6P9a and CYP6P9b, 
identified molecular markers of pyrethroid resistance and discovered cross-resistance genes.  
1.2 Malaria Vectors  
Malarial parasite is transmitted by mosquitoes from the Anopheles genus which comprises nearly 
500 species of which around 70 have been established as vectors (http://seeg.zoo.ox.ac.uk 
/themes/vectors). The continent of Africa bears the brunt of malaria burden because it has the most 
effective and efficient dominant vector specie (DVS) of human malaria (Gillies, 1987, Sinka et al., 2010) 
An. gambiae s.s. (Guerra et al., 2008) with its sibling An. arabiensis, also of major importance (Gillies, 
1987). The DVS members of the An. gambiae complex also include in addition the salt water tolerant, 
coastal species An. melas and An. merus (Harbach, 2004). Other members of the An. gambiae complex 
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are either highly restricted in their distribution (e.g. An. bwambae, known to occur only in some 
geothermal springs in western Uganda (White, 1985) or are zoophilic in behaviour and not considered 
vectors of human malaria (e.g. An. quadriannulatus A and An. quadriannulatus B) (Sinka et al., 2010). 
Recently, two species were added to the An. gambiae complex based on molecular and bionomic 
evidences: the An. gambiae molecular "M form" is now named An. coluzzii Coetzee & Wilkerson sp. n., 
while the "S form" retains the nominotypical name An. gambiae Giles (Coetzee et al., 2013). An. 
quadriannulatus is retained for the southern African populations of this species, while the Ethiopian 
species is named An. amharicus Hunt, Wilkerson & Coetzee sp. n., based on chromosomal, cross-
mating and molecular evidences. Beside the An. gambiae s.l. complex, An. funestus s.s. also play a 
major role in malaria transmission and in some parts of the continent has a greater impact on malaria 
transmission than An. gambiae (Coetzee and Fontenille, 2004). Indeed An. funestus is considered to be 
one of the first species to have adapted to human hosts (Charlwood et al., 1995).  
1.2.1 Anopheles funestus 
 An. funestus is one of the major African vectors of malaria. Its distributed across sub-Saharan 
Africa wherever suitable swampy breeding habitats are available (Coetzee and Koekemoer, 2013). An. 
funestus belongs to a group of thirteen species (Dia et al., 2013) that are morphologically very similar 
in the adult stage (Coetzee and Fontenille, 2004). Four species, An. funestus, An. vaneedeni, An. 
parensis and An. aruni, possess identical morphology at all life stages and (Gillies, 1987, Gilles and De 
Meillon, 1968) and together with An. funestus-like, An. confusus and An. longipalpis type C are known 
as the Funestus sub-group (Dia et al., 2013). The second subgroup is designated Minimus subgroup 
and is composed of An. leesoni and An. longipalpis type A. The third is the Rivulorum subgroup which 
comprise An. rivulorum, An. rivulorum-like, An. brucei and An. fuscivenosus. An. leesoni is the most 
distinct at both egg and larval stage, while An. confusus is easily identified on larval characteristics. An. 
rivulorum and An. brucei also have distinctive larvae although these two species are virtually 
indistinguishable from each other (Coetzee and Fontenille, 2004). Apart from An. funestus, which is 
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highly anthropophilic, the rest of the group are mainly zoophilic (Coetzee and Fontenille, 2004). 
Nevertheless, An. rivulorum has been implicated as a minor vector in a locality in Tanzania (Wilkes et 
al., 1996).  The An. Funestus complex is tabulated below (Table 1.1). 
Table 1.1 African An. funestus complex. Adapted from (Dia et al., 2013). 
 
 
 
 
Figure 1.1: Distribution of species of Funestus complex. Adapted from (Dia et al., 2013). 
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An. funestus, An. leesoni and An. rivulorum exhibit the widest geographical distribution (Dia et 
al., 2013). They are traditionally represented throughout the entire sub-Saharan Africa (Gilles and De 
Meillon, 1968, Gillies, 1987). An. funestus is present everywhere across African continent (Figure 1.1), 
while the other species exhibit local distribution across the continent (Dia et al., 2013).  
Whereas An. gambiae typically breeds in small temporary rain-dependent pools and puddles, An. 
funestus exploits large permanent or semi-permanent bodies of water containing emergent 
vegetation (Serazin et al., 2009). An. funestus reaches maximal abundance in the dry season after 
densities of An. gambiae and An. arabiensis have declined, thereby extending the period of malaria 
transmission (Gilles and De Meillon, 1968). An. funestus is the major vector responsible for malaria 
transmission in many places and has been implicated for malaria epidemics in some places (Fontenille 
et al., 1990, Hargreaves et al., 2003). 
Despite its obvious importance as a vector, An. funestus has been neglected for almost half a 
century, with most of the research focusing on members of the An. gambiae complex (Coetzee and 
Fontenille, 2004). This neglect has been attributed to the difficulty of colonizing An. funestus in the 
laboratory setting and adaptability of the An. gambiae complex to laboratory conditions and the ease 
with which species in the group can be colonized.  
1.3 Malaria Control  
Malaria control has been described as  too complex to be addressed by a single approach and as 
such attempt to describe it is fraught with danger (Shiff, 2002). An integrated approach to control 
using vector control strategies based on the biology of the mosquito, the epidemiology of the parasite, 
and human behaviour patterns is needed to prevent continued upsurge in malaria in the endemic 
areas (Mouchet and Carnevale, 1998). For theoretical purpose, malaria control can be considered from 
three major approaches: (i) treatment of infection caused by Plasmodium, (ii) control of the vector 
(mosquito) that spreads the malarial parasite, and (iii) antimalarial vaccines. 
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1.3.1 Treatment of Infection: Chemotherapy and Chemoprophylaxis 
Malaria chemotherapy has relied largely on a comparatively small number of chemically 
related drugs belonging to four classes of compounds: 4-aminoquinolines (chloroquine, quinine, 
mefloquine, amodiaquine and halofantrine) or 8-aminoquinolines (primaquine), the antifolate 
compounds (pyrimethamine, proguanil, chlorcycloguanil, dapsone, and sulfadoxine), the artemisinin 
and derivatives (artemisinin, artesunate, artemether, arteether, dihydroartemisinin), and most 
recently, the hydroxynapthoquinone atovaquone (Schlitzer, 2008). Unfortunately, resistance to 
antimalarials usually develops within a few years (Ashley et al., 2014, White, 2014, Alker et al., 2008, 
Foote et al., 1990).  Malaria chemoprophylaxis is the use of anti-malarial medication to prevent the 
occurrence of the symptoms of malaria (Schlagenhauf, 2010) especially in travellers (emigrants) from 
malaria-free regions journeying to endemic areas.  
1.3.2 Malaria Vaccines 
This is the idea of using vaccine against the malarial parasite Plasmodium. Presently, there are 
38 P. falciparum and two P. vivax candidate malaria vaccines or vaccine components in preclinical or 
clinical progress (Karunamoorthi, 2014). But, the vaccine Repeat region for T-cell epitope surface 
antigen of free S protein (RTS,S) which targets the circumsporozoite stage of malarial parasite (Targett 
et al., 2013) has been described as the most promising. The RTS,S vaccine has already reached the 
Phase III clinical trials and its hoped that it could get licensed soon (Rts et al., 2012). However, the 
vaccine has been shown to reduce episodes of malaria by only 50%.  Other challenges that need to be 
overcome is polymorphism in many key parasite antigens (Greenwood and Targett, 2011). It is 
likely vaccines that are effective enough to block transmission, will need to contain antigens from 
different stages of the parasite's life cycle. 
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1.3.3 Vector control  
Various approaches are used to control vectors. This range from physical, environmental, 
biological and chemical measures, applied independently or in combination, to deter, reduce the 
number or eliminate mosquito vectors. Recent advances has also made it possible to apply a wide 
range of biotechnological techniques for these purposes.  
1.3.3.1 Physical Methods 
The physical approaches include drainage of stagnant water, frequent clearing of puddles, 
screening of windows and other apertures, and use of untreated bed nets. Larval source management 
(LSM) is one of the most important approaches to reducing malaria transmission which is largely 
forgotten (Fillinger and Lindsay, 2011); in the early twentieth century larviciding and environmental 
management were the only tools available to contain malaria. Screening of windows and other 
apertures can be very effective in keeping out mosquitoes, provided the screening is well fitted and 
without tears (Curtis, 1989). Bednets even untreated are also important and in some places have been 
associated with reduced prevalence (51%) of P. falciparum infection (Clarke et al., 2001b) Houses are 
the main places for contact between humans and night biting mosquitos (Gamage-Mendis et al., 
1991). The impact of improved housing on reduction of indoor malaria vector densities and 
transmission is well established in several studies (Lwetoijera et al., 2013).   
1.3.3.2 Biological Methods 
Biological control methods refer to the use of natural enemies such as predatory fish, 
invertebrate predators and toxins produced by microbial agents such as Bti (Imbahale et al., 2011). B. 
thuringiensis var. israelensis, serotype H14 (Bti) has become the most commonly used microbial 
insecticide (biopesticide) to control pest and vector species (Rowe et al., 2003). Bti is non-toxic to 
humans, mammals, birds, fish, plants and most aquatic organisms and has been established to be a 
potent growth deterrant of the field population of Cx. pipiens (Altalhi, 2005). The active ingredient in 
8 
 
the Bt is the Cry protein which is activated in the gut of the mosquito larvae by proteolysis and binds 
to the receptors on the brush border membranes of epithelial cells, forming pores and disrupting 
movements of solutes (Sanahuja et al., 2011). This eventually leads to cell swelling and lysis. 
 The annual killifish (Aphanius dispar dispar) has also been demonstrated as a means of 
eradicating the aquatic stages of mosquitoes in transient pools (Matias and Adrias, 2010), because 
they can maintain permanent populations in such habitats by undergoing suspended animation or 
diapause during the embryonic stages, to survive periodic drought. Matias and colleagues have 
described the potential of annual killifish, Nothorbronchius. guentheri, for mosquito control because of 
its preference for mosquito larvae as prey, the successful demonstration of introducing the fish in the 
ponds in the form of diapausing eggs and the eradication of mosquito larval population in the ponds.   
Another biological approach is introduction of Wolbachia symbionts into mosquito 
populations. For example, introduction of wMel strain of Wolbachia into field populations of Ae. 
aegypti resulted in a decreased dengue virus transmission (Hoffmann et al., 2011) with invasion 
almost reaching fixation in a few months following releases of wMel-infected Ae. aegypti adults.  The 
wAlb strain of Wolbachia has also been established in the laboratory populations of An. stephensi and 
shown to confer resistance in mosquitoes to P. falciparum (Bian et al., 2013). Wolbachia spreads 
through cytoplasmic incompatibility rendering insects resistant to a variety of human pathogen. 
1.3.3.3  Modern Biotechnological Approaches 
Transgenic mosquitoes are a potential tool for the control or eradication of vectors of diseases 
like malaria (Boete et al., 2014). The idea behind this is to transform mosquitoes with genes that could 
render them refractory to infection by malaria, and then release them, thus making mosquito 
populations incapable of transmitting malaria. Sterile insect technique (SIT) is also increasingly utilised 
for control of malaria vectors. In this technique, reproductive cycles of mosquito vectors are interfered 
with using radiation-induced sterility, as described in the review (Oliva et al., 2014). The SIT conceived 
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by E.F. Knipling in 1937 relies on compromising the integrity of the hereditary machinery and fertility 
(Knipling, 1959) through mutagenic activity of irradiation, and mass release of the competitive, sterile 
insects into natural populations. In a review (Helinski et al., 2009), SIT was described as successfully 
used for the elimination of the New World screwworm Cochliomyia hominivorax from the USA and 
Central America, as well as the tsetse fly Glossina austensi. The technique had been tested in An. 
arabiensis Patton with negative correlation between insemination and dose (Helinski et al., 2006). 
However, in mosquitoes the technique is still in experimental phase with one of the major challenges 
being decreased mating competitiveness of the irradiated males (Helinski et al., 2009).  
1.3.3.4 Chemical Methods 
These are measures which include the use of chemicals in ITNs, LLINs, indoor residual sprays, 
pyrethroid-based coils or repellents, the letter which are applied topically to deter biting mosquitoes. 
1.3.3.4.1 Indoor Residual Spray (IRS)  
 Many malaria vectors  rest inside houses after taking a blood meal (endophily) and thus effective 
indoor residual spraying depends on whether mosquitoes rest indoors (Pates and Curtis, 2005). IRS 
involves spraying the walls and other surfaces of a house with a residual insecticide 
(http://apps.who.int/iris/bitstream/10665/80126/1/9789241505123_eng.pdf). For many months the 
insecticide will kill mosquitoes and other insects that come in contact with these surfaces. IRS kills 
mosquitoes after they have fed, when they come to rest on the sprayed surface. IRS prevents 
transmission of infection to other persons, has the advantage of being able to make use of a much 
wider range of insecticide products in comparison to LLINs and/or ITNs, for which pyrethroids are the 
only class of insecticide currently used (Pluess et al., 2010).    
1.3.3.4.2 Insecticide Treated Bed Nets (ITNs) 
ITNs are the most prominent malaria preventive measure for large-scale deployment in highly 
endemic areas (Lengeler, 2000). An ITN is a mosquito net that repels, disables and/or kills mosquitoes 
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coming into contact with insecticide on the netting material (World Health Organization, 2007). These 
are conventionally treated mosquito nets that have been treated by dipping in a WHO-recommended 
insecticide. To ensure its continued insecticidal effect, the nets are usually re-treated after three 
washes, or at least once a year. Relatively modest coverage with ITNs (around 60%) of all adults and 
children have been described as able to achieve equitable community-wide benefits (Killeen et al., 
2007). ITNs have been shown to hinder around 50% of malaria cases, making its protective efficacy 
significantly higher than that of untreated nets which, under ideal conditions (such as those found in 
research settings), usually provide about half the protection of nets treated with an effective 
insecticide (World Health Organization, 2007, Clarke et al., 2001a). 
1.3.3.4.3 Long-Lasting Insecticide Treated Bed Nets (LLINs) 
Large-scale use of insecticide treated nets has a short-coming in that the impregnation and the re-
impregnation needs technical skills and materials which may not be available (Lines, 1996), especially 
in remote areas. LLINs are developed because of these reasons and it is a factory-treated mosquito net 
made with netting material that has insecticide incorporated within or bound around the fibres (World 
Health Organization, 2007). The nets have been shown to retain its effective biological activity without 
re-treatment for at least 20 WHO standard washes under laboratory conditions and three years of 
recommended use under field conditions.  
1.3.3.4.4 Repellents  
Protection against arthropod bites is best achieved by avoiding infested habitats, wearing 
protective clothing, and applying insect repellent (Curtis, 1992). Commercially available insect 
repellents can be divided into two categories — synthetic chemicals and plant derived essential oils 
(Fradin and Day, 2002). The most widely marketed chemical-based insect repellent is N, N-diethyl-3-
methyl-benzamide (DEET), which has been used worldwide (Fradin and Day, 2002, Karunamoorthi and 
Sabesan, 2009).  
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1.4 Insecticides 
Insecticides are agents of chemical or biological origin that control insects (Ware and Whitacre, 
2004). Insecticides may be natural or manmade and are applied to target pests in a myriad of 
formulations and delivery systems (sprays, baits, slow-release diffusion, etc). There are four major 
classes of insecticides used in public health sector: pyrethroids, organochlorines, carbamates and 
organophosphates (Krieger, 2010).  
1.4.1 Pyrethroids 
1.4.1.1 Introduction 
The term "pyrethrum" refers to the dried and powdered flower heads of a daisy-like plant 
belonging to the Chrysanthemum genus (Schleier III and Peterson, 2011). Pyrethrins, the insecticidal 
ingredient occurring in the flowers of Tanacetum cinerariaefolium (also known as Chr. cinerariaefolium 
or Pyr. cinerariaefolium), have been used widely for human and animal health protection by 
controlling indoor pest insects such as cockroaches, houseflies, and mosquitoes since ancient times 
(Krieger, 2010). Pyrethrum extract contains six closely related insecticidal esters (Figure 1.2) 
collectively referred to as the pyrethrins, which differ only in the terminal substituents in the side 
chains of the acid and alcohol components. The acid is a substituted cyclopropanecarboxylic acid and 
the alcohol a substituted cyclopentenolone. The commercial limitations of pyrethrum extracts 
(pyrethrins), which are a mixture of six lipophilic esters were recognized because of their high rate of  
photodegradation and a short "knockdown" (rapid paralysis) effect (Schleier III and Peterson, 2011).  
After the discovery of the constituents of pyrethrins, researchers searched for derivatives of pyrethrins 
that had a higher resistance to photodegradation; this led to the synthesis of pyrethroids. The 
advantages of pyrethrins and pyrethroids are that they are highly lipophilic, have a short half-life in the 
environment, have low toxicity to terrestrial vertebrates and do not biomagnify like older chemical 
classes, such as organochlorines.  
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Pyrethroids have wide application in agriculture and public health control of vectors, and have 
been described in a review by Gupta to account for approximately 25% of the world insecticide market 
(Gupta, 2014). For the public health market, they are used as indoor residual house sprays, to 
impregnate bednets, curtains and screens, and in coils, mats and aerosols (Hemingway et al., 2004). 
Synthetic pyrethroids can be classified into the first- and second-generation pyrethroids. First-
generation pyrethroids, which are esters of chrysanthemic acid derivatives and alcohols having furan 
ring and terminal side chain moieties, are highly sensitive to light, air, and temperature (Krieger, 
2010). Therefore, these pyrethroids have been used mainly for control of indoor pests, for example 
the chrysanthemates, resmethrin and phenothrin are used against household, veterinary, and stored-
products pests, as reviewed in (Casida et al., 1983). The second-generation pyrethroids, which 
commonly have 3-phenoxybenzyl alcohol derivatives in the alcohol moiety, have excellent insecticidal 
Figure 1.2: The chemical structure of the six constituents of pyrethrum extracts which are 
collectively known as pyrethrins. Adapted from (Schleier III and Peterson, 2011).  
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activity as well as sufficient stability in outdoor conditions conferred by substitution of photolabile 
moieties with dichlorovinyl, dibromovinyl substituent, and aromatic rings. Thus, the second-
generation pyrethroids have been used worldwide for agricultural pests; for example permethrin and 
deltamethrin (Schleier III and Peterson, 2011). Pyrethroids are also grouped according to their 
structure (Figure 1.3) and toxicology, including those lacking α-cyano group (Type I, e.g. permethrin) 
and those with α-cyano group on the phenoxybenzyl moiety (Type II, e.g. deltamethrin) (Schleier III 
and Peterson, 2011). Type I pyrethroids differ from type II based on the distinct symptoms they evoke 
in insect targets and effects on sodium channel gating (Du et al., 2009).  
 
 
 
 
1.4.1.2 Mechanism of Action 
The binding site of pyrethroid in voltage-gated sodium channel (VGSC) is located within a long, 
narrow hydrophobic cavity, delimited by the IIS4-S5 linker and the IIS5/IIIS6 helices (Figure 1.4), which 
Figure 1.3: Chemical structure of type I (resmethrin and permethrin), type II (fenvalerate 
and cypermethrin) and pseudopyrethroid etofenprox. Adapted from (Schleier III and 
Peterson, 2011).  
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is accessible to lipid-soluble insecticides (Davies et al., 2007). During an action potential the sodium 
channel undergoes transitions between closed-resting, activated and inactivated functional states, and 
toxins binding to specific sites on the channel either alter the equilibrium between these functional 
states or block the channel pore (O'Reilly et al., 2006). The lipid soluble and pyrethroid insecticides 
preferentially target the open state of the voltage-gated sodium channel and their binding stabilize the 
open state, inhibiting the transition to the non-conducting deactivated or inactivated states. 
Consequently, the inward conductance of sodium is prolonged. The persistent depolarization of the 
plasma membrane resulting from the prolonged inward sodium conductance induces repetitive nerve 
firing and hyper-excitability, leading to paralysis and death of the insect. 
 
 
 
 
 
Type I pyrethroids (e.g., permethrin) are generally good knockdown agents due to their ability 
to induce repetitive firing in axons, resulting in restlessness, un-coordination and hyperactivity 
followed by prostration and paralysis. Type II pyrethroids significantly prolong channel open time (i.e. 
Figure 1.4: Diagram of the extended transmembrane structure of voltage-sensitive sodium 
channel a subunits showing the four internally homologous domains (labelled I–IV), each 
having six transmembrane helices (labelled S1–S6 in each homology domain), and the identities 
and locations of mutations associated with knockdown resistance. Adapted from (Soderlund and 
Knipple, 2003). 
15 
 
sodium tail currents of 200 milliseconds to minutes), resulting in an increased resting membrane 
potential, inducing a depolarization dependent block of action potentials (Schleier III and Peterson, 
2011) and causes a pronounced convulsive phase that results in better kill because depolarization of 
the nerve axons and terminals is irreversible (Bloomquist, 1996b).     
1.4.1.3 Structure-Activity Relationships 
Though there is no specific substructure, or reactive entity that can be identified as the 
toxophore that confers pyrethroid-like insecticidal activity (Krieger, 2010), there is a small group of 
essential features that pyrethroids require to possess high insecticidal activity, irrespective of the rest 
of the molecule or the nature of the target species (Schleier III and Peterson, 2011). The active esters 
of pyrethroids are 3-substituted cyclopropanecarboxylic acids which all have a 1R-configuration and a 
gem-dimethyl substitution at the C-2 of the cyclopropane ring (Schleier III and Peterson, 2011). 
Pyrethroids have three asymmetric carbon atoms and therefore could have as many as eight possible 
stereoisomers. The presence of two chiral centers in the cyclopropane ring of chrysanthemic acid 
produces two pairs of diastereomers as well, designated cis and trans on the basis of orientation of 
the C-1 and C-3 substitutions in relation to the plane of the cyclopropane ring; however, only isomers 
with the R configuration at the cyclopropane C-1 are insecticidally active (Schleier III and Peterson, 
2011, Soderlund et al., 2002) (Figure 1.5).  
In permethrin the methyl groups of the acid side chain was replaced with chlorine atoms, 
which block photochemical degradation on the adjacent double bond (Elliott et al., 1973). After the 
discovery of permethrin, researchers searched for compounds with a higher insecticidal activity and 
this led to the discovery of the cyano substitute at the benzylic carbon of the 3-phenoxybenzyl group.  
Stereoisomerism is a less common feature of pyrethroid alcohol moieties. Nevertheless, when 
a chiral centre is present in the alcohol moiety at the carbon bearing the hydroxyl group, as in esters of 
α-cyano-3-phenoxybenzyl alcohol (e.g., deltamethrin), only one epimer has high insecticidal activity 
even when esterified to an acid moiety that contains the appropriate stereochemical configuration for 
16 
 
high insecticidal activity. In deltamethrin with 2 rings (3-phenoxybenzyl alcohol) the 1R-cis isomers are 
generally more active than the trans isomers (Gilbert and Gill, 2010). With alcohol moieties that 
contain only a single ring (e.g. pentafluorobenzyl group of fenfluthrin and cyclopentenone of allethrin) 
the trans isomers are more active. Also, contrary to the generalization for pyrethroids containing 3-
phenoxybenzyl alcohol, theta-cypermethrin (trans isomer) is more potent in control of Lepidopteran 
than the cis isomer. In essence, the selective potency of pyrethroid isomers on insects depends on 
several factors one of which is the selective metabolic processes. For example, Pap and colleagues 
(Pap et al., 1996) tested pure optical isomers of phenothrin, permethin and cypermethrin on a wide 
spectrum of insects (Blattella germanica, Leptinotarsa decemlineata, T. confusum, Oncopeltus 
fasciatus, Musca domestica, Ae. aegypti) and discovered that the S isomer was more effective than R 
in all species. However, in the presence of metabolic inhibitors, the R isomer had comparable activity 
to the S towards mosquitoes but not the other species (Gilbert and Gill, 2010).   
 
 
1.4.1.4 Metabolism of Pyrethroids 
The pyrethroids are detoxified by through attack by either esterases at the central ester bond, 
or by P450 monooxygenases at one or more of the acid or alcohol moieties (Schleier III and Peterson, 
Figure 1.5: Structure-Activity Relationship in pyrethroids: (A) insecticidal and non-insecticidal 
isomers of resmethrin. Adapted from (Krieger, 2010).  
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2011). However, presence of a cis-substituted acid moiety and a secondary alcohol moiety makes 
hydrolytic metabolism of pyrethroids limited (Soderlund and Knipple, 2003).  
Analysis of the metabolic pathways of pyrethroid degradation in insects, including cockroach, 
housefly and cabbage looper (Shono et al., 1978) identified forty-two metabolites (including 
conjugates) from permethrin metabolism which occurred by ester cleavage to 3-phenoxybenzyl 
alcohol (3-PBA) and 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylic acid (DCVA). 
Hydroxylation has also been described to occurr at the 4ʹ- and 6- positions of the phenoxybenzyl 
moiety and the cis or trans methyl groups of the DCVA (Gilbert and Gill, 2010).  
In mosquitoes, metabolism of Type II pyrethroids may involve the oxidation of phenoxybenzyl 
ring as reported for An. gambiae CYP6M2 (Stevenson et al., 2011). CYP6M2 metabolised deltamethrin 
into 4ʹ-hydroxydeltamethrin and incubation of HPLC-purified 4ʹ-hydroxydeltamethrin (M4) with 
CYP6M2 produced cyano(3-hydroxyphenyl) methyl deltamethrate (M2), which in turn was found to be 
metabolized by the same enzyme to deltamethric acid (M1) (Figure 1.6). CYP6M2 thus, predominantly 
metabolizes deltamethrin by hydroxylation of the 4ʹ position, cleavage of the ether bond between the 
aromatic rings, and hydrolysis into deltamethric acid.  
 
Figure 1.6: Metabolism of deltamethrin by recombinant An. gambiae CYP6M2. 
Adapted from (Stevenson et al., 2011). 
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1.4.2 Organophosphates (OPs) 
 The toxicity of insecticidally active organophosphorus and carbamate esters to animals is 
attributed to their ability to inhibit acetylcholinesterase (AChE), a class of enzymes which catalyzes the 
hydrolysis of the neurotransmitter acetylcholine (ACh) (Fukuto, 1990). The binding of OPs to AChE 
results in disruption of nerve impulses, killing the insect or interfering with normal activities. OPs are 
normally esters, amides, or thiol derivatives of phosphoric, phosphonic, phosphorothioic, or 
phosphonothioic acids (Singh, 2012). The OPs are a very important group of compounds that vary 
tremendously in chemical structure and chemical properties (Bloomquist, 1996a). The OP compounds 
can be miscible with water, but more typically are miscible in organic solvents. Generally, OPs react 
with a serine hydroxyl group within the enzyme active site, phosphorylating the serine hydroxyl group 
and yielding a hydroxylated "leaving group”. This process inactivates the enzyme and blocks the 
degradation of the neurotransmitter, acetylcholine. There are at least about 13 types of OPs (Gupta, 
2011); of these malathion belongs to phosphorodithioates, sarin belongs to phosphornofluoridates, 
diazinon, parathrion and pirimiphos-methyl belong to phosphorothioates, and dichlorvos belongs to 
phosphonates. OPs used in mosquito control programmes include: fenthion (bytex), temephos 
(abate), chloropyrifos (dursban), fenithrothion (sumithion), pirimiphos-methyl (actelic), malathion, etc. 
1.4.3 Carbamate  
Carbamates are N-substituted esters of carbamic acid (Gupta, 2011). The inhibition of AChE by 
a carbamate insecticide occurs by a mechanism identical to that described for an organophosphates 
(Fukuto, 1990). The first step in the inhibition process involves the formation of the enzyme-inhibitor 
complex with subsequent carbamylation of the serine hydroxyl group and inhibition of the enzyme 
(Metcalf, 1971). Examples of carbamates are carbaryl (SEVIN), oxamyl (VYDATE), carbofuran 
(FURADAN), thiodicarb (LARVIN) (Singh, 2012), bendiocarb (Turcam), propoxur (BAYGON), etc. 
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1.4.4 Organochlorines (OCs) 
Organochlorine pesticides are chlorinated hydrocarbons used extensively from the 1940s 
through the 1960s (Matsumura, 1985). Representative compounds in this group include DDT, 
methoxychlor, dieldrin, chlordane, toxaphene, mirex, kepone, lindane, and benzene hexachloride. 
Since the 1970s, DDT and most other chlorinated hydrocarbon compounds have been restricted or 
banned for agricultural use in most countries, due in part to their unacceptably long persistence in the 
environment and also because of increased concerns arising from their fat solubility (having a high 
partition coefficient in lipids versus water) and resultant long-term accumulation in fatty tissues of 
non-target organisms (Mellanby, 1992). However, DDT continues to be used in limited quantities in 
the control of insect vectors for public health purposes, as its approved by WHO in 2006 for IRS 
(Sadasivaiah et al., 2007). DDT affects the peripheral nervous system; initial contact with the 
insecticide causing neurons to fire spontaneously causing muscles twitch, with resulting tremors 
throughout the body and appendages, the so-called ‘DDT jitters’ (Davies et al., 2007). Over the course 
of a few hours or days, DDT exposure leads to excitatory paralysis and consequent death of the insect.   
1.4.5 Other insecticides 
Other compounds with insecticidal activities used for control of insect pests include 
neonicotinoids and ryanoids. Neonicotinoids, possess either a nitromethylene, nitroimine or 
cyanoimine group (Matsuda et al., 2001) and important neonicotinoids, such as imidacloprid, 
nitenpyram and acetamiprid, all contain a 6-chloro-3-pyridyl moiety and therefore resemble nicotine 
and epibatidine, both of which are potent agonists of nicotine acetylcholine receptors (nAChRs). 
Imidacloprid and other nitromethylene compounds like 1-(pyridine-3-yl-methyl)-2-nitromethylene-
imidazoline (PMNI) are increasingly used worldwide as an insecticides (Bai et al., 1991).  
Ryania insecticide is the powdered stem wood of Ryania speciosa Vahl., a small shrub growing 
extensively in South America, and noted for its pest control properties (Crosby, 1971). The major 
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insecticidal and toxic constituents are ryanodine (Jefferies et al., 1992) and 9,12-didehydroryanodine 
(Waterhouse et al., 1984), which have attracted much attention as natural but expensive insecticides 
and for their action on the Ca2+-ryanodine receptor complex of muscle (Lai and Meissner, 1989). 
Ryanodine has been described from several studies to induce paralysis in insects and vertebrates by 
causing a sustained contracture of skeletal muscle without depolarizing the muscle membrane 
(Bloomquist, 1996a). 
 
1.5  Insecticide Resistance  
1.5.1 Introduction 
The term resistance is defined as the ability of an insect (population) to withstand the effects of 
an insecticide by becoming resistant to its toxic effects by means of natural selection and mutations 
(Davidson, 1957). Repeated exposure to insecticides can select individuals possessing biochemical 
machineries that can detoxify the insecticides more rapidly or are less sensitive to it (Gilbert and Gill, 
2010). These individual survivors could then pass the resistance traits to the succeeding generations 
resulting in pest populations more resistant, until ultimately a situation is reached whereby the pests 
become completely resistant to the insecticide. In a recent review (Corbel and N’Guessan, 2013) 
resistance has been described to be present in more than 500 insect species worldwide and that to 
date malaria vectors have developed resistance to the main chemical classes used in public health, the 
pyrethroids, organochlroines, carbamates and organophosphates.  
1.5.2 Types of Insecticides Resistance Mechanisms 
The various mechanisms that enable insects to resist  insecticides can be grouped into four 
distinct categories including metabolic resistance, target-site resistance, reduced penetration and 
behavioural avoidance, as aptly reviewed in (Corbel and N’Guessan, 2013) (see Figure 1.7). However, 
increased excretion of the insecticides by some pests is also termed another mechanism of resistance.  
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1.5.2.1 Behavioural Resistance 
Continues exposure to an insecticide may trigger changes in behavioural response of insect 
pests (Corbel and N’Guessan, 2013) leading to the avoidance of lethal doses of an insecticide (Chandre 
et al., 2000). This type of response can be divided into direct contact excitation (sometimes referred to 
as ‘irritancy’) and non-contact spatial repellency that is used when insects move away from the 
insecticide-treated area before making direct contact (Roberts et al., 1997). Behaviouristic resistance 
has been established in An. funestus; a shift from indoor to outdoor biting preferences in Tanzania in 
relation to increasing coverage of pyrethroid-impregnated net (Russell et al., 2011b) as well as 
significant changes in the host-seeking behaviour of the An. funestus population from Benin (West 
Africa) where scaling up of LLINs at community level induced a change from night biting to early-
morning biting behaviour (Moiroux et al., 2012). 
Figure 1.7: Scheme of potential behavioural and physiological changes associated with 
insecticide resistance in malaria vectors; (a) susceptible insect; (b) resistant insect. Adapted from 
(Corbel and N’Guessan, 2013). 
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1.5.2.2 Penetration Resistance (Reduced penetration) 
Modifications in the insect cuticle or digestive tracts can prevent, slow the absorption or  
reduce penetration of insecticides (Corbel and N’Guessan, 2013). Reduced uptake of insecticide 
(cuticular resistance) has been observed in some insect pests especially ones where the major route of 
exposure is through ingestion. For mosquito control, where insecticides are applied onto bed nets or 
on wall surfaces, uptake is primarily through the appendages. Therefore, increase in the thickness of 
the tarsal cuticle, or a reduction in its permeability to lipophilic insecticides, could have a major impact 
on the bioavailability of an insecticide in vivo (Corbel and N’Guessan, 2013). Decreased penetration of 
insecticides would allow sufficient time for detoxifying enzymes to metabolize the chemical and 
therefore make it less effective (Plapp, 1976). Microarrays studies have identified two genes encoding 
cuticular proteins that were upregulated in pyrethroid resistant strains of An. stephensi (Vontas et al., 
2007) and An. gambiae (Awolola et al., 2009b).  Also,  it has been established using scanning electron 
microscopy that in a laboratory strain of An. funestus the mean cuticle thickness was significantly 
greater in pyrethroid tolerant mosquitoes than their susceptible counterparts (Wood et al., 2010). 
 
1.5.2.3 Increased excretion 
This is one of the mechanisms of resistance developed by insects. It was shown that larvae of  
Trinidad resistant strain of Ae. aegypti respond to DDT by excreting the insecticide into the 
perithrophic matrix, the production of which was sometime increased so much that it protruded from 
the anus (Abedi and Brown, 1961). This behaviour was more evident in some resistant strains than 
others and occurred to a much lesser extent in larvae of strain that are susceptible. It appeared to 
constitute a resistance mechanism for removing DDT from the alimentary canal. 
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1.5.2.4 Biochemical Resistance 
Biochemical resistance mechanisms are divided into metabolic (alterations in the levels or 
activities of detoxification proteins) and target site (mutations in the sodium channel, AChE and 
gamma-aminobutyric receptor (GABA) genes, etc). Alone or in combination these mechanisms confer 
resistance, sometimes at an extremely high level, to all of the available classes of insecticides. 
1.5.2.4.1 Metabolic-Based Resistance  
Several reviews defined metabolic resistant (Corbel and N’Guessan, 2013, Russell et al., 
2011a) as a resistance which is based on the detoxification enzymes which all insects possess and 
which help them to clear naturally occurring xenobiotics. As reviewed by Schuler and Berenbaum 
(Schuler and Berenbaum, 2013) overexpression of enzymes capable of detoxifying insecticides or 
amino acid substitutions within these enzymes, which alter the affinity/activity of the enzyme for the 
insecticide, can result in high levels of insecticide resistance. Overexpression of detoxification enzymes 
can occur as the result of gene amplification (e.g. duplication), or due to changes in either trans-acting 
regulatory elements or in the promoter region of the gene. The consequence is a significant increase 
of enzyme production/activity in resistant insects that enables them to metabolize or degrade 
insecticide before it exerts its toxic effect. Three major enzyme groups esterases, cytochrome P450s 
(CYP450s) and glutathione S-transferases (GSTs) have been described as being responsible for 
metabolically-based resistance to organochlorines, organophosphates, carbamates and pyrethroids 
(Hemingway and Ranson, 2000, Brooke et al., 2001, Aizoun et al., 2013).  
 
1.5.2.4.1.1 Esterases-Based Metabolic Resistance 
Over-production of non-specific carboxylesterases as an evolutionary response to 
organophosphate and carbamate insecticide selection pressure has been documented in numerous 
arthropod species including mosquitoes, cattle ticks, aphids and cockroaches (Hemingway et al., 
2004). Several reviews have described esterases as responsible for hydrolysis of ester bonds of 
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insecticides or sequesteration (Corbel and N’Guessan, 2013) with the most widely studied mosquito 
species demonstrating this resistance mechanism are members of the Culex genus (Prato et al., 2012). 
In organophosphate-susceptible insects, the active oxon analogues of the insecticides act as esterase 
inhibitors, because they are poor substrates with a high affinity for the enzymes (Karunaratne et al., 
1995). Esterases from susceptible insects exhibited lower activity towards xenobiotics (including 
insecticides) than their counterparts from resistant insects, which sequester the oxon analogues and 
thus protect the AChE target site. Enhanced esterase activities have been described in mosquitoes, for 
example, in permethrin resistant An. gambiae and in resistant Ae. aegypti  (Hemingway et al., 2004, 
Vulule et al., 1999, Mourya et al., 1993) 
In contrast to the situation in Culex, several reviews (Corbel and N’Guessan, 2013, Hemingway 
et al., 2004) reported a number of Anopheles species (ie An. culicifacies, An. stephensi and An. 
arabiensis) having a non-elevated esterase mechanism which confers resistance specifically to 
malathion through increased rates of metabolism. Malathion resistance in Anopheles had been 
associated with an altered form of esterase that specifically metabolizes the molecule at a much faster 
rate than that in susceptible counterparts (Herath et al., 1981, Hemingway, 1983). Recently, Gly137Asp 
and Try251Leu mutations in the active site of the Cotton Bollworm Helicoverpa armigera esterase have 
been shown to increase the OP-hydrolase activity of the enzyme 14- and 6-folds, respectively (Li et al., 
2013). In multiple resistant populations of An. funestus from southern Africa, genome-wide microarray 
analysis have identified candidate carboxylesterases overexpressed (Riveron et al., 2014a). However, 
the role of these esterases in hydrolysis of OPs, carbamates or pyrethroid insecticides have not been 
validated.  
 
1.5.2.4.1.2 Glutathione S-Transferases (GSTs)-Mediated Resistance 
GSTs are dimeric, multifunctional enzymes that play a role in detoxification of a large range of 
xenobiotics by catalyzing the nucleophilic attack of reduced glutathione (GSH) on the electrophilic 
centres of lipophilic compounds (Sherratt and Hayes, 2001). Conjugation of glutathione (GSH) to 
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organic molecules enhances solubility, thus facilitating their eventual elimination (Corbel and 
N’Guessan, 2013). Elevated GST activity has been implicated in resistance to at least four classes of 
insecticides in insects (Hemingway et al., 2004). Higher enzyme activity is usually due to an increase in 
the amount of one or more GST enzymes, either as a result of gene amplification or more commonly 
through increase in transcriptional rate, rather than qualitative changes in enzyme structures until 
recent findings, e.g. see (Riveron et al., 2014b). At least six classes of insect GSTs have been identified 
in An. gambiae (Ranson et al., 2000), found in several large clusters on all three chromosomes. The 
Delta and Epsilon classes found exclusively in insects are the largest classes of insect GSTs. Members 
of both these classes have been implicated in resistance to all the major classes of insecticide.  
It has been suggested that GSTs may play a role in pyrethroid resistance by detoxifying lipid 
peroxidation products induced by pyrethroids and/or by protecting from insecticide exposure induced 
oxidative stress rather than direct metabolism of the pyrethroids (Vontas et al., 2001).  
However, in the case of An. funestus overexpression and qualitative changes in the amino acid 
sequence have been described as the reasons behind extreme DDT resistance and cross-resistance to 
permethrin (Riveron et al., 2014b). A single mutation in GSTe2 gene (Leu119Phe) was found to confer 
both high resistance to DDT and a cross resistance to pyrethroid permethrin in mosquito populations 
from Benin, West Africa. 
1.5.2.4.1.3 P450-Monooxygenases-Mediated Resistance 
Cytochrome P450 monooxygenases (CYP450s) are diverse family of hydrophobic, heme 
containing enzymes involved in the metabolism of numerous endogenous and exogenous compounds 
(Sridhar et al., 2012). P450s are important in adaptation of insects to toxic chemicals in their host 
plants and have been shown to be  involved in the metabolism of virtually all insecticides (Hemingway 
and Ranson, 2000). The action of P450 monooxygenases usually result in the detoxification of the 
substrate, although the OP insecticides from the phosphorothionate are also activated to the more 
toxic oxon form (Bharate et al., 2010). 
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Insect P450s belong to four major clans: CYP3, CYP4, CYP2 and the mitochondrial clan 
(Feyereisen, 2012) and increased transcription of genes belonging to the CYP4 (from CYP4 clan), CYP6 
and CYP9 families (both from CYP3 clan) has been observed in various insecticide-resistant species 
from different taxa (Feyereisen, 2005). Elevated monooxygenase activity is associated with pyrethroid 
resistance in An. stephensi, An. gambiae, Cx. quinquefasciatus, Ae. aegypti  and An. funestus (Brogdon 
and McAllister, 1998, Vulule et al., 1994, Kasai et al., 1998, Stevenson et al., 2012, Cuamba et al., 2010, 
Djouaka et al., 2011). However, higher activity of enzymes and/or expression of detoxification genes in 
insecticide resistant populations do not necessarily correlate with resistance (Corbel and N’Guessan, 
2013); for example elevated transcript levels of an adult-specific P450 gene, CYP6Z1, in pyrethroid-
resistant strain of An. gambiae was reported (Nikou et al., 2003), though the enzyme does not 
metabolise pyrethroids (Chiu et al., 2008).  
 
1.5.2.4.2  Target-site insensitivity 
Insecticides generally act at a specific site within the insect, typically within the nervous 
system (e.g. OPs, carbamates, DDT and pyrethroid insecticides) (Corbel and N’Guessan, 2013) and 
modification in resistant strains of insects of such targets result in insecticide no longer binding 
effectively, rendering it ineffective (Ranson et al., 2000). Reduced sensitivity of the target receptors to 
insecticide results from non-synonymous point mutations in the gene encoding the protein.  
1.5.2.4.2.1 Knockdown Resistance (kdr) 
Mutations in the amino acid sequence in VGSC channels of nerve cell membranes leads to a 
reduction in the sensitivity of the channel to the binding of DDT and pyrethroids (Davies et al., 2007). 
Alterations in the target site that cause resistance to insecticides are often referred to as kdr in 
reference to the ability of insects with these alleles to withstand prolonged exposure to insecticides 
without being ‘knocked-down” (Corbel and N’Guessan, 2013)(see Figure 1.4).    
27 
 
kdr was first recognised in houseflies by Busvine in 1951 (Busvine, 1951) and the kdr factor is 
now known to be a recessive allele conferring cross resistance to the entire class of pyrethroids as well 
as to DDT and its analogues (Davies et al., 2007). More than 20 unique sodium channel sequence 
polymorphisms have been identified in association with pyrethroid resistance. kdr has been reported 
in many important pest species and in many cases is accompanied by a second recessive resistance 
trait designated super-kdr which confers much greater resistance to pyrethroids (Farnham et al., 1987) 
One of the most common amino acid replacements associated with pyrethroid resistance in 
malaria vectors especially An. coluzzii, An. gambiae Giles and An. arabiensis is a substitution of the 
leucine residue found at codon 1014 with either phenylalanine (1014F) (Martinez-Torres et al., 1998) 
or serine (1014S) (Ranson et al., 2000) in  the sodium channel. To date, no kdr mutation has been 
discovered in the VGSC of An. funestus and associated with insecticide resistance. 
1.5.2.4.2.2 Insensitive Acetylcholinesterase 
Several mutations in the gene encoding AChE have been found in insects (Fournier, 2005) and 
the mutations result in reduced sensitivity to inhibition by insecticides (Weill et al., 2003). Gly119Ser 
mutation responsible for carbamate and OP resistance has been reported in An. gambiae and Cx. 
pipiens (Weill et al., 2004). Elevated expression of the AChE gene, due in part from gene duplication of 
Gly119Ser copies confer carbamate resistance in  An. gambiae from West Africa (Edi et al., 2014). 
1.5.2.4.2.3 GABA Receptor Rdl Mutation 
The insect GABA receptor is implicated as a site of action for cyclodienes (Hemingway and 
Ranson, 2000). Several mutations in this receptor which lead to resistance have been described for 
insects (Corbel and N’Guessan, 2013). In An. gambiae substitution of conserved Ala302 in the Rdl locus 
with serine or glycine have been associated with resistance to dieldrin (Du et al., 2005). 
Dieldrin resistance was detected in An. funestus populations from West (Burkina Faso) and 
Central (Cameroon) Africa (Wondji et al., 2011). The Ala296Ser mutation in An. funestus has been 
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associated with dieldrin resistance and is largely distributed in West and Central Africa (Wondji et al 
2011) but absent in southern African populations. East (Uganda) and Southern (Malawi and 
Mozambique) populations were fully susceptible to dieldrin. 
1.5.3 Interaction of Resistance Mechanisms 
The co-presence of multiple resistance mechanisms exist in various insect species such as the 
house fly (Liu and Yue, 2000)  and the mosquitoes Cx. quinquefasciatus (Xu et al., 2005), etc, and can 
confer onto some insect species high levels of resistance. Cross-resistance occurs when a resistance 
mechanism which allows insects to resist one insecticide, also confers resistance to another 
insecticide. Cross-resistance can occur between insecticides from different chemical classes (Ranson et 
al., 2011). Multiple resistance is a situation which occurs when insects develop resistance to several 
compounds by expressing multiple resistance mechanisms. The different resistance mechanisms can 
combine to provide resistance to multiple classes of insecticide products.  
Multiple resistance in Anopheles mosquitoes have been described in several studies. For example, 
co-occurrence of metabolic resistance mechanisms and kdr in a population of An. gambiae s.s. from 
Nigeria was established by Awolola and colleagues (Awolola et al., 2009a). For cross-resistance, the 
gene CYP6M2 from resistant strain of An. gambiae was found to metabolize Type I and Type II 
pyrethroids as well as organochlorine, DDT (Stevenson et al., 2011, Mitchell et al., 2012). Cross-
resistance mechanism conferred by P450s (CYP6P3 and CYP6M2) and ace-1 duplication have been 
described in multiple resistant population of An. gambiae from Côte d’Ivoire (Edi et al., 2014). In An. 
funestus we (Riveron et al., 2014b) have dissected the mechanism of cross-resistance to DDT and Type 
I pyrethroid (permethrin) in multiple resistance populations from Benin Republic, and established that 
the GSTe2 gene can confer cross-resistance between these insecticides. 
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1.6  Cytochrome P450-Dependent Monooxygenases (P450s) 
1.6.1 Introduction 
P450s are ubiquitous, heme-thiolate, 45- to 55-kDa enzymes (Feyereisen, 2012) important in 
oxidative, peroxidative and reductive metabolism of numerous and diverse endogenous compounds 
such as steroids, bile acids, fatty acids, prostaglandins, leukotrienes, biogenic amines, retinoids and 
phytoalexins (Nelson et al., 1996, Bergé et al., 1998). They embody one of the largest family of genes 
that are found in all organisms in all domains of life (Munro et al., 2013). The proteins, named for the 
absorption band of their FeII-CO complex (carbon-monoxide bound form) at 450nm (Omura and Sato, 
1964), are one of the largest superfamilies of enzyme proteins. The P450 genes (also called CYP) are 
found in the genomes of virtually all organisms (Werck-Reichhart and Feyereisen, 2000), from bacteria 
to protists, plants, fungi, and animals (Feyereisen, 2012). Human genome carries about 57 CYP genes 
and insect genomes can carry from 48 as in honeybee Apis mellifera (Scott, 2008) to 170 as found in 
mosquito Cx. quinquifasciatus (Arensburger et al., 2010).  
  As mixed function monooygenases, P450s catalyse the transfer of one atom of molecular 
oxygen to a substrate, reducing the other to water (Equation 1.1), but they also show activity as 
oxidases, reductases, desaturases, isomerases, etc., and collectively are known to catalyse at least 60 
chemically distinct reactions (Feyereisen, 2012, De Montellano, 2005).  
RH + O2 + NADPH + H
+ → ROH + H2O + NADP
+  Equation 1.1 
There are soluble forms of P450 (in bacteria), and membrane-bound forms (in microsomes 
and mitochondria of eukaryotes) (Feyereisen, 2012). Most animal P450s are dependent on redox 
partners for their supply of reducing equivalents (NADPH cytochrome P450 reductase and cytochrome 
b5 in microsomes; a ferredoxin and a ferredoxin reductase in mitochondria). 
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1.6.2 Classes and Structural Features of P450s 
P450s can be divided into four classes depending on how electrons from NAD(P)H are 
delivered to the catalytic site (Werck-Reichhart and Feyereisen, 2000): Class I proteins require both an 
FAD-containing reductase and an iron sulphur redoxin; Class II proteins require only an FAD/FMN-
containing P450 reductase for transfer of electrons; Class III enzymes are self-sufficient and require no 
electron donor; while P450s from Class IV receive electrons directly from NAD(P)H. This classification 
of the interactions with redox partners is unrelated to P450 evolutionary history.   
Sequence identity among P450 proteins is often extremely low and there is only one 
absolutely conserved amino acid (Feyereisen, 2012). Highest conservation in the structure of P450s is 
found in the core of the protein around the heme and reflects a common mechanism of electron and 
proton transfer and oxygen activation. The conserved core is formed of a four-helix (D, E, I and L) 
bundle, helices J and K, two sets of β sheets, and a coil called the 'meander'. These regions comprise: 
motif WxxxR located in the C-helix and easily discernible in multiple alignments; the Arg is thought to 
form a charge pair with the propionate of the heme (Feyereisen, 2012); the heme-binding loop, 
containing the most characteristic P450 consensus sequence (Phe-X-X-Gly-X-Arg-X-Cys-X-Gly), located 
on the proximal face of the heme just before the L helix, with the absolutely conserved cysteine that 
serves as fifth ligand to the heme iron; the conserved Glu-X-X-Arg motif in helix K, also on the proximal 
side of heme and probably needed to stabilize the core structure through a set of salt bridge 
interactions (E–R–R) with the fourth conserved motif, PxxFxPE/DRF (often PERF, but R is sometimes 
replaced by H or N), which is located after the Kʹ helix in the “meander” facing the ExxR motif; and 
finally, the central part of the I helix, containing another consensus sequence considered as P450 
signature (Ala/Gly-Gly-X-Asp/Glu-Thr-Thr/Ser), which corresponds to the proton transfer groove on 
the distal side of the heme (Werck-Reichhart and Feyereisen, 2000). This final conserved motif 
surrounds a conserved threonine in the middle of the long helix I that runs on top of the plane of the 
heme, over pyrrole ring (Feyereisen, 2012). The description of the structure essentially follows the 
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nomenclature of the P450cam protein, the camphor hydroxylase of Pseudomonas putida (Poulos et 
al., 1985) and typical outline of structural arrangement is given in Figure 1.8. 
The most variable regions of P450s are associated with either amino-terminal anchoring or 
targeting of membrane-bound proteins, or substrate binding and recognition; the latter regions are 
located near the substrate-access channel and catalytic site and are often referred to as substrate-
recognition sites (SRSs) as described by Gotoh (Gotoh, 1992). SRSs are described as flexible, moving 
upon binding of substrate so as to favour the catalytic reaction. Other variations reflect differences in 
electron donors, reaction catalysed or membrane localization. Most eukaryotic P450s are associated 
with microsomal membranes, and very frequently have a cluster of prolines (Pro-Pro-X-Pro) that form 
a hinge, preceded by a cluster of basic residues (the halt-transfer signal) between the hydrophobic 
amino-terminal membrane anchoring segment and the globular part of the protein (Werck-Reichhart 
and Feyereisen, 2000). The hinge slaps the globular domain of the P450s onto membrane surface and 
is important for heme incorporation and assembly. Additional membrane interaction seems to be 
mediated essentially by a region, located between the F and G helices that shows increased 
hydrophobicity (Williams et al., 2000). This region is thought to create a hydrophobic environment 
through which substrate can enter the active site.  
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1.6.3 Insects Cytochrome P450s 
The first insect P450s cloned and sequenced were CYP6A1 from Musca domestica (Feyereisen 
et al., 1989). Since then progress has been made in identification of insect P450s especially boosted 
with the successful sequencing of insect genomes including those of the fruit fly D. melanogaster and 
An. gambiae (Feyereisen, 2006, Claudianos et al., 2006, Feyereisen, 2012).  Insect genome sequencing 
projects, starting with that of D. melanogaster in 2000, finally revealed the cast of P450 characters in 
insects (Tijet et al., 2001, Feyereisen, 2012). The cytochrome P450 complement size of an insect 
genome is not a definite number (Feyereisen, 2011); insects can survive with small genomic P450 
complement even in toxic environments and larger number of P450s does not necessarily mean ability 
Figure 1.8: (A) Primary structures of P450 proteins. (a) Typical features of an ER-bound P450 
protein (class II enzyme), (b) Variants of this canonical structure most commonly found: 1, soluble class 
I, 2, mitochondrial class I; 3, membrane-bound or plastidial class III: (B) A ribbon representation of 
the distal face of the folded CYP2C5 showing its putative association with the ER membrane 
(purple), helices and sheets. Heme is in orange and the substrate in yellow. Adapted from 
(Feyereisen, 2012). 
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to resist insecticides. However, insects do have large number of P450s due possibly to one of these 
two reasons (Scott, 2008): (i) detoxification of the numerous environmental and dietary toxins which 
constitutes the primary selective force for presence of P450s in each specie and maintenance of its 
diversity between species; (ii) or alternatively,  the majority of P450s in insect are not involved in 
detoxification of xenobiotics, but rather in the metabolism of other compounds. 
Insect CYP genes fall into four major clans (Feyereisen, 2006), named after the founding family 
in vertebrates (CYP3, CYP4, CYP2 clans) or their subcellular location (mitochondrial CYP clan) 
(Feyereisen, 2012). This classification is given in brief in Table 1.2. Though insect P450s are distributed 
across 48 major CYP families (Amenya et al., 2008) majority of the P450 genes implicated in resistance 
to insecticides are from three main families: CYP4, 6 and 9 (Feyereisen et al., 1989). Insect 
monooxygenases can be detected in a wide range of tissues. Highest activities are usually associated 
with the midgut, fat bodies and Malpighian tubules (Hodgson, 1983) but the expression of individual  
P450s can vary between these tissues (Scott et al., 1998a). Also, dramatic variation in monooxygenase 
activities and P450 levels occur during the development of most insects (Scott, 2008). In general, total 
P450 levels are undetectable in eggs, rise and fall in each larval instar, are undetectable in pupae and 
are expressed at high levels in adults. 
Table 1.2 Four clans of CYP genes in insects, with CYP family numbers. Numbers as in 2010. Adapted 
from (Feyereisen, 2012).  
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1.6.4 Genomic Variation of Insects P450s 
1.6.4.1  Allelic Variants, Copy Number Variation and Alternative Splicing 
Allelic variants of cloned P450 cDNAs and genes are very frequent and were described in the 
earliest studies of insect P450 (Cohen et al., 1994). Examples of this variation were most striking in An. 
gambiae genome found to be  highly polymorphic, with a single nucleotide polymorphism (SNP) 
frequency of 1 every 26bp in CYP genes (Wilding et al., 2009) and An. funestus in which, on average 7 
SNPs per kilobase were observed in DNA fragments from 50 genes (Wondji et al., 2007a). In An. 
funestus CYP gene duplications have been reported in mosquitoes (Wondji et al., 2009, Irving et al., 
2012). Using positional cloning technique, Wondji and colleagues have established that the An. 
funestus CYP6P9 is duplicated into CYP6P9a and CYP6P9b while CYP6M1 is triplicated into CYP6M1a, 
CYP6M1b and CYP6M1c.   
Allelic variants of P450s were also described for P. polyxenes (Wen et al., 2006). Of the two 
paralogous genes CYP6B1 and CYP6B3, the former has three variants (CYP6B1v1, CYP6B1v2 and 
CYP6B1v3) which differ significantly in their linear and angular-furanocoumarin metabolising 
properties compared to the two variants from the CYP6B3. 
There is little evidence for alternative splicing of insect P450 transcripts as additional means of 
generating diversity (Feyereisen, 2012). But, a typical example is the Cyp4d1 gene from D. 
melanogaster which utilizes two alternate first exons, and expressed sequence tags (ESTs) for each 
transcript. The first cDNA cloned   (Gandhi et al., 1992) uses a proximal first exon and corresponds to 
transcript Cyp4d1-PA, whereas several ESTs of transcript Cyp4d1-PB use a more distal first exon 
instead.  
1.6.5 Mechanism of Action of CYP450s 
CYP450s occupy central position in biological system for their ability to activate inert C-H 
bonds (Shaik et al., 2005). The ability to catalyse regiospecific and stereospecific oxidative attack on 
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non-activated hydrocarbons at physiologic temperatures make these enzymes to be compared to a 
nature’s ‘blowtorch’ (Werck-Reichhart and Feyereisen, 2000). As a nanomachine P450 uses dioxygen 
and two reducing equivalents to catalyse a variety of stereospecific and regioselective oxygen 
insertion into diverse organic compounds (Shaik et al., 2005, De Montellano, 2005). There are some 
structural features that are common to all P450 isoforms. The active species of the enzyme is an iron 
ion ligated to a protoporphyrin IX macrocycle and two additional axial ligands: one, called proximal, is 
a thiolate from a cysteinate side residue of the protein, and the other, called distal, is a variable ligand 
which changes during the catalytic cycle of the enzyme and thereby activates the enzyme’s main 
function (Shaik et al., 2005).  
The oxidized P450 is a mixture of a low spin (FeIII) form with water as the sixth coordinated 
ligand on the opposite side of the Cys thiolate ligand and a high spin (FeII) pentacoordinated form 
(Feyereisen, 2012). P450 cylce has a multi-step and cyclical nature comparable to a ticking clock 
(Munro et al., 2013). In a resting state (Figure 1.9, 12 o’clock) the ferric form has distal water ligand. 
Substrate binding displaces water from the sixth liganding position, leading to a shift to high spin 
(1:00h-1:30h). This shift can be observed at 390-435nm (Type I spectrum) and is accompanied by a 
decrease in the redox potential of P450. The P450–substrate complex receives a first electron from a 
redox partner (P450 reductase or adrenodoxin at 2:00h), and the ferrous P450 (FeII) then binds O2 
(3:30h) to form ferric superoxo intermediate (4:30h). At this step carbonmonoxide can compete with 
O2 for binding to P450; its binding leads to a stable complex, with an absorption maximum at 450nm 
which is catalytically inactive. The P450–O2–substrate complex then accepts a second electron (from 
P450 reductase or in some cases cytochrome b5, or from adrenodoxin) to form a ferric peroxide anion 
(6:00h). This second reduction is believed to be, though not always, the rate-determining step in the 
catalytic cycle (Shaik et al., 2005). 
After consecutive protonation, a ferric hydroperoxo complex (the so-called Compound 0 
specie, 7:30h) then leads to the activated oxygen form(s) of the enzyme (Feyereisen, 2012). 
Compound 0 is a good Lewis base and can abstract an additional proton to generate Compound I 
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(Shaik et al., 2005). This intermediate (Compound I, 9:00h) is an iron (IV) oxo species with a delocalized 
oxidizing equivalent. Hydroxylation of an un-activated C–H bond therefore follows a “rebound” 
mechanism, where hydrogen is abstracted from the substrate forming an iron (IV) hydroxide that then 
recombines quickly with the substrate radical (Feyereisen, 2012). This species then transfers an 
oxygen atom to the substrate; in this case the alkane is converted thereby to an alcohol (11:00h). After 
this catalytic reaction the alcohol exits the pocket, water molecules enters and the enzyme is restored 
to the resting state by binding a water molecule (12 o’clock).  
 
 
 
 
 
 
The efficiency of the catalytic cycle is dominated by a few key factors (Shaik et al., 2005). First 
is the donor ability of the thiolate ligand, which is referred to as the “push” effect (Dawson et al., 
1976), and which seems to be crucial for the operation of the catalytic cycle. Second is the protonation 
and hydrogen-bonding machinery of the distal side that converts Cpd 0 into Cpd I and prevents the 
Figure 1.9: The P450 catalytic cycle clock and peroxide shunt pathway. The peroxide shunt 
pathway is depicted by the clock hands and uses H2O2 or related oxygen donors to directly generate 
compound 0 (7:30h) from the ferric substrate-bound form (1:30h). The oxygen rebound mechanism is in 
the base of the clock. This is an expansion of the highlighted portion between 9:00h (compound I) and 
11:00h (hydroxylated product formation and release), and shows hydrogen abstraction from the substrate 
by compound I to form compound II (central image), prior to rebound of the hydroxyl to the substrate 
radical to form the hydroxylated product. Adapted from (Munro et al., 2013). 
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generation of hydrogen peroxide and other oxygen wasting species (“uncoupling” processes that 
result in a loss of the reducing equivalents, NADH or NADPH) (Shaik et al., 2005). Third is the access of 
water molecules into the pocket, which needs to be well controlled. On one hand, water molecules 
seem to be important for protonation (Vidakovic et al., 1998), but on the other hand, too much of it 
leads to uncoupling (Raag et al., 1991). Finally, interaction of amino residues within the active site with 
the sulphur atom of the distal cysteinate ligand may enhance stability and activity (Shaik et al., 2005). 
1.6.6 Redox Partners of Cytochrome P450s 
The monooxygenation catalysed by P450s reaction requires a coupled and stepwise supply of 
electrons, which are derived from NAD(P)H and supplied via a redox partner (Paine et al., 2005). P450s 
can be divided into two major families (Class I and Class II) according to the different types of electron 
transfer systems they utilise (Figure 1.10). P450s in the Class I include bacterial and mitochondrial 
P450s, which use a two-component shuttle system consisting of an iron-sulfur protein (ferredoxin) and 
ferredoxin reductase. The Class II enzymes (microsomal P450s) receive electrons from a single 
membrane-bound enzyme, NADPH cytochrome P450 reductase (CPR), which contains FAD and FMN 
cofactors. Cytochrome b5 may also couple with some members of the Class II P450s family to enhance 
the rate of catalysis. Although P450 redox partners are usually expressed independently, "self-
sufficient" P450 systems have also evolved through the fusion of P450 and CPR genes. These fusion 
molecules are found in bacteria and fungi, e.g., the P450 BM3, a fatty acid ω-2 hydroxylase from 
Bacillus megaterium, which comprises a soluble P450 with a fused carboxyl terminal CPR module.  
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1.6.6.1 NADPH Cytochrome P450 Oxidoreductase (CPR) 
P450 reductase (EC 1.6.2.4) belongs to a family of flavoproteins utilizing both FAD and FMN as 
cofactors (Feyereisen, 2012). The P450 diflavin reductases emerged from the ancestral fusion of a 
gene coding for a ferredoxin reductase with its NADP(H) and FAD binding domains, with a gene coding 
for a flavodoxin with its FMN domain. The insect P450 reductases sequenced to date are orthologous 
to the mammalian P450 reductases, with an overall amino acid sequence identity of 54% for the house 
fly P450 reductase, first cloned and sequenced in 1993 (Koener et al., 1993).  
Apart from plants, which contain multiple CPR genes (Benveniste et al., 1991) most organisms 
contain a single CPR gene (Urban et al., 1997). There is a single CPR gene in insect genomes, although 
Figure 1.10: Electron transfer partners of cytochrome P450. In Class I systems, electrons are 
shuttled from NAD(P)H through an FAD-containing ferredoxin reductase and an iron-sulfur 
containing ferredoxin to P450; in prokaryotes these are typified by putidoredoxin reductase (PdR) 
and putidoredoxin (Pdx), and in eukaryotes by mitochondrial membrane associated adrenodoxin 
reductase (AdR) and adrenodoxin (Adx). Class II systems are driven by electrons delivered from 
NADPH through diflavin (FMN- and FAD-containing) reductases. In eukaryotes these are bound to 
the endoplasmic reticulum, while fused systems such as P450 BM3 exist in bacteria and fungi. Novel 
systems now include P450RhF, which contains an FMN-containing reductase fused with a 
ferredoxin-like centre and a P450. Adapted from (De Montellano, 2005, Paine et al., 2005). 
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there are other diflavin reductases (Feyereisen, 2012). The housefly CPR gene codes for a protein of 
671 amino acids and mapped to chromosome III and is 82% identical to the D. melanogaster CPR 
(Hovemann et al., 1997) and 75% identical to the CPR from An. gambiae (Nikou et al., 2003), which in 
turn is 96% identical to An. funestus CPR.  
The insect, mammalian, and yeast enzymes are functionally interchangeable in reconstituted 
systems of the purified proteins or in heterologous expression systems (Feyereisen, 2012). CPR is 
responsible for transferring electrons to many naturally occurring electron acceptors, including P450 
enzymes and cytochrome b5 (Murataliev et al., 2004), as well as  other redox proteins including  
cytochrome c (Williams and Kamin, 1962), heme oxygenase (Schacter et al., 1972), etc.  
 The microsomal P450 monooxygenase complex is localized to the endoplasmic reticulum 
membrane. Like P450, CPR contains an N-terminal hydrophobic region that spans the lipid membrane 
and anchors it to the surface (Paine et al., 2005). On membrane surface it is thought that CPR lies in 
such an orientation so that both the FMN and FAD/NADPH domains lie close to the membrane 
surface, which would allow optimal communication between the FMN and the P450 heme (Wang et 
al., 1997). Transient monooxygenase complexes are formed on the membrane surface as a result of 
collisions between P450s and CPR as each moves within the endoplasmic reticulum membrane with 
the phospholipid component of the membrane affecting intermolecular interactions of the 
monooxygenase complex and influencing  substrate binding (Paine et al., 2005). Protein-protein 
interactions are also essential to enable electron transfer from the reduced FMN of the flavoprotein to 
the substrate-bound ferric form of the P450. Electrons are transferred from NADPH through the FAD 
and FMN coenzymes of CPR to the iron atom in the prosthetic heme group of the CYPs (Vermilion et 
al., 1981).  The enzymes of  diflavin reductases family have two tightly bound cofactors, FAD and FMN 
(Murataliev et al., 2004). These flavins participate in the transfer of the reducing equivalents from 
NADPH to the terminal electron acceptor (Figure 1.11). Two reducing equivalents are transferred from 
NADPH as a hydride ion, with FAD serving as the acceptor. Electrons are then transferred from FAD 
hydroquinone to the isoalloxazine ring of FMN, which in turn serves as a donor for one-electron 
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terminal acceptors. Diflavin reductases therefore serve to couple a two-electron donor (NADPH) with 
one-electron acceptors.  
 
 
 
 
 
 
Since P450 is present in a 10-25-fold molar excess over CPR in the liver microsome (Estabrook 
et al., 1971, Paine et al., 2005, Backes and Kelley, 2003) and CPR orchestrates the recognition and 
reduction of not only multiple P450 isoforms but cytochrome b5, cytochrome c and heme oxygenase 
as well (Kenaan et al., 2011), rapid association and dissociation of P450:CPR complexes is important 
for the system to work effectively (Paine et al., 2005). Several studies have found electrostatic 
interactions being the driving force behind the binding of P450 with CPR. Charge-pairing interactions 
between a small cluster of positively charged amino acid residues located on the surface of the side at 
which the prosthetic heme ligated to the P450 (proximal) and another cluster of negatively charged 
Figure 1.11: Domain architecture of microsomal P450 reductase. Top: Fusion of the 
genes of flavodoxin and ferredoxin reductase led to a flavoprotein containing both FAD and FMN 
cofactors bound to a single polypeptide chain. The N-terminal membrane anchor of P450 
reductase is shown in yellow. Bottom:  Domains of P450 reductase in the 3D structure. 
FAD/NADPH domain, green; FMN domain, blue; connecting domain, grey. Flavin cofactors are 
shown in yellow, NADP
+
 in red. Adapted from (Murataliev et al., 2004, Feyereisen, 2012). 
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amino acid residues located on the FMN domain of CPR is thought to drive the interaction between 
the P450s and CPR (Kenaan et al., 2011). A number of studies have established critical amino acid 
residues important for coupling of P450 with the CPR and transfer of electrons (Murataliev et al., 
2004, Im and Waskell, 2011, Kenaan et al., 2011, Feyereisen, 2012).  
1.6.6.2 Cytochrome b5 (b5) 
Originally called cytochrome m (for microsomes) (Strittmatter and Ball, 1954) cytochrome b5 
was shown very early to be present in microsomes (Schenkman and Jansson, 2003), to contain 
protoporphyrin IX, not to bind CO, and to possibly serve as an electron transfer link between NADH 
and cytochrome c (Strittmatter and Ball, 1952). Cytochrome b5 was originally discovered in cecropia 
silkworm larvae by Sanborn and Williams (Paine et al., 2005, Sanborn and Williams, 1950). b5  is a small 
polypeptide (~17kDa) containing 129-134 residues, which are divided into an amino-terminal 
hydrophilic heme domain and a carboxyl-terminal hydrophobic membrane-binding region (Paine et al., 
2005, Hlavica and Lewis, 2001, Mitoma and Ito, 1992). Like cytochromes P450 and CPR, b5 is an 
integral membrane protein located on the cytosolic side of the endoplasmic reticulum where it is 
principally involved in lipid biosynthesis (Figure 1.12). It functions along with another ubiquitous 
electron transport protein cytochrome b5 reductase (b5R) as the electron donor to microsomal 
desaturases that synthesize unsaturated fatty acids, plasmalogens, and sterols (Vergeres and Waskell, 
1995). b5R is responsible for transferring electrons from NADH to b5 in these reactions although 
NADPH can also be used as the electron donor in some cases (Gan et al., 2009); for b5 can also accept 
electrons from an alternative reductase, CPR (Guengerich, 2005). 
There is a single cytochrome b5 gene in insect genomes (Feyereisen, 2012). An. gambiae 
cytochrome b5 gene encodes 129 amino acids (Nikou et al., 2003) and its sequence is 58.1%, 53.5% 
and 94% identical with amino acid sequences of D. melanogaster (Kula et al., 1995), Musca 
domestica (Guzov et al., 1996) and An. funestus (Matambo et al., 2010) cytochrome b5. In the 
endoplasmic reticulum, P450 and  b5 are found in approximately equal amounts (Dürr et al., 2007). 
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 b5 is important for P450 catalysis. After binding oxygen, the oxyferrous protein of CYP2B4 
accepts a second electron which is provided by either CPR or b5. When the second electron is donated 
by b5 product formation is ∼10 to 100-fold faster (Im and Waskell, 2011) (Figure 1.13). Presence of  b5 
allows less time for side products formation (hydrogen peroxide and superoxide) and improves by 
∼15% the coupling of NADPH consumption to product formation. Cytochrome b5  thus acts as obligate 
electron donor (Schenkman and Jansson, 2003). 
However, depending on the P450 enzyme and on the reaction catalysed, b5 may be inhibitory, 
or without effect, or its presence may be obligatory (Feyereisen, 2012). Cytochrome b5 can have a 
quantitative effect on overall reaction rates, and/or a qualitative role on the type of reaction catalysed 
and the ratio of the reaction products. 
 
Figure 1.12: Topology and structure of b5. (A) Topology of full-length b5. (B) Structural elements of 
the soluble form of rabbit b5, as seen in the solution-state NMR structure determination 1DO9. Shown in 
red is the heme prosthetic group which is held in the cleft between two helix–turn–helix motifs. These 
are ‘tied together’ by a three-stranded β-sheet (green). The C-terminal residues (lower right) are 
disordered in this structure; in full-length b5 they form the link to the transmembrane anchor domain. 
Adapted from (Dürr et al., 2007). 
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The role of b5 may or may not depend on its electron transfer properties. It can influence the 
overall stoichiometry of the P450 reaction, in particular the “coupling rate” (the utilisation and fate of 
electrons from the NADPH). b5 has been shown to compete with the CPR for the binding site on the 
proximal face of CYP2B4 (Im and Waskell, 2011). In this respect, at low molar ratios (<1) of b5 to CPR, 
the more rapid catalysis results in enhanced substrate metabolism. In contrast, at high molar ratios 
(>1) of b5 to CPR, b5 inhibits activity by binding to the proximal surface of the P450s, preventing the 
reductase from reducing ferric cytochrome P450 to the ferrous protein effectively. 
  Cytochrome b5 can also have effector role in the cytochrome P450 monooxygenase reaction 
(Imai and Sato, 1977, Hlavica, 1984). The b5 binds and causes structural changes to human CYP3A4 
which impact upon the redox changes of the P450 (Schenkman and Jansson, 2003). In reconstituted 
system, in the presence of testosterone or nifedipine, input of the first electron from NADPH to the 
monooxygenase (ferric to ferrous state) and product formation were negligible in the absence of b5 
(Yamazaki et al., 1995). Also, apo-b5 was as effective as the holoprotein in supporting reduction of 
Figure 1.13: Catalytic cycle of P450s; role of CPR and b5. Adapted from (Im and Waskell, 2011). 
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CYP3A4 and product formation indicating that the role of b5 did not require it to undergo redox 
changes or to transfer an electron to the P450 (Yamazaki et al., 1996). Like CPR, it is generally 
accepted that charge-pair interactions drive the formation of P450:b5 complexes (Paine et al., 2005). 
Indeed, b5 and CPR were discovered to bind to the basic, positively-charged residues on the proximal 
surface of CYP2B4 on unique but overlapping sites (Im and Waskell, 2011).  
 
1.7  Molecular Basis of Monooxygenase-mediated Insecticide Resistance  
1.7.1 Introduction 
Metabolic resistance like moonoxygenase-mediated ones is more important than target-site 
insensitivity, for the detoxification has the potential to confer cross-resistance to toxins independent 
of their target sites (Scott, 1999, Dadd et al., 1985). Overexpression of a particular P450 is not 
necessarily an indicator of the involvement of same P450 in resistance. A typical P450 should only be 
considered to be involved in resistance if the following two criteria are met (Scott et al., 1998b): (1) 
the P450 must be shown to detoxify (or sequester) the compound to which the strain has resistance 
to, and (2) the resistant strain should have a greater amount of this P450, or the protein coded for by 
the resistant strain allele should be shown to have a greater catalytic activity (i.e. detoxification) 
compared to the protein coded for by the susceptible strain allele. In essence, there should be 
overexpression of the protein and increased detoxification of the insecticide (Liu and Scott, 1998) 
which can occur by cis- and trans- regulation of the transcription process. Thus, it is possible that 
insecticide resistance as a trait could map to a location in the genome that is different from the P450, 
which is involved in the detoxification (Scott, 1999). It is also noteworthy that the factor(s) responsible 
for trans- regulation of the P450(s) involved in resistance also appear capable of regulating the 
expression of other P450s that are not necessarily involved in resistance (at least in house flies). 
Knowing which subsets of P450s are elevated by the same regulatory factor(s) may help to understand 
cross-resistance patterns.  
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P450s operate in concert with redox partners, CPR and b5 and thus enhancement of 
metabolism can potentially be acquired via multiple pathways (Schuler and Berenbaum, 2013). Schuler 
and Berenbaum summarised different resistance mechanism that could function at the transcriptional 
level: (i) higher constitutive production of transcripts due primarily to mutations in promoter 
sequences, (ii) higher inducible expression of transcripts due primarily to mutations in trans-acting 
factors or their signalling cascades (iii) and/or greater responsiveness to transcriptional inducers in 
food sources and/or environment; at the protein level: (iv) mutations in catalytic site residues which 
affect the range or rate of substrate metabolism, (v) mutations in the substrate access channel 
residues that affect substrate entry, (vi) mutations in the proximal surface residues that affect electron 
transfer from CPR and/or b5, (vii) mutations in these interacting partners that affect coupling and 
electron delivery.  
1.7.2 Distribution of Insecticide Resistance in An. funestus across Africa 
To date, An. funestus has been shown resistant to major insecticides used in public health 
across Africa (Dia et al., 2013, Brown, 1986, Ranson et al., 2011, Coetzee and Koekemoer, 2013, 
Wondji et al., 2009, Wondji et al., 2012) (See Table 1.3 and Figure 1.14). However, pattern of 
resistance to insecticides differ across regions of Africa and this may have impact on insecticide 
resistance management strategies, because variation in the resistance pattern makes extrapolation 
from one locality to another, one region to another,or one country to another not feasible.  
1.7.2.1 Southern Africa:  
First report of pyrethroid resistance in An. funestus was in South Africa. After ~40 years of 
annual spray with DDT and eradication of An. funestus from South Africa, a switch to pyrethroid 
deltamethrin in Kwazulu/Natal (KZN) Province of South Africa in 1996 resulted in six-fold increase in 
malaria incidence by 1999 (Hargreaves et al., 2000). The surge in malaria incidence in KZN was due to 
a highly endophilic An. funestus, established to be resistant to pyrethroid insecticides. Thereafter, in 
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2001 Brooke (Brooke et al., 2001) reported high Type II pyrethroids and propoxur resistance in An. 
funestus from southern Mozambique, and in 2006 An. funestus highly resistant to Type II pyrethroids 
deltamethrin and ʎ-cyahalothrin were described from southern Mozambique (Casimiro et al., 2006). 
The population from Mozambique were also resistant to permethrin and marginally resistant to 
bendiocarb and propoxur, but fully susceptible to malathion and DDT.  
Since then rapidly growing resistance to pyrethroids insecticides (Coetzee et al., 2013) as well 
as multiple resistant populations of An. funestus have been continuously reported in southern Africa.  
For example, Cuamba and colleagues in 2010 reported highly pyrethroid resistant populations of An. 
funestus from Chokwe, Mozambique (Cuamba et al., 2010), a region from which pyrethroid 
susceptibility have been described by Casimiro (Casimiro et al., 2006). In Malawi, high and multiple 
resistance to pyrethroids permethrin and deltamethrin as well as carbamates bendiocarb and 
propoxur were reported in 2010 (Hunt et al., 2010) in An. funestus population that are in turn fully 
susceptible to malathion, fenitrothion, pirimiphos methyl, dieldrin and DDT. A contrasting pattern of 
resistance was observed in Zambian populations of An. funestus (Chanda et al., 2011) that were found 
to be pyrethroid and DDT-resistant but susceptible to malathion consistent with other southern 
African populations. The Zambian population were also susceptible to bendiocarb in contrast to the 
Malawian and Mozambican populations described above.  
The increase in pyrethroid resistance in An. funestus became finally selected: “pyrethroid 
resistance has been selected in Malawi over the last 3 years  in the two major malaria vectors An. 
gambiae and An. funestus, with a higher frequency of resistance in the latter” (Wondji et al., 2012). 
Wondji and colleagues found that An. funestus from the Chikwawa, Malawi are resistant to the 
carbamate, bendiocarb and three pyrethroids (permethrin, deltamethrin and λ-cyhalothrin) and 
susceptible to DDT and pirimiphos methyl. This pattern of pyrethroid resistance for permethrin and 
deltamethrin was further confirmed in An. funestus population from Malawi and Mozambique, with 
Mozambican population exhibiting higher resistance with no mortality recorded after 1h, 30 minutes 
exposure to discriminating dose of pyrethroids (Riveron et al., 2013). 
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Table 1.3 Mechanism of resistance in An. funestus to main insecticide used in public health 
Country Insecticides Resistance Mechanism Reference 
South Africa Pyrethroids, Type II N.D. (Hargreaves et al., 2000) 
Mozambique Pyrethroids, Type I and II, propoxur Mixed function oxidases (Brooke et al., 2001) 
Mozambique 
Pyrethroids, Type I and II, bendiocarb, 
propoxur 
Mixed function oxidases (Casimiro et al., 2006) 
Mozambique Pyrethroids, Type I and II P450 monoxygenases: CYP6P9a, CYP6P9b (Cuamba et al., 2010) 
Malawi 
Pyrethroids, Type I and II, bendiocarb, 
propoxur 
N.D. (Hunt et al., 2010) 
Zambia Pyrethroids, Type I and II, DDT N.D. (Chanda et al., 2011) 
Malawi Pyrethroids, Type I and II, bendiocarb P450 monoxygenases: CYP6P9a, CYP6P9b (Wondji et al., 2012) 
Uganda Pyrethroids, Type I and II, DDT P450 monoxygenases: CYP6P9a, CYP6P9b (Morgan et al., 2010) 
Kenya Pyrethroids, Type I and II, DDT Mixed function oxidases 
(McCann et al., 2014), 
(Kawada et al., 2011) 
Uganda Pyrethroids, Type I and II, DDT P450 monoxygenases: CYP6P9a, CYP6P9b (Mulamba et al., 2014b) 
Ghana Pyrethroids, Type I, DDT Mixed function oxidases (Okoye et al., 2008) 
Ghana Bendiocarb, DDT N.D. (Hunt et al., 2011) 
Burkina Faso Dieldrin Rdl mutation 
(Dabire et al., 2007), (Wondji 
et al., 2011) 
Benin 
Pyrethroids, Type I and II, DDT, 
bendiocarb 
P450 monoxygenases: CYP6P9a, 
CYP6P9b, CYP6Z1; GSTs: GSTδ1_5, GSTe2 
(Djouaka et al., 2011) 
Benin Pyrethroids, Type I, DDT GSTe2 (Riveron et al., 2014b) 
N.D. Resistance mechanism not determined.  
 
 
 
Figure 1.14: Insecticide resistance in An. funestus in Africa. Symbols indicate the 
presence of resistance in a country, and their position is not representative of actual 
geographical sites. Abbreviation: DDT, dichlorodiphenyltrichloroethane; DR Congo, 
Democratic Republic of the Congo. Adapted from (Coetzee and Koekemoer, 2013). 
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These and other studies not cited established that southern African An. funestus (from 
Malawi, Mozambique and Zambia) are resistant to pyrethroids and the resistance had been steeply 
increasing. While Malawian and Mozambican populations were resistant to carbamates bendiocarb 
and propoxur but susceptible to DDT, in contrast, Zambian population were resistant to DDT but 
susceptible to bendiocarb (Coetzee and Koekemoer, 2013). And all populations from these three 
countries were fully sensitive to organophosphate malathion and organochlorine dieldrin.  
1.7.2.2 East Africa 
Prior to 2010 there was no in-depth report on the resistance status of An. funestus to major 
insecticides used in public health in Uganda. In 2010, pyrethroid resistance was described in An. 
funestus from Uganda (Morgan et al., 2010). The population from Tororo was highly resistant to 
pyrethroids, marginally resistant to DDT, but fully susceptible to carbamate bendiocarb and 
organophosphates malathion and organochlorine dieldrin. Pyrethroids (permethrin and deltamethrin) 
and DDT resistance was reported as well in some populations of An. funestus from Masindi, north-
western Uganda (Mulamba et al., 2014a) confirming the observations of Morgan and colleagues. This 
pattern of resistance was confirmed as increasing across Uganda and in Kisumu, western Kenya.  
Widespread resistance to Type I and Type II pyrethroids and DDT was recently confirmed by Mulamba 
and colleagues (Mulamba et al., 2014b) in An. funestus from several localities across Uganda, as well 
as populations from Kisumu, Kenya. However, as observed in the previous studies full susceptibility to 
bendiocarb, malathion and dieldrin was reported in these Ugandan and Kenyan populations.   
After long term implementation of insecticide treated bed nets in western Kenya, An. funestus 
re-emerged as a major malarial vector in 2008 (McCann et al., 2014) with high infection rate and 
resistance to permethrin and deltamethrin, with mortalities lower than obtained with An. gambiae 
from the same locality.  
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1.7.2.3 West and Central Africa 
Reliable literature on resistance status of An. funestus from West and Central Africa is only 
published from studies carried out in Benin, Ghana, Burkina Faso and Cameroon (Coetzee and 
Koekemoer, 2013).  
In Ghana, in 2006 An. funestus and An. gambiae were described as the major vector species in 
Obuasi gold mine (Coetzee et al., 2006) with the An. funestus  from the study resistant to DDT and 
bendiocarb but susceptible to pyrethroids and malathion. A follow up study in this locality (Okoye et 
al., 2008) confirmed DDT resistance and discovered in addition resistance to permethrin. Further 
studies documented pyrethroid resistance in other regions of Ghana including Kassena-Nankana 
district (Anto et al., 2009) and four other localities were resistance to bendiocarb and DDT was 
discovered (Hunt et al., 2011). However, the populations tested from all localities by Hunt and 
colleagues were 100% susceptible to deltamethrin and malathion.  
In contrast, in Burkina Faso study carried out in three sites confirmed that An. funestus 
populations were resistant to dieldrin but susceptible to pyrethroids and DDT (Dabire et al., 2007). 
Few years later another study published a result in agreement with the previous observation. In An. 
funestus populations from Burkina Faso and Cameroon, Wondji and colleagues (Wondji et al., 2011) 
reported high dieldrin resistance while Southern (Malawi and Mozambique) and East African 
(Ugandan) populations were fully susceptible to this insecticide. However, within the last few decades 
few researches have been conducted in Burkina Faso, Cameroon and other neighbouring West African 
countries to establish resistance status of An. funestus populations toward pyrethroids and other 
insecticides used in public health.  
In 2011 multiple resistant populations of An. funestus were reported in Pahou, southern 
Benin, West Africa (Djouaka et al., 2011). In contrast with the findings in most southern African 
populations (susceptibility to DDT and high resistance to Type I and Type II pyrethroids), the 
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population from Benin were highly resistant to DDT with no mortality in females at all after one hour 
exposure. The population were also resistant to permethrin and deltamethrin (moderate), as well as 
bendiocarb. In line with the observations from Burkina Faso and Cameroon, the population from Benin 
exhibited moderate resistance to dieldrin as well. Full susceptibility to malathion was observed in line 
with the observation all across Africa. Further study in population of An. funestus from Kpome, Benin 
Republic and Gounougou, Cameroon confirmed that the populations from Kpome were highly 
resistant to DDT (just like in Pahou), and revealed moderate resistance to the organochlorine in the 
population from Gounougou, Cameroon (Riveron et al., 2014b).  
In essence, across Africa, insecticide resistance in An. funestus show contrasting pattern and is 
increasing (Nkya et al., 2013), possibly due to selection pressure from agricultural practices and 
escalated usage of insecticides used in public health related vector controls.  
1.7.3 Role of Cytochrome P450s in Insecticide Resistance in An. funestus 
To date no kdr mutation has been detected in An. funestus (Hemingway, 2014, Coetzee and 
Koekemoer, 2013); rather, metabolic resistance caused by increased activity of P450s appears to be 
the major resistance mechanism both in laboratory and field populations of An. funestus (Corbel and 
N’Guessan, 2013, Coetzee and Koekemoer, 2013). In the beginning synergist assays and biochemical 
analyses were used to identify involvement of P450 resistance mechanisms (see Table 1.3); however, 
within the last ten years molecular analyses are increasingly used for identification and confirmation 
of P450 involvement in resistance especially to pyrethroids, in addition to other mechanisms.  
In Southern Africa (Mozambique), synergist assays with piperonyl butoxide (PBO) and 
biochemical analysis suggested elevated levels of mixed function oxidases in An. funestus from 
Mozambique that are highly resistant to Type II pyrethroids and propoxur (Brooke et al., 2001). 
Thereafter, biochemical analysis revealed high levels of mixed function oxidases in multiple resistant 
populations of An. funestus from southern Mozambique (Casimiro et al., 2006). Since the population 
studied by Casimiro and colleagues were highly resistant to pyrethroids and marginally resistant to 
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bendiocarb and propoxur, monooxygenases were suspected to confer cross resistance to more than 
one class of insecticide. Further studies linked pyrethroid resistance to elevated levels of 
monooxygenases in Mozambique a year later (Casimiro et al., 2007).   
 Molecular tools were also applied to unveil the mechanism of pyrethroid resistance in An. 
funestus populations. Quantitative trait locus (QTL) mapping using resistant (FUMOZ-R) and pyrethroid 
susceptible (FANG)  strains identified three pyrethroid resistance locus on chromosomes 2R, 2L and 3L 
(Wondji et al., 2007b) with the major one named rp1 (resistance to permethrin 1) spanning a cluster of 
CYP6 genes. The rp1 locus explained the bulk of pyrethroid resistance phenotype in FUMOZ-R An. 
funestus (Wondji et al., 2007a, Amenya et al., 2008). In 2009, Wondji and colleagues reported that the 
rp1 QTL compose of 14 proteins coding genes of which 10 are P450s from CYP6 family and four of 
these genes (CYP6P9, CYP6P4, CYP6AA4 and CYP6P1) are overexpressed in pyrethroid resistant An. 
funestus in comparison with the fully susceptible laboratory strain, FANG (Wondji et al., 2009). These 
findings suggested that P450 genes and their duplication could contribute to pyrethroid resistance in 
An. funestus adding another twist to the already complex pyrethroid resistance pattern in An. 
funestus. Another positional cloning approach was used by Wondji and colleagues (Irving et al., 2012) 
to identify genes conferring resistance in the uncharacterised rp2 (resistance to pyrethroids 2) QTL in 
An. funestus. Apart from high number of SNP and triplication of CYP6M1 observed in the rp2 locus, 
gene expression profiling and validation indicated significant overexpression in the resistant FUMOZ-R 
strain of P450s CYP6Z1, CYP6Z3 and CYP6M7.  
Using An. gambiae ‘detox chip’ Christian and colleagues (Christian et al., 2011) investigated 
the genes up-regulated in male and female pyrethroid resistant An. funestus from southern Africa 
(Mozambique) and discovered three genes CYP6P9,  cytochrome oxidase I (COI) and CYP6M7 as 
significantly, differentially overexpressed compared with FANG. This confirmed the observations made 
by Wondji and colleagues.  
Meanwhile in 2010 Cuamba and colleagues reported involvement of CYP6P9a and CYP6P9b in 
resistance in a highly pyrethroid resistant populations of An. funestus from Chokwe, Mozambique 
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(Cuamba et al., 2010). Transcription profiling revealed CYP6P9a and CYP6P9b as overexpressed 
compared with the susceptible laboratory colony KELA from Mali. The same year in Uganda (East 
Africa) biochemical and transcriptional analysis of the Tororo Anophele funestus revealed the P450 
CYP6P9b 12 times overexpressed compared with the FANG (Morgan et al., 2010). The Tororo 
population studied were highly resistant to pyrethroids but fully susceptible to carbamate bendiocarb 
and malathion and dieldrin. Still in Uganda, recently (Mulamba et al., 2014b) synergist assays and 
transcriptional analysis implicated metabolic resistance through elevated P450 monooxygenases in 
play, with CYP6P9a and CYP6P9b overexpressed in An. funestus resistant to Type I and Type II 
pyrethroids as well as DDT, compared with the FANG. In neighbouring Kenya (Kawada et al., 2011) 
widespread pyrethroid resistance was also reported in An. funestus with the involvement of metabolic 
resistance suspected from synergy assay with PBO.  
In West Africa biochemical and transcriptional analysis of An. funestus from Benin (Djouaka et 
al., 2011) implicated CYP6P9a, CYP6P9b as well as CYP6Z1 from resistant individuals as overexpressed 
compared with the laboratory susceptible strain, FANG. The CYP6P9a and CYP6P9b were found to be 
overexpressed in pyrethroid and DDT resistant mosquitoes compared with FANG, but with lesser 
overexpression compared with resistant populations from Southern Africa.  
In 2012, Wondji and colleagues (Wondji et al., 2012) reported multiple resistance to 
pyrethroids and bendiocarb in An. funestus from Malawi and described the pyrethroid resistance in 
Malawi and Mozambique as metabolically-based. Biochemical assays in these resistant mosquitoes 
revealed that the pyrethroid resistance was metabolically-based and together with the transcription 
analysis implicated CYP6P9a and CYP6P9b overexpressed, as the major pyrethroid resistance genes in 
An. funestus from Southern Africa.  
Further studies using genome-wide transcription analysis (microarrays) established consistent 
overexpression of duplicated P450s CYP6P9a and CYP6P9b in southern African (Malawi and 
Mozambique) populations of An. funestus compared with FANG (Riveron et al., 2013). The 
involvement of these P450s in pyrethroid resistance was validated via in vitro and in vivo functional 
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characterisation (Riveron et al., 2013, Riveron et al., 2014a). Analysis of sequences of CYP6P9a and 
CYP6P9b cDNA sequences Malawi and Mozambique revealed that the southern African alleles 
possessed significantly lower polymorphisms with reduced nucleotides substitutions compared with 
sequences from FANG which are highly polymorphic. Haplotypes from the southern African alleles 
formed clade together excluding sequences from FANG. The resistant alleles from southern Africa 
were described as undergoing directional selection with beneficial mutations selected and as such 
Malawi and Mozambique sequences of CYP6P9a and CYP6P9b share a group of intra-allelic amino acid 
substitutions in common which makes them different from FANG. Thus, in addition to overexpression 
and duplication, allelic variations in the coding regions of these major pyrethroid resistance genes 
could also impact on pattern of resistance in An. funestus populations from Africa.   
Even though DDT and carbamate resistance observed across Africa is suspected to be 
monooxygenase mediated, in An. Funestus, to date, no single P450 has been characterised and 
validated as responsible for the resistance to either of these insecticides. For carbamate resistance 
PBO synergist assays have been used to show the potential role of monoxygenase, and for DDT 
resistance as well,  no P450 has been confirmed as responsible for it, though CYP6P9a, CYP6P9b and  
CYP6Z1 has been shown to be overexpressed in Benin populations that are resistant to DDT, 
carbamates as well as pyrethroids (Djouaka et al., 2011).   
1.8  Hypothesis 
The duplicated P450s CYP6P9a and CYP6P9b are overexpressed in resistant strains of An. funestus 
across Africa compared to the corresponding genes from the insecticide-susceptible strain, FANG. The 
two genes from southern African populations of An. funestus exhibited extensive allelic polymorphism 
in their coding regions compared with the FANG. The significant polymorphism patterns observed 
suggests that allelic variation in both genes could be one of the main mechanisms conferring 
resistance in these populations. Our hypothesis is that such allelic variations, in addition to 
overexpression is one of the main factors driving pyrethroid resistance. Specifically, variation in the 
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amino acid sequences in the coding regions of these genes may confer higher pyrethroids 
metabolizing efficiency. A handful of candidate P450s from the other well characterised QTLs, were 
also suspected to be able to metabolise pyrethroids and possibly confer cross-resistance to other 
classes of insecticides, especially DDT and bendiocarb. These include CYP6M7 from rp2 QTL in the light 
of its being overexpressed in multiple resistant An. funestus s.s. from southern Africa and CYP6Z1 
overexpressed in southern and West African populations. Other genes commonly overexpressed in 
southern African populations that are resistant to pyrethroids, carbamate and organochlorine 
insecticides include CYP9J11 from rp3 and CYP6AA4 from the rp1 QTLs. The potential role of these 
genes in pyrethroid metabolism and cross resistance to other insecticides used in public health will be 
elucidated in this study. 
1.9  Aim and Objectives  
 The main aim of this study is to elucidate the molecular mechanisms through which P450 
genes confer pyrethroid resistance or cross resistance to other insecticides, in the major malaria 
vector An. funestus s.s., using  functional characterisation approaches. 
More specifically, the objectives of this study were: 
 (i) to investigate the impact of allelic variation in two genes (CYP6P9a and CYP6P9b) on pattern of 
pyrethroid resistance in An. funestus through polymorphism survey and in silico prediction of activity;  
(ii) to assess the metabolic efficiency of the alleles of CYP6P9a and CYP6P9b using heterologous 
expression and functional characterisation in order to find out if allelic variation is impacting their 
metabolic activities; (iii) to detect causative mutation(s) linked with pyrethroid resistance, with the 
aim to design a DNA-based diagnostic tools that will allow detection of the mutation(s) in the field 
population of An. funestus, and (iv) to identify candidate cross-resistance detoxification genes that can 
metabolize Type I and Type II pyrethroids as well as other non-pyrethroid insecticides, for example 
carbamates (bendiocarb and propoxur) and organochlorine (DDT).   
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2. POLYMORPHISM SURVEY AND PREDICTION OF IMPACT BY MODELLING 
AND DOCKING SIMULATIONS 
2.1 Background 
 
With the kdr type mutation in the VGSC not yet selected in An. funestus s.s. (Amenya et al., 2008, 
Hemingway, 2014), resistance to pyrethroids is mainly metabolic and mediated by detoxification 
enzymes-P450 monoxoygenases (Coetzee and Koekemoer, 2013, Wondji et al., 2012). QTL mapping  
(Wondji et al., 2007b) identified a major pyrethroid resistance locus on chromosome arm 2R which 
coincides with cluster of CYP6 genes (Amenya et al., 2008). This rp1 QTL which explained 87% of 
genetic variance in pyrethroid susceptibility in two families from reciprocal crosses between 
susceptible and resistant strains (Wondji et al., 2009), encoded 14 protein coding genes, 10 of which 
are cytochrome P450s. Two of these P450s CYP6P9 and CYP6P4, which were found to be 25 and 51 
times overexpressed in resistant females An. funestus s.s., were also found to be tandemly duplicated 
in the BAC clone as  well as laboratory and field samples, suggesting that this P450 duplication could 
contribute to pyrethroid resistance. Since then, the duplicated CYP6P9 (CYP6P9a and CYP6P9b) were 
found to be highly overexpressed in resistant populations of An. funestus s.s. compared with the fully 
insecticide susceptible population (FANG), in southern Africa: including Mozambique (Cuamba et al., 
2010, Christian et al., 2011, Riveron et al., 2013);  Malawi (Wondji et al., 2012, Riveron et al., 2013)  
and Zambia (Riveron et al., 2014a). The genes were also found to be overexpressed in resistant 
populations of An. funestus s.s. from Benin, West Africa (Djouaka et al., 2011) and Uganda, East Africa 
(Morgan et al., 2010), compared with FANG, though with lower fold change. Overexpression of 
CYP6P9a and CYP6P9b was described as the major mechanism driving pyrethroid resistance in 
southern Africa (Riveron et al., 2013). The two genes from resistance strains were discovered to be 
undergoing  directional selection in the southern African population of An. funestus s.s. (Riveron et al., 
2013, Wondji et al., 2012) and exhibited extensive allelic polymorphisms (Riveron et al., 2013). The 
copy number variation in the coding regions of CYP6P9a and CYP6P9b could be impacting metabolic 
activity of the genes toward pyrethroid insecticides, augmenting resistance. Pyrethroid resistance 
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profiles in An. funestus s.s. varied across African continent (Cuamba et al., 2010, Djouaka et al., 2011, 
Riveron et al., 2013, Morgan et al., 2010) and it possibly mirrors the polymorphism variation in the 
major resistance genes CYP6P9a and CYP6P9b. 
 In silico homology modelling and docking simulations could be utilised to predict the potential 
impact of such polymorphisms in the activity of these P450s. This is because three-dimensional (3D) 
structure prediction using modelling and molecular docking of ligand insecticides into the active site of 
the models can help elucidate potential  binding sites (Zhou and Johnson, 1999) and predict substrate 
specificity (De Rienzo et al., 2000), as well as key amino acid residues within contact distance of the 
substrate. Narrowing down the potential amino acid replacements that could impact on pyrethroid 
activity can help tailor the next set of experiments (e.g. functional characterisation and site-directed 
mutagenesis) to be done for fast validation and facilitate design of proper diagnostic tools that could 
allow for the detection of such mutations in the field. In terms of structure-activity relationship 
predictions modelling and docking simulations have been applied to predict interaction of pyrethroid 
insecticides with the insect P450s, including An. gambiae CYP6M2 (Stevenson et al., 2011), An. 
minimus CYP6AA3, CYP6AA7 and CYP6AA8  (Lertkiatmongkol et al., 2011), as well as Ae. aegypti  
CYP6Z8 (Chandor-Proust et al., 2013).  
2.2 Objectives 
 
This chapter aims at describing sequence characterisation of CYP6P9a and CYP6P9b and to map 
across Africa the polymorphisms and mutations that make the CYP6P9a and CYP6P9b genes from 
resistant and susceptible strain of An. funestus different. It also aims at predicting the potential impact 
of such polymorphism in the ability of these genes to confer pyrethroid resistance using homology 
models of these genes, molecular docking simulations and prediction of substrate access/products 
egress channels.   
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2.3 Methods 
2.3.1 Mosquito Strains 
 
Mosquito strains from different regions of Africa with different resistance profiles and the fully 
susceptible, laboratory strain, FANG (An. funestus from Angola) were used in this study. The FANG 
strain originated from Calueque, southern Angola: 16˚45ʹS, 15˚7ʹE and had been colonised in 
laboratory since 2002 (Hunt et al., 2005, Wondji et al., 2005). The field strains were collected from 
Pahou (6˚23ʹN, 2˚13ʹE), southern Benin Republic (Djouaka et al., 2011), Tororo district (0˚45ʹN, 34˚5ʹE), 
eastern Uganda (Morgan et al., 2010), Tihuquine, Chokwe district (24˚33ʹS, 33˚01ʹE), in southern 
Mozambique (Cuamba et al., 2010), Chikwawa (12˚19ʹS, 34˚01ʹE), Malawi (Wondji et al., 2012) and 
Katete (14˚11ʹS, 31˚52ʹE), Zambia (Riveron et al., 2014a). Details of resistance profile of these 
mosquitoes and transcriptional analysis of CYP6P9a and CYP6P9b alleles were already established in 
the studies cited above. The field populations from southern Africa were resistant to pyrethroids and 
carbamate insecticides, while those from East Africa were pyrethroid- and DDT-resistant, but 
susceptible to carbamates. West African populations were resistant to pyrethroids and carbamates 
and highly resistant to DDT, several magnitude compared with the levels observed in East Africa. 
Levels of pyrethroids resistance has been consistently higher in southern African populations of An. 
funestus compared to populations from other regions of Africa, with the highest resistance observed 
in populations from Mozambique (no mortality observed up to 1.5 hours). The variations in resistance 
profile could be due to differences in the underlying mechanisms or the same type of resistance 
mechanisms subtly changed; for example, polymorphism in the alleles of CYP6P9a and CYP6P9b could 
be impacting the pyrethroid resistance. Also, other candidate P450 genes, GSTs and carboxylesterases 
could independently or in concert with CYP6P9a and CYP6P9b be responsible for this widespread 
resistance to the three major classes of insecticides used in public health. No resistance to 
organophosphorus malathion was observed in all the field populations of An. funestus across Africa 
consistent with the reported absence of Gly119Ser mutations in the acetylcholinesterase gene.      
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2.3.2 Amplification of full length CYP6P9a and CYP6P9b Alleles 
2.3.2.1 RNA Extraction 
 
All mosquitoes used for RNA extraction were previously confirmed to be An. funestus s.s. using 
cocktail PCR (Koekemoer et al., 2002). Total RNA was extracted from pools of 10 females from 
resistant populations, as well as from FANG using the PicoPure RNA Extraction Kit from Arcturus (Life 
Technologies, CA, USA) according to manufacturer’s protocol. RNA was extracted using Extraction 
Buffer (XB) and Conditioning Buffer (CB); isolated using 70% methanol, Wash Buffers W1 and W2 and 
eluted using Elution Buffer (EB). To enhance quality, RNA was DNase-treated following washing with 
W1. Quantity and quality of isolated RNA were determined with NanoDrop ND1000 Spectrophoto- 
meter (Thermo Fisher) and Agilent 2100 Bioanalyzer.  
2.3.2.2 cDNA Synthesis (RT-PCR) 
 
1µg of total RNA from resistant and susceptible (FANG) mosquitoes was used as a template for 
cDNA synthesis using the SuperScript® III First Strand Synthesis Kit (Invitrogen) according to the 
manufacturer’s instructions. 13µl reaction mix consisting of 1µl (1µg) RNA diluted in 8µl DEPC-treated 
water, 1µl of Oligo(dT)20 (50mM), 3µl DEPC-treated water and 1µl of 10mM dNTP mix was initially 
incubated for 5 mins at 650C. 4µl of 5X first strand buffer, 1µl of 0.1M DTT, 1µl of RNase Out (40U/µl) 
and 1.5µl of SuperScript® III Reverse Transcriptase (200U/µl) was added to make the total volume to 
20.5µl. The mix was then incubated at 250C for 5 mins, and then 500C for 60 mins, followed by 700C for 
15 mins. 1µl of E. coli RNase H was added to the newly synthesized cDNA and incubated at 370C for 20 
mins to remove residual RNA. Quantity and quality of the DNA was finally assessed using NanoDrop 
ND1000 Spectrophotometer (Thermo Fisher).  
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2.3.2.3 Cloning and Sequencing of An. funestus CYP6P9a and CYP6P9b full-length from cDNA 
 
(i) Amplification of CYP6P9a and CYP6P9b alleles 
The full length coding sequences of CYP6P9a and CYP6P9b alleles were amplified from cDNA 
sets from Benin, Uganda, Malawi, Mozambique, Zambia, and the FANG, using the primers listed in 
Table 2.1. To 14µl PCR mix made up of 3µl 5X Phusion HF Buffer (with 1.5mM MgCl2 in final reaction), 
0.12µl dNTP mix (85.7µM), 0.51µl each of forward and reverse primers (0.34µM), 0.15µl (0.015U) of 
Phusion High-Fidelity DNA Polymerase (Fermentas) and 10.71µl of dH20, 1µl cDNA was added. 
Amplification was carried out using the following conditions: one cycle at 95°C for 5 mins; 35 cycles of 
94°C for 20s (denaturation), 57°C for 30s (annealing), and extension at 72°C for 90s; and one cycle at 
72°C for 5mins (final elongation). 3µl PCR products were separated on 1.5% agarose gel stained with 
ethidium bromide (0.5μg/μl) and visualised using transilluminator to confirm products size.  
Table 2.1: Primers used for gene amplification and plasmid sequencing 
Primer Forward Sequence Reverse Sequence 
 Size 
(bp) 
CYP6P9a_Full ATGGAGCTCATTAACGTGGTGTTGGC TCA CAA TTT TTC CAC CTT CAA GTA 
ATT ACC CGC 
1527 
CYP6P9b_Full ATGGAGCTCATTAACGTGGTGTTGGC TTA CAC CTT TTC TAC CTT CAA GTA 
ATT ACC CGC 
1527 
pJET1.2 CGACTCACTATAGGGAGAGCGGC AAGAACATCGATTTTCCATGGCAG ~1727 
pJET725 CCGAAAAGTGCCACCTGAACGTCTAA TCCTGTCTCAGTTTCCTGAAGCTTGCTC ~2277 
 
(ii) Purification of PCR Product Ligation into pJET1.2 Blunt Vector 
  PCR products were cleaned individually with QIAquick® PCR Purification Kit (Qiagen) 
according to the manufacturer's instructions and cloned into pJET1.2/blunt cloning vector using the 
CloneJET PCR Cloning Kit (Fermentas) as described in Table 2.2.   
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Table 2.2: pJET1.2/Blunt ligation protocol 
Component 
Volume (µl) = 10 
Blunting Reaction 
2X Reaction Buffer 5 
Purified PCR Product  3.5 
DNA Blunting Enzyme 0.5 
Vortex briefly and microfuge for 5 seconds - 
Incubate blunting mix at 70°C for 5 mins  - 
Chill on ice - 
Ligation Reaction  
pJET1.2/Blunt Cloning Vector (50ng/ µl) 0.5 
T4 DNA Ligase 0.5 
Vortex briefly and microfuge for 5 seconds  - 
Incubate mix at 22°C for 30 mins  - 
 
(iii) Transformation and small-scale plasmids isolation 
4µl (~5-10ng) of ligation product was added to 40µl Subcloning EfficiencyTM DH5α Competent 
Cell (Invitrogen), chilled in sterile 1.5ml microcentrifuge tube. Reaction was mixed by gently flicking 
the bottom of the tube and left on ice for 30 mins. The cells were shocked for 45s at 42°C and then 
chilled immediately on ice for 2 mins. 950µl of pre-warmed S.O.C. medium was added and the tubes 
incubated at 37°C and 200 rpm for 1 hour. 50-100µl of transformants were spread onto LB plates 
containing 100mg/ml ampicillin and allowed to grow overnight at 37°C. Colonies were suspended 
separately in 20µl dH20 and screened for presence of the gene in a PCR reaction using Kappa Taq DNA 
Polymerase (KAPABIOSYSTEMS) and the pJET1.2 primers listed in Table 2.1. 1.5µl of 10X Taq Buffer A, 
0.75µl of MgCl2 (25mM), 0.12µl of dNTP mix (10mM), 0.4µl each of forward and reverse primers, 
0.12µl of 5U/µl KAPA Taq DNA Polymerase and 10.71µl dH20 were mixed in total volume of 14µl, to 
which 1µl of colony was added. PCR was conducted using the following conditions: one cycle of 95°C 
for 3 mins; 25 cycles each of initial denaturation (94°C for 30 seconds), annealing (57-60°C for 30 
seconds) and extension (72°C for 90 seconds); one cycle of final extension for 90 seconds at 72°C. PCR 
product was run on 1.5% agarose gel stained with ethidium bromide to confirm products size.  
4µl of positive colonies were grown (miniprep) at 37°C for 16 hours in a 6ml LB medium 
containing 3µl ampicillin (100mg/ml), with shaking at 200 rpm. Plasmids were isolated using the 
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QIAprep® Spin Miniprep Kit (QIAGEN) according to the manufacturer’s protocol. Quantity and quality 
of plasmid DNA was determined using NanoDrop ND1000 Spectrophotometer (Thermo Fisher).  
The isolated plasmids were sequenced on both strands using the pJET725 primers (Table 2.1).  
2.3.3 Sequence Analysis and Mapping of Polymorphisms 
 
Analysis of sequences was conducted by detection of polymorphic positions through manual 
examination of sequence traces using BioEdit version 7.2.3.0 (Hall, 1999) and nucleotides differences 
in multiple alignments using CLC Sequence Viewer 6.8 (http://www.clcbio.com/).  
DnaSP 5.10.01 (Librado and Rozas, 2009) was used to analyse intra-allelic genetic variation such as 
nucleotides and haplotypes diversity. Phylogenetic neighbour-joining trees of all haplotypes of 
CYP6P9a and CYP6P9b alleles were constructed using MEGA 6.0 (Tamura et al., 2013).  After sequence 
analyses, the predominant haplotype of each gene from each country was selected for further 
analysis. Amino acids sequences were generated in silico using the CLC Sequence Viewer nucleotides 
analysis module and used for further analyses and identification of mutations.   
2.3.4 Modelling of CYP6P9a and CYP6P9b alleles by Satisfaction of Spatial Restraints  
 
Homology modelling (HMM) is simply a computational approach for 3D prediction of protein 
structure. It involves construction of an atomic-resolution model of the "target" protein (query) from 
its amino acid sequence using experimental, 3D structure of a related homologous protein ("template" 
also referred to as a reference). The profound success of HMM is because the 3D structure of proteins 
from the same family is more conserved than their primary sequences (Lesk and Chothia, 1980) and 
proteins that share low sequence similarity often possess similar structures (Fiser and Sali, 2003).  
(i) Template Selection 
The program BLASTp (Altschul et al., 1990) from NCBI (http://blast.ncbi.nlm.nih.gov/Blast.cgi) 
was used to search for the best template structure available in the protein data bank (PDB) database 
(Berman et al., 2002). A pairwise sequence alignment with the query protein sequences of CYP6P9a 
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and CYP6P9b recovered as top hit a crystal structure of human microsomal 450 CYP3A4 (PDB:1TQN), 
with sequence similarities of 33% and 32% and lowest expectation value (E-value) of 1.0e-67 and 6.0-69 
respectively for CYP6P9a and CYP6P9b. 1TQN is a crystal structure of CYP3A4 resolved to 2.05Å 
without the N-terminal transmembrane leader sequence amino acids 3-23 (Yano et al., 2004) and 
deposited in protein database (http://www.rcsb.org/pdb/).  
(ii) Template-Target Alignment 
In order to maximise the alignment score between the template and the queries, pair-wise 
alignment of protein sequences (FASTA format) was done using T-Coffee (Notredame et al., 2000). The 
3D-Coffee Expresso (http://tcoffee.crg.cat/apps/tcoffee/do:expresso) algorithm (Armougom et al., 
2006) using sequence-structure threading (Fugue) generated a multisequence alignment by identifying 
template structure using a BLAST and substitution matrix of scores for each aligned pair of residues 
minus the penalties assigned to gaps, as explained elsewhere (Pierri et al., 2010). Residues present in 
the template and absent in the query were deleted, because misalignment of even a single residue can 
result in an error of about 4.0Å in the final model generated (Fiser and Sali, 2003).  
(iii) Model Building 
MODELLER is a standalone computer program that models 3D structures of proteins and their 
assemblies by satisfaction of spatial restraints (Sali and Blundell, 1993). The alignment files of a 
sequence to be modelled with known related structures is used by the MODELLER to automatically 
calculate a model with all non-hydrogen atoms. The input to the program are restraints on the spatial 
structure of the amino acid sequence(s) and ligands to be modelled and the output is a 3D structure 
that satisfies these restraints as well as possible. CYP6P9a and CYP6P9b models were created using the 
MODELLER 9.0v2 (https://salilab.org/modeller/) and human CYP3A4 (PDB:1TQN) as a template. 
MODELLER uses its SALIGN3D module to carry out template-query alignments and then extract spatial 
restraints from two sources: (i) homology-derived restraints on the distances and dihedral angles in 
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the target sequence extracted from its alignment with template structure (Sali and Blundell, 1993); (ii) 
stereochemical restraints such as bond length and bond angle preferences are obtained from the 
molecular mechanics force field of CHARMM-22 (MacKerell et al., 1998). Statistical preferences of 
main chain dihedral angles and non-bonded atomic distances are calculated by comparing the 
sequences of the target to the template, and a model calculated by optimisation employing methods 
of conjugate gradients and molecular dynamics (Braun and Go, 1985) with simulated annealing in 
Cartesian space. The loop-module in the MODELLER automatically models all the loops in the query by 
energy optimisation approach as well (Fiser et al., 2000). The software refines the models by tuning 
alignments and side chains automatically and then relaxes the backbone. The script used for template-
query alignments and model building is given in Appendix 2.1B. 
2.3.5 Models Assessment (Validation) 
 
Models generated using the MODELLER were assessed by comparing the PROSAII Z score of the 
models and the template structure(s) (Sippl, 1993). The PROSAII Z score (scoring function) of a model 
is a measure of compatibility between its sequences and the structure and ideally the Z score of the 
model should be comparable to that of the template. One of the shortcomings of the Z score is that it 
is an internal evaluation between the modelled structure and the template to determine whether or 
not the model satisfies the spatial restraints imposed. Because of this an independent assessment 
tool, Errat was used to further validate the models.   
2.3.5.1 Errat 
For each query sequence 50 models were iteratively generated and externally assessed 
individually using Errat v2.0 (http://nihserver.mbi.ucla.edu/ERRAT/) in order to determine incorrectly 
determined structures. Errat analyses the statistical patterns of non-bonded interactions between 
different atom types (Colovos and Yeates, 1993). A single output plot is produced that gives the value 
of the error function vs position of a 9-residue sliding window of 96 reliable, high-resolution protein 
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structures. Regions of candidate protein structures that are mis-traced or mis-registered were then 
identified by analysis of the pattern of non-bonded interactions from each window. Out of 50 models 
generated from each query sequence, one model is selected based on Errat scores for molecular 
docking. Errat scores for the all the models with the lowest incorrectly folded regions selected for 
further analysis, as well as the score of the template (1QTN) could be found in Appendix 2.2.  
2.3.6 Ligand Structures 
 
Virtual datasets of ligand insecticides: permethrin (ZINC01850374), bifenthrin (ZINC02516821), 
deltamethrin (ZINC01997854), λ-cyhalothrin (ZINC01843672), etofenprox (ZINC02558051), DDT 
(ZINC01530011) and bendiocarb (ZINC02015426) were retrieved from the library of ZINC12 
(https://zinc.docking.org/) database in MOL2 format (Irwin and Shoichet, 2005).  
2.3.7 Preparation of Receptors (Models) and Ligands for Molecular Docking  
 
MODELLER generates a model of main chain and side chain atoms devoid of hydrogen atoms and 
before docking simulation models were prepared by adding hydrogen atoms. This was done using 
using the Molegro Molecular Viewer 2.5 (MMV) software from CLC bio (http://www.clcbio.com/) and 
both receptor and ligands were prepared in PDB format following the assigning of chirality to some of 
the insecticide ligands, e.g. permethrin.   
2.3.8 Molecular Docking with GOLD 
 
Molecular docking is basically a conformational sampling procedure in which various docked 
conformations are explored to attempt to predict the potential right one (Wang et al., 2003).  
Conformational sampling must be guided by a scoring or energy function (Warren et al., 2006) that is 
used to evaluate the fitness between the protein and the ligand. The final docked conformations are 
usually selected according to their scores and/or productive poses. The accepted hypothesis is that 
lower energy scores represent better protein-ligand bindings compared to higher energy values. A 
number of approaches for the choice of scoring functions have been reported and can be roughly 
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grouped into three approaches: force field methods (Goodsell et al., 1996), empirical scoring functions 
(Wang et al., 2007) and knowledge-based potentials (Gohlke et al., 2000).  
Genetic algorithm for ligand docking (GOLD) is an automated ligand docking program which uses 
genetic algorithm to perform protein docking (Jones et al., 1997). GOLD utilises evolutionary strategy 
to explore the conformational variability of a flexible ligand while simultaneously sampling available 
binding modes of the ligand into a partially flexible protein active site. Hydrogen bond motifs have 
been encoded into the GOLD algorithm in order to search the spaces of available binding modes 
efficiently. Also, a simple scoring function is used to rank generated binding modes. The program has 
been documented to achieve up to 71% success rate of predicting correct binding mode of a ligand 
onto a protein when compared with the results from X-ray crystals of protein-ligand complexes (Jones 
et al., 1997, Verdonk et al., 2003). GOLD employs artificial mimicry to simulate nature (CCDC, 2011); 
each potential docking mode (solution) is considered as a chromosome and is assigned a specific 
score. The chromosome contains information about the mapping of a ligand H-bond atom onto 
(complementary) protein H-bond atoms, mapping of hydrophobic points on the ligand onto protein 
hydrophobic point and the conformation around flexible ligand bonds and protein -OH groups. Sets of 
solutions are termed a population and corresponding chromosomes ranked according to fitness. Two 
individual chromosomes share the same niche if the r.m.s.d. between the coordinate of their donor 
and acceptor is less than 1.0Å (1.0Å = 0.1nm) apart. The population of chromosomes is iteratively 
optimised so that at each step of the run, a point mutation may occur in the chromosome, or two 
chromosomes may mate to produce a child (crossover) and migration of a population member from 
one island to another can take place. The optimised chromosome then becomes a parent and 
selection of parent chromosome is biased towards the fitter members of the population (ligand 
dockings with better fitness score). 
For docking with GOLDv3.2, ChemScore fitness function was chosen for it has been trained by 
regression against binding affinities data (Eldridge et al., 1997). The function was derived empirically 
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from a set of 82 protein-ligand complexes for which measured binding affinities were available (Baxter 
et al., 1998). ChemScore estimates the total free energy change as the ligand binds to its respective 
receptor. Docking was performed using the genetic algorithm (GA) protocol as implemented on the 
user-friendly Hermes graphical user interface of GOLD. The active site of the protein was defined as a 
binding cavity (sphere) of 20Å radius centred on the heme-iron atom. 50 docking solutions (poses) of 
each ligand with respective receptor protein ranked according to their ChemScore fitness were 
generated. Solutions with the highest scores (best-ranked docking poses) which are in potentially 
productive orientations were selected for further analysis. Visualisation and preparation of figures 
from the docking were carried out using the PyMOL 1.7 and MMV.  
2.3.9  In silico Analysis of Protein Pockets and Cavities  
 
To investigate how the pyrethroid ligand could enter the active site of two models each from 
CYP6P9a (MALCYP6P9a and FANGCYP6P9a) and CYP6P9b (MOZCYP6P9b and FANGCYP6P9b) and how 
product could egress, a search of channels leading into and out of the  the active site to the surface of 
the protein (bulk solvent) was conducted using the algorithm tool CAVER 3.1 (Petrek et al., 2006). 
CAVER models protein body on a discrete 3-dimensional grid space with all grid nodes clustered into 
two classes: inside nodes (inside atomic vdW radii) and outside nodes (nodes located outside the 
protein body). CAVER then spans the grid nodes avoiding nodes that are located in the convex hull in 
its calculation and then find channels by evaluating a cost-function every time a new grid node is 
reached (Cojocaru et al., 2007). Settings were set as described in CAVER PyMOL plugin v3.0 
(http://www.caver.cz/fil/download/manual/caver_plugin_userguide.pdf): (i) maximum Java heap size 
~6000; (ii) maximum probe radius  which species the minimum radius a tunnel must have to be 
identified was set as 0.9; (iii) shell depth (the maximal depth of a surface region) was set as 4; (iv) shell 
radius (the radius of the shell probe which will be used to define which parts of the Voronoi diagram 
represent the bulk solvent) was set as 3; (v) clustering threshold which specify the level of detail at 
which the tree hierarchy of tunnel clusters will be cut was set as 3.5; (vi) number of approximating 
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balls which specify the number of balls that will be placed right under the surface of each larger atom 
to represent individual atoms in the input structure was set as 12. Starting points were set as x (-16.4), 
y (-22.6) and z (-9.6) using the input PDB file with search centre above the heme iron, and with a 
maximum distance of calculation starting point set as  3.0Å and desired radius of 5.0Å.  
2.4 Results 
2.4.1 Sequence Characterisation of CYP6P9a and CYP6P9b Alleles   
To establish the genetic distances between African populations of An. funestus based on CYP6P9a 
and CYP6P9b DNA sequences, phylogenetic trees of predominant haplotypes of CYP6P9a and CYP6P9b 
alleles were constructed using MEGA 6.06. A best-fit substitution model was tested based on Bayesian 
information criteria using four haplotypes each of CYP6P9a and CYP6P9b and Kimura-2 model best 
described the haplotypes dataset. The model was then used with 500 bootstrap replicates and a 
maximum likelihood tree generated (Appendix 2.1A). Haplotypes from the same country form clade 
with one another. However, in both CYP6P9a and CYP6P9b haplotypes from Uganda clustered closer 
to southern African haplotypes followed by haplotypes from FANG. Benin haplotypes were the most 
distant from southern African haplotypes and the closest to the haplotypes of the susceptible FANG.  
2.4.1.1 CYP6P9a Alleles 
Thirty one cDNA sequences of CYP6P9a from across Africa were analysed for nucleotide 
variations and haplotypes diversity. CYP6P9a has 17 haplotypes (Appendix 2.8) and 71 polymorphic 
sites of which 21 were established as non-synonymous (Table 2.3). Highest polymorphism was 
observed with Benin alleles and the susceptible strain FANG, both of which show high nucleotides 
diversity  with 34 and 23 polymorphic sites respectively of which 32 and 19 were synonymous. Uganda  
and Zambia alleles portrayed lowest diversity with only 2 haplotypes and one non-synonymous 
mutation each. Malawi and Mozambique also portrayed reduced nucleotides variations (4 and 5 
nucleotides substitution respectively) of which 3 and 5 led to amino acids mutation respetively. This 
established that the East and southern African alleles of CYP6P9a with reduced diversity and high 
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number of amino acids mutations per substitution site were undergoing directional selection as 
documented for Malawi and Mozambique alleles of CYP6P9a and CYP6P9b (Riveron et al., 2013).  
Table 2.3: Summary statistics for polymorphism of CYP6P9a  between FANG and the resistant strains 
from Malawi and Mozambique, Zambia, Uganda and Benin 
Samples N h S Syn NonSyn π (k) D (Tajima) 
D* 
(Fu and Li) 
Malawi 5 4 4 1 3 0.010 (1.60) -1.09
ns
 -1.09
ns
 
Mozambique 5 4 5 0 5 0.0013 (2.0) -1.12
ns
 -1.12
ns
 
Zambia 5 2 1 0 1 0.00039 (0.60) 1.22
ns
 1.22
ns
 
Fang 6 3 23 19 4 0.0053 (8.13) -1.209
ns
 -1.25
ns
 
Uganda 5 2 1 0 1 0.00026 (0.4) -0.816
ns
 -0.816
ns
 
Benin 5 3 34 32 2 0.0090 (13.80) -1.157
ns
 -1.157
ns
 
Total 31 17 71 50 21 0.0142 (21.80) 0.853
ns
 0.140
ns
 
N= number of sequences (n); h = number of haplotypes; S = number of polymorphic sites; Syn = synonymous mutations; Nsyn = non-
synonymous mutations; π = nucleotide diversity; k = mean number of nucleotide differences; D and D* = Tajima’s and Fu and Li’s statistics; ns 
= not significant; s = significant (p<0.05). 
 
 
With amino acid sequences, alleles from different regions formed clades unique to their 
origins; however  the predominant alleles of FANG cluster between the East (Uganda) and southern 
African alleles reflecting its distance from West African alleles (Figure 2.1A and B) and closer coding 
sequences similarity to East and southern African alleles.  
 
 
Figure 2.1: Schematic representation of haplotypes of CYP6P9a genes between the resistant 
mosquitoes from Malawi, Mozambique, Zambia, Uganda, Benin and the susceptible FANG. (A) 
The polymorphic amino acid positions with the  column Nb indicating the number of individuals sharing the 
haplotype, (B) Neighbor-joining tree of CYP6P9a showing clades specific to each phenotype and origin 
(region). A number has been given to each haplotype preceded by MAL, MOZ, ZMB, UGA, BEN or FANG if it is 
unique to Malawi, Mozambique, Zambia, Uganda, Benin or FANG strains, respectively.  
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However, three mutations were found to be shared by resistant alleles from two or more 
regions across Africa compared with the susceptible FANG (Table 2.4). Polymorphic positions of these 
important mutations in DNA sequences of CYP6P9a, country of origin, amino acid changes, its location 
in the protein sequence and possible impact on enzyme activity are outlined in the Table below.   
Table 2.4: Nucleotide polymorphism and amino acid substitutions between resistant alleles of 
CYP6P9a and CYP6P9b compared with FANG 
Amino acid 
substitution 
Mutation Countries Location and potential Impact 
CYP6P9a 
Ala
51
Ser 151:G->T Benin and Uganda 
Possibly located within the hydrophobic domain targeting 
the endoplasmic reticulum membrane 
Gln
52
Leu 153: C->T Benin and Uganda 
Possibly located within the hydrophobic domain targeting 
the endoplasmic reticulum membrane 
Phe
63
Leu 189: T->G 
Malawi, Mozambique, 
Zambia 
Within the highly variable αA region 
Gln
66
Lys 196: C->A 
Malawi, Mozambique, 
Zambia 
Within the highly variable αA region 
His
301
Gln 903: A->C 
Uganda, Malawi, 
Mozambique, Zambia 
Two residues upstream the substrate recognition site 4  
(SRS4) 
Tyr
320
Ser 959: A->C 
Benin, Uganda, Malawi, 
Mozambique, Zambia 
Middle of the αI helix and within SRS-4; one residue 
downstream the oxygen binding pocket (AGFETS) in 
CYP6P9a 
Ser
431
Phe 1292: T->C 
Benin, Uganda, Malawi, 
Mozambique, Zambia 
Within the loop joining the meander with the cysteine 
pocket; the loop is purported to house the reductase 
interaction site 2 (RIS-2) 
CYP6P9b 
Ser
32
Asn 95: G->A 
Benin, Uganda, Malawi, 
Mozambique, Zambia 
Within the hydrophobic residues anchoring the protein to 
membrane. May impact on protein stability 
Ile
109
Val 325: A->G 
Benin, Uganda, Malawi, 
Mozambique, Zambia 
Within the SRS-1 and the BʹC loop purported to be involved 
in substrate access and channelling 
His
169
Arg 506: A->G 
Benin, Uganda, Malawi, 
Mozambique, Zambia 
C-terminus of D helix 
Gln
171
Pro 512: A->C 
Benin, Uganda, Malawi, 
Mozambique, Zambia 
N-terminus of the E helix 
Glu
172
Asp 516: G->T 
Benin, Uganda, Malawi, 
Mozambique, Zambia 
N-terminus of the E helix 
Glu
335
Asp 
1005: A->C 
Benin, Uganda, Malawi, 
Mozambique, Zambia 
In the –COOH terminus of the αI helix, possible impact as 
RIS-1 residues mediating  interaction with P450 reductase 
Ser
384
Asn 
1151: G->A 
Uganda, Malawi, 
Mozambique, Zambia 
In the  β1_4 (αKʹ) and within the highly conserved SRS5, 
with possible impact on substrate recognition 
Ala
401
Pro 
12001: G->C 
Benin, Uganda, Malawi, 
Mozambique, Zambia 
Within the β2_2 domain; pyrrolidine ring can restrict 
conformational space 
 
2.4.1.2 CYP6P9b Alleles 
CYP6P9b has 15 haplotypes (Appendix 2.9) and 138 polymorphic sites (Table 2.5) the bulk of 
which were contributed from variations of Benin and FANG alleles compared with Uganda and 
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southern African alleles. Nucleotide diversities between all alleles of CYP6P9b were statistically 
significant (p<0.05; D* Fu and Li). Highest diversity was observed with FANG which has 38 polymorphic 
sites compared with 1 polymorphic site each for Uganda and Zambia alleles. Malawi, Mozambique and 
Benin alleles have 5, 2 and 3 polymorphic sites, respectively. 49 of the 138  polymorphisms in CYP6P9b 
alleles were non-synonymous with FANG alleles having only 7 non-synonymous mutations out of its 38 
polymorphic positions. Unlike BENCYP6P9a, the CYP6P9b allele from Benin (BENCYP6P9b) exhibited 
reduced polymorphism and seems to be undergoing directional selection (3 polymorphic positions all 
of which are non-synonymous) just like the Uganda and southern African alleles of CYP6P9b.  
Table 2.5: Summary statistics for polymorphism of CYP6P9b  between FANG and the resistant strains 
from Malawi and Mozambique, Zambia, Uganda and Benin 
Samples N h S Syn NonSyn π (k) D (Tajima) D* 
(Fu and Li) 
Malawi  5 4 5 4 1 0.0013 (2.00) -1.123ns -1.123ns 
Mozambique 5 3 2 1 1 0.0006 (1.00) 0.243ns 0.243ns 
Zambia 5 2 1 0 1 0.00039 (0.6) 1.224ns 1.224ns 
Fang 5 3 38 31 7 0.010(15.40) -1.169ns -1.169ns 
Uganda 5 2 1 0 1 0.00039(0.60) 1.224ns 1.224ns 
Benin 6 2 3 0 3 0.00065(1.00) -1.233ns -1.260ns 
Total 31 15 138 89 49 0.029(44.625) 0.945ns 1.424s 
N= number of sequences (n); h = number of haplotypes; S = number of polymorphic sites; Syn = synonymous mutations; Nsyn = non-
synonymous mutations; π = nucleotide diversity; k = mean number of nucleotide differences; D and D* = Tajima’s and Fu and Li’s statistics; ns 
= not significant; s = significant (p<0.05) 
 
As in CYP6P9a alleles of CYP6P9b (amino acid sequences from different regions) formed clades 
unique to their origins; however, alleles of FANG cluster between the East (Uganda) and West (Benin) 
African alleles and away from the Malawi, Mozambique and Zambia (Figure 2.2A and B). Up to eight 
amino acids shared by the haplotypes from resistant alleles make them different from the alleles from 
the major haplotypes of FANG. Countries sharing such polymorphism, polymorphic positions in cDNA 
and amino acid sequences, as well as location on the protein sequence and potential impact on 
functional activity are summarised in  Table 2.4. 
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2.4.1.3 Candidate Resistance Mutations 
 
2.4.1.3.1 CYP6P9a 
Comparison of the sequences of predominant haplotypes of CYP6P9a from FANG with those 
of the resistant strains revealed that only two substitutions Ser431Phe and Tyr320Ser are relatively fixed 
all across Africa (see Figure 2.1 and Figure 2.3). His301Gln present in southern African and Ugandan 
alleles is absent in alleles from Benin. The Tyr320Ser mutation replaces a bulky, polar, aromatic side 
chain with a smaller, polar, neutral serine. Prediction of structurally conserved regions of CYP6P9a 
using CYPED (Sirim et al., 2010) placed this mutation within the well-conserved αI helix that forms the 
heme-binding structural core and one residue downstream the oxygen-binding pocket of CYP6P9a. 
The mutation also mapped to the substrate recognition site number 4 (SRS4) determined by 
comparing the CYP6P9a amino acid sequences with that of the CYP101A from Pseudomonas putida 
Figure 2.2: Schematic representation of haplotypes of CYP6P9b genes between the resistant 
mosquitoes from Malawi, Mozambique, Zambia, Uganda, Benin and FANG. (A) The polymorphic 
amino acid positions with the  column Nb indicating the number of individuals sharing the haplotype (B) 
Neighbor-joining tree of CYP6P9b showing clades specific to each phenotype and origin (region).  
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(P450cam), whose substrate-binding residues have been identified by x-ray crystallography of a 
substrate-bound form (Gotoh, 1992). In Ser431Phe mutation polar, neutral serine is replaced with non-
polar, aromatic phenylalanine. This substitution occured within the loop joining the meander (position 
421-429) to the cysteine pocket (position 446-456). This loop consisting of 16 residues in CYP6P9a has 
been previously proposed to house the reductase interacting site 2 (RIS2) of the P450s (Hasemann et 
al., 1995) in three crystal structures of P450s (P450cam, P450terp and P450BM-3). In His
301Gln polar 
positive (basic) side chain of histidine is replaced with polar, neutral, amido side chain of glutamine. 
This mutation in the αI helix is located two residues from the putative SRS4. Other substitutions of 
particular interest include Ala51Ser and Gln52Leu observed in Benin and Uganda alleles and Phe63Leu 
and Gln66Lys (αA region) present in southern African alleles. However, analysis of CYP6P9a and also 
CYP6P9b sequences using DAS (Dense Alignment Surface) transmembrane prediction server 
(http://www.sbc.su.se/~miklos/DAS/) revealed that residues around these regions are not involved in 
contact with the membrane (Appendices 2.3 and 2.4 respectively). 
 
 
Figure 2.3: Comparison An. funestus CYP6P9a amino acid sequences from resistant and 
susceptible strains. Red solid lines represent helices A-L, while blue dashed lines correspond with 
the substrate recognition sites 1-6. Different residues are highlighted in pink.  
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2.4.1.3.2 CYP6P9b 
CYP6P9a from southern Africa was described as more polymorphic than CYP6P9b with more DNA 
haplotypes (9 vs 5) and amino acid sequences of 11 vs 5 (Riveron et al., 2013) compared with FANG. 
Here, its confirmed  with more sequences from Benin (West) and Uganda (East) Africa. CYP6P9a with 
17 haplotypes has 15 different sequences across Africa, while CYP6P9b with 15 haplotypes possess 
only 11 different sequences (Figure 2.2). The His301Gln mutation absent in BENCYP6P9a appears in 
CYP6P9b in addition to the Ala51Ser, Gln52Leu, Phe63Leu and Gln66Lys replacement (Figure 2.4). With 
the exception of BENCY6P9b all the haplotypes of CYP6P9b possess Ser384Asn mutation, a replacement 
of a polar neutral amino acid, serine with another (asparaine). This mutation present in the N-
terminus of the highly-conserved β1-4 domain of CYP6P9b in FANGCYP6P9b mapped to the  SRS5.  
Seven amino acid substitutions (Ser32Asn, Ile109Val, His169Arg, Gln171Pro, Glu172Asp Glu335Asp 
and Ala401Pro) (Table 2.4) are fixed in all the dominant haplotypes of CYP6P9b alleles from resistant 
individuals across Africa compared with the FANG. The Ile109Val mutation replaced nonpolar, larger 
side chain of isoleucine with a corresponding non-polar, hydrophobic side chain of smaller valine. This 
mutation is within the Bʹ-C loop described as being highly variable (Sirim et al., 2010) and can result in 
an increase in the radius of the binding cavity and/or enhanced substrate access or product egress. In 
all CYP6P9b sequences the mutations His169Arg (C-terminus of D helix), Gln171Pro and Glu172Asp (the N-
terminus of the E helix) are linked. In position 169 basic imidazole containing side chain of histidine 
was replaced with a basic side chain of arginine possessing guanidinium moiety. In position 171, polar, 
neutral glutamine was replaced with non-polar, aliphatic proline with its secondary imino group that 
could be held in rigid conformation which can reduce structural flexibility. The Glu335Asp replacement 
occurred in the last residue in the C-terminus of the αI helix downstream SRS4. The Ala401Pro mutation 
in β2-2 domain resulted in replacement of non-polar alanine with non-polar proline. The bulky 
pyrrolidine ring of proline can restrict the conformational space and affect backbone dihedral angles 
and side chain rotations (MacArthur and Thornton, 1991). 
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2.4.2 Modelling and Molecular Docking Simulation Analyses 
2.4.2.1 Models Production and Assessment 
 
CYP6P9a and CYP6P9b models were generated with heme already in place and verifications with 
Errat v2.0 indicated that the models have reasonably good scores with highest overall quality factor 
obtained from UGANCYP6P9b and FANGCYP6P9b models (Appendix 2.2). For CYP6P9a models, regions 
with high disorderliness (backbone deviation from the crystal structure of the template used) shown in 
Figure 2.4: Structurally-conserved regions of An. funestus CYP6P9b sequences from resistant 
and susceptible strains. Red solid lines represent WxxxR motif, O2-binding pocket/proton transfer 
group, ExxR motif, meander and cysteine pocket/heme-binding region; blue solid lines correspond with 
the protein β-sheets. Amino acids substitution is highlighted in pink.  
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black (Figure 2.5A and B) include amino acids 20-40 corresponding to the hydrophobic terminal 
domains that anchor the P450 to the surface of the membrane and residues preceding the αA helix, 
amino acids 60-120 encapsulating αA helix, β1-1, β1-2, αB helix and β1-5 containing the putative SRS1, 
amino acids 280-300 corresponding to the loop joining the C-terminus of αH to the N-terminus of αI.  
 
 
 
Regions with high disorder (backbone deviation from the folding pattern of the template) in 
CYP6P9b models (Figure 2.5C and D) include amino acids 10-40 corresponding to the sequences that 
constitute the hydrophobic membrane anchor, amino acids 70-90 corresponding to β1-1 and β1-2, 
amino acids 110-120 mapped to β1-5 containing the putative SRS1, as well as amino acids 195-220 
which corresponds to the part of the F-G loop. 
Figure 2.5: Errat plot for the lowest energy model. Disordered regions are identified on the error 
axis*, where 2 lines are drawn to indicate the confidence with which it’s possible to reject regions that 
exceed the error value. The Overall Quality Factor represents the percentage of the protein within which the error 
value is below 95% rejection limit as given in Appendix 2.2. A and B are plots from MALCYP6P9a and FANGCYP6P9a 
models, while C and D represent plots of models of MOZCYP6P9b and FANGCYP6P9b respectively. 
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CYP6P9b models exhibited lesser backbone deviation compared with CYP6P9a models, though the 
models were created from the same 1TQN template which shares 32% and 33% identity respectively. 
2.4.2.2 Molecular Docking Simulations 
 
  Binding energy of a ligand is defined as the difference in free energy of the protein plus the 
unbound ligand, and their complex; ChemScore estimates the total free energy change that occurs on 
ligand binding (Jones et al., 1997). Docking scores along with other relevant regression terms for 
binding of insecticide structure to CYP6P9a and CYP6P9b models are given in Tables 2.6 to 2.10 
respectively. The general atom type parameters assigned to both atoms of ligand and that of receptor 
in contact with the ligand include Slipo (lipophilic term: chlorine, bromine and iodine atoms which are 
not ions; sulphurs which are not acceptor or polar types; carbons which are not polar type); Hbond (H 
bond donor: nitrogens with hydrogens attached, hydrogens attached to N or O; H-bond 
donor/acceptor: oxygens attached to hydrogens, imine nitrogen; H-bond acceptor: oxygens not 
attached to hydrogens, N with no hydrogens and one or two connections, halogens that are ions, 
sulphurs with one connection); SPolar(non-H bond: nitrogens with no hydrogens attached and more 
than two connections, phosphorus, sulphurs attached to one or more polar atoms (including H-
bonding atoms and not including polar carbon atoms or fluorine atoms), carbons attached to two or 
more polar atoms (including H-bonding atoms and not including polar carbon atoms or fluorine 
atoms), carbons in nitriles or carbonyls, nitrogen atoms with no hydrogens and four connections, 
fluorine atoms); ΔEclash (clash penalties between ligand atoms and receptor heavy atoms); SMetal 
(contact between acceptor and/or donor atom in the receptor with the metal atom of the ligand, if 
any)(Verdonk et al., 2003, Eldridge et al., 1997, Baxter et al., 1998).  
Detoxification of pyrethroids in insects follow two principal routes: ester hydrolysis catalysed 
by esterases and P450s, and hydroxylation of aromatic rings or methyl groups by P450s (Gilbert and 
Gill, 2010). Infra-red and NMR spectroscopy and TLC analysis established that housefly P450s 
preferentially hydroxylate permethrin isomers at position 4ʹ or 6 of the phenoxybenzyl ring and the 
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trans-methyl group (Shono et al., 1979), while trans-permethrin can be hydroxylated in position 6 of 
the benzyl ring and cis-permethrin in cis-methyl group as well as hydroxylation at 2ʹ position. Other 
spectroscopic analysis, for example an LC-MS determined metabolism of deltamethrin by An. gambiae 
CYP6M2 to proceed preferentially via 4ʹ hydroxylation (Stevenson et al., 2011).    
Docking solutions obtained from this study were manually analysed, and productive poses 
with highest scores and lowest free binding energy selected for further analysis.  
 
Docking of Permethrin: Permethrin docked in BENCYP6P9a with 2ʹ position exposed for 
hydroxylation at  a distance of 4.2Å (Figure 2.6A).  In UGANCYP6P9a, FANGCYP6P9a and MALCYP6P9a, 
permethrin docked with the trans methyl group oriented toward the heme at a distance of 2.6Å,  5.7Å 
and 3.6Å respectively (Figure 2.6B, C and D) indicating that with the exception of BENCYP6P9a 
permethrin metabolism is predicted to proceed via trans methyl group hydroxylation. However, the 
pose with resistant models has the lower clash penalty and higher score (Table 2.6) indicating that the 
resistant alleles possibly possess the higher activity, compared with FANGCYP6P9a allele whose model 
produced lowest score and highest clash penalty. 
 
Table 2.6: ChemScores of the productive binding of permethrin in CYP6P9a and CYP6P9b models 
Models 
 
Rank 
 
ChemScore 
(kJ/mol) 
 
ΔG 
(kJ/mol) 
S(hbond) 
 
S(metal) 
 
S(lipo) 
 
ΔE(clash) 
 
ΔE 
(int) 
 
BENCYP6P9a 2
nd
 44.14 -45.60 0.00 0.00 374.66 0.24 1.22 
UGANCYP6P9a 1
st
 45.77 -47.54 0.00 0.00 391.27 0.50 0.27 
FANGCYP6P9a 1
st
  37.91 -38.91 0.00 0.00 317.47 0.90 0.19 
MALCYP6P9a 2
nd
 40.79 -43.49 0.00 0.00 356.63 0.15 2.55 
BENCYP6P9b 1
st
 43.44 -44.22 1.01 0.00 362.91 0.22 0.57 
UGANCYP6P9b 1
st
 43.32 -44.04 0.21 0.00 332.92 0.23 0.50 
FANGCYP6P9b 1
st
  41.25 -42.88 1.00 0.00  346.85 1.94 1.68 
MOZCYP6P9b 1
st
  46.07 -47.82 0.76 0.00 393.69 0.81 0.94 
ΔG = free energy of binding, S(hbond) = contribution from hydrogen bonds, S(lipho) = lipophilic term, ΔE(clash) = clash penalties between 
ligand and receptors heavy atoms, and ΔE(int) = internal energy of the ligand or receptor. 
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In BENCYP6P9b permethrin docked productively with the 4ʹ spot of the phenoxy ring oriented 
above the heme at a distance of 3.3Å (Figure 2.7A), while in the active site of UGANCYP6P9b the 
insecticide docked with the 6 position of the phenyl ring at a distance of 3.7Å (Figure 2.7B).   
Permethrin docked to the active site of FANGCYP6P9b with dihalovinyl groups approaching the heme 
and the possible sites of attack away from the catalytic centre; trans-methyl group located 9.1Å from 
heme iron (Figure 2.7C) and 2ʹ spot of phenyl ring at a 11.8Å distance. This unproductive conformation 
is the only pose in the ten top ranked solutions which exhibited a very high clash penalty.  
In MOZCYP6P9b model the pyrethroid approached the heme with 4ʹ spot of the phenoxy 
group docked above the heme iron, at a respectful distance of 3.1Å (Figure 2.7D). This binding mode 
Figure 2.6: Binding modes of permethrin in (A) BENIN, (B) UGANDA, (C) FANG and (D) MALAWI 
CYP6P9a models. Permethrin is in stick format and hot pink. Heme atoms are in spectrum. Possible sites 
of metabolism are indicated with yellow arrows. 
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has the highest score and lowest free energy of binding, and thus MOZCYP6P9b was predicted to have 
highest activity for permethrin compared with all the other CYP6P9a and CYP6P9b alleles.  
 
 
 
 
Docking of Deltamethrin: P450-mediated biotransformation of deltamethrin  possessing an α-
cyano group have been shown to proceed via ester cleaved products and the 4ʹ-hydroxy metabolites 
in the bulb mite Rhizoglyphus robini (Ruzo et al., 1988). Sequential metabolism of deltamethrin by An. 
gambiae CYP6M2 was revealed (Stevenson et al., 2011). Using in silico modelling and docking, LC-MS 
and NMR spectroscopy, Stevenson and colleagues have shown that CYP6M2 preferentially hydrolyses 
deltamethrin to initial product at 4ʹ position, with trans-methyl hydroxylation being a minor route.  
Analysis of the binding conformation of BENCYP6P9a and UGANCYP6P9a docked with 
deltamethrin revealed that the insecticide docked with the 2ʹ position at a distance of 1.7Å and 4.0Å 
Figure 2.7: Binding modes of permethrin in (A) BENIN, (B) UGANDA, (C) FANG and (D) 
MOZAMBIQUE CYP6P9b models. Permethrin is in stick format and hot pink. Heme atoms are in stick 
format and spectrum. Possible sites of metabolism are indicated with red arrows.  
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respectively from the heme iron, with high score, very low binding energy and low clash penalties 
(Table 2.7, Figure 2.8A and B). The 4ʹ spot however pointed away from the heme iron in both these 
solutions.  
In contrast, in FANGCYP6P9a and MALCYP6P9a deltamethrin docked with the trans methyl 
group above the heme at a distance of 6.4Å and 3.4Å respectively (Figure 2.8C and D). These binding 
modes shared by these two alleles make them different from Benin and Uganda models in that cis 
and/or trans methyl hydroxylation is predicted in the top ranked poses for Malawi and FANG alleles. 
However, the trans methyl group in MALCYP6P9a was positioned closer to the heme compared with 
the situation in FANGCYP6P9a in which the deltamethrin is away for productive contact. Also, 
FANGCYP6P9a exhibited the highest clash penalty and MALCYP6P9a exhibited the lowest penalty 
compared with the other alleles. The high clash score for FANG may reflect steric hindrance/clashes 
with heavy atoms of the protein, restricting access to the catalytic hotspot and reducing catalysis.  
 
Table 2.7: ChemScores of the productive binding of deltamethrin in CYP6P9a and CYP6P9b models 
Models 
 
Rank 
 
ChemScore 
(kJ/mol) 
ΔG 
(kJ/mol) 
S(hbond) 
 
S(metal) 
 
S(lipo) 
 
ΔE(clash) 
 
ΔE 
(int) 
BENCYP6P9a 1st  43.31 -46.31 0.00 0.00 384.88 0.79 2.03 
UGANCYP6P9a 3rd 42.82 -44.14 0.00 0.00 366.31 0.76 0.75 
FANGCYP6P9a 5th 41.01 -42.47 0.00 0.00 333.00 1.69 0.77 
MALCYP6P9a 2nd 43.21 -45.81 0.00 0.00 380.88 0.32 3.87 
BENCYP6P9b 1st  44.02 -45.31 0.00 0.00 347.54 0.25 0.74 
UGANCYP6P9b 1st  42.90 -44.47 0.00 0.00 369.16 0.09 1.49 
FANGCYP6P9b 1st  39.77 -41.38 1.97 0.00 307.33 0.98 0.69 
MOZCYP6P9b 1st  45.90 -49.76 0.49 0.97 364.36 0.23 1.43 
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With BENCYP6P9b and UGANCYP6P9b deltamethrin docked productively with 4ʹ spot above 
the heme iron at a distance of 3.5Å and 4.1Å respectively (Figure 2.9A and B), with UGANCYP6P9b 
exhibiting low clash penalty (Table 2.7). Though, the insecticide docked in the active site of 
FANGCYP6P9b productively but in contrast the target 4ʹ spot of the phenoxy ring is 8.9Å from heme 
iron catalytic hotspot (Figure 2.9C) with lower chances of optimal metabolism. Equally also, the 
binding mode of this model has the lowest scores and portrayed a very high contribution of hydrogen 
bonds than obtained with the other models.  
Figure 2.8: Binding modes of deltamethrin in (A) BENIN, (B) UGANDA, (C) FANG and (D) MALAWI 
CYP6P9a models. Deltamethrin is in stick format and magenta. Heme atoms are in spectrum. Possible 
sites of metabolism are indicated with yellow arrows.  
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The insecticide docked into MOZCYP6P9b in a perfect pose with the 4ʹ position exposed for 
hydroxylation at reasonable distance of 3.6Å from the heme iron and 2’ position, 4.0Å away (Figure 
2.9D). This mode has the highest score of all the CYP6P9b models and lowest binding energy 
predicting highest activity toward deltamethrin compared with the results from models from FANG, 
and other models from resistant alleles. The fifth and sixth ranked solution with CYP6P9b model has 
the gem dimethyl moiety close to the heme at a distance of about 4-5Å (figure not provided). Thus 
cis/trans-methyl hydroxylation is predicted to occur from MOZCYP6P9b-mediated metabolism of 
deltamethrin, leading to multiple primary metabolites. 
 
Figure 2.9: Binding modes of deltamethrin in (A) BENIN, (B) UGANDA, (C) FANG and (D) 
MOZAMBIQUE CYP6P9b models. Deltamethrin is in stick format and purple. Heme atoms are in 
spectrum. Possible sites of metabolism are indicated with yellow arrows.  
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Docking of Etofenprox: Docking scores with etofenprox were comparable to values obtained 
with permethrin and deltamethrin (Table 2.8) with BENCYP6P9a having highest score, while 
FANGCYP6P9a exhibited lowest scores and largest clash penalty. In BENCYP6P9a, UGANCYP6P9a and 
MALCYP6P9a etofenprox docked in the top ranked solutions with aromatic groups above the heme 
and 2ʹ spot of phenoxy ring 3.3Å, 3.1Å and 2.2Å respectively from the heme (Appendix 2.5). In 
contrast, the insecticide docked in FANGCYP6P9a with ethoxy group positioned 5.7Å above the heme. 
In this posture sites of attack are predicted as the ether group or methyl groups (the closest being 
3.5Å from heme iron), but etofenprox has been shown to be metabolised through aromatic ring 
hydroxylation, specifically in rats and dogs via 4ʹ hydroxylation (Hawkins, 1985) and these postures 
may not support optimal metabolism. Etofenprox is thus predicted to be metabolised by all the 
resistant alleles of CYP6P9a but not by FANGCYP6P9a. 
In  BENCYP6P9b and MOZCYP6P9b etofenprox docked possibly productively with 2ʹ spot of 
phenoxy ring oriented above the heme catalytic center at a distance of 3.4Å and 3.7Å respectively 
(Appendix 2.5). Though the insecticide docked in the same productive fashion in FANGCYP6P9b the 2ʹ 
spot is 6.6Å from the heme and this placed the insecticide away from the catalytic center and possibly 
reflect lower activity compared with the alleles from resistant strains. In UGANCYP6P9b the insecticide 
docked with 6 position of the benzyl ring at a distance of 5.5Å from the heme in all the top ranked 
solutions. A characteristic feature of docking with etofenprox is the unusually high clash penalty 
obtained from all models of CYP6P9b, indicating that this insecticide may not fit optimally in the active 
site of CYP6P9b for metabolism compared with the prediction the software made for the other 
pyrethroids. 
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Table 2.8: ChemScores of the productive binding of etofenprox in the  CYP6P9a and CYP6P9b models 
Models 
 
Rank 
 
ChemScore (kJ/mol) 
 
ΔG 
(kJ/mol) 
S(hbond) 
 
S(metal) 
 
S(lipo) 
 
ΔE(clash) 
 
ΔE (int) 
 
BENCYP6P9a 1
st
 51.73 -54.38 0.00 0.00 449.12 0.65 0.74 
UGANCYP6P9a 1
st
 50.84 -52.15 0.19 0.00 430.07 0.42 0.89 
FANGCYP6P9a 1
st
  47.60 -49.88 0.83 0.00 386.99 0.95 1.32 
MALCYP6P9a 1
st
  49.13 -50.93 0.00 0.00 419.62 0.06 1.73 
BENCYP6P9b 5
th
 46.18 -47.34 0.89 0.00 363.42 1.36 0.98 
UGANCYP6P9b 1
st
 51.07 -53.21 0.91 0.00 413.30 1.24 0.90 
FANGCYP6P9b 1
st
  48.49 -49.51 0.00 0.00 407.52 1.38 0.64 
MOZCYP6P9b 1
st
  52.41 -55.41 0.00 0.00 457.95 1.61 1.61 
 
Docking of DDT: DDT is converted to dichlorodiphenyldicholoroethane (DDD) by reductive 
dechlorination in insects and higher animals (Kitamura et al., 2002), for example the reaction effected 
by CYP6G1 in D. melanogaster (Joussen et al., 2008).  However, DDT is mainly converted to DDE by 
dehydrochlorination in mammals and insects (Gold and Brunk, 1983, Smith, 2012) though dicofol 
(kelthane) is also generated. Mitchell and colleagues (Mitchell et al., 2012) have reported An. gambiae 
CYP6M2 capable of metabolizing DDT to dicofol, in presence of solubilising factor sodium cholate.  
DDT exhibited good but lower docking scores with CYP6P9a and CYP6P9b models compared 
with values obtained from docking with pyrethroids (Table 2.9). But in all alleles of CYP6P9a p,pʹ-DDT 
docked  away from heme iron for productive metabolism to take place. In the case of BENCYP6P9a, 
UGANCYP6P9a and FANGCYP6P9a the best ranked poses have target C-2 at a distance of 10.1Å, 8.5Å 
and 9.2Å respectively from heme (Appendix 2.6), away for metabolism to be effected. The second 
ranked DDT pose in MALCYP6P9a has chlorine group of the benzyl ring pointing unproductively at the 
heme and the C-4ʹ at a distance of 4.5Å. 
In BENCYP6P9b and UGANCYP6P9b DDT docked unproductively, away from  the heme with C-
2 at a distance of 8.7Å and 5.5Å respectively from heme iron. In Benin model the second benzyl ring of 
DDT clashes with the heme ring while in Uganda model its the trichloroethyl group that clashes with 
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the heme ring with a high penalty. The second ranked pose in FANGCYP6P9b has C-2 of DDT 
positioned at 9.8Å from heme iron, while in MOZCYP6P9b DDT docked away from heme iron with C-2 
at 16.6Å distance.  
The potentially unproductive binding conformation of DDT in all CYP6P9a and CYP6P9b models 
from field resistant populations, as well as the susceptible strain (FANG) suggests that these P450s are 
poor binders and/or poor metabolizers of this organochlorine insecticide.  
Table 2.9: ChemScores of the productive binding of DDT in CYP6P9a and CYP6P9b models 
Models 
 
Rank 
 
ChemScore (kJ/mol) 
 
ΔG 
(kJ/mol) 
S(hbond) 
 
S(metal) 
 
S(lipo) 
 
ΔE(clash) 
 
 ΔE (int) 
BENCYP6P9a 1
st
 36.20 -37.47 0.00 0.00 295.30 0.33 0.95 
UGANCYP6P9a 2
nd
 38.36 -39.71 0.00 0.00 314.43 0.24 0.61 
FANGCYP6P9a 2
nd
 35.46 -36.43 0.00 0.00 286.40 0.78 0.18 
MALCYP6P9a 2
nd
 35.59 -39.20 0.00 0.00 284.48 2.55 0.19 
BENCYP6P9b 1
st
 31.89 -32.91 0.00 0.00 256.36 0.65 0.37 
UGANCYP6P9b 1
st
 29.23 -31.03 0.00 0.00 240.24 1.67 0.13 
FANGCYP6P9b 2
nd
 33.20 -33.40 0.00 0.00 260.55 0.17 0.03 
MOZCYP6P9b 1
st
 29.20 -31.75 0.00 0.00 246.38 0.85 1.69 
 
Docking of Bendiocarb: In animals including man, rats and insects bendiocarb can be 
metabolised in several ways; these include hydrolytic cleavage to generate benzodioxol-4-ol, 
hydroxylation of the phenyl ring  and hydroxylation of the N-methyl moiety (Roberts and Hutson, 
1999). Ester hydrolysis to generate bendiocarb phenol has been described as the major pathway of 
metabolism of bendiocarb in the maize pest D. undecimpunctata howardi (Hsin and Coats, 1987). 
Recently Edi and colleagues (Edi et al., 2014) have reported a recombinant CYP6P3 from An. gambiae 
able to metabolise bendiocarb in vitro but more needs to be done to functionally characterise the 
mechanism of bendiocarb metabolism in Anopheline mosquitoes, especially An. funestus.  
Binding scores of bendiocarb in CYP6P9a and CYP6P9b models were the lowest of all the 
insecticides screened. The insecticide docked in BENCYP6P9a and BENCYP6P9b in unproductive mode, 
in a tight embrace with heme in BENCYP6P9a and the phenyl ring clashing with the heme ring in 
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BENCYP6P9b (Appendix 2.7). The insecticide docked in UGANCYP6P9a with the C-5 of the phenyl ring 
pointing towards the heme iron at a distance of 5.4Å. In this mode, metabolism is possible through 
aromatic ring hydroxylation but the Chemscore as in the rest of docked poses with all alleles is very 
low (Table 2.10). In FANGCYP6P9a bendiocarb docked away with the C-5 of the phenyl ring 12.9Å from 
heme iron, while in MALCYP6P9a it docked with 2,2-dimethyl carbon atom pointing to the heme iron 
at a distance of 7.6Å. This potentially productive pose makes it possible for N-methyl hydroxylation 
were it not for the very low scores obtained.  
Bendiocarb docked to UGANCYP6P9b unproductively with phenyl ring and N-methyl moiety 
clashing with the heme ring. For FANGCYP6P9b only the 10th ranked pose did not clash with the heme 
ring. In this pose the phenyl ring is located 14.7Å from heme iron and thus away for catalysis to take 
place. The insecticide docked unproductively, way from the heme in MOZCYP6P9b with 2,2-methyl 
group positioned 8.7Å from heme iron. Thus, the software predicted that CYP6P9a and CYP6P9b from 
both resistant and susceptible alleles do not bind bendiocarb and possibly have no activity towards the 
representative carbamate insecticide.  
 
Table 2.10: ChemScores of the productive binding of bendiocarb in CYP6P9a and CYP6P9b models 
Models 
 
Rank 
 
ChemScore (kJ/mol) 
 
ΔG 
(kJ/mol) 
S(hbond) 
 
S(metal) 
 
S(lipo) 
 
ΔE(clash) 
 
ΔE (int) 
 
BENCYP6P9a 1
st
 22.49 -23.37 1.73 0.00 132.91 0.82 0.05 
UGANCYP6P9a 1
st
 21.13 -22.17 0.98 0.00 144.16 0.53 0.52 
FANGCYP6P9a 8
th
 13.57 -14.03 0.88 0.00 77.50 0.22 0.24 
MALCYP6P9a 1
st
 21.02 -21.19 0.99 0.00 135.48 0.00 0.16 
BENCYP6P9b 1
st
 20.53 -20.97 2.16 0.00 100.29 0.07 0.38 
UGANCYP6P9b 1
st
 23.20 -23.34 1.95 0.00 126.39 0.00 0.13 
FANGCYP6P9b 10
th
 11.53 -11.91 0.93 0.00 57.89 0.00 0.37 
MOZCYP6P9b 1
st
 21.74 -22.04 1.81 0.00 119.45 0.07 0.23 
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2.4.3 Active Site Residues and Enzymes-Substrates Interactions 
The majority of enzymes combine several strategies to enhance the rate of catalysis (Nelson et al., 
2012). These include (1) covalent catalysis: acid-base catalysis involving key active sites amino acid 
residues, catalysis involving side chain(s)/cofactor(s) nucleophile, as well as the metal ion catalysis 
(metal taken up from the solution or tightly bound to the enzyme); (2) weak, non-covalent 
interactions: hydrophobic interactions, hydrogen bonds, vdW forces and electrostatic attractions. 
Evidences have shown that P450-mediated metabolism is carried out using the weak, non-covalent 
intra- and inter-molecular/atomic interactions to boost up the binding energy several orders of 
magnitude (Kenaan et al., 2011, Szklarz and Paulsen, 2002, Yoshioka et al., 2002, Paine et al., 2003).   
To understand the key amino acid residues lining the active/binding sites of CYP6P9a and CYP6P9b 
models pattern of non-bonded interaction in the binding cavities were compared between southern 
African alleles and FANG using the productive poses of pyrethroids in the binding cavity of the models. 
The southern African alleles were chosen because highest resistance to pyrethroids were observed in 
southern Africa, where the two genes CYP6P9a and CYP6P9b are highly overexpressed compared with 
same genes from Benin (West Africa) and Uganda (East Africa), because of the highest signature of 
selection from them, and because the docking with pyrethroids predicted the southern African alleles 
of CYP6P9a and especially CYP6P9b to possess the highest activities compared with the FANGCYP6P9a 
and FANGCYP6P9b. 
2.4.3.1 Deltamethrin 
2.4.3.1.1 Active site residues of CYP6P9a models 
Within MALCYP6P9a deltamethrin is surrounded by eleven nonpolar, aliphatic side chains notably 
from SRS1 (Ala113, Leu118, Ala124 and Leu125) and Ile310, Leu313 and Ala314 all from SRS4. Bulky, 
hydrophobic residue within 5.0Å of deltamethrin include Phe110 of the SRS1 which  π-stack in T-shaped 
fashion with the phenoxy ring of deltamethrin at a distance of 4.31Å, Phe123 of SRS-1 which π-stack 
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face to face with the benzyl ring of deltamethrin at 3.7Å distance, Phe216 (SRS2), which π-stack in T-
fashion with the phenoxy ring, as well as Phe309 positioned  at a distance of 4.6Å from the phenoxy 
ring, two histidine residues, His107 and His121 both from SRS1 (Figure 2.10A). This cluster of 
phenylalanine forms a roof above the active site maximizing hydrophobicity and together with the 
large number of nonpolar, aliphatic side chains, make the binding site of deltamethrin highly 
hydrophobic. The aromatic residues may also contribute to catalysis via resonance stabilisation of 
aromatic rings of deltamethrin as it approached the heme. 
 
 
 
Though the cavity contains polar side chains including Ser119 of SRS1, Glu215 of SRS2, Thr242 and 
Thr318 of SRS4 (oxygen binding pocket) all of which could participate in a network of hydrogen 
bonding, MMV analysis predicted no hydrogen bonds between deltamethrin and amino acid residues 
Figure 2.10: Binding modes of deltamethrin in MALCYP6P9a (A) and (C) and FANGCYP6P9a (B) 
and (D) models, showing residues involved in hydrophic contact, within 5.0Å radius (A and B) 
and residues from the predicted inter-molecular hydrogen bonds (C and D). Amino acid residues 
are annotated with numbers and heme atoms in red.  
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of MALCYP69a (Figure 2.10C) in agreement with the docking parameters with deltamethrin. This 
suggests that distal residues are not fully exploited in hydrogern bonding machinery to optimise 
conversion of Cpd O into Cpd I. For CYP6P9a, hydrogen bonds and ionic interactions might be 
secondary in importance compared with hydrophic and aromatic group interaction and π-anchorage. 
In FANGCYP6P9a deltamethrin is  surrounded within 5.0Å radius by seven nonpolar, aliphatic 
residues notably from SRS4 (Leu313 and Ala314) and SRS5 (Val380 and Leu383) (Figure 2.10B). This is in 
sharp contrast to the nonpolar residues in the binding site of deltamethrin within MALCYP6P9a the 
majority of which belong to SRS1. However, six phenylalanine residues surrounded deltamethrin in 
FANGCYP6P9a, four of which are less than 6.0Å from the aromatic rings. These include Phe110 (SRS1) 
which is in face to face π-stacking with benzyl ring (3.98Å), Phe123 (SRS1) which π-stack in sandwich 
fashion with phenoxy ring (distance of 3.63Å), as well as Phe216 (SRS2) and Phe225 both of which π-
stack in a T-fashion with the benzyl ring (distances of 3.80Å and 5.86Å, respectively). The presence of 
large number of aromatic residues surrounding the insecticide indicated that FANGCYP6P9a employs 
hydrophobic interactions and resonance stabilisation as well, to effect catalysis.  
Though the binding site harbors residues that could be involved in hydrogen bonding with 
deltamethrin ( e.g. Glu215 (SRS2), Thr318 (SRS4) and Ser384 (SRS5), as obtained from analysis with 
MALCYP6P9a, no inter-molecular hydrogen bond was predicted between FANGCYP6P9a and 
deltamethrin (Figure 2.10D).  
The absence of hydrogen bonding in the docking of deltamethrin these allele models is in line 
with the docking parameters obtained (no hydrogen bonding score for CYP6P9a with pyrethroids) and 
further strengthen the assumption that hydrophobic contacts, resonance stabilisation and π-π 
interactions are the major mechanisms for catalysis in CYP6P9a. However, from this analysis, no clue 
was found to substantiate the differences in the other binding parameters (ChemScore and free 
energy of binding) obtained from the resistant MALCYP6P9a and susceptible FANGCYP6P9a models.  
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2.4.3.1.2 Active site residues of CYP6P9b models 
 Deltamethrin in MOZCYP6P9b is surrounded within 5.0Å radius by eight nonpolar, aliphatic side 
chains (Figure 2.11A). There are only three bulky, hydrophobic side chains from Phe316 located 3.27Å 
from phenoxy ring, Phe226 and Phe312. However, the insecticide is surrounded by a network of polar, 
neutral side chains of Ser119, Thr111 , Asn112, Ser319 and Ser320 (all residues from SRS1). These amino 
acids together with Arg114 (SRS1) and Glu247 (SRS3) could create a hydrogen bonding network that 
could bind the acid group allowing the alcohol group to approach the heme. They can also be involved 
in ionic interactions, enhancing catalysis. A hydrogen bond is predicted to be donated by the alcohol 
side chain of Thr111 to the acyl group of the acid moiety of deltamethrin (acceptor) with a distance of 
2.95Å and a maximum binding energy of -2.5kJ/mol (Figure 2.11C).  
 
 
Figure 2.11: Binding mode of deltamethrin in MOZCYP6P9b (A) and (C) and FANGCYP6P9b (B) 
and (D) with residues involved in hydrophobic contact (5.0Å radius) (A and B) and residues 
involved in intermolecular hydrogen bonds (C and D). Amino acid residues are annotated with 
numbers and heme atoms in red. Inter-molecular hydrogen bondings are depicted in broken blue lines. 
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This distal hydrogen –bonding machinery are thought to accelerate formation of Cpd I from 
Cpd O, reducing generation of H2O2 and other O2-wasting species (Shaik et al., 2005), as well as 
regulating the redox potential of the heme. The negatively charged side chain of Glu247 and the 
positive, guanidinium moiety of Arg114 are thought to be involved in ionic interaction stabilizing the 
ligand through electrostatic interactions. In contrast with the MALCYP6P9a and FANGCYP6P9a models, 
the MOZCYP6P9b binding cavity is not crowded with bulky aromatic side chains or proline residues. 
This property is predicted to increase the active site volume of MOZCYP6P9b and the access of 
pyrethroid insecticides to  the heme catalytic center, enhancing catalysis.  
In FANGCYP6P9b deltamethrin is surrounded within 5.0Å radius by eleven aliphatic, 
hydrophobic side chains  (Figure 2.11B) and  three bulky, aromatic rings: Phe224, Phe110 (located 3.40Å 
from phenoxy ring with a possibility of parallel displaced π-stacking) and Phe123 which is positioned at 
3.37Å distance from the phenoxy ring and could π-stack in a T-shape fashion. These two aromatic rings 
are also very close to each and could π-stack with each other to increase resonance stability of the 
phenoxy-benzyl moiety of deltamethrin. Thus, the topology of the binding site of deltamethrin in 
FANGCYP6P9b reflects a highly hydrophobic environment and extensive hydrogen bond networks. 
Two intermolecular hydrogen bonds were predicted (Figure 2.11D): (i) between the alcohol side 
chain of Ser382 (SRS5) and the α-cyano group of the deltamethrin; within a distance of 2.96Å and 
contributed a maximum of -2.5kJ/mol binding energy; (ii) between the acyl oxygen of the acid group 
and the peptide bond between Arg107 and Gly108 (3.06Å and -1.86kJ/mol energy). In addition the 
binding site contains the His121 of SRS1, the Glu215 of SRS2 as well as Met493 which maps to SRS6 which 
could also be involved in hydrogen bonding network and ionic interactions enhancing catalysis. 
Though additivity of hydrogen bonds is beneficial, presence of so many hydrogen bonding interactions 
could be one of the mechanism which stabilised the insecticide a considerable distance (8.9Å away) 
from the heme catalytic center and possibly resulted in lower ChemScore towards deltamethrin as 
compared with the docking solutions from the resistant models, especially of MOZCYP6P9b.  
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2.4.4  Identification of Substrate Access Channel pw2a  
Substrate access/product egress channels have been described as one of the most important 
factors that determine P450 activity toward substrates (Wade et al., 2004). Possible routes through 
which substrate can enter the active site or product egresses were searched in two models each from 
resistant (MALCYP6P9a and MOZCYP6P9b) and susceptible (FANGCYP6P9a and FANGCYP6P9b) strains.  
 For MOZCYP6P9b model a total of 30 substrates access and/or products egress tunnels were 
predicted from the interior active site of the protein to the bulk solvent. Of these channels the first 
ranked with highest throughput (0.86) (Figure 2.12A), lowest energy cost (0.27), and which is longest 
(21.42Å) has its gorge lined with about 41 residues. These tunnel-lining residues of which none is more 
than 3.0Å from the tunnel include those from the SRS1 (Arg107, Gly108, Val109, Thr111, Ser119, Leu122, 
Phe123, Leu125), those from SRS2 (Phe214, Glu215, Leu216, and Asp217), residues from SRS3 (Asp245, Val246 
and Glu247), residues from SRS4 and O2-binding pocket (Phe
316, Ser319, Ser320 and Ser324), residues from 
SRS5 including Arg385, Val386, Val387, Ser388, Asp390, Tyr391 and residues from  heme-binding region 
including  Arg452, Val453, Cys454. These tunnel-lining residues from BC loop, F/G loop, β1_4 (SRS5), αI 
helix (SRS4) correspond to the channel pw2a described for many P450s (Wade et al., 2004, Cojocaru et 
al., 2007). Channel pw2a has been found to be common to many proteins studied by simulation; has 
been established to be the most energetically favourable of all the pathways observed in CYP101 
(Wade et al., 2004) and is proposed to be common to all P450s. It was also established as a product 
egress route for CYP101 and CYP2B4. This later property was described as possible because the pw2a 
is a holey channel, made possible due to the potential motion in the FG loop and/or the BC loop.  
CAVER computed 23 possible tunnels for FANGCYP6P9b of which the first ranked (Figure 
2.12B) with lower throughput (0.74) and higher cost (0.30) than the one from MOZCYP6P9b, is almost 
half short in length (13.91Å). Only 24 amino acid residues lined the tunnel gorge including those from 
SRS1 (Arg107, Phe110, Thr111, Leu118, His121, Phe123 and Ala124); residues from the SRS2 (Phe214, Glu215, 
Leu216), residues from FG loop (Phe224, Lys240, Ile241); one residue from SRS3 (Phe243); residues from 
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SRS4 (including Gly315 and Thr318, Phe309, Val310 and Leu313); Val380 of the SRS5 as well as Cys454 of the 
cysteine pocket. The corresponding Ile109 of FANGCYP6P9b is not part of any of the channels predicted 
for FANGCYP6P9b model. Another important difference observed is that deltamethrin docked in active 
site of MOZCYP6P9b is surrounded by this tunnel, the same insecticide in the model of FANGCYP6P9b 
is not enshrouded by the substrate access channel.  
CAVER computed 27 channels for MALCYP6P9a and 22 channels for FANGCYP6P9a; however 
the first five top ranked tunnels for two alleles were not different in their composition and 
parameters.  
These findings suggest that substrate access maybe playing a great role in the resistant alleles 
from CYP6P9b with tunnel lining residues for example the Val109 playing a critical role in proper 
positioning and affinity/specificity toward pyrethroids.  
 
 
Figure 2.12: Trajectory of the substrates access channel pw2a in (A) MOZCYP6P9b and (B) 
FANGCYP6P9b models docked with deltamethrin. Helix I and BC loops are annotated; pw2a is in blue; 
deltamethrin is in stick format and pink; heme atoms are presented in stick format and spectrum. Val
109
 and 
Ile
109 
are annotated respectively.  
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2.5 Discussion and Conclusion 
 
CYP6P9a with 17 haplotypes across Africa and 15 amino acid sequences is more polymorphic than 
CYP6P9b which posseses only 15 haplotypes and 11 different sequences. This is as observed in 
previous studies with alleles of CYP6P9a and CYP6P9b from southern Africa (Malawi and Mozambique) 
compared with the susceptible strain, FANG (Riveron et al., 2013). The East and southern African 
alleles of CYP6P9a exhibited reduced nucleotide variatins and seem to be undergoing directional 
selection while the West African BENCYP6P9a and the susceptible FANGCYP6P9a show high nucleotide 
diversity and are not undergoing directional selection.  
CYP6P9b from FANG portrayed high polymorphic variations compared with the resistant alleles all 
across Africa (East, West and southern Africa). However, in contrast to West African CYP6P9a, 
BENCYP6P9b allele which portrayed extensive inter-allelic variation compared with the other resistant 
alleles of CYP6P9b is undergoing intra-allelic directional selection in its unique way. This phenomenon 
suggests a central importance of CYP6P9b over CYP6P9a within the context of directional selection 
and possibly pyrethroid resistance in general.  
Comparison of the predominant haplotypes of CYP6P9a and CYP6P9b from resistant strains with 
corresponding sequences from FANG revealed that CYP6P9a has only two amino acids replacement 
that seem to be relatively fixed, while CYP6P9b possess seven mutations that are fixed in all the 
resistant strains compared with FANG. These 7 mutations in addition to Ser384Asn substitution (absent 
in BENCYP6P9b) map to catalytically important domains of CYP6P9b and are predicted to impact on 
the catalytic property of CYP6P9b from resistant alleles, making it possibly different from 
FANGCYP6P9b in terms of metabolic activity.   
ChemScore of less than -30 was described as a predictor of tight binding ligands (Marechal et al., 
2006), and based on this, pyrethroids etofenprox, permethrin and deltamethrin were predicted to be 
the tightest binders in order of listing. Docking analyses revealed dramatic differences in regio-
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selectivity of different CYP6P9a and CYP6P9b models toward pyrethroid insecticides. The southern 
African models have the highest scores on average and all the models from resistant strains exhibited 
productive poses with pyrethroids, consistent with the established docking solution with other P450s. 
The FANG models have lower scores, docked away from the heme catalytic centre for optimal 
metabolism, or unproductively as observed with permethrin in FANGCYP6P9b (dihalovinyl group 
approaching the heme) and etofenprox in FANGCYP6P9a (ethoxy group above the heme).  
While etofenprox docked into the active site of both CYP6P9a and CYP6P9b from resistant alleles 
with 2ʹ spot of phenoxy ring oriented for attack (suggesting that these two genes may not differ in 
their activities toward etofenprox and primary product generated), remarkable differences were 
observed in the conformations of permethrin and deltamethrin within the active site of CYP6P9a and 
CYP6P9b. For example, the top ranked solutions of permethrin in UGANCYP6P9a, FANGCYP6P9a, 
MALCYP6P9a and deltamethrin in FANGCYP6P9a and MALCYP6P9a predicted trans methyl 
hydroxylation as the preferential mode of metabolism, while in BENCYP6P9b and MOZCYP6P9b with 
permethrin, as well as all CYP6P9b models (BEN-, UGAN-, FANG- and MOZCYP6P9b) with deltamethrin 
it’s the 4ʹ spot of the phenoxy ring which is oriented for metabolism. This established that CYP6P9a 
and CYP6P9b differ in their regio-selectivity toward permethrin and deltamethrin, with gem dimethyl 
attack favoured by CYP6P9a while 4ʹ spot of phenoxy is the most preferred site of attack by CYP6P9b. 
The only exception is MOZCYP6P9b which produced multiple bound conformations with permethrin 
and deltamethrin (trans methyl group oriented for attack in some top ranked solutions) indicative of 
more than one primary metabolite.  
The 4ʹ spot has been described as the major site of attack on deltamethrin by insect P450s 
(Stevenson et al., 2011) and this productive pose is the one obtained especially with CYP6P9b from 
resistant alleles, and was predicted to have high activity towards pyrethroids. Its possible that 
CYP6P9b alleles are more efficient in pyrethroid metabolism compared with their CYP6P9a 
counterparts.  
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CYP6P9a and CYP6P9b models were also discovered to differ considerably in the composition of 
their pyrethroid binding sites, and this is reflected in the topology and geometry of their respective 
active sites. While the binding site of pyrethroids in CYP6P9a contains large number of aromatic 
(bulky) residues and possibly utilizes hydrophobic interactions, π-stacking, vdW interactions and 
resonance stabilization to drive catalysis, the active site of CYP6P9b especially from southern Africa 
contains few bulky residues and thus hydrophobic interaction is secondary in importance to ionic 
interactions and hydrogen bonding. The active site of CYP6P9b is rich in polar charged and neutral side 
chains with possibility of ionic attractions and hydrogen bonds driving catalysis. Ionic interactions have 
been described as the important non-bonded phenomena through which residues Glu216 and Asp301 
exert substrate specificity and product region-selectivity in CYP2D6 (Paine et al., 2003). Thus, 
hydrogen bondings are predicted to be the most important factor for non-bonded interactions within 
the active site of both resistant MOZCYP6P9b and susceptible FANGCYP6P9b models, while its 
predicted to be of secondary importance in MALCYP6P9a and FANGCYP6P9a which showed no 
intermolecular hydrogen bonds with both permethrin and deltamethrin.  
Analysis of the substrate access channels predicted that MOZCYP6P9b differs considerably in 
its topology compared with FANGCYP6P9b. The MOZCYP6P9b possesses a wide open channel pw2a 
which may enhance access of pyrethroids to the binding site and catalysis. The MOZCYP6P9b channel 
pw2a housed the Val109 residue predicted to be involved in affinity/specificity toward pyrethroids.  
Analysis of nucleotide diversities and amino acid sequences of alleles of CYP6P9a and CYP6P9b 
coupled with modelling and docking simulations predicted that allelic variation is  impacting on the 
activity of CYP6P9a and CYP6P9b toward pyrethroid insecticides with the alleles from resistant strains 
(especially from southern Africa) having high activity compared with alleles from susceptible strain 
(FANG) which were predicted to have lowest activity.  
Allelic variation has been shown to impact on the catalytic activity of other P450s. For 
example, comparison of allelic variants CYP6AB3v1 and CYP6AB3v2 (a difference of only five amino 
97 
 
acid residues) of D. pastinacella (parsnip webworm) established that only a single amino acid 
difference Val92 in CYP6AB3v1 and Ala92 in CYP6AB3v2 makes the latter able to metabolize 
imperatorin, a toxic furanocoumarin with a high rate (Mao et al., 2007). It was also recently shown 
that a single mutation in the GSTe2 gene (Leu119Phe substitution) from resistant strain of An. funestus 
from Benin resulted in an increased binding cavity making the Phe119 variant capable of metabolizing 
DDT and conferring resistance in this specie.  
DDT has ChemScore of less than -30 but the fact that DDT produced unproductive poses in all 
the docking solutions with alleles from the resistant strains as well as FANG suggests that even if this 
organochlorine insecticide binds to the pyrethroid, it may not be metabolized. DDT is established from 
several studies to be metabolized by CYP450s by dehalogenation of trichloromethyl group (Chiu et al., 
2008, Amichot et al., 2004) and thus the docking results obtained here predicted DDT docking in either 
unproductive mode or away from the heme catalytic center for optimal metabolism.  
Bendiocarb produced very low docking scores on average half or three-fold less than values 
obtained with the pyrethroid insecticides. The docking parameters and conformation of bendiocarb in 
the active sites of CYP6P9a and CYP6P9b indicated no activity toward this carbamate insecticide.  
 Docking simulations predicted CYP6P9a and CYP6P9b models from resistant alleles from southern 
Africa as having high activity towards pyrethroid insecticides. This is consistent with the widespread 
pyrethroid resistance in An. funestus strains where these genes are the most overexpressed. The 
docking software predicted no activity towards DDT predicting that these genes are not involved 
directly in DDT resistance observed in East and West African population of An. funestus. For DDT 
resistance in West Africa, it has been established that CYP6P9a and CYP6P9b are not involved; rather a 
GSTe2 variant is responsible for the extreme resistance in An. funestus from Benin, West Africa 
(Riveron et al., 2014b). The software predicted no activity toward bendiocarb as well, suggesting that 
these P450s are not involved in carbamate resistance observed in West and southern African 
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population of An. funestus. Factors responsible for carbamate resistance in these regions need to be 
found urgently.  
Molecular docking predictions are subject to experimental validation and thus pyrethroid-
metabolizing activity predicted by the docking algorithm and inactivity toward DDT and bendiocarb 
must be validated with laboratory experiments including probes assay to assess binding affinities and 
metabolism assays to determine catalytic activities toward these insecticides screened.  
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3. ASSESSMENT OF METABOLIC EFFICIENCY OF ALLELIC VARIANTS USING 
FLUORESCENT PROBES, METABOLISM ASSAY AND TRANSGENIC 
EXPRESSION OF CYP6P9a and CYP6P9b ALLELES 
 
3.1 Background 
Modelling and docking analyses predicted that the CYP6P9a and CYP6P9b alleles from resistant 
strains of An. funestus are capable of metabolizing Type I and Type II pyrethroids with higher efficiency 
compared with corresponding alleles from susceptible strain. Even between the resistant alleles, 
variations in metabolic activities were predicted with the southern African alleles especially of 
CYP6P9b anticipated to have highest activity of all the alleles screened. The docking software also 
predicted that recombinant CYP6P9a and CYP6P9b possess no enzymatic activity toward non-
pyrethroid insecticides DDT and bendiocarb. However, docking is in silico simulations and not enough 
evidence in itself and therefore subject to experimental validations. In vitro heterologous expression 
and estimation of P450 activity as established using mammalian cells (COS cells), yeast cells like S. 
cerevisiae, insect cells (Baculovirus sf9 cells), as well bacterial (E. coli) expression systems (Gonzalez 
and Korzekwa, 1995, Waterman and Johnson, 1991, Pritchard et al., 2006a) have been widely applied 
to characterise the metabolic activity of candidate P450s. Heterologous expression of P450s and 
functional characterisation using fluorescent probes assays have been  used for functional validation 
of modelling predictions. For example: (i) modelling analysis, heterologous expression in E. coli, probes 
assay and metabolism assays revealed that An. gambie CYP6Z2 can bind pyrethroids permethrin and 
cypermethrin but cannot metabolize them (McLaughlin et al., 2008), (ii) in silico modelling and 
heterologous expression of Ae. aegypti CYP6Z8 (ortholog of An. gambiae CYP6Z2) in recombinant 
yeast cells coupled with fluorescent probes assay, HPLC metabolism assays and MS/MS identification 
of metabolites have revealed that this P450 is capable of metabolizing primary products of pyrethroid 
metabolism from carboxylesterases, including 3-phenoxybenzoic alcohol and 3-phenoxybenzaldehyde  
into 3-phenoxybenzoic acid (Chandor-Proust et al., 2013).  
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Site-directed mutagenesis (SDM) have evolved into a powerful approach that allows molecular 
biologists to unveil the protein-structure function relationships. It is an invaluable tool that makes it 
realisable to modify DNA sequences for desired end (Zheng et al., 2004) with random or target 
mutations introduction in the protein coding sequence followed by screening the mutant library for 
functional activity changes. SDM has been used extensively to identify key amino acid residues that 
are involved in catalysis. For example, (i) Glu216Leu/Gln/Phe mutation of CYP2D6 have been shown to 
result in 100-fold decrease in affinity in the KM of bufurarol and dextromethorphan (Paine et al., 2003); 
(ii) Asp293Ala replacement in human CYP2C9 resulted in 90% decrease in activity and 3-10 times 
increased KM for diclofenac, dextromethorphan and tolbutamide (Flanagan et al., 2003); (iii) Val
92Ala 
substitution in D. pastinacella CYP6AB3v1 caused quantitative changes making the P450 as efficient as 
CYP6AB3v2 in metabolizing plants allelochemical imperatorin (Mao et al., 2007).  
Several other insect P450s implicated as insecticides metabolisers have been functionally 
characterised by various approaches, including liquid chromatography (Stevenson et al., 2012, 
Duangkaew et al., 2011, Mitchell et al., 2012) as well as combination of LC/MS and NMR-spectroscopy 
(Stevenson et al., 2011). On Anopheles funestus, we have already functionally characterized the role of  
duplicated P450s (CYP6P9a and CYP6P9b alleles from southern Africa: see Appendix 5 for list of 
publications derived from this study). Both CYP6P9a and CYP6P9b recombinant proteins metabolize 
Type I and II pyrethroids (Riveron et al., 2013, Riveron et al., 2014a).  
In vivo transgenic expression of candidate genes has also been used in several studies to establish 
the role of P450s in metabolism of insecticides and resistance. For example, D. melanogaster CYP6G1 
has been implicated as the cause of DDT resistance using transgenic overexpression (Daborn et al., 
2007), and transgenic expression of T. castenaum CYP6BQ9 in D. melanogaster established its 
involvement in deltamethrin resistance (Zhu et al., 2010). Using transgenesis, we have also established 
that the southern African CYP6P9a and CYP6P9b, as well as CYP6M7 confer resistance to Type I and 
Type II pyrethroids in An. funestus, in vivo (Riveron et al., 2013, Riveron et al., 2014a) (Appendix 5).  
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3.2 Aim and Objectives 
The main aim of this section was to establish whether the allelic variation observed in the major 
pyrethroid resistance genes- the cytochrome P450s CYP6P9a and CYP6P9b, impacts their metabolic 
efficacy as predicted by modelling and thus could be the key factor responsible for pyrethroid 
resistance in field populations of An. funestus.  The specific aims of this  study were to: 
1-Assess the metabolic activity of various alleles using fluorescent probes followed by kinetics with 
diethoxyfluorescein and inhibition assays; 
2-Establish the activity of various alleles of both genes with pyrethroids, organochlorine and 
carbamate insecticides, followed by kinetics analyses with permethrin and deltamethrin; 
3- Identify the key amino acid change(s) which confer pyrethroid-metabolizing efficiency in the 
resistant alleles of these genes using site-directed mutagenesis; 
4-  Predict in silico the mechanism by which such amino changes modify metabolic activity of CYP6P9b. 
4- Validate the role of allelic variation of CYP6P9a and CYP6P9b in pyrethroid resistance by comparing 
resistant and susceptible alleles with in vivo transgenic expression in D. melanogaster using the GAL4-
UAS system. 
 
3.3  Methods 
3.3.1  Cloning and Co-Expression of Recombinant CYP6P9a and CYP6P9b cDNA with An. 
gambiae Cytochrome P450 Reductase (CPR) 
3.3.1.1 Construction of pB13::ompA+2-CYP6P9a and pB13::ompA+2-CYP6P9b Plasmids 
Six alleles each from CYP6P9a and CYP6P9b (were selected for cloning and heterologous 
expression (Table 3.1).  
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Table 3.1: Country of origin, CYP6P9a and CYP6P9b alleles selected for functional characterisation  
Country Allele Amino Sequence Replacement Mutations 
CYP6P9a 
Benin BENCYP6P9a Ala51Ser, Gln52Leu, His301Gln, Tyr320Ser, Ser431Phe 
Uganda UGANCYP6P9a Ala51Ser, Gln52Leu, His301Gln, Tyr320Ser, Ser431Phe 
Malawi MALCYP6P9a Phe63Leu, Gln66Lys, His301Gln, Tyr320Ser, Ser431Phe 
Mozambique MOZCYP6P9a Phe63Leu, Gln66Lys, His301Gln, Tyr320Ser, Ser431Phe 
Zambia ZMBCYP6P9a Phe63Leu, Gln66Lys, His301Gln, Tyr320Ser, Ser431Phe 
Angola FANGCYP6P9a Ala51, Gln52, Phe63, Gln66, His301, Tyr320, Ser431 
 CYP6P9b 
Benin BENCYP6P9b Ser32Asn, Ile109Val, His169Arg, Gln171Pro, Glu172Asp, Glu335Asp, Ala401Pro 
Uganda UGANCYP6P9b 
Ser32Asn, Ile109Val, His169Arg, Gln171Pro, Glu172Asp, Glu335Asp, Ser384Asn, 
Ala401Pro 
Malawi MALCYP6P9b 
Ser32Asn, Ile109Val, His169Arg, Gln171Pro, Glu172Asp, Glu335Asp, Ser384Asn, 
Ala401Pro 
Mozambique MOZCYP6P9b 
Ser32Asn, Ile109Val, His169Arg, Gln171Pro, Glu172Asp, Glu335Asp, Ser384Asn, 
Ala401Pro 
Zambia ZMBCYP6P9b 
Ser32Asn, Ile109Val, His169Arg, Gln171Pro, Glu172Asp, Glu335Asp, Ser384Asn, 
Ala401Pro 
Angola FANGCYP6P9b Ser32, Ile109, His169, Gln171, Glu172, Glu335, Ser384, Ala401 
 
Full-length, unmodified cDNA of CYP6P9a and CYP6P9b alleles were expressed as microsomal 
proteins using ompA+2 strategy (Pritchard et al., 2006a). cDNA fragment encoding the bacterial outer 
membrane protein A (ompA) leader sequence (21 amino acids) and 2 additional spacer residues (Ala-
Pro linker) were introduced as signal peptide ompA+2 to the NH2-terminus of the P450 cDNAs in frame 
with the P450 initiation codon as shown in scheme in Figure 3.1. The signal peptide directs the P450 to 
the membrane surface (Pritchard et al., 1997) and is thereafter cleaved upon expression in a fashion 
enhanced by the Ala-Pro spacer residues.  
 
Figure 3.1: General scheme for the PCR-mediated fusion of bacterial leader sequences to P450 
cDNAs. Adapted from  (Pritchard et al., 1997). 
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3.3.1.1.1 Construction of ompA+2-CYP6P9a and ompA+2-CYP6P9b cDNA 
Initially, a short DNA fragment was synthesized in a fusion PCR using 50ng E. coli JM109 gDNA 
as a template with a leader sequence-specific forward primer ompA+2F: GGAATTCCATATGAAAAAG 
ACAGCTATCGCG (EcoRI and NdeI sites are underlined in green and purple respectively) and a reverse 
linker primer: ompA+2CYP6P9a/bR: CAACACCACGTTAATGAGCTCCATCGGAGCGGCCTGCGCTACGGTAG 
CGAA which is complementary to the first 24 nucleotides 5ʹ end of CYP6P9a and CYP6P9b cDNA, 
underlined in  dark red, joined to the last 21 bases linker of the leader sequence. This reverse primer is 
common to both CYP6P9a and CYP6P9b that have identical NH2-terminus. PCR reaction mix is given in 
Table 3.2 and the High-Fidelity PCR conditions were as follows: 1 cycle at 95°C for 5 min; 35 cycles 
each of 94°C for 20s, 58°C for 30s, and elongation at 72 °C for 45s; and 1 cycle of final extension at 
72°C for 5 min. The PCR product, an intermediate fragment (linker) of less than 100bp (containing the 
ompA+2 signal sequence and the first 24 nucleotides  was confirmed using gel electrophoresis (Figure 
3.2), cleaned with QIAquick® PCR Purification Kit (Qiagen) as explained in section 2.3.2.3(ii) and its 
quality and quantity assessed with Nanodrop Spectrophotometer (Thermo Fisher).  
Table 3.2: PCR reaction mix for ompA+2 intermediate linker fragment synthesis 
Reagent Final Concentration Volume (µl) 
10x  Qiagen Buffer (containing 5mM MgCl2) 1x 5 
dNTP mix (25mM) 0.66mM 0.4 
ompA+2F (10µM) 1µM 1.5 
ompA+2CYP6P9a/bR (10µM) 1µM 1.5 
JM 109 gDNA template 50ng 1.0 
dH2O - 39.6 
HotStar Taq Polymerase 1U/µl 1.0 
Total Volume - 50 
 
 
 
 
Figure 3.2: ~100 bp intermediate linker product resolved on 1.5% agarose gel stained 
with Ethidium Bromide. 
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Next, cDNA minipreps of CYP6P9a and CYP6P9b alleles prepared in section 2.3.2.3(iii) were 
used as templates with limiting concentrations of the linker prepared above for second PCR, using the 
leader sequence-specific forward primer (ompA+2F) and reverse primers:- ompA+2CYP6P9aR: TCTAGA 
GAATTCTCACAATTTTTCCACCTTCAAG and ompA+2CYP6P9bR: TCTAGAGAATTCTTACACCTTTTCTACCTTC 
AAG. These reverse primers designed with XbaI and EcoRI restriction sites underlined in red and green 
respectively are complementary to the 3ʹ-terminus of CYP6P9a and CYP6P9b cDNA. PCR reaction mix is 
given in Table 3.3 and the High-Fidelity conditions were as follows: 1 cycle at 95°C for 15 mins; 35 
cycles each of 94°C for 20s, 50°C for 30s, and elongation at 72 °C for 90s; and 1 cycle of final extension 
at 72°C for 5 mins. The PCR product, a cDNA containing the ompA+2 signal peptide joined to the full 
length cDNA (~1600bp) was confirmed using agarose gel electrophoresis, cleaned with QIAquick® PCR 
Purification Kit (Qiagen) and its quality and quantity assessed with Nanodrop Spectrophotometer 
(Thermo Fisher). 5-7ng of these PCR products were ligated into pJET1.2/blunt cloning vector using 
the CloneJET PCR Cloning Kit (Fermentas) as described in Table 2.2 and transformed into DH5α 
(section 2.3.2.3). Positive colonies screened with pJET1.2 primers listed in Table 2.1 were miniprepped 
overnight and sequenced using the pJET725 primers for presence of ompA+2 signal peptide sequence 
and restriction sites.   
 Table 3.3: PCR reaction mix for fusion of ompA+2 leader sequence to CYP6P9a/b cDNA  
Reagent Final Concentration Volume (µl) 
10x  Qiagen Buffer (containing 15mM MgCl2) 1x 5 
dNTP mix (25mM) 0.66mM 0.4 
ompA+2F (10µM) 1µM 1.5 
ompA+2CYP6P9aR/ ompA+2CYP6P9bR (10µM) 1µM 1.5 
Linker fragment 1ng/µl 0.5 
dH2O - 40.1 
HotStar Taq Polymerase 1U/µl 1.0 
Total Volume - 50 
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3.3.1.1.2 Restriction Digestion of pJET1.2::ompA+2-CYP6P9a/CYP6P9b Construct  
The pJET1.2::ompA+2-CYP6P9b plasmids were double-digested with restriction enzymes NdeI 
and XbaI (Table 3.4) from Fermentas and purified by gel-extraction using the QIAquick® Gel Extraction 
Kit (QIAgen). Efforts to digest pJET1.2::ompA+2CYP6P9a plasmids were unsuccessful and as such the 
cleaned PCR products from section 3.3.1.1.1 were double digested directly and used for the next step. 
Table 3.4: Double digestion of ompA+2CYP6P9a and pJET1.2::ompA+2CYP6P9b products 
Reagent Final Concentration Volume (µl) 
10x  Fast Digest Green Buffer 1x 5 
Fast Digest NdeI - 2 
Fast Digest XbaI - 2 
Plasmid/PCR product 0.1-0.5µg 10-20 
dH2O As required 20-30 
Total Volume - 50 
 Digestion condition: 37oC for 2 hours and 65oC for 15 mins 
3.3.1.1.3 Ligation of Restriction Digests into pCWOri+ Plasmid and Cloning into DH5α 
The ompA+2-CYP6P9a PCR product and ompA+2CYP6P9b plasmid digests were ligated 
overnight into pCWOri+ expression plasmid already linearized with NdeI and XbaI restriction enzymes 
(Table 3.5). pCWOri+ is one of the most convenient expression vector with two tac promoter cassettes 
upstream of NdeI (CA↓TATG) restriction site coincident with initiation codon ATG (Barnes et al., 1991) 
as well as a gene encoding Lac repressor molecule which prevents transcription from tac promoters 
before addition of inducing agents. A map in Figure 3.3, prepared using the NEB Cutter v2.0 (Vincze et 
al., 2003) shows the strategy for the construction of the expression plasmid: pB13::ompACYP6P9b. 
Table 3.5: Ligation of ompA+2CYP6P9a and pJET1.2::ompA+2CYP6P9b products 
Reagent Final Concentration Volume (µl) 
Restriction Digest 20-50ng 10-25 
pCWOri+ Digest 5-10ng 2-4 
10x  T4 DNA Ligase Buffer 1x 1 
dH2O - As required 
T4 DNA Ligase 1U/µl 1 
Total Volume  50 
 Ligation condition: 16oC for 16 hours 
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4µl of the ligation product was used to transform high efficiency DH5α using the protocol 
outlined in section 2.3.2.3. Positive colonies were screened with  forward (seqpCWF) and reverse 
(seqpCWR) primers (Table 3.6) designed within the pCWOri+ sequence approximately 100 nucleotides 
upstream of the NdeI restriction site and downstream of the XbaI restriction site respectively. A band 
of around 1800bp comprising the insert gene (1527bp), the ompA+2 leader sequence as well as the 
~200 nucleotides from pCWOri+ flanking the insert confirm the presence of the candidate genes in the 
expression vector. These colonies were miniprepped overnight and sequenced using the ompA+2F and 
ompA+2CYP6P9a/bR primers as well as the seqpCWF and seqpCWR primers to confirm the presence 
of ompA+2 signal peptide sequence and restriction sites.   
Table 3.6: Primers for sequencing of ompA+2-CYP6P9a/b in pCWOri+ and CPR in pACYC-184 
Primer Forward Sequence Reverse Sequence Product 
Size (bp) 
seqpCW ATCCCCCTGTTGACAATTAATCATC ACCTATAAAAATAGGCGTATCACGA ~1800 
SeqCPR CTACTCGATCCATATGACGACGGTGAACAC TACGGATCCTACAGCACATCCTCGCCCGTGCTC ~600 
 
3.3.1.2 Construction of pACYC-184:: Cytochrome P450 Reductase Plasmid 
pACYC-184 (New England Biolabs) containing  the ancillary protein An. gambiae cytochrome 
P450 reductase (AgCPR) as well as the His-tagged An. gambiae cytochrome b5 (Agb5) used on the 
course of this study were kindly provided by Dr. M.J.I. Paine at LSTM. The P450 reductase expression 
cassette was prepared as described previously (Pritchard et al., 1998, Pritchard et al., 2006a) with 
P450 reductase cDNA modified by fusing it with pelB leader sequence in a strategy similar to that of 
the ompA+2 for P450s but using the plasmid pET-20b as a template for the initial linker PCR. The 
pACYC-184 expression vector encodes gene for chloramphenicol resistance. More details of the 
engineering method of this plasmid could be found in (Pritchard et al., 2006a).  
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3.3.1.3 Construction of pB13 ::( His) 4-Cytochrome b5 and Purification of b5 
Agb5 cDNA isolated by Nikou and colleagues (Nikou et al., 2003) was tagged with histidine 
residues in its NH2-terminus and engineered into pB13 plasmid already linearized with NdeI and HindIII 
restriction sites. Expression of b5 protein was done using A183 E. coli cells, harvested after 24-30 hours 
post-induction with 0.5mM δ-ALA and 1mM IPTG to the final concentration. The protein was prepared 
using the technique outlined by Holmans and colleagues (Holmans et al., 1994) in which the 
solubilized hemoprotein was purified by nickel affinity chromatography. Concentration of 
membranous b5 was measured by determining spectral activity (Omura and Takesue, 1970, Omura 
and Sato, 1964) as difference between reduced and oxidized b5 (OD423 vs OD490) using the extinction 
coefficient of 185mM-1cm-1. Total protein was determined using Bradford assay. The enzyme was 
frozen in aliquot in -80oC until required. 
 
 
 
 
Figure 3.3: Map of pB13::ompA+2CYP6P9b showing expression plasmid construct in 
circular form. a: 21 amino acids of signal peptide plus alanine proline spacer residues, and 
509 amino acids encoded by CYP6P9b cDNA. b: LacI repressor (NCBI: WB_0002485631); c: β-
lactamase (NCBI: WP_000027057.1); d: LacZ-alpha (GenBank: ACA63830.1); e: Ori+. Prepared 
using the NEB Cutter v2.0 (http://tools.neb.com/NEBcutter2/index.php). 
 
108 
 
3.3.1.4 Co-transformation of pB13:: ompA+2CYPP9a and pB13::ompA+2CYP6P9b with 
pACYC-184-An. gambiae CPR 
High Efficiency E. coli JM109 cells (Promega) were co-transformed with plasmid pB13 
containing An. funestus CYP6P9a/CYP6P9b and pACYC-184 bearing AgCPR in a ratio of 2:1. AgCPR was 
used due to the unavailability of An. funestus CPR cloned into pACYC vector; and because AgCPR (96% 
identical to An. funestus CPR) had been used as a surrogate redox partner with other P450s of even 
lower similarity like Ae. aegypti (87% identical) successfully (Stevenson et al., 2012). Co-transformation 
strategy has been described in (McLaughlin et al., 2008). 100µl of JM 109 cells was introduced into 
15ml tube chilled on ice. 4µl of pB13 plasmid bearing candidate P450 and 2µl of pACYC plasmid 
bearing CPR were introduced into the tubes. After 30 mins incubation on ice, cells were heat shocked 
for 90 seconds at 42oC and then chilled on ice for 2 mins. 950µl of S.O.C medium was added and tubes  
incubated at 37oC with shaking at 200rpm for 2 hours. 100µl of the co-transformed cells were spread 
onto LB plates with 100mg/ml ampicillin and 34mg/ml chloramphenicol and allowed to grow at 37oC 
for 16 hours.   
Individual colonies were suspended in 20µl distilled water the next day and screened using KAPA 
PCR (section 2.3.2.3(iii)) using the  primers for pCWori+ (seqpCWF and seqPCWR) to confirm presence 
of candidate P450s and primers seqCPRF and seqCPRR (Table 3.6) for CPR. The seqCPR primers are 
internal primers designed inside the P450 reductase itself and produced a band of around 600bp on 
1.5% agarose gel stained with ethidium bromide.    
3.3.1.5 Heterologous co-expression of pB13:: ompA+2-An. funestus CYPP9a and pB13:: 
ompA+2-An. funestus CYP6P9b with pACYC-184-An. gambiae CPR in E. Coli JM109 
For co-expression of CYP6P9a/-b and CPR, 4µl of co-transformed colony suspended in distilled 
water was introduced into a 15ml tube containing 3ml LB medium, 3µl of 100mg/ml ampicillin and 
5.1µl of 20mg/ml chloramphenicol. Culture was allowed to grow for 12-14 hours at 37oC with shaking 
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at 200 rpm. The next day 1-2ml of this culture was used to inoculate 200ml of pre-warmed (37oC) TB 
medium containing 200µl ampicillin and 340µl chloramphenicol. This culture was allowed to grow for 
3-4 hours at 37oC and 200 rpm orbital shaking until the optical density at 600nm reached 0.6-0.7. The 
log-phased cells was then transferred to 21oC (22oC optimal for CYP6P9a) and 150 rpm orbital shaking 
(155 rpm optimal for CYP6P9a alleles) and allowed to cool for 30 minutes. Induction was carried out 
by adding 1mM IPTG and 0.5mM δ-ALA to the final concentrations. Cultures were monitored for P450 
activity at 6 hours interval starting from 18 hours. Once P450 activity was detected cultures were then 
transferred into 250ml tubes chilled on ice and centrifuged at 2800 rpm and 4oC for 20 minutes. Detail 
of this protocol could be found in (McLaughlin et al., 2008, Pritchard et al., 2006a, Stevenson et al., 
2012) and specifically the procedure for co-expression, harvesting of cells, spheroplast preparation 
and isolation of membranes are given in Appendix 3.1. 
3.3.1.6 Determination of concentration of An. funestus CYP6P9a/CYP6P9b proteins and An. 
gambiae cytochrome P450 reductase activity 
3.3.1.6.1 Measurement of Total Protein, P450 and CPR Activities 
Protein content of the membranes was measured colorimetrically with Bio-Rad Protein Assay 
Kit (Life Science Research) using the Bradford method (Bradford, 1976) with bovine serum albumin 
standard.  
The P450 concentration was quantified through spectral activity as described (Omura and Sato, 
1964) by measuring the size of the peak (absorbance) at 450nm and using the absorbance at 490nm as 
a reference and an extinction coefficient (ecyt450 = 0.091µM
-1cm-1) for P450s. 50µl of membrane was 
diluted in 1.5ml of P450 spectrum buffer (80% of 0.1M potassium phosphate buffer, pH 7.5, with 20% 
v/v glycerol). Few grains of sodium dithionate was added and the mix swirled gently and then divided 
(750µL each) into two optical cuvettes labelled E (experimental) and B (blank). After running a baseline 
between 500-400nm, carbon monoxide was bubbled into E for 60s. The extinction coefficient, dilution 
factor and the Fe2+-CO (E) and Fe2+ (B) difference spectra were used to calculate the P450 activity.  
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CPR activity in the prepared membranes was measured by cytochrome c reduction assay (Strobel 
and Dignam, 1978). Details of the protocol for this assay could be found elsewhere (Pritchard et al., 
2006a). Reductase activity was measured spectrophotometrically based on extinction coefficient of 
reduced cytochrome c (21.4 mM-1cm-1) as nmol of cytochrome c reduced/min/mg protein.  
3.3.2 Comparative Assessment of the Activity of Various Alleles of CYP6P9a and CYP6P9b 
Using Fluorescent Probes 
Four membranes each from CYP6P9a (BENCYP6P9a, UGANCYP6P9a, FANGCYP6P9a and  
MALCYP6P9a) and CYP6P9b (BENCYP6P9b, UGANCYP6P9b, FANGCYP6P9b and MOZCYP6P9b) were  
used in a fluorescent probes assay to compare their O-dealkylating catalytic efficiency towards four 
fluorogenic probes (7-ethoxyresorufin: 7-ER, 7-ethoxy-4-trifluoromethylcoumarin:EFC, 7-methoxy-4-
trifluoromethylcoumarin: MFC and diethoxyfluorescein: DEF). ER is an O-alkyl derivative of resorufin 
which undergoes O-deethylation (Burke et al., 1985) with a large Stoke shift which is quantified 
fluorometrically (ʎexc = 544nm, ʎemi = 590nm); EFC and MFC are ethoxy- and methoxy- derivatives of 
coumarin respectively, which undergo deethylation and demethylation to yield fluorescent 7-
hydroxytrifluoromethyl-coumarin (7-HFC) detected at wavelength range ʎexc =410nm and ʎemi = 535nm 
respectively. DEF undergoes deethylation into ethoxyfluorescein and fluorescein (White et al., 1987) 
with excitation and emission wavelength ranges of 485nm and 530nm, respectively.  I conducted the 
probe assay experiments in Cypex BioDundee, Scotland (http://www.cypex.co.uk/intro.htm).  
3.3.2.1 Screening of Probes 
2mM stock of probe substrates in dimethylsulfoxide (DMSO) was prepared and kept at 2-8oC. 
Fresh NADPH regeneration system was prepared using 50mM potassium phosphate buffer (KPi at pH 
7.4) for each experiment. Initially, 1µM of the probe substrates (ER, EFC, MFC and DEF) were screened 
for activity with 45pmol of membranes of CYP6P9a and CYP6P9b (Table 3.7) following the protocols 
previously established (Stevenson et al., 2012, McLaughlin et al., 2008). For each of the four probes 
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screened, in a total volume of 250µ/well (in an opaque, white 96-well plate) containing 45pmol P450 
membrane buffered with 50mM potassium phosphate buffer (KPi at pH 7.4 with 5mM MgCl2), 1µM 
probe substrate was added. These reactions were carried out in triplicate and one negative control to 
which 25µl KPi buffer was added instead of the NADPH regeneration buffer to allow for determination 
of enzymatic activity due only to dealkylation mediated by the P450 activity. The plate was inserted 
into the fluorescence spectrophotometer Infinite® M200 (TECAN) already set to 37oC. After incubation 
for 5 mins, 25µl of regeneration buffer was added to the experimental wells and product(s) 
fluorescence monitored for 11 cycles with shaking and reading 2 seconds apart. The regeneration 
system contains 1mM glucose-6-phosphate (G6P), 0.25mM MgCl2, 0.1mM NADP and 1U/ml glucose-6-
phosphate dehydrogenase (G6PDH). Rate of fluorescent product formation was determined as relative 
fluorescence per minute by linear regression of measurement between 2- and 8 mins after start of the 
reaction. Results were analysed with MagellanTM v6.2 Wizard. The excitation and emission wavelength 
for the probes used on the course of this research are given in Appendix 3.3. 
Table 3.7: Reaction mix for fluorescence probes assay 
Component Stock 
Concentration 
Final Reaction 
Concentration 
Volume 
 (µl) 
 KPi Buffer (containing 5mM MgCl2) 50mM 50mM Varies 
P450 protein  Varies (nmol/ml) 45pmol Varies 
Probe substrate 2mM 1µM 0.125 
Incubation at 37oC for 5 minutes  
10X Regeneration system 10x 1X 25µl 
                 Total Volume 250 
 
3.3.2.2 Linearity Measurements 
For all membranes highest activities were obtaind with diethoxyfluorescein (DEF). DEF was 
therefore selected for kinetics analysis and inhibition assays to establish respectively the possible 
differences in the steady state kinetic parameters from different alleles and to carry out inhibition 
assays. In order to establish the amount of membranes that produce optimal activity with 1µM DEF 
substrate protein linearity was conducted with two membranes each from CYP6P9a (BENCYP6P9a and 
112 
 
MALCYP6P9a) and CYP6P9b (MOZCYP6P9b and UGANCYP6P9b). Time-dependent measurement of 
activity against 1µM DEF was carried out with variable amounts of membranes, prepared by serial 
dilution (90pml, 30pmol, 10pmol, 3.33pmol, 1.11pmol and 0.37pmol) prior to addition of the 
substrate. The final solvent concentration was less than 3% of the total volume of the incubation 
mixture. Plates were read in fluorometer for 30 mins at 30 seconds interval following addition of 
NADPH-regenerating solution.  
3.3.2.3 Kinetic Analysis of  Various CYP6P9a/CYP6P9b proteins with Diethoxyfluorescein 
Kinetic analysis was conducted using all alleles utilised for initial screening of probes. This was 
to establish if there were any differences in the turnover of these alleles with DEF and to establish the 
Michaelis constant (KM values) which could indicate differences in the affinity of the different alleles 
toward DEF substrate. 0-2µM concentrations of DEF (0µM, 0.0009µM, 0.0027µM, 0.0082µM, 
0.0247µM, 0.0741µM, 0.2222µM, 0.6666µM and 2.0µM) were assayed with 10pmol membranes of 
CYP6P9a and 3.33pmol of CYP6P9b proteins in a total volume of 250µl/well. The protocol was as 
outlined in the initial screening for activity (above), only that the substrate concentration varies and 
incubation was done under conditions shown to be linear with respect to time and enzyme 
concentration. Steady-state kinetic parameters were obtained by measuring the rate of reaction under 
linear conditions for 10 mins while varying the substrate concentration from 0 to 2µM. KM and Vmax 
were established from the plot of substrate concentrations against the initial velocities through a non-
linear regression by fitting the data to the Michaelis-Menten equation using GraphPad Prism 6.03 
(GraphPad Software Inc., La Jolla, CA, USA). Catalytic constants (KM and Vmax) were determined from 
the steady-state parameters  efficiencies calculated as the ratio of Kcat to KM. 
3.3.2.4 Inhibition Assay  
Inhibition assay is important as it can establish whether a potential subsrate (e.g. insecticide) 
binds to the candidate enzyme and the degree of binding. It gives information on the affinity but not 
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metabolic activity of candidate enzyme toward substrate of interest. Fluorometric inhibition assay was 
conducted with DEF as the probe substrate, a panel of insecticides (test compounds) as inhibitors, and 
miconazole as positive control inhibitor. Miconazole is a potent polyene azole antifugal agent. It 
contains imidazole group which binds to the iron of heme P450 C14α-lanesterol demethylase) 
preventing the demethylation of lanosterol into demethyl-lanosterol intermediate of the HMG-CoA 
pathway (Lupetti et al., 2002). The ten test insecticides used include pyrethroids: permethrin, 
bifenthrin, deltamethrin, lambdacyhalothrin, cypermethrin and etofenprox; organochlorine: DDT; 
carbamates: bendiocarb and propoxur; organophosphate: chlorpyrifos.  
The assay was carried out as described in previous studies (Kajbaf et al., 2011, Bambal and 
Bloomer, 2006) and as described for An. gambiae CYP6Z2 with benzyloxyresorufin and pyrethroids, 
permethrin and cypermethrin, as well as other conventional substrates (McLaughlin et al., 2008). Two 
96 well plates: opaque-walled (inhibitors plate) and black (assay plate) were set.  
Premix 1: Into well A1 of the inhibitors plate, 200µl of 50mM KPi  (with 5mM MgCl2) was 
added; 200µl of 50mM KPi with MgCl2 containing 2.5mM miconazole prepared in DMSO and dH2O was 
added to well A2; into well A3:A12, 200µl each of 50mM KPi containing 2.5mM test inhibitor 
substrates  were individually added. 150µl of 50:50 (v/v) dH2O:DMSO was added to column B1:H1 for 
blank, B2:H2 for miconazole and B3:H3 through to B12:H12 for the test insecticides. Next, 50µl mix 
from rows A1:A12 (spikes) was serially diluted down to row H1:H12 using multichannel pipette with 
mixing at each row (step). Finally 50µl of mix was removed from rows H1:H12 and discarded. 5µl of 
this premix 1 were aliquot in correct order onto the black assay plate.  
Premix 2: 220µl of 50mM KPi buffer pH 7.4 (with 5mM MgCl2), containing 0.1-0.3µM final 
concentration of probe substrate (KM values) and 10pmol membrane (CYP6P9a) or 3.33pmol 
(CYP6P9b) were aliquoted into the assay plate already containing 5µl (25µM) of miconazole well B2:H2 
and 25µM test insecticides serially diluted into eight-fold concentrations (25µM, 8.33µM, 2.77µM, 
0.92µM, 0.308µM, 0.102µM, 0.034µM and 0.011µM) B3:H3 to B12:H12.  
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After incubation for 5 mins at 37oC, reaction was started by addition of 25µl of regeneration 
system to all wells. The regeneration buffer contains 7.8mg glucose-6-phosphate (G6P), 0.25mM 
MgCl2, 1.7mg NADP, 6U/ml glucose-6-phosphate dehydrogenase and 2% w/v NaHCO3. Fluorescence 
was monitored for 21 cycles at interval of 1 min with shaking at every step. Results were analysed 
using Magellan v6.2 and inhibition at each concentration of inhibitor insecticide was calculated as 
residual control activity observed from the probe.  
 
3.3.3 Comparative Assessment of Metabolic Activity of CYP6P9a/CYP6P9b Alleles on Different 
Insecticide Classes with Reverse-Phase High-Performance Liquid Chromatography (RP-
HPLC) Metabolism Assay 
The same membranes from CYP6P9a and CYP6P9b used for fluorescent probes assay were 
used for metabolism assay with panel of insecticides, including representative pyrethroids 
(permethrin, bifenthrin, deltamethrin, λ-cyhalothrin, etofenprox), organochlorine (DDT) and 
carbamates (bendiocarb and propoxur). Protocols used followed the procedure as described in 
previous studies (Muller et al., 2008, Stevenson et al., 2011) for metabolism assays of pyrethroids with 
An. gambiae CYP6P3 and CYP6M2 recombinant proteins, respectively. 
3.3.3.1 Substrate Depletion Assay 
  Initially, 2mM stock concentration of all insecticides were prepared in HPLC-grade methanol 
and kept in -20oC prior to use. Substrates working solution was prepared by diluting stock to 0.8mM 
with methanol to reduce precipitation of insecticide. The reaction mix for this protocol including the 
membrane expressing P450 and CPR, b5, NADPH-regeneration system as well as the buffer used are 
tabulated below (Table 3.8). 0.2M Tris-HCl and NADPH-regeneration components (1mM glucose-6-
phosphate, 0.25mM MgCl2, 0.1mM NADP
+ and 1U/ml glucose-6-phosphate dehydrogenase) were 
added to the bottom of 1.5ml tube chilled on ice. 
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Table 3.8: Reaction mix for HPLC metabolic assay 
Component Stock Concentration Final Reaction 
Concentration 
Volume 
 (µl) 
  Tris-HCL pH 7.4 0.2M 0.2M Varies 
Membrane (CYP450 + CPR) Varies (nmol/ml) 45pmol Varies 
Cytochrome b5 Varies (nmol/ml) ~180-500pmol ~10-20 
NADPH +/- (containing 0.25mM 
MgCl2) 
10X 1x 50 
Incubation at 30oC and 1200 rpm for 5 mins 
Substrate (Working) 0.8M 20µM 5.0 
                 Total Volume 200 
 DDT analysis: with or without 1mM sodium cholate as previously described (Mitchell et al., 2012). 
Membrane expressing P450 and CPR, and the b5 proteins were added to the side of the tube 
and pre-incubated for 5 mins at 30oC, with shaking at 1200 rpm to activate the membrane. 20µM of 
test insecticide was then added into the final volume of 0.2ml (less than 2.5% v/v methanol in final 
volume of reaction mix) and reaction started by vortexing at 1200 rpm and 30oC for 1 hour. Reactions 
were quenched with 0.1ml ice-cold methanol and incubated for 5 more mins at 1200 rpm and 30oC, to 
dissolve all residual insecticide. Tubes were then centrifuged at 16400 rpm and 4oC for 12 mins and 
150µl of supernatant transferred into HPLC vials for analysis. All reactions were carried out in 
triplicates with experimental samples (+NADPH) and negative control (-NADPH) not containing NADP. 
100µl of sample was loaded into an isocratic mobile phase of Agilent 1260 Infinity with a flow rate of 
1ml/min and peaks separated with a 250mm C18 column (Acclaim TM 120, Dionex) at 23oC. Details of 
the mobile phase composition, column temperatures, and wavelength of detection and retention time 
of  insecticides used in this study are given in the Table 3.9. 
Enzyme activity was calculated as the percentage depletion (the difference in the amount of 
insecticide(s) remaining in the +NADPH tubes compared with the –NADPH) and a paired t-test was 
used for statistical analysis.   
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Table 3.9: Conditions used for Reverse-Phase HPLC Analysis 
Insecticides 
 
 
Mobile Phase (v/v) 
 
 
Column 
Temperature  (oC) 
 
UV-Vis Wavelength 
(nm) 
 
Retention Time 
(min) 
 
Permethrin MeOH:H2O (90:10) 23 226 cis ~12, trans ~ 14 
Bifenthrin MeOH:H2O (90:10) 23 226 ~16 
Deltamethrin MeOH:H2O (90:10) 23 226 cis ~9, trans ~11 
λ-cyhalothrin MeOH:H2O (90:10) 23 226 ~8 
Etofenprox MeOH:H2O (90:10) 23 226 ~17.5 
DDT MeOH:H2O (90:10) 23 232 ~11 
Bendiocarb ACN:H2O (65:35) 40 205 
cis ~13, trans ~15 
 
Propoxur ACN:H2O (60:40) 40 270 ~6 
MeOH = Methanol and ACN = Acetonitrile 
3.3.3.2 Steady-State Kinetic Parameters Analysis 
Establishment of kinetic parameters for CYP6P9a and CYP6P9b protein variants will provide 
important information on turnover (the speed with which the different alleles metabolise and clear 
pyrethroid insecticides) and KM (the affinity of the different alleles toward different insecticides). This 
will help establish differences in the catalytic efficiencies of the different alleles from resistant strain 
and identify whether the alleles from resistant strains differ in their pyrethroid-metabolising activity 
compared to alleles from susceptible strain. Enzyme response to variation in substrate concentration 
was determined using the pyrethroids permethrin and deltamethrin. Steady-state kinetic parameters 
were obtained by measuring the rate of reaction under linear conditions for 10 minutes while varying 
the substrate concentration from 2.5 to 20µM (2.5, 5.0, 7.5, 10, 12.5, 15, 17.5 and 20µM). Reactions 
were performed in triplicates with +NADPH (experimental tubes) in parallel with –NADPH (negative 
control). KM and Vmax were established from the plot of substrate concentrations against the initial 
velocities and fitting of the data to the Michaelis-Menten equation using the non-linear regression as 
implemented in the GraphPad Prism 6.03. Catalytic constants and efficiencies were automatically 
predicted from the steady-state parameters by the software. 
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3.3.4 Detection of Key Amino Acid Changes Conferring Pyrethroid Resistance Using Site-
Directed Mutagenesis  
Modelling and docking analyses of the allele variants of CYP6P9a and CYP6P9b as well as  
fluorescent and metabolism assays established  profound differences  in the metabolic profiles of the 
resistant alleles compared with the susceptible ones. It becomes apparent that amino acid differences 
may be the driving force behind such differences. As such finding out which amino acid(s) is/are 
responsibe for these difference is of paramount importance. Such information will shed light on the 
mechanism of resistance at molecular level and make it possible to design appropriate diagnostic tool 
that can allow detection of the mutation(s) in the field. For example, a PCR diagnostic tool for the 
single mutation Leu119Phe in GSTe2 gene in highly DDT-resistant strain of An. funestus from Benin 
allows for a fast detection and tracking of such type of resistance across Africa (Riveron et al., 2014b). 
3.3.4.1 Selection of Candidate Amino Acids 
A hypothesis-driven approach was used to select candidate amino acids that may impact on 
catalytic activity of the resistant alleles. Characterisation of amino acid sequences of CYP6P9a and 
CYP6P9b, as well modelling and docking analyses of alleles with pyrethroid insecticides (Chapter Two) 
helped in the choice of candidate mutations to investigate. For both CYP6P9a and CYP6P9b alleles, list 
of amino acids selected for mutagenesis, their polymorphic positions, as well as the potential 
contribution of the substitution are summarised in Table 3.10, below. Details of the potential impact 
of these mutations have been discussed in details in Chapter Two.  
Candidate amino acids were substituted individually with amino acid variant present in the allele 
from susceptible individual (FANGCYP6P9a and FANGCYP6P9b, respectively). The mutant proteins 
were then expressed and used alongside wild type proteins to screen fluorescent probes for activity, 
as well as metabolism assay with permethrin and deltamethrin to assess the impact of each mutation. 
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Table 3.10: Nucleotide polymorphism and amino acid substitutions between resistant alleles of 
CYP6P9a and CYP6P9b and FANG: the amino acid substitutions selected for mutagenesis 
Amino acid 
substitution 
Mutation Countries Location and potential Impact 
CYP6P9a 
Phe
63
Leu 189: T->G 
Malawi, Mozambique, 
Zambia 
Within the highly variable αA region, possible membrane 
targeting increasing stability 
Gln
66
Lys 196: C->A 
Malawi, Mozambique, 
Zambia 
Within the highly variable αA region, possible membrane 
targeting increasing stability 
His
301
Gln 903: A->C 
Uganda, Malawi, 
Mozambique, Zambia 
Two residues upstream the substrate recognition site 4  
(SRS4) 
Tyr
320
Ser 959: A->C 
Benin, Uganda, Malawi, 
Mozambique, Zambia 
Middle of the αI helix and within SRS4; one residue 
downstream the oxygen binding pocket in CYP6P9a 
Ser
431
Phe 1292: T->C 
Benin, Uganda, Malawi, 
Mozambique, Zambia 
Within the loop joining the meander with the cysteine 
pocket; the loop is purported to house the reductase 
interaction site 2 (RIS-2) 
CYP6P9b 
Ile
109
Val 325: A->G 
Benin, Uganda, Malawi, 
Mozambique, Zambia 
Within the SRS1 and the BʹC loop purported to be involved 
in substrate access and channelling 
Glu
335
Asp 
1005: A->C 
Benin, Uganda, Malawi, 
Mozambique, Zambia 
In the –COOH terminus of the αI helix, possible impact as 
RIS-1 component mediating  interaction with CPR 
Ser
384
Asn 
1151: G->A 
Uganda, Malawi, 
Mozambique, Zambia 
In the  β1_4 (αKʹ) and within the highly conserved SRS5, 
with possible impact on substrate recognition 
Ala
401
Pro 
12001: G->C 
Benin, Uganda, Malawi, 
Mozambique, Zambia 
Within the β2_2 domain; pyrrolidine ring can restrict 
conformational space and 3D folding 
 
3.3.4.2 Primer Design 
Mutagenic sense and antisense oligonucleotide primers were designed to incorporate the 
desired mismatch into the template DNA in a double-stranded DNA-plasmid constructs. Primer pair 
incorporates at least 10 oligonucleotide residues upstream and downstream of the target nucleotide 
to mutate. With the exception of primer pair for MALCYP6P9a Leu63Phe_Lys66Gln double mutant, all 
primers contain no more than 30 nucleotides so as to narrow the Tm to less than 70
oC to avoid primer 
dimer formation (Zheng et al., 2004) becoming more favourable than primer-template annealing. Care 
was also taken to avoid GC content of more than 50% though unavoidable in some of the primers. 
Though primers were  designed using an automated web tool PrimerX (http://www.bioinformatics.org 
/primerx/), CYP6P9a mutants PCR amplifications did not work over several attempts. List of all primers 
used are given in Table 3.11 with mutagenised positions  in red.  
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Table 3.11: List of mutagenic primer pairs with respective Tm 
Primer  Sequence Tm (
oC) 
MALCYP6P9a_L63F_K66Q_F CTGGAATTTTACAAACAATTCAAGCAGCGCCGTG 69.09 
MALCYP6P9a_L63F_K66Q_R CTTGAATTGTTTGTAAAATTCCAGATGGATGTCGG 65.33 
MALCYP6P9a_Q301H_F GAATGACACACCGAGAACTTGCGG 64.38 
MALCYP6P9a_Q301H_R GTTCTCGGTGTGTCATTCCTACTTC 61.36 
MALCYP6P9a_S320Y_F GACATCATACACGACGCAAAGCTTC 62.88 
MALCYP6P9a_S320Y_R GCGTCGTGTATGATGTCTCGAAACC 64.09 
MALCYP6P9a_F431S_F GATCGCTCCTCACCGGAGGAAGTGAAG 68.15 
MALCYP6P9a_F431_R CTTCACTTCCTCCGGTGAGGAGCGATCC 69.66 
MOZCYP6P9b_V109I_F GATCGCGGTATTTTCACTAATGCAAG 61.26 
MOZCYP6P9b_D335E_F GAACCCTGAAATCCAGGAGCGCCTTAG 67.06 
MOZCYP6P9b_D335E_R CCTGGATTTCAGGGTTCTTTGCCAGC 66.28 
MOZCYP6P9b_N384S_F GAATCGTTGAGTCGTGTGCCGTC 64.29 
MOZCYP6P9b_N384S_R CACGACTCAACGATTCTACCGGG 63.09 
MOZCYP6P9b_P401A_F CACGTGATTGCCAAACGAACGTTAG 63.47 
MOZCYP6P9b_P401A_R CGTTTGGCAATCACGTGTTTCG 61.71 
 
 
3.3.4.3 Construction of Mutant ompA+2-CYP6P9a and ompA+2-CYP6P9b Plasmids 
3.3.4.3.1 Primer Extension PCR 
Efforts to introduce mutations using the plasmidic expression vector pB13::ompA+2CYP6P9a/ 
pB13::ompA+2CYP6P9b were not fruitful due possibly to the larger size of pCWOri+ (5030bp) over the 
pJET1.2 (2974bp). Full length pJET1.2::ompA+2CYP6Pb mutants were successfully amplified via primer 
extension PCR (Zheng et al., 2004) using as a template pJET1.2 miniprep from section 2.3.2.3(ii). This 
one-step approach involved linear amplification of whole plasmid with the mutagenic primers as 
described by Rabhi and colleagues (Li and Wilkinson, 1997) followed by self-ligation at the 
transformation step. Primers annealed back-to-back on the opposite strands of the target template 
and through primer extension amplified the whole plasmid without need for introduction of 
restriction sites. Details of the reaction mix are given in Table 3.12 and the strategy of primer 
extension technique depicted in Figure 3.4.  
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The reaction mix contains 5X Buffer HF with 7.5mM MgCl2, dNTP mixes, forward and reverse 
mutagenic primers, 1-4ng/µl plasmidic DNA template, 0.5-1U of High-Fidelity Phusion Hot Start II DNA 
Polymerase (Thermo SCIENTIFIC, MA, USA) and sterile water. The reaction was started by preheating 
the mixture to 98oC for 10 mins; followed by 35 cycles of 94oC for 30 seconds, annealing (at 65oC) for 
30 seconds and extension at 72oC for 2.5 mins. This is followed with final extension at 72oC for 10 mins 
and 4oC hold. 3µl of the PCR product was then electrophoresed on 1.5% (w/v) with visualisation using 
ethidium bromide. Mutagenic amplification from plasmid pB13::ompA+2CYP6P9a failed even with 
QuickChangeTM Site-Directed Mutagenesis Kit (Stratagene). Even though mutagenic PCR worked with 
pJET1.2::ompA+2-CYP6P9a plasmid, the cloned product refused to get digested from the pJET1.2, and 
as such could not be ligated into the expression vector pCWori+. Consequently, efforts were then 
concentrated on cloning, expression and characterisation of  CYP6P9b mutant proteins.  
Table 3.12: PCR reaction mix for mutant pJET1.2-ompA+2-CYP6P9b Amplification 
Reagent Final Concentration Volume (µl) 
5x Buffer HF (containing 7.5mM MgCl2) 1x 10 
dNTP mix (10mM) 80µM 0.4 
Mutagenic Primer_F (10µM) 0.3µM 1.5 
Mutagenic Primer_R (10µM) 0.3µM 1.5 
Plasmidic DNA Template 2-4ng 0.5-1.0 
dH2O - 35.1-34.6 
HotStart Taq Polymerase II 0.04/µl 1.0 
Total Volume - 50 
 
 
Figure 3.4: Schematic diagram of the primer extension PCR. Adapted from (Zheng et al., 2004, 
Reikofski and Tao, 1992). 
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3.3.4.4 Restriction Digestion of the Parental DNA Template 
The parental plasmidic template is Dam+-methylated from transformation into DH5α. This 
makes it possible to cleave the unwanted template by restriction enzyme DpnI (Thermo SCIENTIFIC, 
MA, USA) as described in (Zheng et al., 2004). 2µl of 1X FastDigest Buffer and 1µl of DpnI was added to 
the PCR-amplification product and incubated for one hour at 37oC. The restriction enzyme cut the 
parental template at position 5ʹ…G m6 ↓ATC…3ʹ which is absent in the desired mutant PCR product 
since its newly synthesized and not passed through E. coli DH5α cloning.   
3.3.4.5 Construction of Plasmidic Expression Vector pB13::ompA+2CYP6P9b  
4µl of the digest was transformed into DH5α, positive colonies mini-prepped and sequenced 
on both strands with pJET725 primers to confirm presence of mutations. The PCR product was then 
digested with NdeI and XbaI (see Table 3.4), gel extracted with QIAquick Gel Extraction Kit (QIAGEN) 
and then ligated into pCWOri+ already linearized with the same restriction enzymes (Table 3.5).  
3.3.4.6 Transformation and Co-transformation of Expression Vector with An. gambiae CPR  
The ligation product was then transformed into DH5α as described in section 3.3, positive 
colonies mini-prepped and sequenced on both strands with seqPCW primers to confirm the presence 
of the ompA leader and target mutations again. The miniprep was then co-transformed with AgCPR 
using the protocol outlined in section 3.3 into JM109 cells.  
3.3.4.7 Heterologous Co-Expression pB13::ompA+2-CYP6P9b mutant with An. gambiae CPR 
Expression and preparation of mutant membranes (Val109Ile, Asp335Glu, Asn384Ser and 
Pro401Ala), with the wild type MOZCYP6P9b membrane protein was conducted as previously described 
previously. Membrane concentrations were determined from difference in Fe2+-CO vs Fe2+ spectra.   
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3.3.4.8 Fluorescent Probes Assay  
3.3.4.8.1 Screening for Activity, Linearity and Kinetics 
10pmol of mutant CYP6P9b protein successfully expressed were screened with 1µM of 7-ER, 
resorufin-benzylether: RBE, resorufin methyl ether: RME and resorufin-pentylether: RPE); two 
cuomarin-based probes (7-EFC and MFC) and diethoxyfluorescein (DEF). The initial test of O-
dealkylating activity and protein linearity was as described in sections 3.3.2.1 and 3.3.2.2 respectively.  
Protein linearity was carried out as described previously and steady-state kinetic parameters 
established with 0-2µM DEF and 3.33pmol or 6.66pmol mutant membranes depending on activities 
obtained from test of linearity. This was carried out as  described in section 3.3.2.3. 
3.3.4.9 Metabolism Assay 
3.3.4.9.1 Substrate Depletion Assays and Kinetics 
To determine whether the amino acid substitutions lead to lose of activity or modify kinetic 
parameters, metabolism assay was conducted with the mutant membranes with permethrin and 
deltamethrin. Substrate depletion was carried out as previously described (section 3.3.3.1).  
Steady-state kinetic parameters were established varying the amount of pyrethroid substrates 
from 1-16µM, in a total volume of 200µl incubated for 15 mins for all mutants excepting the Asn384Ser 
mutant, which was assayed with 30 mins incubation following its unusually low activity. The protocol 
used for the experiment and interpretation of the results were as described in section 3.3.3.3. 
3.3.4.10 In silico Analysis of Key Amino Acid Residues 
To establish spatial positioning and role of key amino acid changes with respect to pyrethroid 
activity, MOZCYP6P9b and FANGCYP6P9b models docked with pyrethroids were overlayed and 
analysed using the PyMOL and MMV.  Position of residues Asp335 and Asn384 in MOZCYP6P9b were 
compared with the corresponding variants Glu335 and Ser384 from FANGCYP6P9b. 
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3.3.5 Comparative Assessment of Ability of Allele Variants of CYP6P9a and CYP6P9b to Confer 
Pyrethroid Resistance in D. melanogaster Using GAL4-UAS System 
Predictions of a drug’s in vivo clearance is usually made based on kinetic parameters obtained 
from in vitro estimated intrinsic clearance (Tracy, 2003). However, in vitro-in vivo extrapolation is an 
assumption with some shortcomings, for in vitro experiments discount the influence of other 
metabolizing enzymes and factors within the biological system. Other proteins may be involved in 
binding and/or metabolism of a substrate and as such in vitro results may not reflect the holistic 
pharmacokinetics taking place. In vitro kinetic analyses have revealed differences in kinetic profiles 
between the membrane proteins from resistant and susceptible alleles of CYP6P9a and CYP6P9b. But, 
to further confirm the involvement of the resistant alleles of these genes, a comparative analysis was 
conducted by introducing and expressing these genes in D. melanogaster using GAL4-UAS system. The 
transgenic flies over-expressing the genes were then screened for pyrethroid resistance. GAL4-UAS 
system is a veritable Swiss army knife  (Duffy, 2002) which allows ectopic and targeted expression of 
gene of interest in vivo in a temporal and/or spatial fashion (Elliott and Brand, 2008, Duffy, 2002). The 
technology is increasingly used to validate insecticide resistance genes as described in the background 
to this chapter (Daborn et al., 2007, Zhu et al., 2010, Riveron et al., 2013, Riveron et al., 2014a). GAL4-
UAS system is a bipartite system in which the expression of gene of interest (responder) is controlled 
by the presence of the UAS element, a 5 tandemly arrayed and optimized GAL4 binding sites (Duffy, 
2002). Transcription of the responder requires presence of GAL4, thus the absence of GAL4 in the 
responder lines maintains them in a transcriptionally silent state; to activate transcription, the 
responder lines are mated to flies expressing GAL4 in a particular pattern termed the driver (Duffy, 
2002). The progeny then expresses the responder (target gene) in a configuration that reflects the 
GAL4 pattern of the respective driver (Figure 3.5). The success of this technique is because GAL4 
equivalent is absent in most species, and as such the candidate gene is only expressed in the progeny 
of the crosses between drivers and responder lines, when GAL4 and UAS transgenes are brought 
together in the same genome (Lynd and Lycett, 2012).   
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3.3.5.1 Cloning and Construction of pUASattB::CYP6P9a and pUASattB::CYP6P9b Plasmids 
Forward and reverse primers were designed for CYP6P9a and CYP6P9b with BglII and XbaI 
restriction sites respectively to allow cloning into pUAST vector. Full length cDNA encoding CYP6P9a 
(MALCYP6P9a and FANGCYP6P9a) and CYP6P9b (MOZCYP6P9b and FANGCYP6P9b) were amplified 
using HotStarTaq Polymerase (QIAGEN) and 0.5-1µg miniprep templates prepared in section 2.3.2.3. 
Protocol for amplification (Table 3.13) involves initial denaturation at 95oC for 15 mins followed by 35 
cycles each of 94oC for 30 seconds; 57oC for 30 seconds and 72oC for 90 seconds. This is followed with 
final extension for 5 mins at 72oC and holding at 4oC. The primers for the amplification of these genes 
as well as primers for qPCR validation are given in Table 3.14.  
Table 3.13: PCR reaction mix for amplification of CYP6P9a/CYP6P9b cDNA for transgenic analysis 
Reagent Final Concentration Volume (µl) 
10x  Qiagen Buffer (containing 15mM MgCl2) 1x 1.5 
dNTP mix (25mM) 0.8mM 0.2 
CYP6P9a/CYP6P9b_pUAS_BglII_F (10µM) 0.22µM 0.325 
CYP6P9a/CYP6P9b_pUAS_XbaI_R (10µM) 0.22µM 0.325 
Miniprep Template 0.5-1µg 0.5-1.0 
dH2O variable variable 
HotStarTaq Polymerase 1U 0.2 
Total Volume  15 
Figure 3.5: The GAL4-UAS System for directed gene expression. Adapted from (St 
Johnston, 2002) 
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PCR product was cleaned and cloned into pJET1.2 blunt, transformed into DH5α, as described 
previously (section 2.3.2.3) and screened with the pJET1.2 primers. Positive colonies were 
miniprepped overnight and sequenced on both strands to confirm presence of genes. The minipreps 
were then double-digested with BglII and XbaI restriction enzymes using the protocol as described in 
Table 3.4. Restriction digests were then gel extracted and ligated into pUASattB vector already 
linearised with same restriction enzymes, overnight and at 16oC as described (Table 3.5). 4µl of ligation 
product, a construct of target genes in pUAS vector were transformed into DH5α and screened for 
positive colonies using the KAPPA PCR. 
Table 3.14: Primers used for cloning into pUASattB vector and plasmid sequencing 
Primer Sequences 
CYP6P9a_pUAS_BglII_F AGATCTATGGAGCTCATTAACGTGGTG 
CYP6P9a_pUAS_XbaI_R TCTAGATCACAATTTTTCCACCTTCAAGTAA 
CYP6P9b_pUAS_BglII_F AGATCTATGGAGCTCATTAACGTGGTGTT 
CYP6P9b_pUAS_XbaI_R TCTAGACTACAAAAACCCCTTCCGCT 
CYP6P9a_qPCR_F CAGCGCGTACACCAGATTGTGTAA 
CYP6P9a-qPCR_R TCA CAA TTT TTC CAC CTT CAA GTA ATT ACC CGC 
CYP6P9b_qPCR_F CAGCGCGTACACCAGATTGTGTAA 
CYP6P9b_qPCR_R TTA CAC CTT TTC TAC CTT CAA GTA ATT ACC CGC 
RPL11_F CGATCCCTCCATCGGTATCT 
RPL11_R AACCACTTCATGGCATCCTC 
BglII restriction site is in green and underlined and XbaI is in red and underlined.  
Medium scale plasmid preparation (Midiprep) was carried out using HiSpeed Plasmid Midi Kit 
(QIAGEN) according to manufacturer’s protocol. 5ml TB medium starter culture containing 5µl of 
100mg/ml ampicillin, 5µl colony in dH2O was allowed to grow at 37
oC and 300 rpm for 6 hours. 4ml of 
the starter was transferred into a 1L flask with 150ml pre-warmed TB medium and 150µl of ampicillin 
and allowed to grow at 37oC and 220 rpm for 14-16 hours. Bacterial culture was then harvested and 
divided into three 50ml tubes chilled on ice and centrifuged for 10 mins at 4oC and 5000 rpm. Pellets 
were miniprepped and sequenced to confirm presence of the genes. Midiprep was sent to Genetic 
Services, MA, USA (http://www.geneticservices.com/) for injection into flies. Using PhiC31 system 
clones were transformed into germ line of a D. melanogaster strain carrying the attP40 docking site on 
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chromosome 2[“y1w67c23; P attP40”, “1; 2”]. Four transgenic lines, UAS-MALCYP6P9a, UAS-
FANGCYP6P9a, UAS-MOZCYP6P9b and UAS-FANGCYP6P9b were constructed successfully. 
3.3.5.2 Crossing and Preparation of Flies 
GAL4 lines were purchased from Bloomington Stock Centre (http://flystocks.bio.indiana.edu/).  
Ubiquitous expression of candidate genes in the transgenes in adult F1 progeny (the experimental 
group) was achieved after crossing homozygote males (UAS line with gene of interest) with virgin 
females from the driver strain Actin5C-GAL4 ["y [1] w[*]; P(Act5C-GAL4-w)E1/CyO","1;2"]. For control 
group, flies with the same background as the experimental group but devoid of the UAS and the 
candidate genes were crossed with the driver Actin5C-GAL4 lines to generate null-Actin5C-GAL4 lines 
without insertion. All flies were maintained at 25oC in plastic vials with food.   
3.3.5.3 Drosophila Insecticides Contact Assay 
Insecticide papers  (2% permethrin and 0.15% deltamethrin-impregnated ) filter papers were 
prepared in acetone and Dow Corning 556 Silicone Fluid (BDH/Merk, Germany) and kept at 4oC prior 
to bioassay. These papers were rolled and introduced into 45cc plastic vials. The vials were then 
plugged with cotton wool soaked in 5% sucrose. 20-25 (2-4 days old post-eclosion females) were 
selected for the bioassays and introduced into the vials. Mortality plus knockdown was scored after 1 
hr, 2hrs, 3hrs, 6hrs, 12hrs and 24hrs post-exposure to the discriminating doses of the insecticides. For 
each assay, at least six replicates were performed and t-test was used to carry out statistical analysis 
of mortality plus knockdown obtained between experimental groups and control.  
3.3.5.4 qRT-PCR validation of Overexpression  
In order to confirm relative expression of the candidate genes in the experimental flies and 
absence of expression in the control groups qRT-PCR was carried out as described previously (Riveron 
et al., 2014a, Riveron et al., 2013). RNA was extracted from three pools of 5 F1 experimental and 
control flies separately and cDNA synthesized as described in section 2.3.2. qPCR for both CYP6P9a 
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and CYP6P9b was conducted using the qPCR primers given in Table 3.14, with normalization using the 
housekeeping gene RPL11. A serial dilution of cDNA was used to establish standard curves for each 
gene in order to validate PCR efficiencies of the target and endogenous control(s) and assess 
quantitative differences between samples. qPCR ampilification was carried using MX 3005 real-time 
PCR system (Agilent Technologies) with Brilliant III Ultra-Fast SYBR® Green qPCR Master Mix. 10ng of 
cDNA was utilised as a template in a 3-steps thermocycling involving denaturation at 95oC for 3 mins, 
followed by 40 cycles each of 10 seconds at 95oC and 10 seconds at 60oC; this is then followed with 1 
min at 95oC, 30 seconds at 55oC and 30 seconds 95oC. The relative expression and fold-change of each 
target gene from the resistant and experimental and control samples was calculated using the 
comparative CT Method (2
-ΔΔC
T) as described (Schmittgen and Livak, 2008).  
 
3.4 Results 
3.4.1 Pattern of Co-expression of ompA+2CYP6P9a/ompA+2CYP6P9b  Alleles with CPR 
 
Recombinant CYP6P9b proteins were successfully expressed as we did previously (Riveron et 
al., 2013) with optimal expression at 48-56 hours post-induction. For CYP6P9a, I obtained optimal 
expression at 36-40 hours with modifications of growth conditions and concentrations of δ-ALA and 
IPTG as I described in this paper (Riveron et al., 2014a) (Appendix 5). The two P450s differ in their 
expression patterns  in that CYP6P9a show consistently higher expression than CYP6P9b (Figure 3.6). 
On average for CYP6P9a lowest expression was observed from ZMBCYP6P9a (4.35nmol/ml±0.12, n =2) 
and highest with FANGCYP6P9a (16.28nmol/ml±3.53, n = 3); while for CYP6P9b, lowest expression was 
obtained from ZMBCYP6P9b (7.05nmol/ml±0.25, n= 2) and highest with UGANCYP6P9b (12.02nmol/ml 
± 9.29)(Figure 3.7).  
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Membranes contain comparable amount of CPR with BENCYP6P9a on average exhibiting the 
lowest reductase activity (119.6nmol cytochrome c reduced/min/mg protein±20.01) and MOZCYP6P9b 
having the highest activity (205.29nmol cytochrome c reduced/min/mg protein±19.19) (Figure 3.8B). 
Figure 3.7: Amount of P450 expressed by CYP6P9a and CYP6P9b recombinant proteins. Error bars 
are variations in the amount of membrane independently expressed from same allele at different times. n 
(number of  replicates = 3 for all alleles except ZMBCYP6P9a and ZMBCYP6P9b in which n = 2) 
Figure 3.6: Fe2+-CO vs Fe2+ difference spectrum obtained from some of An. funestus CYP6P9a 
and CYP6P9b recombinant proteins.  Soret peak at 450nm shown in red spectra. 
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No statistically significant differences were obtained when reductase content of the membranes from 
resistant alleles were compared to those from susceptible individuals (p>0.05). The total protein 
content of all membranes were also within same range (Appendix 3.2) with few differences. For 
CYP6P9a lowest protein content was obtained from UGANCYP6P9a (15.79mg/ml±1.58) and highest 
with MALCYP6P9a (19.49mg/ml±1.74). CYP6P9b produced slightly higher protein content with the 
lowest observed from FANGCYP6P9b (24.54mg/ml±1.95) and highest obtained from BENCYP6P9b 
(27.72mg/ml±3.23). Membrane content was calculated as the ratio of P450 yield (amount expressed) 
to the total protein content. On average CYP6P9a show higher membrane content than CYP6P9b 
(Figure 3.8A). Protein concentration was not quantified for ZMBCYP6P9a and ZMBCYP6P9b alleles and 
as such membrane content and CPR activity were not determined for these alleles. This is because 
MALCYP6P9a and MOZCYP6P9b alleles were already pre-selected for analysis as representative alleles 
from southern Africa and were to be used in subsequent experiments.  
 
 
 
 
Figure 3.8: Membrane content (A) and CPR activity (B) of CYP6P9a and CYP6P9b proteins. 
Error bars represent (A) variation in the amount of membrane and/or total protein; (B) variations in the 
CPR activities determined independently from membranes expressed from the same allele. Number of 
replicates, n = 3. 
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3.4.2 Comparative Analysis of Metabolic Activity of Various Alleles of CYP6P9a and CYP6P9b 
Using Fluorescent Probes 
3.4.2.1 Probe Substrates Metabolism 
Four probe substrates: ER, EFC, MFC and DEF were screened with membranes from variants of 
CYP6P9a (BENCYP6P9a, UGANCYP6P9a, MALCYP6P9a and the susceptible FANGCYP6P9a) and 
CYP6P9b (BENCYP6P9b, UGANCYP6P9b, MOZCYP6P9b and the susceptible FANGCYP6P9b).  
CYP6P9a: Lowest fluorescent activities were observed with 7-ER and MFC, while higher 
activities were obtained with 7-EFC and especially DEF. However, in all cases FANGCYP6P9a has lowest 
activity for all test probes. For example, with DEF, FANG has the lowest activity (0.13RFU/min/pmol± 
0.01), followed by UGANCYP6P9a and MALCYP6P9a with 0.50RFU/min/pmol±0.02 and 0.76 
RFU/min/pmol±0.11, respectively (Figure 3.9). BENCYP6P9a exhibited the highest activity towards DEF 
with an average activity  of 0.92RFU/min/pmol±0.16. This initial test of dealkylation clearly reveals the 
resistant alleles as having several fold higher activity than the allele from FANG. However, lower 
activities toward all probes were obtained with CYP6P9a alleles compared with CYP6P9b though 
MALCYP6P9a has a very high activity towards 7-ER, compared with the rest of the proteins screened.   
CYP6P9b: The same pattern of activity was observed with CYP6P9b proteins with lowest 
activity obtained from 7-ER and MFC, and highest with 7-EFC and DEF. However, lowest activity with 
DEF was obtained from FANGCYP6P9b (0.49RFU/min/pmol±0.001), followed by West African 
(BENCYP6P9b) and southern African (MOZCYP6P9b) proteins with activities of 4.36RFU/min/pmol±1.2 
and 5.61RFU/min/pmol±0.8 respectively (Figure 3.9). East African (UGANCYP6P9b) exhibited the 
highest activity with DEF with turnover of 7.93RFU/min/pmol±1.33. Thus, the activities obtained from 
recombinant proteins from resistant alleles range from 11-fold higher for BENCYP6P9b to 16-fold 
higher for UGANCYP6P9b compared with the susceptible FANGCYP6P9b protein.  
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Both FANGCYP6P9a and FANGCYP6P9b proteins exhibited lowest activity toward all the 
probes tested reflecting their low efficiency of O-dealkylation compared with proteins from resistant 
strains (especially CYP6P9b) which exhibited high turnover (O-dealkylation) for ER, EFC, MFC and DEF. 
Higher activities were obtained from CYP6P9b, on average 4 to 8-folds than obtained with CYP6P9a 
reflecting the possible higher enzymatic activity of CYP6P9b gene over CYP6P9a.  
 
 
 
3.4.2.2 Test for Linearity and Enzymes Kinetics  
In order to establish optimal conditions for linear activity with respect to time and enzyme 
concentrations, 1µM diethoxyfluorescein (DEF) was incubated with varying amount of CYP6P9a and 
CYP6P9b membranes proteins (Appendix 3.4). Increase in activity  was measured up to 30 minutes. 
Higher activities were obtained from CYP6P9b  compared with CYP6P9a proteins. 
 Figure 3.10 depicts the  plot initial velocities of O-deethylation of DEF by the P450 proteins screened. 
Reactions followed Michaelis-Menten fashion with proteins expressed from resistant strains having 
higher activities compared with those from the susceptible strain, FANG.  
Figure 3.9: Metabolism of probe substrates by variants of recombinant CYP6P9a and CYP69b. 
The solid bars indicate average of significant turnovers of three experimental replicates (n =3) compared to 
negative controls (NADPH-). FG = FANG, BN =Benin, UG = Uganda, MAL = Malawi, and MOZ = Mozambique.  
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CYP6P9a Alleles: Membranes expressed from resistant alleles (BENCYP6P9a, UGANCYP6P9a 
and MALCYP6P9a) showed higher maximal catalytic activity (Kcat) and affinity (lower KM) with DEF 
compared with that from FANG (FANGCYP6P9a) (Table 3.15 and Figure 3.11). These KM values are 
statistically significant (p<0.05) compared with KM from FANGCYP6P9a, with the lowest KM value 
obtained from BENCYP6P9a (0.091µM±0.006) and highest KM produced by FANGCYP6P9a 
(0.34µM±0.035). The catalytic activity (Kcat) for BENCYP6P9a and MALCYP6P9a were also statistically 
significantly different from that of FANGCYP6P9a, with values  from MALCYP6P9a being more than 
two-fold the Kcat from FANGCYP6P9a. Therefore, UGANCYP6P9a protein was calculated as more than 
two-fold as catalytically efficient than FANGCYP6P9a while BENCYP6P9a and MALCYP6P9a were more 
than six-fold more efficient than FANGCYP6P9a. These differences in catalytic efficiencies were 
established as statistically significant using ANOVA Tukey’s multiple comparison test (p<0.05) 
 
 
 
Figure 3.10: Michaelis-Menten plots for (A) CYP6P9a and (B) CYP6P9b  recombinant proteins 
metabolism of diethoxyfluorescein. 
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Table 3.15: Kinetic constants for CYP6P9a- and CYP6P9b proteins-mediated DEF metabolism 
Recombinant Proteins Membrane (pmol) KM (µM) Kcat (min
-1) Kcat/KM (min
-1 µM-1) 
BENCYP6P9a 10 0.091±0.006a 14.16±0.23c 155.60±10.56* 
UGANCYP6P9a 10 0.226±0.035a 12.98±0.61 57.43±9.29* 
FANGCYP6P9a 10 0.34±0.035 9.52±0.33 27.99±3.04 
MALCYP6P9a 10 0.14±0.013a 22.84±2.21c 163.1±22.24* 
BENCYP6P9b 3.33 0.13±0.01b 135.43±3.12d 1049.84±84.92$ 
UGANCYP6P9b 3.33 0.13±0.01b 171.86±3.76d 1301.96±102.66$ 
FANGCYP6P9b 3.33 0.24±0.02 14.93±0.500 62.20±5.58 
MOZCYP6P9b 3.33 0.12±0.01b 156.27±3.306d 1220.85±98.81$ 
Values are  mean ±S.D. of three  replicates 
Apparent Kcat was calculated as pmol fluorescein produced/min/pmol P450; Catalytic efficiency was calculated as Kcat/KM 
a,b
 Significantly different KM values compared with FANGCYP6P9a and FANGCYP6P9b respectively.  
c,d
 Significantly different Kcat values compared with FANGCYP6P9a and FANGCYP6P9b respectively. 
*
,$
 Significant differences between Kcat/KM values respectivelycompared with FANCYP6P9a and FANGCYP6P9b  
 
 
CYP6P9b Alleles:  The same pattern of O-deethylation of DEF was also evident from alleles of 
CYP6P9b in which the Kcat of BENCYP6P9b, UGANCYP6P9b and MOZCYP6P9b with DEF were on 
average ten-fold higher than obtained with FANGCYP6P9b protein (p<0.05) (Table 3.15 and Figure 
3.11). The affinities of the resistant CYP6P9b proteins towards DEF were also within the same ranges 
and on average twice the affinities (half the KM values, p<0.05) obtained from FANGCYP6P9b. Thus, 
the catalytic efficiency of BENCYP6P9b with DEF was established as sixteen-fold higher than that of 
FANGCYP6P9b (p<0.05) and values from UGANCYP6P9b and MOZCYP6P9b were approximately 
twenty-fold higher (p<0.05) than those obtained from FANGCYP6P9b.  
These results supported initial testing of O-dealkylation that CYP6P9b proteins from resistant 
alleles are more enzymatically efficient than the corresponding enzymes from susceptible strain. 
Equally also, in agreement with the initial testing of O-dealkylation, the turnover with CYP6P9b 
proteins from resistant strains were more than ten-fold higher than values obtained with CYP6P9a, 
demonstrating the central role of CYP6P9b as more efficient P450 in comparison with CYP6P9a.  
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3.4.2.3 Inhibition Assays 
In order to investigate the enzymatic affinity of various recombinant proteins of CYP6P9a and 
CYP6P9b towards different classes of insecticides: pyrethroids, carbamates (bendiocarb and 
propoxur), DDT and chlorpyrifos were used in an inhibition assay with diethoxyfluorescein (DEF). The 
mean values of IC50 for the test inhibitors for the fluorogenic probe DEF used in this study is shown in 
Figure 3.12. Lowest IC50 was obtained with the positive control inhibitor miconazole, a potent 
reversible inhibitor shown from several studies to have very low IC50 against several recombinant, 
human CYP450s including CYP3A4, CYP1A2, CYP2D6, CYP2E1 and CYP2B6  (Yan et al., 2002, Niwa et al., 
2005, Zhang et al., 2002). Type II pyrethroids deltamethrin, λ-cyhalothrin and α-cypermethrin showed 
the most potent inhibitory activity against CYP6P9a/CYP6P9b-mediated deethylation of DEF, with IC50 
of less than 0.5µM of  which the lowest IC50 was produced by MOZCYP6P9b. This trend of low IC50 was 
followed by Type I pyrethroids, the pseudo-pyrethroid etofenprox and the organophosphate, 
Figure 3.11: 4D plot of the kinetic constants and catalytic efficiencies of 
recombinant CYP6P9a and CYP6P9b dealkyaltion of DEF.  
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chlorpyrifos. MALCYP6P9a exhibited the lowest IC50 with bifenthrin and MOZCYP6P9b lowest with 
permethrin and etofenprox. The IC50 for  chlorpyrifos was found to be lower than values obtained from 
Type I pyrethroids. It’s possible that this organophosphate binds more tightly to these P450s than the 
Type I pyrethroids. With DDT, IC50 values were on average 10µM for all proteins except UGANCYP6P9b 
(IC50 >25µM) suggestive of low affinity of these P450s to  DDT, even though the low potency of DDT 
maybe caused by its low partitioning in water when compared with pyrethroids (Laskowski, 2002).  
IC50 values greater than 25µM of the test insecticides  were obtained with bendiocarb and propoxur 
indicating that the carbamate insecticides are weak binders to the recombinant P450s CYP6P9a and 
CYP6P9b. This low affinity toward these P450s is in line with the docking prediction for bendiocarb 
which produced the lowest score.  
 
 
 
All the pyrethroids insecticides tested and chlorpyrifos showed reversible inhibitory trend 
towards CYP6P9a and CYP6P9b-mediated dealkylation of DEF; the IC50 increased though not sharply 
with increase in incubation time. In theory, IC50 value of a reversible inhibitor does not change 
significantly with incubation time if the inhibitor strictly follows simple Michaelis-Menten kinetics (Yan 
Figure 3.12: Mean IC50 of the test insecticide inhibitors against CYP6P9a and CYP6P9b 
dealkylation of DEF. Data represent mean IC50 at eight concentrations of each insecticide ±S.D. Error bars 
variation in the values of the IC50 between different concentrations.  
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et al., 2002). As such non-Michaelis-Menten kinetics for pyrethroids cannot be ruled out with the 
alleles tested. However, IC50 with the positive control inhibitor miconazole was found to be non-time 
dependent. It remained consistent with little variation throughout the incubation time (regression 
coefficient, r2 = 0.18). The summary of IC50 for all the insecticides tested as well as miconazole are 
given in Appendix 3.5 and Figure 3.13 depicts the plot of the effect of incubation time on IC50 of the 
test insecticides and miconazole for MOZCYP6P9b, with the highest activity towards DEF and highest 
affinity toward permethrin and deltamethrin from this assay. A good correlation was observed 
between increase in IC50 with time in the case of the following insecticides: cypermethrin (r
2 = 0.94), 
deltamethrin (r2 = 0.98), lambda-cyhalothrin (r2 = 0.96), etofenprox (r2 = 0.98), chlorpyrifos (r2 = 0.98), 
permethrin (r2 = 0.7) and bifenthrin (r2 = 0.8). Bendiocarb and propoxur both have a perfect fit with r2 
= 1, because these insecticides exhibited a very low affinity towards CYP6P9a and CYP6P9b. DDT 
exhibited poor correlation with r2 of 0.24 indicative of possible low affinity which decreased with time. 
 
 
To determine the robustness of docking software, ChemScore values obtained with the model 
of MOZCYP6P9 with insecticide ligands were compared with the IC50s from the same insecticides.  A 
good correlation (Figure 3.14) was observed between IC50 and Chemscores in the case of the following 
Figure 3.13: Effect of increase in incubation time on IC50 of test insecticide inhibitors on 
MOZCYP6P9b dealkylation of diethoxyfluorescein.  
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insecticides: permethrin (r2 = 0.55), deltamethrin (r2 = 0.85) and etofenprox (r2 = 0.93). No correlation 
was observed from bendiocarb (r2 = 1), while DDT produced a very poor correlation (r2 = 0.06).  
 
 
 
 
 
3.4.3 Comparative Assessment of Metabolic Activity of Various Alleles of CYP6P9a and 
CYP6P9b on Different Insecticide Classes Using  Metabolism Assay 
3.4.3.1 Metabolism of Insecticides 
To assess the metabolic profiles of the different CYP6P9a and CYP6P9b proteins with different 
classes of insecticides (Types I and II pyrethroids, etofenprox, bendiocarb, propoxur, DDT and 
malathion), metabolism assay was conducted using HPLC. Both CYP6P9a and CYP6P9b metabolizes 
Type I and Type II pyrethroids, with statistically significant depletion (+NADPH vs –NADPH) obtained 
from all proteins from resistant alleles compared with corresponding proteins from FANG. No 
significant activities were obtained against DDT, bendiocarb, propoxur and malathion), consistent with 
the molecular docking predictions as well as probes substrates analysis, in which no activities were 
respectively predicted and/or obtained against bendiocarb, propoxur and DDT.  
Figure 3.14: Correlation between IC50 of test insecticide inhibitors on MOZCYP6P9b bmetabolism 
of DEF and the ChemScore values from docking with GOLD.  IC50 values vs Chemscore for 
MOZCYP6P9b with (I) permethrin, (II) deltamethrin, (III) etofenprox, (IV) DDT, and (V) bendiocarb.  
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CYP6P9a Alleles:  
Recombinant proteins expressed from alleles of resistant strains produced higher activities 
against pyrethroid insecticides compared with FANGCYP6P9a. These differences were statistically 
significant (p<0.05) for all pyrethroid insecticides. Highest activities were obtained from MALCYP6P9a 
which deplete 65.38%±1.5, 60.48%±2.65, 68.38%±1.83, 75.41%±1.72 and 46.04%±1.26 each of 
permethrin, bifenthrin, deltamethrin, λ-cyhalothrin and etofenprox, respectively (Table 3.16 and 
Figure 3.15A). In contrast, FANGCYP6P9a with lowest activities deplete only 29.0%±1.42, 16.6%±5.41, 
18.11%±2.5, 15.46%±4.43 and 7.28%±1.53 each  of permethrin, bifenthrin, deltamethrin, λ-cyhalothrin 
and etofenprox, respectively. This clearly indicated that the protein from the susceptible allele, FANG 
is a poor metaboliser of pyrethroid insecticides compared with those from the resistant alleles.  
Table 3.16: Percentage depletion of pyrethroid insecticides by recombinant CYP6P9a and CYP6P9b 
Recombinant Proteins Permethrin Bifenthrin Deltamethrin λ-cyhalothrin Etofenprox 
FANGCYP6P9a 29.0±1.42 16.6±5.41 18.11±2.15 15.46±4.43 7.28±1.53 
UGANCYP6P9a 60.71±0.92* 50.31±3.8* 57.9±2.74* 47.74±1.5* 42.55±1.03* 
BENCYP6P9a 66.42±2.23* 51.02±0.75* 59.54±5.11* 52.45±1.74* 41.22±1.54* 
MALCYP6P9a 65.38±1.5* 60.48±2.65** 68.38±1.83** 75.41±1.72* 46.04±1.26* 
FANGCYP6P9b 13.7±4.23 22.38±5.08 6.2±1.5 15.49±3.13 16.88±3.06 
UGANCYP6P9b 88.58±3.48** 88.8±1.61** 62.53±4.04** 78.76±1.31** 57.91±1.55* 
BENCYP6P9b 89.63±0.63** 89.19±1.01** 62.03±1.14** 49.35±4.41* 37.15±4.15* 
MOZCYP6P9b 91.6±2.5** 81.6±0.25** 81.69±2.27** 86.51±1.14** 71.59±1.42** 
Values are mean ± S.D. of three replicates compared with negative control (-NADPH);  
* and **Significantly different from FANGCYP6P9a or FANGCYP6Pb at p<0.05 or p<0.01 respectively.  
 
CYP6P9b Alleles: 
Recombinant proteins from CYP6P9b of resistant strains metabolizes pyrethroid insecticides 
with higher activities several fold more than the protein from susceptibe allele, FANGCYP6P9b (Table 
3.16 and Figure 3.15B). These differences were statistically significant with the southern African allele 
MOZCYP6P9b having highest activity: 91.6%±2.5, 81.6%±0.25, 81.69%±2.27, 86.51%±1.14, 
71.59%±1.42 depletion, respectively for permethrin, bifenthrin, deltamethrin, λ-cyahalothrin and 
etofenprox, compared with FANGCYP6P9b which depleted only 13.7±4.23, 22.38%±5.08, 6.2%±1.5, 
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15.49%±3.13 and 16.88%±3.03 of these insecticides. The differences between the resistant and 
susceptible alleles possibly explained the reason why FANG strain is susceptible to pyrethroids.  
As observed with CYP6P9a, recombinant protein from the southern African allele of CYP6P9b 
(MOZCYP6P9b) has the highest activity consistent with the highest pyrethroid resistance reported in 
this region. However, as in fluorescent probes assay, CYP6P9b proteins exhibited higher activities 
against pyrethroids compared with CYP6P9a, confirming that CYP6P9b is more efficient metaboliser 
than CYP6P9a. MOZCYP6P9b has the highest activity of all the alleles screened with pyrethroids is not 
surprising for MOZCYP6P9b protein was predicted to have the highest activity of all alleles, and has 
been established as having high activity with probe substrates and portrayed the tightest binding to 
Type I and Type II pyrethroids from inhibition assay.   
 
 
 
 
3.4.3.2 Kinetics Analysis with Permethrin and Deltamethrin  
Kinetics analysis  was carried out with recombinant protein variants of four alleles each of 
CYP6P9a and MOZCYP6P9b, in order to establish the catalytic constant (Kcat) and Michaelis constant 
Figure 3.15: Percentage depletion of 20µM pyrethroids by  recombinant CYP6P9a (A) and 
CYP6P9b (B). Results are average of three replicates (n = 3) compared with negative control (-NADPH).  
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(KM) for permethrin and deltamethrin. The Kcat provides information on the speed with which different 
protein variants metabolise (clear) insecticide toxicant in vitro, while the KM will highlight the affinity of 
each allele toward the insecticides tested. These parameters can help in assessing any differences in 
metabolic efficiencies between the alleles from resistant strains and those from FANG. Steady-state 
kinetic parameters for CYP6P9a and CYP6P9b with permethrin and deltamethrin are given in Table 
3.17. Reactions followed Michaelis-Menten pattern (Figure 3.16) with KM values within ranges (1-
50µM) described for binding and metabolism of pyrethroids by insect cDNA-expressed P450s 
(Stevenson et al., 2012, Stevenson et al., 2011) and lower than KM values obtained from An. minimus’ 
CYP6P7 and CYP6AA3 with pyrethroids (Duangkaew et al., 2011). Kcat values obtained were also within 
the broad ranges recorded in the literature (1-20min-1)  for the activities of insect P450s with 
pyrethroids (Stevenson et al., 2012) but higher than established for some cDNA-expressed P450s, 
including An. gambiae CYP6M2, Ae. aegypti CYP9J families, as well as An. gambiae CYP6P3 with 
permethrin (Stevenson et al., 2011, Stevenson et al., 2012, Muller et al., 2008). 
 
Figure 3.16: Michaelis-Menten plot of permethrin (A) and (B) and deltamethrin (C) and (D) 
metabolism by recombinant CYP6P9a and CYP6P9a. Each point is a mean±S.E.M. of three replicates. 
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CYP6P9a Alleles:  
Kinetic parameters obtaind revealed that CYP6P9a proteins from the resistant alleles possess 
higher Kcat and higher affinity (low KM) compared with proteins expressed from the susceptible FANG. 
The Kcat of UGANCYP6P9a and MALCYP6P9a with permethrin are two- and three-fold higher than 
values obtained from FANGCYP6P9a, respectively (Table 3.17), and that of BENCYP6P9a and 
MALCYP6P9a with deltamethrin are as well two- and three-fold higher compared with the Kcat 
obtained from FANGCYP6P9a. These differences were statistically significant (p<0.05) for BENCYP6P9a 
and MALCYP6P9a compared with FANGCYP6P9a. In terms of KM, for permethrin, statistically significant 
differences were also obtained with FANGCYP6P9a on average having half the affinity (KM values two-
fold higher) compared with the CYP6P9a from resistant alleles. This translated into statistically 
significant differences (ANOVA Tukey’s test of significant at p<0.05) in terms of efficiency with 
BENCYP6P9a and UGANCYP6P9a having catalytic efficiencies for permethrin (three-fold higher) than 
FANGCYP6P9a while MALCYP6P9a exhibited catalytic efficiency for permethrin six-fold higher than 
FANGCYP6P9a. While FANGCYP6P9a exhibited higher affinity for deltamethrin than permethrin, the 
CYP6P9a from resistant alleles showed comparable KM for both permethrin and deltamethrin. As a 
result of these differences the catalytic efficiencies of BENCYP6P9a and UGANCYP6P9a for 
deltamethrin were on average three-fold the values from FANGCYP6P9a while the Kcat for 
deltamethrin from MALCYP6P9a was four-fold higher than values from FANGCYP6P9a (Figure 3.17). 
CYP6P9b Alleles: 
For permethrin CYP6P9b alleles from resistant individuals produced higher Kcat values 
compared with FANGCYP6P9b; these statistically significant differences ranged from twice the Kcat of 
FANGCYP6P9b as obtained from UGANCYP6P9b, to three-fold higher Kcat as observed from 
MOZCYP6P9b, to four-fold higher Kcat as obtained from BENCYP6P9b (Table 3.17). 
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Table 3.17: Kinetic Constants for Recombinant CYP6P9a- and CYP6P9b Permethrin and Deltamethrin 
Metabolism 
Recombinant Proteins Kcat (min
-1
) KM  (µM) Kcat/KM (min
-1
 µM
-1
) 
  Permethrin  
BENCYP6P9a 9.37±3.32
a 
19.02±3.13
c 
0.49±0.19* 
UGANCYP6P9a 7.35±1.02 20.11±3.91
c 
0.37±0.08* 
FANGCYP6P9a 4.95±1.92 36.25±15.22 0.14±0.07 
MALCYP6P9a 15.41±6.30
a
 18.77±11.76
c 
0.82±0.06* 
BENCYP6P9b 15.91±5.45
b 
21.94±7.97
 
0.73±0.36
$
 
UGANCYP6P9b 8.61±3.40
b 
21.22±10.32 0.41±0.3
$
 
FANGCYP6P9b 4.5±1.35 20.47±8.31 0.21±0.11
$
 
MOZCYP6P9b 12.38±4.5
b 
12.68±2.68
d 
0.97±0.41
$
 
  Deltamethrin  
BENCYP6P9a 8.78±2.62
a 
15.67±4.64
c
 0.56±0.23* 
UGANCYP6P9a 7.96±3.62 14.48±3.58
c 
0.54±0.28* 
FANGCYP6P9a 4.87±2.06
a 
24.03±3.12 0.20±0.08 
MALCYP6P9a 14.65±4.12
a 
18.26±6.97 0.80±0.38* 
BENCYP6P9b 13.63±5.40
b 
15.98±5.63 0.85±0.45
$
 
UGANCYP6P9b 10.44±4.00
b 
12.97±4.96
d 
0.80±0.35
$
 
FANGCYP6P9b 4.92±0.82 19.5±5.53 0.25±0.08 
MOZCYP6P9b 12.09±1.44
b 
9.9±1.65
d 
1.22±0.25
$
 
BENCYP6P9a 8.78±2.62
a 
15.67±4.64
c
 0.56±0.23* 
Values are  mean ±S.D. of three  replicates 
Apparent Kcat was calculated as pmol/min/pmol P450; Catalytic efficiency was calculated as Kcat/KM 
a,b
 Significantly different Kcat values compared with FANGCYP6P9a and FANGCYP6P9b respectively, p<0.05.  
c,d
 Significantly different KM values compared with FANGCYP6P9a and FANGCYP6P9b respectively, p<0.05. 
*
,$
 Significant differences between Kcat/KM values, respectively compared with FANCYP6P9a and FANGCYP6P9b, p<0.05.  
 
 
Same pattern was obtained with deltamethrin, with UGANCYP6P9b having two-fold Kcat 
compared with FANGCYP6P9b, while BENCYP6P9b and MOZCYP6P9b exhibited Kcat values on average 
three-fold that of FANGCYP6P9b. No major difference in terms of KM for permethrin and deltamethrin 
were observed between recombinant proteins from susceptible and resistant alleles of CYP6P9b, with 
the exception of UGANCYP6P9b with deltamethrin, and the southern African MOZCYP6P9b which 
consistently exhibited lowest, reproducible KM both for permethrin and deltamethrin). These low KM 
values from MOZCYP6P9b protein showed that the MOZCYP6P9b allele occupies a central position in 
terms of pyrethroid metabolism and the high affinity it exhibited, which is consistent with the 
molecular docking simulations in which the MOZCYP6P9b portrayed multiple, productive binding 
conformations, as well as fluorescent probes assay from which recombinant MOZCYP6P9b portrayed a 
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very high activity with the probe substrate diethoxyfluorescein, as well as tightest binding with 
pyrethroids, especially the Type II class, as obtained from inhibition assay.  
For permethrin, UGANCYP6P9b, BENCYP6P9b and MOZCYP6P9b were calculated as having 
two-fold, three-fold and five-hold higher catalytic efficiencies respectively compared with 
FANGCYP6P9b (Figure 3.17). With deltamethrin, BENCYP6P9b and UGANCYP6P9b possess catalytic 
efficiencies more than three-fold higher than FANGCYP6P9b, while MOZCYP6P9b with the highest 
catalytic efficiency of 1.22 min-1µM-1±0.25 is five times more efficient in deltamethrin metabolism than 
the recombinant FANGCYP6P9b from the susceptible allele.  
 
 
 
In agreement with the results from fluorescent probes assays and initial testing of depletion of 
pyrethroids, recombinant CYP6P9b exhibited higher activities compared with their corresponding 
CYP6P9a, reflecting the central position of CYP6P9b in pyrethroid metabolism and resistance, 
especially MOZCYP6P9b with highest intrinsic clearance (CLint) for both permethrin and deltamethrin.  
Figure 3.17: 4D plot of the kinetic constants and catalytic efficiencies of recombinant 
proteins of CYP6P9a and CYP6P9b with  (A) permethrin and (B) deltamethrin.  x-axis is the 
Kcat (min
-1
); y-axis is the KM (µM); catalytic efficiency is calculated as  x/y (min
-1
 µM
-1
). 
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3.4.4 Detection of Key Amino Acid Changes Conferring Pyrethroid Resistance  
To assess the potential role of key amino acids in metabolism of pyrethroids, amino acid variants 
from MOZCYP6P9b were mutagenized into residues present in FANGCYP6P9b. Proteins were 
expressed and used in probe susbtrates and metabolism assays with pyrethroids, to establish the 
impact of the replaced amino acids on catalysis. Efforts to amplify mutant sequences from CYP6P9a 
were not successful on several attempts and several approaches. As resistant CYP6P9b alleles possess 
higher potential mutations compared with FANGCYP6P9b, seems to be undergoing more directional 
selection than CYP6P9a alleles, has portrayed higher activities with probes substrates and pyrethroids 
insecticides, it was decided to proceed with the mutagenesis using the resistant allele, MOZCYP6P9b.  
3.4.4.1 Sequence Characterisation of CYP6P9b of Mutant Libraries 
The mutant libraries were screened with pJET1.2 primers, sequenced on both strands and 
manually analysed using the BioEdit to confirm presence of desired nucleotides substitutions. The 
sequencing results confirmed presence of the desired mutations and absence of any unwanted 
substitutions in the mutated DNA sequence  of CYP6P9b. 
3.4.4.2 Pattern of Expression of Mutant CYP6P9b Membranes 
Recombinant proteins of the mutant membranes of MOZCYP6P9b along with the wild type were 
expressed successfully at 21oC and 150 rpm using JM109 cells as described previously. The only 
exception was the Val109Ile mutant that was successfully expressed rather using E. coli DH5α by 
lowering the orbital shaking speed to 120 rpm after induction of the log-phased cells with 0.5mM each 
of δ-ALA and IPTG to the final concentration in 200ml culture. With the exception of Pro401Ala mutant 
all the mutants have lower expression (<3.0 nmol/ml) compared with the wild type MOZCYP6P9b 
(Table 3.18). Specifically, the Val109Ile mutant produced functional P450 with concentrations of less 
than 1.0nmol/ml in all the three successful attempts. Pro401Ala mutant consistently produced higher 
functional protein than all the other mutants as well as the wild type MOZCYP6P9b. Time to optimal 
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expression for all the mutants is around 40-48 hours with the exception of Pro401Ala mutant which 
expresses optimally before 30 hours after induction and  the Val109Ile mutant which as a result of low 
concentration of IPTG and/or different E. coli system (DH5α cells) expressed more slowly with optimal  
expression between  60 to 72 hours.  
Table 3.18: Pattern of expression of MOZCYP6P9b mutants 
Recombinant Proteins 
Time to optimal 
expression (hr) 
n Yield (nmol/ml) 
Val109Ile-MOZCYP6P9b 60-72 3 0.85±0.28 
Asp335Glu-MOZCYP6P9b 40-48 3 2.97±0.47 
Asn384Ser-MOZCYP6P9b 40-48 4 2.77±0.41 
Pro401Ala-MOZCYP6P9b 24-30 3 5.31±1.81 
MOZCYP6P9b (Wild Type) 36-40 4 4.89±0.46 
  Yield of P450 presented as means ± S.D. of concentrations of membranes independently expressed.  
  n = number of times membrane is expressed. 
 
 
 
3.4.4.3 Comparative Assessment of Role of Amino Acids Replacement on Metabolic 
Activities Using Fluorescent Probes Assays 
Seven fluorogenic probe substrates were tested for O-dealkylating activity with the mutant 
CYP6P9b membranes alongside the wild type MOZCYP6P9b. More probes were screened with the 
mutants because of availability and for replacement of key amino acid residues is known to change 
both qualitative and quantitave activities of some P450s (Szklarz and Halpert, 1997). Highest activity 
was observed with DEF and lowest with the resorufin and coumarin-based substrates (Figure 3.18). 
However, significant reduction in  activity towards DEF was observed in all the mutants compared with 
MOZCYP6P9b. This reduction in activity is most profoundly significant (p<0.001) with Asp335Glu mutant 
as well as the Asn384Ser mutant (p<0.05) compared with MOZCYP6P9b. Val109Ile acquired some 
quantitative activity towards RME, values which are statistically significant compared with Pro401Ala 
and MOZCYP6P9b, while the other mutants exhibited no activity at all towards RME. The Asp335Glu 
mutant exhibited lowest activity towards all probes tested with no detectable of even low activity 
toward all the resorufin-based probes. The mutants and the wild type allele exhibited some activity 
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toward 7-EFC and MFC as described previously, but with sharp decline in activity within seconds of  
initial burst of activity which makes it unwise to use these probes for kinetic analysis.  
 
 
 
Kinetic analysis was carried out with DEF which produced highest and more consistent 
activities from the initial test of dealkylation. For all mutants and MOZCYP6P9b proteins fluorescein 
formation follows Michaelis-Menten pattern (Figure 3.19) but kinetic parameters of MOZCYP6P9b-
mediated O-dealkylation of DEF differed greatly from that of the mutant proteins. In terms of 
turnover, the Kcat produced by MOZCYP6P9b is 19-fold, 14-fold and five-fold higher than obtained with 
Asn384Ser, Val109Ile and Asp335Glu mutants, respectively (Figure 3.20 and Appendix 3.6A) reflecting a 
quantitative decrease in the catalytic activity of these mutants. No major difference was observed 
between the wild type MOZCYP6P9b and the Pro401Ala mutant in terms of Kcat.      
Figure 3.18: Metabolism of probe substrates by mutant CYP6P9b membranes. The solid bars 
indicate average of  activity in three experimental replicates compared to negative control (NADPH-).       
* and **statistically significant at p<0.05 and p<0.01 compared with MOZCYP6P9b; †statistically 
significant compared with Val
109
Ile mutant. 
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While no major shift in KM was observed between the wild type MOZCYP6P9b and the mutants 
Val109Ile and Asn384Ser, the affinity for DEF is halved (KM values doubled) with Asp
335Glu and Pro401Ala 
replacements suggesting that modification in this position reduces affinity to DEF. This is in opposition 
to the observation made from in CYP1A2 Glu318Asp substitution, shown to increase the Kcat of O-
dealkylation of 7-ethoxycoumarin 13-fold without affecting the KM. Hiroya and colleagues (Hiroya et 
al., 1994) reported that conservative replacement of glutamate to aspartate resulted in the large 
increase in the Kcat without any apparent change in KM, because the aspartate carboxyl group is better 
positioned for oxygen activation than the glutamate carboxyl moiety. Neutralization of Glu216 and 
Asp301 have also been shown to result in both qualitative and quantitative changes in catalysis by 
human CYP2D6 protein (Paine et al., 2003) with the negatively charged group of Asp and Glu playing a 
role in electrostatic attraction, enhancing binding of basic substrates.  
The catalytic efficiency of the wild type MOZCYP6P9b is established as more than two-fold, eight-
fold, ten-fold and fifteen-fold greater than values from Pro401Ala, Asp335Glu, Val109Ile and Asn384Ser 
mutants, respectively, suggesting that each of this amino acid change impact the metabolic efficiency 
Figure 3.19: Michaelis-Menten plots of mutant CYP6P9b proteins 
dealkylation of DEF. 
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of CYP6P9b. However, the Asn384Ser mutant has the lowest catalytic efficiency among all the mutant 
proteins tested.  
 
 
 
3.4.4.4 Comparative Assessment of Role of Amino Acids Replacement on Metabolic 
Activities of Mutant Proteins  Using Pyrethroids Metabolism Assays 
Significant differences in the metabolic profiles of the mutant membranes compared with the wild 
type MOZCYP6P9b were discovered using metabolism assay with permethrin and deltamethrin. Initial 
depletion assay repeated three times consistently established that the mutants Asp335Glu and 
Asn384Ser, as well as Val109Ile have low activity against pyrethroid insecticides especially deltamethrin.  
Deltamethrin:  With the exception of Pro401Ala mutant, profound quantitative decrease in the 
activity towards deltamethrin was observed in all the mutants (Figure 3.21A). Asp335Glu mutant has 
the lowest activity with only 4.15%±1.41 depletion on one hour of incubation; a loss of 96% activity 
Figure 3.20: 4D plot of the kinetic constants and catalytic efficiencies from 
dealkylation of diethoxyfluorescein by mutant recombinant proteins CYP6P9b. 
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which is statistically significant (p<0.01) compared with the wild type MOZCYP6P9b with depletion of 
92.04%±0.34. Asn384Ser and Val109Ile mutants with depletions of 18.15%±0.42 and 17.88%±1.00 
respectvely, have lost on average 80% of activity compared with MOZCYP6P9b (p<0.01). This loss of 
activity clearly reflects that these three amino acid variants (Asp335, Asn384 and Val109) in MOZCYP6P9b 
are critical for catalysis. Of course, analysis of substrate access channel in Chapter Two have identified 
Val109 residue as a pw2a tunnel lining residue important for  pyrethroids affinity. Its not surprising that 
replacement of this amino acid into isoleucine variant of FANG resulted in a drastic loss of activity. 
Lowest activities were observed with Asp335Glu mutant with only one-fourth activity compared with 
Asn384Ser and Val109Ile mutants. Only 12% loss of activity was observed when depletion of Pro401Ala 
mutant (81.25%±0.17) was compared with MOZCYP6P9b, indicating that replacement of prolyl residue 
with aliphatic side chain did not modify the activity of the enzyme significantly towards deltamethrin. 
This is not surprising as of all the four mutations, Pro401Ala replacement is the least expected to have 
the most significant impact from sequence characterisation and mapping of mutations to critical 
domains of the P450. The percentage depletion from this mutant was also found to be statistically 
significant compared with the other mutants (Asp335Glu, Asn384Ser and Val109Ile).   
 
 
Figure 3.21: Percentage depletion of 20µM deltamethrin (A) and permethrin (B) by CYP6P9b 
mutants. Results are an average of three replicates (n = 3) compared with negative control.  
** and *** Significantly different at p<0.05 and p<0.01 compared with MOZCYP6P9b and Pro
401
Ala mutant. 
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Permethrin: Surprisingly, the mutants Val109Ile exhibited higher activity with depletions for 
permethrin doubled the values from deltamethrin, while Asn384Ser mutant exhibited comparable 
depletion for both permethrin and deltamethrin and Asp335Glu activity for permethrin was nine-fold 
higher than obtained with deltamethrin. However, these depletions were statisitically significantly 
lower (p<0.05) compared with the values from wild type MOZCYP6P9b and the mutant Pro401Ala, 
which show comparable depletions (Figure 3.21B and Appendix 3.6B). Compared with MOZCYP6P9b 
(depletion of 82.59±3.15 for permethrin), Asp335Glu, Asn384Ser and Val109Ile mutants with percentage 
depletion of 35.65%±1.55, 18.33%±0.64 and 46.02%±1.43 respectively, have lost 57%, 78% and 43% of 
their enzymatic activities. This clearly established that the three mutations resulted in a drastic loss of 
activity and the amino acids knocked down are critical for affinity and/or activity towards permethrin. 
Unlike the case of deltamethrin, Pro401Ala replacement was found not to modify activity towards 
permethrin.  
From the inhibition assays MOZCYP6P9b was established to have highest affinity towards Type 
II pyrethroids especially deltamethrin and its assumed that the profound loss of activity observed in 
the mutants reflects the loss of affinity due to the change of the critical amino acid residues into the 
variants present in FANG.  
To establish kinetic constants for all the mutants alongside the reference MOZCYP6P9b, 
kinetic analysis was conducted with permethrin. The decision to use permethrin was because 
experiments with deltamethrin and Asp335Glu, Val109Ile and Asn384Ser produced no reasonable activity 
for calculation of KM and Kcat. Reactions follow typical Michaelis-Menten pattern with differences 
observed between the mutants and wild type enzyme (Figure 3.22A and Appendix 3.6C). Remarkable, 
statistically significant differences were observed when the Kcat of the four mutants were compared 
with the values obtained from the wild type MOZCYP6P9b. Lowest Kcat was obtaind with the Asn
384Ser 
(0.98min-1 ±0.12) compared with MOZCYP6P9b in line with the lowest activity towards permethrin in 
this mutant as obtained from the initial depletion assay. The Kcat of MOZCYP6P9b with permethrin was 
151 
 
two-fold that of Pro401Ala mutant and, on average six-fold, eight-fold and nine-fold the Kcat from 
Val109Ile, Asp335Glu and Asn384Ser mutants respectively. Significant increase (p<0.05) in KM for 
permethrin were observed when Pro401Ala, Asn384Ser and Val109Ile mutants were compared with the 
wild type MOZCYP6P9b. This established that the wild type amino acid variants in MOZCYP6P9b are 
important for affinity towards permethrin. Surprisingly, Asp335Glu mutant exhibited lowest KM (highest 
affinity) with values half those obtained from the wild type MOZCYP6P9b. This demonstrates that 
whatever was the catalytic attribute conferred by Asp335 in MOZCYP6P9b has no effect on affinity 
towards permethrin, but rather via another mechanism which could quantitatively modify the Kcat.  
The differences of the mutant alleles’ kinetic constants reflected in their catalytic efficiencies 
compared with MOZCYP6P9b which was established to be three-fold, four-fold, thirteen-fold and 
nineteen-fold more catalytically efficient towards permethrin, than the mutants Pro401Ala, Asp335Glu, 
Val109Ile and Asn384Ser, respectively (Figure 3.22B).  
 
 
 
 
Figure 3.22: (A) Michaelis-Menten plot of mutant CYP6P9b proteins metabolism of permethrin (B) 
4D plot of kinetic constants and catalytic efficiency of CYP6P9b mutants with for permethrin.  
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3.4.4.5 Comparative Assessment of Spatial Positioning of Criticial Amino Acid Residues in 
MOZCYP6P9b and FANGCYP6P9b Models 
Overlay of MOZCYP6P9b and FANGCYP6P9b revealed striking differences in the overall 3D 
folding and backbone of the proteins though models were generated from identical template (Figure 
3.23). Ser384 in FANGCYP6P9b is located within the β-1_4 placing the guanidinium group of Arg385 away 
(within 9.6Å from 4’ spot of deltamethrin), while the peptide bond between Asn384 and Arg385 in 
MOZCYP6Pb (~120o) positioned Asn384 and Arg385 within the loop joining β-1_4 with β-2_1. The amido 
group of Asn384 is thus situated within 6.6Å distance from guanidinium group of Arg385 which in turn is 
within 6.9Å of the 4’ spot of the phenoxybenzyl group of deltamethrin oriented towards the heme.  
 
 
 
These subtle difference may account for the reason why Arg385 is a pw2a tunnel lining residue 
in MOZCYP6P9b and involved in substrate accessing the heme catalytic centre, while the 
corresponding residue is absent in pw2a from FANGCYP6P9b. The Asn384-Arg385 peptide bond 
positioned guanidinium moiety of Arg385 within 5.0Å distance of Ser324 (Figure 3.24). Its assumed that 
Figure 3.23: Overlay of MOZCYP6P9b model (helices A-L in spectrum and cartoon format) and 
FANGCYP6P9b (helices A-L in purple cartoon) with deltamethrin (spectrum lines) docked in 
productive conformation. Ser384: yellow stick; FANGCYP6P9b_Arg385: green stick; Asn384 : blue stick; 
MOZCYP6P9b_Arg
385
: red stick; heme atoms: cyan lines. 
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catalysis may be effected in MOZCYP6P9b through hydrogen bonding network involving polar residues 
arrayed round the binding site, including Asn384 and Arg385 (SRS5), Arg452 and Cys454 (heme-binding 
region), Asn502, Asp217 (of SRS2), Ser320 (O2-binding pocket), Ser
324 as well as Gln323 (αI). 
 
 
In contrast, in the productive pose of deltamethrin in FANGCYP6P9b, residues Ser384 and Arg385 
located within the β-1_4 are not within 9.0Å of deltamethrin or heme (Figure 3.25). 
 
Figure 3.24: Active site residues of MOZCYP6P9b docked with deltamethrin. Asn384 is in green, 
Arg
385
 in yellow, distance between its guanidium group to Ser
324
 and 4ʹ spot of deltamethrin annotated. 
Figure 3.25: Active site residues of FANGCYP6P9b docked with deltamethrin, showing residues 
within 9.0Å.  
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The same pattern of differences in the backbone folding of CYP6P9b models affected the 
positionin of residue 335. In this respect Glu335 residue in the FANGCYP6P9b is located in the N-
terminus of αJ helix and within a distance of 30.7Å from the heme (Figure 3.26), while the smaller 
Asp335 in MOZCYP6P9b is positioned in the C-terminus of helix I and within 20.3Å from heme. Glu335 in 
FANGCYP6P9b mapped to the putative reductase interaction site 1 (RIS-1) (Sirim et al., 2010) and its 
assumed that the presence of this residue in the αJ helix may result in ionic repulsion with the 
corresponding negatively charged residues at the FMN face of CPR reducing optimal interaction with 
the redox partner and by that the overall catalysis.  
Each of the residues in MOZCYP6P9b implicated as critical are assumed to contribute towards 
catalysis either through channeling and/or affinity (Val109 and Asn384), hydrogen bonding network 
(Asn384 through proper positioning of Arg385) or interaction of the proximal residues with CPR (absence 
of Asp335 in the MOZCYP6P9b RIS-1, which optimizes interation with the FMN binding domain of CPR).  
 
 
 
Figure 3.26: Overlay of MOZCYP6P9b models (helices A-L in spectrum and cartoon format) and 
FANGCYP6P9b (helices A-L in purple cartoon) with deltamethrin (spectrum stick) docked in 
productive conformation. Asp335: blue stick; Glu335: green stick; heme atoms: magenta lines. 
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3.4.5 Comparative Assessment of Ability of CYP6P9a and CYP6P9b Alleles to Confer Pyrethroid 
Resistance in D. melanogaster Using GAL4-UAS System 
3.4.5.1 Insecticides Contact Bioassay 
To find out whether the allelic variation observed between the resistant and susceptible alleles of 
CYP6P9a and CYP6P9b alone was sufficient to confer pyrethroid resistance in vivo, transgenic D. 
melanogaster overexpressing these genes from resistant and susceptible populations were 
constructed separately, using the GAL4-UAS System. Bioassays with permethrin and deltamethrin 
revealed that the flies overexpressing CYP6P9a and CYP6P9b from resistant individuals were 
significantly more resistant to both pyrethroids, resulting in a reduced mortality and knockdown 
compared with the flies overexpressing same genes from susceptible strain, (FANG) and control flies.   
Permethrin: With permethrin, lower mortality was observed in flies expressing CYP6P9b than 
those expressing CYP6P9a (Figure 3.27A and B). However, transgenic Actin5C-UAS-MALCYP6P9a flies 
showed statistically significant (p<0.05), lower mortalities (less than 10%, 30% and 45% in the first 
2hrs, 3hrs and 6hrs, respectively) from permethrin exposure, compared with Actin5C-UAS-
FANGCYP6P9a (30%, 60% and 70% mortalities respectively, at the same time). The same pattern was 
observed with CYP6P9b with flies overexpressing the gene from resistant strain (Actin5C-UAS-
MOZCYP6P9b) showing significantly lower mortalities compared with the flies overexpressing gene 
from susceptible strain (Actin5C-UAS-FANGCYP6P9b) in the following exposure times: 12hrs (30% vs 
55%, p<0.05), 24hrs (30% vs 60%, p <0.01). This demonstrated that MALCYP6P9a and MOZCYP6P9b 
alleles from resistant strains can confer higher resistance to permethrin compared with corresponding 
genes from susceptible, FANG (FANGCYP6P9a and FANGCYP6P9b) and the control flies. Nevertheless, 
the mortalities from MALCYP6P9a flies in the first 12 hours reached 70% compared with only less than 
30% mortality from MOZCYP6P9b flies. MOZCYP6P9b conferring higher tolerance to permethrin is in 
keeping with the higher in vitro activities of recombinant CYP6P9b with pyrethroid insecticides 
compared with results from CYP6P9a protein variants.  
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Deltamethrin: The Actin5C-UAS-MALCYP6P9a flies showed lower mortalities with deltamethrin 
compared to Actin5C-UAS-FANGCYP6P9a (Figure 3.27C); however these mortalities were only 
statistically significant at 3 different hours of exposure: 3 hours (28% vs 53%, p<0.05); 12 hours (55% 
vs 78%, p<0.05) and 24 hours (62% vs 88%, p<0.05). Highest tolerance to deltamethrin was obtained 
with flies overexpressing Actin5C-UAS-MOZCYP6P9b, compared with the flies expressing susceptible 
alleles of CYP6P9a and CYP6P9b, as well as those expressing the resistant allele MALCYP6P9a. The 
Actin5C-UAS-MOZCYP6P9b flies exhibited lowest mortality, of less than 21% up to 12 hours after 
exposure to discriminating dose of deltamethrin (Figure 3.27D). Specifically compared with flies 
overexpressing gene from susceptible strain (Actin5C-UAS-FANG-CYP6P9b), significant differences 
were obtained at every hour of exposure: 1 hour (1.5% vs 20%, p <0.05), 2 hours (7.5% vs 53%, p 
<0.001), 3 hours (12.5% vs 62%, p <0.001), 6 hours (16% vs 70%, p <0.001), 12 hours (21% vs 81%, p 
<0.001) and 24 hours (41% vs 93%, p <0.001).  
Figure 3.27: Bioassay results with transgenic strains of (A) Actin5C-UAS-CYP6P9a flies with 
permethrin; (B) Actin5C-UAS-CYP6P9b flies with permethrin; (C) Actin5C-UAS-CYP6P9a flies 
with deltamethrin, and (D) Actin5C-UAS-CYP6P9b flies with deltamethrin. Results are mean 
±S.E.M. significantly different: * p<0.05, ** p<0.01 and *** p<0.001 
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These results strengthened the pattern obtained from in vitro metabolism assay and kinetics in 
which highest Kcat and efficiencies were obtained with deltamethrin compared with permethrin and 
especially with MOZCYP6P9b allele. Also, from the site-directed mutagenesis analysis it was observed 
that mutants have higher activities toward permethrin than deltamethrin; a result which is consistent 
with lower mortalities obtained with permethrin (62% at 24 hours) from the FANGCYP6P9b flies 
compared with the higher mortalities obtained with deltamethrin (93% at 24 hours). In conclusion, 
overexpression of MALCYP6P9a and MOZCYP6P9b from resistant populations of An. funestus confer 
spermethrin and deltamethrin resistance to naive transgenic flies, with the latter conferring higher 
tolerance to these insecticies, reflecting once more its central position in pyrethroids resistance.  
 
3.4.5.2 qPCR Confirmation of Expression of  CYP6P9a and CYP6P9b Transgenes in Flies  
To validate the overexpression of the candidate genes (CYP6P9a and CYP6P9b) in the experimental 
flies, qPCR was carried out using the flies expressing both resistant alleles (Actin5C-UAS-MALCYP6P9a 
and Actin5C-UAS-MOZCYP6P9b) and susceptible alleles (Actin5C-UAS-CYP6P9a and Actin5C-UAS-
CYP6P9b), as well the control flies (Actin5C-UAS-null flies).  
Both CYP6P9a and CYP6P9b were found to be expressed only in the transgenic F1 progenies from 
the crosses with Actin5C, used for the contact bioassays, and not expressed in the control flies (Figure 
3.28A and B).  The CYP6P9a mRNA were found to be overexpressed with a fold change of 22% and 
24% respectively, in the flies overexpressing the gene from Malawi (Actin5C-UAS-MALCYP6P9a) and 
gene from FANG (Actin5C-UAS-FANGCYP6P9a). CYP6P9b was also found to be overexpressed in the 
transgenic flies but in contrast, the fold change of the gene from flies expressing susceptible gene 
(Actin5C-UAS-FANGCYP6P9b) was four times higher compared with the flies expressing the resistance 
gene (Actin5C-UAS-MOZCYP6P9b).  
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3.5 Discussion and Conclusions 
The membrane contents and reductase activity obtained with both recombinant CYP6P9a and 
CYP6P9b were comparable to those reported from several studies, including respectively the amounts 
reported from An. gambiae CYP6M2 (0.5-1.0nmol/mg and 100-200nmol cytochrome c 
reduced/min/mg) (Stevenson et al., 2011),  CYP6Z2 (0.9-1.5nmol/mg and 100-120 nmol cytochrome c 
reduced/min/mg  (McLaughlin et al., 2008), as well as Ae. aegypti CYP9J sub-family (0.3-1.56nmol/mg 
protein and 32-157 nmol cytochrome c reduced/min/mg)(Stevenson et al., 2012).  Measurement of 
reductase activity is important for differences in its content may possibly influence its interaction with 
the P450 and enhance/diminish catalysis and thus making it difficult to compare different metabolic 
activities in case of significant difference between membrane preparations. However, the ratio of CPR 
to P450 in endoplasmic reticulum was estimated to be 1:20 (Kenaan et al., 2011), and thus even small 
amount of the reductase may be sufficient to drive the P450-mediated catalysis. Both membrane 
contents of P450 and reductase contents were within the same ranges for both recombinant CYP6P9a 
and CYP6P9b from resistant and susceptible strains. In fact FANGCYP6P9a exhibited the highest P450 
Figure 3.28: Quantitative PCR Results:  Fold change of CYP6P9a (A) and CYP6P9b (B) mRNA from 
transgenic flies relative to house-keeping gene RPL11.  
159 
 
content of all the CYP6P9a proteins and thus its safe to assume that whatever differences observed in 
terms of P450 activities between the resistant and susceptible proteins does not stem from variation 
in P450 contents and/or reductase activities.  
Recombinant CYP6P9a and CYP6P9b from resistant strains are capable of dealkylating fluorogenic 
probes particularly DEF with consistently high efficiency. The proteins from resistant alleles exhibited 
very low KM (high affinity) towards DEF compared with corresponding ones from susceptible FANG. 
The KM values obtained with CYP6P9a and CYP6P9b from resistant alleles were comparable to the KM 
established for An. gambiae CYP6Z2- and Ae. aegypti CYP6Z8-mediated de-benzylation of 
benzyloxyresorufin (KM ~0.13µM)(McLaughlin et al., 2008, Chandor-Proust et al., 2013) while the KM 
from FANGCYP6P9a and FANGCYP6P9b are three-fold and two-fold higher than these values, 
respectively. The dealkylation of DEF proceeds with high turnover, greater than established for some 
probes with insect P450s; e.g. An. gambiae CYP6Z2 with benzyloxyresorufin (Kcat ~1.5 min
-1) 
(McLaughlin et al., 2008) and Ae. aegypti CYP6Z8 with benzyoxyresorufin and ethoxyresorufin 
(0.097min-1 and 1.19min-1), respectively. This resulted in higher catalytic efficiency obtained from the 
resistant CYP6P9a and CYP6P9b compared with FANGCYP6P9a and FANGCYP6P9b, and above the 
values from the studies cited above. The CYP6P9a and CYP6P9b from resistant strains are in essence 
more efficient as probe substrate metabolisers compared with the corresponding proteins from 
susceptible alleles. For example, MOZCYP6P9b with catalytic efficiency of 1220.85 min-1µM-1 is roughly 
20-fold more efficient than FANGCYP6P9b. Allelic variation seems to be impacting on enzymatic 
activity towards fluorescent probes, modifying kinetic constants and efficiency of O-dealkylation of  
the probe substrates.   
Pyrethroids, especially of Type II class, pseudo-pyrethroid etofenprox, as well as the 
organophosphate chlorpyrifos diminished the catalytic activity of both CYP6P9a and CYP6P9b with 
DEF, while DDT, bendiocarb and propoxur were established not to inhibit the O-dealkylation of DEF. 
Tight-binding inhibitors have been defined as compounds with a ChemScores of < -30 kJ/mol and an 
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IC50 values of <10µM (Kemp et al., 2004). Based on this Type II pyrethroids (cypermethrin, 
deltamethrin and λ-cyhalothrin can be described as the most potent binders (inhibitors) of CYP6P9a 
and CYP6P9b of all test insecticides screened. Type I pyrethroids and chlorpyrifos also show very low 
IC50 indicating tight binding. DDT, bendiocarb and propoxur with high IC50 displayed very low affinity 
and were expected not to be metabolised by CYP6P9a and CYP6P9b screened. These findings were 
confirmed with substrate metabolism assays with pyrethroids, DDT, bendiocarb and propoxur.  
Metabolism assay established that the recombinant CYP6P9a and CYP6P9b metabolise 
permethrin and deltamethrin insecticides with a very high turnover (depletion) compared with the 
proteins from susceptible alleles, which exhibited low depletion. Highest activities were obtained from 
southern African alelles consistent with the highest pyrethroid resistance recorded in this region 
(Riveron et al., 2013, Riveron et al., 2014a). Very low (insignificant) activities were obtained from DDT, 
bendiocarb, propoxur and malathion metabolism consistent with the results from molecular docking 
simulations and probe assays. DDT is interesting in this case for it exhibited an IC50 on average of less 
than 10µM for both CYP6P9a and CYP6P9b and its assumed that it could be metabolised but as stated 
above binding of substrates to the P450 enzyme does not necessarily reflect metabolism.  
Kinetic constants (parameters) also differ significantly between recombinant CYP6P9a and 
CYP6P9b from resistant and the susceptible alleles. The proteins from resistant alleles exhibited high 
turnover (high Kcat) and high affinity (lower KM) compared with those from susceptible alleles, 
translating into a very high efficiency of pyrethroid metabolism several fold in the former compared 
with the latter. The KM values obtained for both permethrin and deltamethrin  from resistant CYP6P9a 
and CYP6P9b were very close to the KM values established for An. gambie CYP6M2 with permethrin 
(12.0µM) and higher than with deltamethrin (2.0µM) (Stevenson et al., 2011). The Kcat values obtained 
from the resistant recombinant CYP6P9a and CYP6P9b, for both permethrin and deltamethrin are 
higher than values established in the study cited above (6.1min-1 and 1.1min-1, respectively).  
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The differences observed in activities resulted in a very high catalytic efficiency in the resistant 
CYP6P9a and CYP6P9b, especially those from southern Africa compared with FANGCYP6P9a and 
FANGCYP6P9b, as well as other P450s. For example, MOZCYP6P9b exhibited catalytici efficiency of 
0.97min-1µM-1 and 1.22min-1µM-1 respectively, for permethrin and deltamethrin, compared with 
FANGCYP6P9b (0.21min-1µM-1 and 0.25min-1µM-1), An. gambiae CYP6M2 (0.5min-1µM-1) (Stevenson et 
al., 2011) and some CYP9J P450s from Ae. aegypti (<1min-1µM-1) (Stevenson et al., 2012). This 
established that the resistant CYP6P9a and CYP6P9b (especially those from southern African strains) 
are efficient metabolisers of pyrethroids (permethrin and deltamethrin) compared with corresponding 
enzymes from the susceptible strain (FANGCYP6P9a and FANCYP6P9b), and also compared with some 
insect 450s functionally characterised. If its assumed that the only differences between the resistant 
and susceptible alleles of these genes is in the coding region its safe to reason that the amino acid 
variations are responsible for these differences in the metabolic profile; and that the allelic variation 
alone modify the enzymatic activities, impacting on catalysis, making the alleles from resistant strains 
more efficient in terms of pyrethroid metabolism and conferring pyrethroid resistance to resistant 
populations of An. funestus.  
With allelic variation impacting on pyrethroid metabolism successfully established, the next 
task was to identify the potential amino acids that are critical to high efficiency pyrethroids 
metabolism. Site-directed mutagenesis identified three key residues (Val109, Asp335 and Asn384) whose 
replacement in MOZCYP6P9b with variants from FANGCYP6P9b correlated with significant loss of 
metabolic efficiency towards permethrin and deltamethrin. The three mutants above exhibited 
significant, quantitative reduction in activity towards probe substrate DEF compared with recombinant 
MOZCYP6P9b, with the lowest activity towards all 7 probes screened produced by Asp335Glu mutant, 
while Val109Ile mutant acquired quantitative enhancement in activity towards RME compared with the 
rest of the alleles. The maximum catalytic rate of MOZCYP6P9b metabolism of DEF was several-fold 
higher than the three mutants Val109Ile, Asp335Glu and Asn384Ser; mutants Pro401Ala and Asp335Glu 
portaryed a shift in KM (reduced affinity for DEF). This resulted in higher catalytic efficiency several 
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folds from the wild type MOZCYP6P9b compared with all the four mutants, Val109Ile, Asp335Glu, 
Asn384Ser and Pro401Ala, with Asn384Ser having the lowest efficiency. This phenomena established the 
fact that mutants have lost significant potency for O-dealkylation of probe substrates and the reason is 
because the amino acids replaced are critical for catalysis toward DEF. This kind of phenomenon was 
reported before in several studies, including the Glu318Asp substitution in CYP1A2 that has been shown 
to increase the Kcat of O-dealkylation of 7-ethoxycoumarin 13-fold without affecting the KM. Hiroya and 
colleagues (Hiroya et al., 1994) reported that conservative replacement of glutamate to aspartate 
resulted in the large increase in the Kcat without any apparent change in KM, because the aspartate 
carboxyl group is better positioned for oxygen activation than the glutamate carboxyl moiety. 
Leu209Ala replacements in CYP2B1 has been established to result in qualitative changes in activity, 
allowing progesterone to bind in a new orientation (Szklarz et al., 1995). The larger Leu hinders the 
substrate from assuming productive orientation due to vdW overlaps. This maybe the case in Val109Ile 
mutant in which the smaller side chain of valine is replaced with the larger isoleucine.  
With pyrethroids, same pattern of metabolic profiles were observed. Initial depletion assay 
revealed that the mutants with the exception of Pro401Ala have lost activities compared with 
MOZCYP6P9b, with Asp335Glu mutant having lowest activity for deltamethrin while Asn384Ser 
portrayed lowest activity with permethrin. Kinetic analysis revealed that with the exception of 
Asp335Glu which exhibited low KM with permethrin, the mutants have lost significant affinities toward 
permethrin. Maximal catalytic rate also fell compared with MOZCYP6P9b and as a result of that the 
wild type protein was several fold more efficient than all the four mutants. This is in line with the 
probes assays and reflect the importance of the amino acids knocked down in MOZCYP6P9b. This kind 
of lose or gain of function due to single amino acid change has been described in several studies. For 
example, Val92Ala replacement in CYP6AB3v1 makes this allelic variant capable of metabolising plant 
allelochemical imperatorin nearly as effective as CYP6AB3v2 furanocoumarins metaboliser (Mao et al., 
2007). Neutralization of Glu216 and Asp301 have also been shown to result in both qualitative and 
quantitative changes in catalysis by human CYP2D6 (Paine et al., 2003). Replacement of Asp293 to Ala293 
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in human CYP2C9 has been shown to result in decrease in activity by more than 90%, as well as 3-10 
fold increase in KM for tolbutamide, dextromethorphan and diclofenac (Flanagan et al., 2003). Thus, 
replacement of even a single amino acid can have profound effort on regio-selectivity, specificity, 
affinity and/or activity towards particular substrate or broad range of substrates.  
With the exception of Pro401 (amino acid located neither in the active site of MOZCYP6P9b nor 
near the putative RIS), the three residues Val109, Asp335 and Asn384 could be described as important 
residues which confer pyrethroid-metabolising efficiency to recombinant CYP6P9b from resistant 
alleles (strains). Val109 is assumed to exert its effect by the virtue of being part of substrate access 
channel pw2a and as such important for accessibility, specificity and/or affinity; Asp335 exert its effect 
by being present in the tip of helix I and thus away from the putative RIS-1, reducing ionic repulsion as 
the FMN-binding domain of CPR approaches the P450; while Asn384 by the virtue of its location within 
the loop joining β-1_4 with β-2_1 placed itself and guanidinium group of Arg385 within vdW contact 
with the heme and other polar charged and neutral side chain with possibility of hydrogen bonding 
networks, enhancing catalysis several fold. These three amino acids are assumed to be working in 
concert each one contributing in its way to catalysis, efficient metabolism of pyrethroids, especially 
deltamethrin, conferring pyrethroids resistance.  
Expression of alleles of CYP6P9a and CYP6P9b from resistance strains in D. melanogaster 
alone, confers resistance to pyrethroids permethrin and deltamethrin, in vivo. Flies overexpressing 
CYP6P9a and CYP6P9b from susceptible FANG have higher mortalities (values which are statistically 
significant) for permethrin and deltamethrin compared with transgenes overexpressing MALCYP6P9a 
and MOZCYP6P9b from the resistant alleles. The experiments with the flies further confirmed the 
pattern observed from the in silico and in vitro analysis that CYP6P9b is more potent P450 than 
CYP6P9a, able to confer higher tolerance to pyrethroids, in vivo. As confirmed from qPCR validation of 
expression of transgenes, FANGCYP6P9b was overexpressed four-fold higher than MOZCYP6P9b, but 
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even that failed to make the susceptible allele match MOZCYP6P9b in conferring resistance to 
transgenic D. melanogaster.  
Transgenic expression of candidate P450s and bioassays with insecticides have been 
conducted in several studies. For example, transgenic expression of T. castenaum CYP6BQ9 
responsible for deltamethrin resistance in D. melanogaster resulted in tolerance of a diagnostic dose 
of 10µg deltamethrin with a survival rates of 40% at 25oC compared with control flies (survival rates of 
less than 10%) (Zhu et al., 2010). Transgenic expression of CYP6G1 and CYP12D1 in D. melanogaster 
was also reported to result in an resistance to chemically unrelated insecticides (DDT, nitenpyram and 
dicyclanil in the case of CYP6G1) and DDT and dicyclanil in the case of CYP12D1 (Daborn et al., 2007). 
Also, we have used transgenic analysis (Appendix 5) to show that a single mutation  Leu119Phe in 
GSTe2 gene from An. funestus population is responsible for extreme resistance to DDT and cross-
resistance to permethrin. Thus, transgenic analysis allow for establishment of cross-resistance genes. 
In conclusion, allelic variation is impacting pyrethroid resistance, with the resistant alleles of 
CYP6P9a and especially CYP6P9b able to metabolise pyrethroid insecticides with a significantly, very 
high efficiency compared with the corresponding alleles from susceptible strain, FANG. These 
pyrethroid-metabolising efficiency is as a result of differences in amino acid sequences between 
resistant and susceptible alleles. Specifically, in CYP6P9b three amino acid Val109, Asp335 and Asn384 in 
the resistant alleles accounted for these metabolic differences. Replacement of these residues into 
variants from susceptible allele (FANGCYP6P9b) resulted in profound loss of activity towards 
pyrethroid insecticides as well as probe substrates. The resistant alleles from CYP6P9b all across Africa 
are undergoing directional selection in their coding regions with these and possibly other beneficial 
mutations not characterised becoming fixed. These three amino acids could be used to design a 
diagnostic tool that can allow detection of the resistance alleles in field populations of An. funestus 
across Africa, which will make possible tracking the spread of the resistant alleles and helping the 
selection of appropriate insecticide intervention tools.  
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4. FUNCTIONAL CHARACTERISATION OF ADDITIONAL An. funestus 
CYTOCHROME P450s 
 
4.1  Background 
The tandemly duplicated An. funestus CYP6P9a and CYP6P9b have been implicated as the major 
pyrethroid resistance genes across Africa, but several candidate genes have always appeared also as 
top up-regulated genes from genome-wide transcriptional analysis. Irving and colleagues reported two 
genes CYP6M7 and CYP6Z1 from resistant An. funestus (FUMOZ-R) significantly overexpressed, with a 
fold change of a 2.4 and 2.82 respectively, compared with same genes from the susceptible strain 
FANG (Irving et al., 2012). These genes were located within the pyrethroid resistance rp2 QTL. 
Genome-wide transcription analysis using microarrays and validation of up-regulation through qRT-
PCR revealed that the most commonly overexpressed genes from pyrethroid resistant An. funestus 
from Malawi and Mozambique were CYP6P9a and CYP6P9b, as well as CYP6Z1, CYP9J11 and CYP6Z3 
(Riveron et al., 2013). However, the Zambian population of An. funestus from the northern range of 
the pyrethroid resistance front were recently found to be multiple resistant to pyrethroids, bendiocarb 
and DDT (Riveron et al., 2014a). Synergist assays with piperonyl butoxide (PBO) restored susceptibility 
to permethrin, bendiocarb and to some extent (though moderately) DDT, suggesting possible 
involvement of P450s in resistance to these insecticides, in the absence of kdr mutation in the VGSC 
(Riveron et al 2014a). The pre-eminent role of P450s even in DDT resistance was  further strengthened 
by the absence in the southern African An. funestus population of the GSTe2 Leu119Phe mutation 
shown to confer extreme DDT resistance in West/Central Afican An. funestus (Riveron et al., 2014b). 
Transcriptional profiling of the multiple resistant, Zambian An. funestus along with Malawi and 
Mozambique, using  new custom Agilent microarray chip with 60, 000 probes (60mer) revealed that 
the CYP6M7 was more overexpressed than the duplicated CYP6P9a and CYP6P9b, indicating that this 
gene could play a bigger role in pyrethroid resistance in this population. But no evidence exist that it 
could actually metabolise pyrethroid and if it does it remain to be known how it compares to the 
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duplicated P450s CYP6P9a and CYP6P9b. Additionally, beside CYP6M7 and CYP6P9a and CYP6P9b, the 
top 10 up-regulated genes also included other P450 genes, such as CYP6AA4, CYP9J11, CYP6Y2, 
CYP6Z1, CYP6AG1 and CYP6P2 (Riveron et al., 2014a). Their ability to confer pyrethroid resistance 
remain unclear in these populations of An. funestus. In addition, the contribution of these various 
P450s to the multiple resistance observed in these populations has not yet been investigated. It is 
possible that some of these P450s could be conferring cross-resistance between pyrethroids and 
carbamates as previously suggested by (Brooke et al., 2001) or even confer DDT resistance. It is crucial 
to address these questions in order to help design suitable resistance management strategies in the 
region as suggested by the Global Programme of insecticide Resistance Management (WHO, 2012). 
4.2  Aim and Objectives 
The aim of this section was to validate the role of other overexpressed cytochrome P450 genes in 
the resistance to insecticides in southern African populations of An. funestus. 
More specifically, this chapter aims to: 
1-Validate the role of the overexpressed P450s: CYP6M7, CYP6Z1, CYP9J11 and CYP6AA4 in the 
resistance to pyrethroids, and compare them to the duplicated CYP6P9a and CYP6P9b; 
2-Assess the contribution of these additional P450s to the multiple resistance observed or to possible 
cross-resistance between pyrethroids and other insecticide classes. 
4.3  Methods 
4.3.1 Cloning and Heterologous Co-expression of CYP6M7, CYP6Z1, CYP9J11 and CYP6AA4 
Proteins with An. gambiae Cytochrome P450 Reductase 
Cloning and plasmid preparation for these candidate genes follow the ompA+2 strategies 
(Pritchard et al., 1997). Plasmids pB13::ompA+2-CYP6M7, pB13::ompA+2-CYP6Z1, pB13:ompA+2-
CYP9J11 and pB13::ompA+2-CYP6AA4 were constructed as described for CYP6P9a and CYP6P9b in 
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Chapter 3. The primer pairs used for amplification of each gene with the ompA+2 leader for optimal 
expression is given in Table 4.1. Plasmid bearing An. gambiae P450 reductase (pACYC-184-CPR) was 
also constructed as described previously. Each P450 construct was individually co-transformed 
together with CPR into JM109 cells as described in Chapter 3. CYP6M7 (Afun007663), CYP6Z1 
(Afun012197), CYP9J11 (Afun007469) and CYP6AA4/CYP6AA1(Afun008614) are orthologs of An. 
gambiae CYP6M3 (AGAP008213-PA), CYP6Z1 (AGAP003066-PA), AGAP012296-PA and AGAP002862-
PA, respectively. Functional membranes of these P450s were co-expressed with ompA+2 modifications 
together with CPR at 21oC and 150 rpm as described previously (Pritchard et al., 1997, Pritchard et al., 
2006b) to produce recombinant CYP6M7 (rCYP6M7), rCYP6Z1, rCYP9J11 and rCYP6AA4. Optimal 
expression was obtained 36-40 hours post-induction with 0.5mM δ-ALA and 1mm IPTG for all the 
genes. P450 activity was measured using the spectral analysis (Omura and Sato, 1964). Total protein 
content was measured using the Bradford assay (Bradford, 1976) and CPR activity determined using 
cytochrome c reduction assay (Strobel and Dignam, 1978).  
Table 4.1: Primers used for amplification of candidate P450s with ompA+2 modifications 
Primer Sequences 
ompA+2F GGAATTCCATATGAAAAAGACAGCTATCGCG 
ompA+2CYP6M7_F CAAAATGTCTAGCGGCTCCATCGGAGCGGCCTGCGCTACGGTAGCGAA 
ompA+2CYP6M7_R TCTAGAGAATTCTCATGTGCTCAGCTTTTCCACC 
ompA+2CYP6Z1_F CACCGCGATAGCGTAAAGGATCATCGGAGCGGCCTGCGCTACGGTAGCGAA 
ompA+2CYP6Z1_R TCTAGAGAATTCTCACACTCTTCTTTCAATCCTC 
ompA+2CYP9J11_F AACCATCAAATCGATCTCCATCGGAGCGGCCTGCGCTACGGTAGCGAA 
ompA+2CYP9J11_R TCTAGATCTAGATTACATACTAACTTCGTTATCTTTC 
ompA+2CYP6AA4_F CACCACGTTGACGTAACCCATCGGAGCGGCCTGCGCTACGGTAGCGAA 
ompA+2CYP6AA4_R TCTAGAGAATTCCTACAGCTTAGTGCCATTCAGCCAGAT 
 Restriction site (s) are underlined; EcoRI: green, XbaI: red. NdeI for common primer ompA+2F: purple.  
 
4.3.2 Preparation of Cytochrome b5 
The ancillary protein b5 from An. gambiae was expressed and prepared as described (Stevenson et 
al., 2011, Holmans et al., 1994) and quantified through spectral activity (Omura and Takesue, 1970).  
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4.3.3 Insecticides Metabolism Assays 
Pyrethoids permethrin and deltamethrin, carbamates bendiocarb and propoxur, organochlorine 
DDT and organophosphate malathion were tested with the recombinant protein of CYP6M7, CYP6Z1, 
CYP9J11 and CYP6AA4 in a metabolism assay reconstituted with b5.  
4.3.3.1 Substrate Depletion Assay and Kinetics Analysis 
Substrate depletion assays and kinetics analysis were carried out as described in Chapter 3 with 
conditions as outlined in Table 3.8, section 3.33. Enzyme activity was calculated as the percentage 
depletion (the difference in the amount of insecticide(s) remaining in the +NADPH tubes compared 
with the –NADPH) and a paired t-test was used for statistical analysis.  
4.3.3.2 Fluorescent Probes Assay with Recombinant CYP6Z1 
Probes assay was conducted only with rCYP6Z1, partly because evidences from metabolism assay 
with bendiocarb suggests it to be a cross resistance gene, and also for the ortholog of this gene, An. 
gambiae CYP6Z1 (83%) identity had been established as DDT dechlorinase (Chiu et al., 2008); as such 
An. funestus CYP6Z1 is suspected to metabolise DDT as well, unless otherwise established.  
In order determine potential O-dealkylating property CYP6Z1 a battery of test was conducted with 
seven fluorescent probes (the same probes utilised to assay mutant membranes of CYP6P9b in 
Chapter 3). Protocol for initial test of dealkyaltion as well as kinetic was as described  in Chapter 3. For 
kinetics, 0 to 2µM DEF, RBE and RME was assayed with 3.33pmol rCYP6Z1 in a total volume of 250µl. 
Assay was was carried out under conditions shown to be linear with respect to time. 
In order to find out if the results from metabolism assays with pyrethroids, bendiocarb and DDT 
can be consistent with binding parameters of these insecticides (IC50) inhibition assay was conducted 
with DEF, test inhibitors (permethrin, deltamethrin, etofenprox, bendiocarb, propoxur, DDT, 
malathion and chlorpyrifos) and miconazole as positive inhibitor. The assay was carried out as 
described in section 3.3.2 with 0.13µM DEF (KM  with CYP6Z1) and 3.33pmol rCYP6Z1 membrane.  
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4.3.4 In silico Analysis of CYP6Z1 
In order to establish the binding free energy and binding conformations of CYP6Z1 with pyrethroid 
insecticides, bendiocarb and DDT, 3D model of this P450 was created using the crystal structure of 
human CYP3A4 (PDB:1TQN) (as described in Chapter 2) and molecular docking simulation carried out 
with the GOLD software. The docking parameters and conformations of insecticide ligands were 
analyzed using PyMOL and MMV and compared with results from established literature and those  
from dockings with CYP6P9a and CYP6P9b models.  
 
4.4 Results 
4.4.1 Pattern of Co-xpression of  Recombinant CYP6M7, CYP6Z1, CYP9J11 and CYP6AA4  
On average CYP6Z1 consistently expressed at low concentration (0.10±0.05nmol/mg protein) 
compared with CYP9J11 (0.13±0.007nmol/mg protein), CYP6M7 (0.15±0.0nmol/mg protein) and 
CYP6AA4 (0.17±0.02nmol/mg protein). For all proteins however, membrane content of P450 were 
lower than obtained for CYP6P9a (0.42-1.0 nmol/mg) and CYP6P9b (0.35-0.42nmol/mg), respectively. 
CYP9J11 and CYP6Z1 exhibited higher reductase content (91.29- and 77.68 nmol cytochrome c 
reduced/min/mg protein, respectively), higher than reductase contents obtained from  CYP6M7 (44.93 
nmol cytochrome c reduced/min/mg protein) and CYP6AA4 (31.46 nmol cytochrome c reduced/min/ 
mg protein) recombinant proteins.   
4.4.2 Assessment of Insecticide Activities Using Metabolism Assays  
4.4.2.1 Pyrethroids 
Disappearance of 20µM insecticides substrates was determined after one hour of incubation with 
the recombinant enzymes, in the presence of reconstituted cytochrome b5 and NADPH-regeneration 
buffer. All the recombinant enzymes screened metabolise permethrin and deltamethrin (Figure 4.1).  
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CYP6M7 is of special importance for we have recently discovered that its highly overexpressed in 
southern African populations of An. funestus (Riveron et al., 2014a). Specifically, from microarray 
studies, this gene was found to be the most consistenly overexpressed in Zambian population of 
multiple resistant An. funestus with a higher fold change (FC = 37.7) compared with CYP6P9a (FC = 
12.5) and CYP6P9b (FC =25.7). CYP6M7 metabolizes permethrin and deltamethrin with significant 
depletions of 68.28%±0.16 (p<0.001) and 53.60%±3.5 (p<0.001), respectively. The depletion obtained 
for permethrin is slightly higher than values from CYP6P9a-mediated metabolism (60-66% depletion), 
but lower than obtained from CYP6P9b (89-92%). However, both CYP6P9a and CYP6P9b have slightly 
higher depletion for deltamethrin (57-68% and 63-82%, respectively) compared with CYP6M7.    
The other three genes studied are also of field importance for they are as well overexpressed 
across southern Africa in the resistant populations of An. funestus, compared with susceptible strains 
(Riveron et al., 2014a, Riveron et al., 2013) with relatively high fold change: CYP6AA4 (FC = 5.2, 5.3 and 
13.2, for Malawi, Zambia and Mozambique, respectively); CYP6Z1 (FC = 2.8, 2.9 and 3.9 for Zambia, 
Malawi and Mozambique, respectively) and CYP9J11 (FC = 4.0, 4.1 and 4.8, respectively for Malawi 
and Mozambique).  
 
 
 
Figure 4.1: Percentage depletion of permethrin and deltamethrin by various 
recombinant P450s. Results are mean±S.E.M. of 3 replicates. Error bars: variation in the 
depletion between replicates. 
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CYP6Z1 depleted 96.28%±1.002 (p<0.001) of permethrin and 99.21%±0.11 (p<0.001) of 
deltamethrin after one hour of incubation. CYP9J11 metabolize permethrin and deltamethrin with 
significant depletions of 88.05%±3.23 (p<0.0001) and 95.05%+0.74 (p<0.0001) respectively. This is 
comparable to the depletion obtained with permethrin (83.48%±4.64, p<0.0071 and deltamethrin 
(92.77%±1.23, p<0.0001) from CYP6AA4-mediated metabolism. These depletions were higher than 
obtained with recombinant proteins from CYP6P9a and CYP6P9b.  
 
4.4.2.2 Carbamates and Organophosphate 
Carbamates, bendiocarb and propoxur, as well as the organophosphate malathion were screened  
in order to investigate potential cross-resistance phenomenon. None of the recombinant enzymes 
screened (CYP6M7, CYP6Z1, CYP6AA64 and CYP9J11) depleted more than 5% of malathion incubated 
for up to 90 minutes; same results not as obtained from recombinant CYP6P9a and CYP6P9b. This 
result is consistent with malathion susceptibility across Africa. CYP6Z1 and CYP9J11 significantly 
depleted bendiocarb (Figure 4.2); particularly, CYP6Z1 depleted more than 50% bendiocarb incubated 
(54.72%±0.45, p<0.05), while CYP9J11 and CYP6AA4 with lower depletion consumed 38.34%±7.01 (p = 
0.05) and 17.72%±4.84 (p=0.07) of this carbamate, respectively. In constrast with results from 
CYP6M7, CYP6P9a and CYP6P9b (less than 10% depletions), CYP6Z1, CYPJ11 and CYP6AA4-mediated 
metabolism of bendiocarb proceeded with polar metabolites eluting in the beginning of the HPLC 
chromatogram (Figure 4.3). Of course, initial reaction of carbamate metabolism has been described to 
produce very polar products that remain at the origin of the chromatogram (Kuhr, 1970).  
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Figure 4.2: Percentage depletion of 20µM carbamate insecticides with An. funestus CYP450s. 
Results are an average of three replicates (n = 3) compared with negative control. *Significantly different 
from negative control (-NADPH) at p<0.05. 
 
Figure 4.3: Overlay of HPLC chromatogram of the CYP6Z1 metabolism of bendiocarb with 
–NADPH in red and +NADPH in blue. Bendiocarb peaks are designated B1 and B2 and putative 
metabolites peaks from +NADP samples designated M1-M7 (4.396-7.75 mins) and M8 (18.026 mins). 
173 
 
These findings implicated CYP6Z1 as well as CYP9J11 and CYP6AA4 as cross-resistance genes 
that can confer resistance to Type I and Type II pyrethroids as well as bendiocarb. 
However, only CYP6M7 showed significant depletion of propoxur (22.22%±7.08, p = 0.05) but with 
no polar metabolites different from the control (-NADPH). Possibly, recombinant CYP6M7 sequester 
this carbamate insecticide. 
4.4.2.3 DDT 
With DDT, metabolism assay was conducted with CYP6Z1, CYP9J11, CYP6AA4, CYP6M7. Only 
CYP6Z1 was established to be capable of oxidative attack on DDT to produce kelthane with depletion 
of 46.04% ±2.34 (p<0.05). Though CYP6M7 could significantly deplete 37.46%±0.52 of DDT (p<0.05) 
the absence of metabolite peaks make it difficult to ascertain the nature of metabolism. Its assumed 
that like the case of propoxur, CYP6M7 sequesters DDT. The southern African CYP6P9a and CYP6P9b 
also depleted 25.79%±2.96 and 26.32%±2.34 of DDT respectively, but with no metabolite peaks. This is 
somehow consistent with the results from probes inhibition assay in which recombinant CYP6P9a and 
CYP6P9b portrayed an IC50  value of averagely less than 10µM for DDT. Possibly DDT can bind to these 
P450s but is not metabolised. CYP9J11 and CYP6AA4 depleted only less than 10% of the DDT following 
90 minutes incubation. 
4.4.2.4 Establishment of Kinetic Constants with  Metabolism Assay 
4.4.2.4.1 Pyrethroids: Permethrin and Deltamethrin 
 CYP6M7: CYP6M7 metabolism of permethrin and deltamethrin follows Michaelis-Menten pattern 
(Figure 4.4) with Kcat, KM and catalytic efficiency respectively of 6.6±0.24min
-1, 13.81±7.08µM and 
0.45±0.034 min-1µM-1 for permethrin and 7.035±0.204min-1, 19.64±10.69µM and 0.36±0.04 min-1µM-1 
for deltamethrin (Appendix 4.1A). Compared with CYP6P9a and CYP6P9b this enzymes is less efficient, 
especially with deltamethrin to which it exhibited high KM. However, it has KM values for pyrethroids 
and catalytic efficiencies closer to those described for An. gambie CYP6M2 (Stevenson et al., 2011).  
174 
 
 
 
 
CYP6Z1: CYP6Z1 metabolism of pyrethroids also followed Michaelis-Menten pattern with a 
high affinity toward permethrin and deltamethrin (Figure 4.5 and Appendix 4.1A); KM in magnitude 
almost three-fold lower than values we established for the An. funestus CYP6P9a and CYP6P9b 
(Riveron et al., 2014a). This sharp difference in terms of KM possibly reflects a contrasting pattern of 
mechanism of metabolism in which CYP6P9a, CYP6P9b and CYP6M7 with high catalytic rate portrayed 
lower affinity for pyrethroids while CYP6Z1 with low turnover bind pyrethroid insecticides more tightly 
leading to comparable efficiencies. Thus, the catalytic efficiencies of CYP6Z1 towards permethrin and 
deltamethrin are comparable to values we have established with CYP6P9a and CYP6M7 but lower than 
values from southern African CYP6P9b (Riveron et al., 2014a).   
 
 
Figure 4.4: Michaelis-Menten plot of CYP6M7 metabolism of permethrin and 
deltamethrin. Results are average of 3 replicates (n = 3) compared with control (-NADPH).  
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CYP9J11: The CYP9J11 metabolism of permethrin and deltamethrin follows Michaelis-Menten 
pattern, but sharp decline in activity was observed with deltamethrin, above 12.5µM concentration 
(Figure 4.6). This is attributed to substrate or product inhibition especially as evident from the apparen 
KM of the enzyme toward deltamethrin. The Kcat with permethrin was higher than with deltamethrin, 
but the high KM obtained with permethrin makes the enzyme exhibit catalytic efficiency towards 
deltamethrin almost two-fold the value obtained with permethrin (Figure 4.6 and Appendix 4.1A). 
CYP9J11 exhibited high Kcat and high KM with permethrin and low Kcat and a very low KM for 
deltamethrin, leading to catalytic efficiency for deltamethrin approximately two-fold the efficiency 
with permethrin, but lower than obtained from CYP6P9a and CYP6P9b metabolism.  
 
Figure 4.5: Michaelis-Menten plot of CYP6Z1 metabolism of permethrin and deltamethrin. 
Results are an average of three replicates (n = 3) compared with negative control (-NADPH).  
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CYP6AA4: Pyrethroids metabolism by recombinant P450s followed Michael-Menten pattern 
Recombinant (details of kinetic profile of this P450 coud be found in Kayla et al., 2015, the title which 
is given in the list of publications: Appendix 5). CYP6AA4 exhibited high turnover for permethrin 
(Appendix 4.1A), comparable to ranges obtained with CYP6P9a and CYP6P9b and two-fold higher than 
the Kcat obtained from CYP6M7 and CYP9J11. It showed higher activity towards deltamethrin with a 
very high Kcat  double the values obtained with CYP6M7 and eight-fold higher than the Kcats 
respectively from CYP6Z1 and CYP9J11. The KM values obtained from CYP6AA4 are comparable to 
those from CYP9J11 with permethrin and approximately double the values from CYP6M7 with both 
pyrethroids. Thus, CYP6AA4 exhibited catalytic efficiencies for permethrin and deltamethrin, 
respectively of 0.36- and 0.52min-1 µM-1, values which are comparable to those obtained from CYP6Z1 
and CYP6M7 but lower than CYP6P9a and CYP6P9b from resistant alleles.   
 
Figure 4.6: Michaelis-Menten plot of CYP9J11 metabolism of permethrin and 
deltamethrin. Results are average of three replicates (n = 3) compared with  control (-NADPH). 
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4.4.2.4.2 Bendiocarb 
CYP6Z1 and CYP9J11 were tested with 20µM bendiocarb and both enzymes were discovered 
to behave in allosteric fashion with this carbamate insecticide, with positive cooperativity (h = 
5.82±0.34 for CYP6Z1) and for CYP9J11 (h = 2.29±0.38) (Appendix 4.1B). Allosteric enzymes exhibit 
positive cooperativity, which refers to the binding of the substrate at one site of the enzyme which 
affects the affinity of the other sites for the substrates (Atkins, 2004). Presence of multiple substrate 
binding sites increase affinity for the substrate with a rapid but coordinated increase in velocity until 
maximal rate is achieved. Allosteric enzymes are modulated by the presence of effectors which can be 
the substrate itself, a coenzyme or a cofactor. For example, in the case of reconstituted P450 system 
for metabolism assays, substrate concentrations and presence and concentrations of cytochrome b5 
can change the whole kinetic profile of the reaction leading to varying catalytic output. Degree of 
cooperativity is measured by the Hill coefficient (h); when h<1 there is a negative cooperativity, when 
h = 1 there is no cooperativity and when h>1 there is a positive cooperativity.  
CYP6Z1 and CYP9J11 portrayed sigmoidal curve with low Khalf (lower than KM obtained with 
pyrethroids) and low maximal catalytic rate (Figure 4.7) (Appendix 4.1B). Dose-response curve was 
thus modelled using the GraphPad prism with relevant module as described (Copeland, 2004). The 
catalytic efficiencies for bendiocarb were very low compared with the values obtained with pyrethroid 
insecticides.  
Various P450s that exhibit allosteric phenomenon have already being documented, including 
the promiscuous CYP3A4 (Wang et al., 2000) and CYP2C9 (Tracy et al., 2002). Functional allostery using 
distributive catalysis, has been described for some P450s that exhibit atypical kinetics to minimize 
toxicological effect of substrates (Atkins et al., 2002). Its been described that at low substrate 
concentrations, the slower substrate turnover afforded by cooperative CYPs compared with Michaelis-
Menten enzymes can be a significant toxicological advantage, when toxic thresholds exist. Possibly, 
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bendiocarb is highly toxic to CYP6Z1 and CYP9J11, though the two P450s can metabolise it, and this is 
why the enzyme employ distributive catalysis to effect catalysis. 
These results revealed that CYP6Z1 and at some extent CYP9J11 confer a cross-resistance between 
pyrethroids and carbamates, using different mechanisms to effect catalysis. 
 
 
 
4.4.2.4.3 DDT 
In line with the established literature on insects P450s from CYP6 family metabolizing the 
organochlorine, DDT (Chiu et al., 2008, Mitchell et al., 2012), we tested the P450 candidates with DDT. 
An. funestus CYP6Z1 metabolizes DDT, generating dicofol (kelthane) with a minor peak around 7th 
minute on HPLC chromatogram. Unlike An. gambiae CYP6M2, DDT metabolizer which breaks down 
DDT into dicofol and DDE (as a minor metabolite) (Mitchell et al., 2012), An. funestus CYP6Z1 oxidized 
DDT into dichlorodiphenyltrichloroethanol (dicofol). The dicofol formation also portrayed atypical 
Figure 4.7: Sigmoidal curve of CYP6Z1 and CYP9J11 metabolism of bendiocarb. Results 
are  average of three replicates (n = 3) compared with negative control (-NADPH).  
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kinetics with cooperativity (h = 2.603±0.67) (Figure 4.8 and Appendix 4.1B). The Vmax for DDT 
metabolism is several fold higher than obtained with bendiocarb and thus catalytic efficiency for DDT 
metabolism was 100-fold higher than with bendiocarb. This result reveals that CYP6Z1 is possibly 
involved in the cross-resistance to carbamates and DDT observed in southern Africa populations of An. 
funestus such as those from Zambia, as well as populations from Benin where this gene is 
overexpressed. 
 
 
 
 
4.4.3 Assessment of O-dealkylating Properties and Insecticides Binding Affinities of 
Recombinant CYP6Z1 using Fluorescent Probes Assays  
In order to establish more information that can implicate CYP6Z1 as a  potential cross-resistance 
gene, the recombinant CYP6Z1 was used to screen fluorescent probes, establish kinetic profiles and 
affinity toward pyrethroid, carbamate, organochlorine and organophosphate insecticides using 
Figure 4.8: Sigmoidal curve of CYP6Z1 metabolism of DDT. Results are average of three 
independent replicates (n = 3) compared with negative control (-NADPH).  
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inhibition assay. It was hoped that the inhibition assay can shed light on affinity of the CYP6Z1 to 
different insecticide classes, the ones it could metabolise (permethrin and deltamethrin, bendiocarb 
and DDT) and those it could not metabolise (propoxur, malathion, etc).   
4.4.3.1 Screening of Probes and Kinetics with Diethoxyfluorescein 
CYP6Z1 showed preferential activity toward diethoxyfluorescein especially and resorufin-based 
probe RME and RBE, as well (Figure 4.9). Dealkylation of DEF followed Michaelis-Menten pattern 
(Figure 4.10) with kinetic constants different from values obtained with CYP6P9a and CYP6P9b. The 
P450 portrayed strong affinity toward DEF with KM comparable with CYP6P9b, but a maximal catalytic 
activity three fold higher than obtained with CYP6P9b (Appendix 4.1C). Therefore, the catalytic 
efficiency of CYP6Z1 toward DEF was almost three-fold higher the values from CYP6P9b. This shows 
that CYP6Z1 is more efficient O-dealkylating enzyme compared with CYP6P9a and CYP6P9b.  
 
  
 
RME and RBE were also used for kinetics analysis. CYP6Z1 exhibited highest maximal catalytic rate 
with RBE (two-fold higher than values from DEF), but with a very high KM which resulted in low 
Figure 4.9: Metabolism of probe substrates by CYP6PZ1. The solid bars indicate average of 
significant activity in three experimental replicates compared to negative controls (-NADPH). 
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catalytic efficiency, six-fold and four-fold lower than the efficiency obtained with DEF and RME, 
respectively (Appendix 4.1C). The KM of An. funestus CYP6Z1 with RBE is 15-fold higher than the KM 
established for RBE with Ae. aegypti CYP6Z8 (Chandor-Proust et al., 2013)  and An. gambiae CYP6Z2 
(McLaughlin et al., 2008). However, the Kcat of de-benzylation of RBE from the above researchers are 
way too low compared with the Kcat obtained from An. funestus CYP6Z1.   
 
 
 
4.4.3.2 Determination of Affinity of CYP6Z1 to Insecticides Using Inhibition Assays  
In order to establish the affinity of recombinant CYP6Z1 towards different insecticide classes, 
inhibition assay was conducted with DEF and a panel of insecticides. The mean values of IC50 for the 
test inhibitors for the fluorogenic probe DEF used in this study is shown in Figure 4.11. Lowest IC50s 
were obtained with miconazole, a potent P450 inhibitor (Lupetti et al., 2002) used in various inhibition 
studies (Niwa et al., 2005). CYP6Z1 shows lower affinity for both permethrin (IC50 = 6.80µM±0.18) and 
deltamethrin (IC50 = 4.98µM±0.07) compared with CYP6P9a and CYP6P9b respectively, with IC50s 
Figure 4.10: Michaelis-Menten plots of CYP6Z1 dealkylation of probe substrates DEF, 
RBE and RME.  
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slightly lower with deltamethrin than permethrin. The enzyme shows comparable affinity towards 
etofenprox and stronger affinity to chlorpyrifos (IC50 = 0.7µM±0.01). It exhibited low affinity towards 
malathion (IC50 = 16.9µM±3.9. In contrast with CYP6P9a and CYP6P9b, IC50 values of 9.5µM±0.9 and 
8.9µM±0.9 respectively, were obtained for bendiocarb and DDT, with CYP6Z1, indicative of binding 
especially toward bendiocarb to which IC50s for CYP6P9a and CYP6P9b were greater than 25µM. Tight-
binding inhibitors have been defined as compounds with a  IC50 values of <10µM (Kemp et al., 2004) 
and thus bendiocarb and DDT are considered good binders of CYP6Z1. The IC50 values increased 
drastically with decrease in the concentration of those insecticides that show strong inhibition toward 
the CYP6Z1-mediated dealkylation of DEF (Figure 4.11B). The high IC50 obtained with propoxur is 
consistent with the inability of CYP6Z1 to metabolise this insecticide as established from substrate 
depletion assays.  
 
 
 
 
 
 
 
Figure 4.11: (A) Mean IC50 of the test insecticide inhibitors against CY6Z1 dealkylation of DEF. 
Data represent mean IC50 at eight concentrations of each insecticide ± S.D. Error bars represent variation in 
the values of the IC50 between different concentrations; (B) Effect of test insecticides on the CYP6Z1-
mediated metabolism of DEF. Results are mean ± S.D. of three independent replicates. 
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4.4.4 Comparative Modelling  and Molecular Docking Simulation of CYP6Z1 with Insecticides 
 
In order to shed more light on the possible pattern of binding of insecticides to CYP6Z1 model 
virtual insecticide structures were docked to its active site. It was hoped that the docking simulation 
could shed light on what makes the gene able to metabolise non-pyrethroid insecticides, conferring 
cross-resistance in contrast with CYP6P9a and CYP6P9b pyrethroid-metabolism specialists. Here 
docking results with deltamethrin, bendiocarb and DDT were analysed.  
  The docking parameters of CYP6Z1 with permethrin, deltamethrin, bendiocarb and DDT were 
summarized in Appendix 4.2. ChemScore values lower than observed with CYP6P9a and CYP6P9b were 
obtained with permethrin and deltamethrin. In contrast, docking with DDT produced higher 
ChemScore values and lower free binding energy than obtained with CYP6P9a and CYP6P9b, though 
no hydrogen bonding contribution was predicted for all 50 solutions. Another exception is the 
ChemScore values for docking with bendiocarb; these values were consistently higher than those 
obtained with  CYP6P9a and CYP6P9b models.  
Within the active site of CYP6Z1 permethrin docked above the heme plane with 4ʹ spot of the 
phenoxy group positioned at a distance of 3.6Å. Two of the ten top docking solutions in CYP6Z1 have 
gem dimethyl group at close proximity to the heme, thus, just like MOZCYP6P9b, multiple metabolites 
can be generated with permethrin. Deltamethrin also docked with the 4ʹ spotof the phenoxy ring at a 
distance of 3.54Å. One of the top ten ranked poses has the gem dimethyl group facing the heme, 
implying possibility of more than one primary metabolite, as well. It has been established that 
recombinant An. gambiae CYP6M2 preferentially hydrolyses deltamethrin to initial product at 4ʹ 
position, with trans-methyl hydroxylation being a minor route (Stevenson et al., 2011); thus its 
interesting that CYP6P9b and CYP6Z1 which metabolise deltamethrin docked with the same 
conformation multiple conformations.  
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Within the active site of CYP6Z1 deltamethrin is surrounded within 5.0Å radius by nonpolar 
aliphatic residues Val101 (SRS1), Ile216(SRS2),  Lue295 and Ala299 (SRS4), Ala364, Leu365, Ala366 and Leu368 
(SRS5), all of which makes the binding site highly hydrophobic (Figure 4.12A). Bulky hydrophobes 
include Phe212 (SRS2) and Phe115 (SRS1), the latter which point toward and could π-stack with the 
phenoxybenzyl ring of deltamethrin at a distance of 3.8Å (Figure 4.13A). The catalytic importance of 
this Phe together with other critical residues (Leu295, Leu365, Ala366, Leu368, Asn369 and Arg99) has been 
described for An. gambiae CYP6Z1 model (Chiu et al., 2008).   
The polar neutral residues Asn208 (SRS2), Thr303 (SRS4) and Asn369 (SRS5) could possibly be 
important residues involved in hydrogen bonding network with Tyr102 while the positive guanidinium 
group of Arg99 could be involved in electrostatic interactions or form a salt-bridge with the propionate 
moiety of the heme stabilizing the binding cavity. This residue is conserved between CYP6Z1 and 
CYP6P9b, and occupies the same spacial position. A hydrogen bonding was predicted between the ɛ-
amino group of Lys48 and the acyl carbon atom of the acid moiety (Figure 4.14A). This hydrogen bond 
within 2.98Å alone is predicted to contribute -2.5kJ/mole of energy and possibly is networked to. The 
hydrogen bonding network is predicted to Glu210 and Ser211 both residues from the SRS2.  
 
Figure 4.12: Predicted residues within 5.0Å of (A) deltamethrin, (B) bendiocarb and (C) DDT in 
the active site of CYP6Z1. 
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Bendiocarb docked into the active site of CYP6Z1 above the heme with the C-4 of the phenyl 
ring and the carbamate ester located 3.73Å and 6.33Å respectively, from the heme iron (Figure 4.12B). 
In this posture, ring hydroxylation product (4- or 5-hydroxybendiocarb) are predicted to be the major 
metabolites, with ester cleavage to generate benzodioxol-4-ol being of minor priority. The dimethyl 
group are pointed away from the heme catalytic site. Phe115 of SRS1 and occupying the same position 
as Phe123 of CYP6P9a and CYP6P9b is located at a distance of 4.17Å from the phenyl ring of 
bendiocarb, with the possibility of a face-to-face π-stacking. Critical residues within 5.0Å radius of 
bendiocarb (Figure 4.13B) include: (i) non-polar aliphatic side chains important for hydrophobicity: 
Met110 and Ala116 of SRS1, Ala235, Ala237, Leu236 all three belonging to SRS3, Leu295 and Ala298 both from 
SRS4 as well as Ala299 which belongs both to the SRS4 and the O2-binding pocket, as well of Leu
365 from 
the SRS5; (ii) polar residues that could be involved in ionic interaction and/or hydrogen bonding 
include two residues from SRS1, His106 and Tyr102; (iii) polar neutral side chains that could be involved 
in hydrogen bonding include Asn104 and Asn113 both from SRS1, Thr207 and Asn208 both from SRS2.  
The residue Arg99 of SRS1 which was found to be within close contact with the propionate 
moiety of heme in docking with pyrethroids also appeared in the same position with the docked pose 
of bendiocarb. As with docking with deltamethrin we hypothesize that this residue forms a salt-bridge 
with the propionate moiety of the heme stabilizing the active site and enhancing catalysis.    
Two hydrogen bonding were predicted: (i) the alcohol side chains of Thr207 to the N-methyl 
group of the carbamate moiety (2.94Å and -2.5kJ/mol) (ii) the phenyl oxygen of Tyr102 (2.89Å and -
2.5kJ/mol) (Figure 4.14B). Both this intermolecular hydrogen bonding appeared to have  no acceptor 
group from bendiocarb; possibly they were meant for the N-dimethyl group of bendiocarb which was 
out of reach as the insecticide docked closer to the heme.  
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All the 50 predicted bound conformation on DDT in the active site of CYP6Z1 were not 
optimally productive. One of the benzyl rings approached the heme obstructing access to the 
trichloromethyl group. Though ChemScore values were higher than obtained with deltamethrin, with 
all the poses with DDT no hydrogen bonding contribution was predicted by GOLD (see Figure 4.14C). 
Individual residues within 5Å of DDT include the non-polar aliphatic Ala116 of SRS1, Leu206 of SRS2, 
Leu236 of SRS3, Leu295 and Ala299 both of which belong to SRS4, as well as Leu365 of SRS5 (Figure 4.12C). 
Other polar residues include Thr303 of SRS4, Tyr102 of SRS1, His106 of SRS1, and two polar, neutral 
asparagine residues (Asn208 of SRS2 and Asn113 of SRS1). The binding site of DDT in CYP6Z1 contains 
many bulky hydrophobes including Phe115 of SRS1 which point toward the benzyl group approaching 
heme at a distance of 3.52Å with possibility of π-stacking leading to stabilization, Phe294 and Phe296 
both of which belong to SRS4. Arg99 of SRS1 is also located as usual close to the propionate moiety of 
the heme with possibility of forming a salt-bridge. Residues predicted to be in hydrophobic contact 
Figure 4.13: Predicted residues in hydrophobic contact with substrates within 5.0Å of (A) 
deltamethrin, (B) bendiocarb and (C) DDT in the active site of CYP6Z1 
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with the substrate include Phe431, Gly440 and Ile439 (both of heme-binding domain), Phe296, Leu295, 
Gly300, Ala299 (all four from SRS4) Lue365 as well as Phe115 (Figure 4.13C). No residue within 5.0Å residue 
of DDT was predicted to be involved in intermolecular hydrogen bonding with the substrate. Results 
from docking with DDT just like the case of CYP6P9a and CYP6P9b was not conclusive. It opened more 
questions than it answered, for none of the first top ten ranked poses seems to be reliably productive.  
 
  
 
 
4.5 Discussion and Conclusion 
 
Molecular docking simulations predicted CYP6Z1 to have activities toward pyrethroid insecticides 
comparable to CYP6P9a and CYP6P9b. The gene was also predicted to have activity against bendiocarb 
and to some extent DDT. Fluorescent probes and inhibition assays, and pyrethroid metabolism assays 
have implicated CYP6Z1 as cross-resistance gene that binds to pyrethroids, bendiocarb and DDT. This 
is in contrast with CYP6M7, CYP6P9a and CYP6P9b, established to specialize only on pyrethroids 
metabolism, with no activity towards organochlorine DDT, and carbamate, bendiocarb. I have 
Figure 4.14: Predicted residues within 5.0Å of (A) deltamethrin, (B) bendiocarb and (C) DDT in 
the active site of CYP6Z1. Hydrogen bonds between insecticide atom (s) and amino acids residue (s) are 
shown as blue dotted lines. 
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established herein that CYP6Z1 can metabolise pyrethroids, bendiocarb and DDT, but has no 
significant activity towards propoxur and malathion. The presence of benzodioxol- ring in bendiocarb 
and simpler phenyl ring in propoxur, or the presence of isopropoxy- group in propoxur and its absence 
in bendiocarb may account for the incapability of the CYP6Z1 and CYP9J11 to metabolize propoxur. I  
also discovered another gene CYP6M7 which was highly overexpressed in multiple resistant 
populations from Zambia, able to metabolise Type I and Type II pyrethroids with high efficiency. While 
the gene has no significant activity towards bendiocarb and DDT, based on the data obtained I suspect 
it to sequester propoxur and possibly DDT.  Other pyrethroid metabolisers discovered include CYP9J11 
and CYP6AA4 both which also exhibited low activity towards bendiocarb. 
Its now apparent that in An. funestus resistance to pyrethroid is mediated by more than  P450s 
CYP6P9a and CYP6P9b as previously thought. Pyrethroid resistance is mediated by all these P450s 
studied: CYP6P9a, CYP6P9b, CYP6M7, CYP6Z1, CYP9J11 and CYP6AA4, and possibly other P450s yet to 
be characterized. All these genes fall within the originally described three QTLs: rp1 (2R chromosomal 
arm for CYP6P9a, CYP6P9b and CYP6AA4), rp2 (2L in the case of CYP6M7 and CYP6Z1) and rp3 (3L in 
the case of CYP9J11) (Wondji et al., 2009, Wondji et al., 2007b, Irving et al., 2012) associated with 
pyrethroid resistance. In addition to the ability to metabolise pyrethroids and confer resistance to An. 
funestus  by all of these genes, we found that some of these genes, CYP6AA4, CYP9J11 and especially 
CYP6Z1 are cross-resistance genes, meaning that they can metabolise non-pyrethroid insecticides used 
in public health using subtler kinetic mechanisms. An important property observed with CYP9J11 and 
CYP6Z1 with bendiocarb and also CYP6Z1 with DDT is that the metabolism of these insecticides 
proceed allosterically with positive cooperativity, while metabolism of pyrethroids followed canonical 
Michaelis-Menten fashion. As described earlier, functional allostery using distributive catalysis has 
been described for some P450s that exhibit atypical kinetics to minimize toxicological effect of 
substrates (Atkins et al., 2002). These genes possibly utilize this mechanism in the face of challenge 
from highly toxic insecticides. This makes establishment of the catalysis by the P450s conferring 
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resistance difficult and parameterization and extrapolation of kinetics from resistance P450s all the 
more difficult to easily interprete. 
Cross-resistance had been described for many resistant insect populations. For example, a 
multiple resistance An. gambiae  populations from Tiassaleʹ, Coˆte d’Ivoire, West Africa, was recently 
described (Edi et al., 2014). Two P450s CYP6P3 and CYP6M2 were implicated via microarray and 
transgenic studies as responsible for the pyrethroid resistance and cross-resistance to bendiocarb in 
these populations from Tiassaleʹ, while CYP6M2 was also fingered as responsible for DDT resistance. In 
the same study, recombinant CYP6P3 was shown to be able to metabolize bendiocarb in vitro.  An. 
gambiae CYP6M2 however, had already been established as pyrethroid and DDT metaboliser from 
several studies (Mitchell et al., 2012, Stevenson et al., 2011). In D. melanogaster, transgenic 
expression of two P450s CYP6G1 and CYP12D1 conferred cross-resistance to chemically unrelated 
insecticides (DDT, nitenpyram and dicyclanil in the case of CYP6G1) and DDT and dicyclanil in the case 
of CYP12D1 (Daborn et al., 2007), clearly confirming that presence of cross-resistance gene can confer 
resistance to more than one class of insecticide.  
The impact of many genes conferring resistance and cross-resistance to multiple resistant 
populations of An. funestus in sub-Saharan African is a source of concern. This phenomenon makes the 
resistance highly heterogenous and complex, making design of appropriate diagnostic tools 
operationally challenging. Equally, also the flow of these resistance genes can introduce resistance 
hitherto unknown into new environments confounding problems; for example, underlying resistance 
could shift according to region as observed with the highly overexpressed CYP6M7 from Zambia which 
can metabolise Type I and Type II pyrethroids and possibly sequester propoxur. There is thus an urgent 
need to find newer tools to combat insecticide resistance. Also, there is an overwhelming need for 
newer classes of insecticides that are safe (low mammalian toxicity) but potent enough to control 
mosquito vectors of malaria, and other diseases effectively. But caution must be exercised because 
the number of new enzymes classes that can confer cross-resistance is in increase and a new 
190 
 
insecticide may already be doomed before being deployed if resistance genes can already metabolise 
it. There is a need to also find more of the new chemical entities (synergists) that can be incorporated 
into the insecticides formulation so that they can block the enzyme systems from breaking down the 
insecticides in question.   
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5. DISCUSSION, CONCLUSION AND FUTURE PERSPECTIVES 
5.1 Discussion  
An. funestus s.s. is a major malaria vector in the African continent, and it is the most widely, 
geographically distributed amongst all vectors from the An. funestus complex. It has high vectorial 
capacity, an attribute conferred by its highly anthropophilic and endophilic behaviours, and in some 
localities its ability to transmit malarial parasite (parasite infection rates) exceed those of An. gambiae. 
Several studies across Africa have documented An. funestus becoming increasingly resistant 
especially to three of the four classes of insecticides used in public health (pyrethroids, carbamates 
and organochlorines) with resistance patterns being heterogeneous. The pyrethroid resistance in 
particular is threatening to derail the effectiveness of malaria intervention tools, e.g. ITNs and LLINs. In 
the absence of kdr and AChE-type mutations in An. funestus, evidences have implicated a handful of 
monooxygenases (especially from CYP6 family) as mediators of pyrethroid resistance, while GSTs 
(especially GSTe2) have been shown to be responsible for DDT resistance, especially in some regions 
of Africa (Riveron et al., 2014b). Despite the progress made, there is an overwhelming need to 
elucidate the actual molecular mechanisms of metabolic resistance because the bulk of the studies so 
far carried out involves analysis of overexpression of candidate genes, which neither establish the 
ability of the genes in question to metabolise the insecticide(s) of interest nor does it pinpoint the 
factors responsible for the resistance. Presence of polymorphism in the main candidate genes 
established as metabolisers of pyrethroids suggested a role of allelic variation in resistance pattern. 
Equally also the role of other candidate genes overexpressed in the multiple resistance populations of 
An. funestus still needed to be confirmed, for such information can identify other genes that confer 
pyrethroid resistance, as well as cross-resistance to different insecticide classes used in public health.  
The continued effectiveness of vector control through insecticide-based tools require design and 
implementation of suitable resistance management strategies, to limit the negative impact of  
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resistance (WHO, 2012). One prerequisite that can help is the development of appropriate resistance 
diagnostic tools to facilitate the monitoring of insecticide resistance at an early stage, in order to 
inform control programs of the best course of action to take, to minimise the impact of the resistance. 
However, the design of DNA-based diagnostic tools requires a thorough understanding of the 
molecular basis of pyrethroid resistance especially in major malaria vectors such as An. funestus in 
which resistance is mainly metabolic. To date, efforts to characterise pyrethroid resistance in An. 
funestus have revealed metabolic resistance through elevated expression of cytochrome P450s as the 
underlying mechanism playing the major role (Wondji et al., 2012, Riveron et al., 2013, Coetzee and 
Koekemoer, 2013). Despite the numerous reports of implications of P450s in pyrethroid resistance, 
the detailed molecular mechanisms through which P450s confer pyrethroid resistance in mosquitos 
remain largely uncharacterised. Overexpression of several P450s is commonly reported in association 
with resistance, however, it remains unclear what drives the overexpression or whether other 
mechanisms in addition to overexpression are involved. These other factors may include variation in 
the coding sequences through substitutions of catalytically important amino acid which could modify 
the activity of the enzymes or cis and/or trans mutations that could impact the up-regulation of the 
candidate P450s linked with resistance. Previous works have reported that allelic variations through 
amino acid changes in the CYP6A2 gene variants in D. melanogaster impacted DDT metabolism with 
striking quantitative changes in catalytic activity, and recently, in An. funestus, a single point mutation 
detected in resistant populations was established to alone confer DDT resistance. However, little was 
known on the impact of allelic variation of P450 genes on pyrethroid resistance. Observation of 
important polymorphism variation for the two most important pyrethroid resistance genes CYP6P9a 
and CYP6P9b (Riveron et al., 2013, Wondji et al., 2009) in An. funestus suggested that this mosquito 
species is an excellent candidate to assess the impact of allelic variation on insecticide resistance.  
The goal of this study was to assess whether allelic variation is impacting pyrethroid resistance 
and if causative mutation(s) could be identified for pyrethroid resistance mediated by P450 genes, 
which will facilitate the design of DNA-based diagnostic tools to easily detect and track such resistance 
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in field populations. Additionally, several other candidate P450 genes previously associated with 
pyrethroid resistance or cross resistance to other insecticides, still needed to be validated to confirm 
their role in respective resistance in the field.  
In this study, molecular basis of monooxygenase-mediated resistance to pyrethroid in An. 
funestus was dissected. Exisence of cross-resistance genes that metabolise bendiocarb and DDT was 
also established. The major findings of this study include: (i) Allelic variation is a key mechanism 
conferring pyrethroid resistance in An. funestus, (ii) Key amino acid changes in pyrethroid metabolising 
P450 CYP6P9b, from resistant populations are responsible for pyrethroids-metabolising efficiency; this 
finding could help create DNA-based diagnostic tools that can allow for detection of such mutations in 
the field, (iii) Pyrethroid resistance is multi-genic in field populations of An. funestus; in addition to 
CYP6P9a and CYP6P9b (the major pyrethroid resistance genes in An. funestus), other genes 
overexpressed in resistant populations were functionally validated for ability to metabolise 
pyrethroids and non-pyrethroid insecticides,  (iv) Validation of these other genes led to the discovery 
of P450s that confer cross-resistance to pyrethroids, as well as DDT and bendiocarb in An. funestus. 
These findings are discussed in detail below:   
5.1.1 Allelic Variation is a Key Mechanism Conferring Pyrethroid Resistance in An. funestus 
The fact that the predominant haplotypes of the pyrethroid resistance genes CYP6P9a and 
CYP6P9b from resistant mosquito populations across Africa share key amino acid variants in common 
compared with the haplotypes from FANG suggested that allelic variation in these genes is impacting 
their ability to metabolise the pyrethroids, and confer resistance. This was also supported by in silico 
simulation of the activities of these P450s towards different classes of insecticides which predicted the 
allelic variants from the resistant populations to metabolise pyrethroids with high efficiency compared 
with the susceptible alleles. In silico predictions have been applied in several studies to predict the 
ability of insect P450s to metabolise pyrethroids and other substrates (Stevenson et al., 2011, 
Chandor-Proust et al., 2013, Schuler and Berenbaum, 2013). Validation of in silico predictions 
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confirmed that allelic variation is conferring pyrethroid-metabolising efficiency in the CYP6P9a and 
CYP6P9b alleles from resistant populations of An. funestus compared with the corresponding genes 
from FANG which has lower metabolic activities toward pyrethroid insecticide and probe substrates. 
The robustness of the in silico prediction was also strengthened by the inability of the recombinant 
proteins of these genes to metabolise non-pyrethroid insecticides, including bendiocarb, propoxur and 
DDT. These findings were further strengthened through in vivo analysis; with presence of alleles from 
resistant populations (MALCYP6P9a and MOZCYP6P9b) alone conferring pyrethroid resistance to 
transgenic D. melanogaster. This established that CYP6P9a and CYP6P9b gene products which are 
overexpressed in resistant populations of An. funestus across Africa, compared with FANG are 
specialist pyrethroid metabolising P450s. The findings of these genes especially CYP6P9b undergoing 
directional selection all across Africa is in line with the previous observations from several studies 
(Riveron et al., 2013, Wondji et al., 2012). Important polymorphisms in the resistant alleles of CYP6P9a 
and CYP6P9b were mapped to catalytic domains (active sites) of these genes with potential impact on 
activity and substrates specificity. This is an important finding that identifies markers of resistance in 
An. funestus which can allow for tracking of these pyrethroids metabolically-mediated resistance 
alleles across Africa, with special operational applications towards management of insecticides 
resistance. It also set a pace for studies of this kind to be carried out on other organisms, e.g. major 
malaria vectors (An. gambiae and An. arabiensis), dengue vector Ae. aegypti, as well filarial worm 
vector Cx. quinquefasciatus. These insects have been shown to be resistant to a wide variety of 
insecticides, and like An. funestus and the major enzyme systems which confer the resistance to them 
may possess allelic variants that need to be investigated. Markers of resistance and diagnostic tools 
can be established in these insect species helping towards implementation of well-informed resistance 
management strategy. To establish whether allelic variation in pyrethroid/insecticide resistance genes 
is multi-genic, further studies need to be carried out to find out whether allelic variants exist in the 
other overexpressed P450s from resistant populations across Africa. 
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However, the mechanism of pyrethroid resistance in An. funestus is complex and non-uniform. 
For example, allelic variation may not explain all the pyrethroid resistance, for it was not observed in 
the other major pyrethroid metabolising P450, CYP6M7 (Riveron et al., 2014a).  
Another important frontier to investigate is the role of overexpression compared with allelic 
variation in An. funestus. Which one amongst these two phenomena is more important to insecticide 
resistance?  Overexpression is obviously important for higher turnover of a particular candidate gene, 
which can make it more abundant to detoxify insecticides, but if and only if the gene product can 
metabolise the insecticide in question, then activity can be several-fold higher. Coupled with allelic 
variation through replacement of key residues, the activity can become sharpen via several 
mechanisms which can modify catalytic activity toward range of substrates, enhancing catalysis.   
5.1.2 Key Amino acid Changes Control Pyrethroid Resistance and Could Lead to DNA-based 
Diagnostic Tools  
Site-directed mutagenesis implicated three major amino acid residues in the resistant allele 
(MOZCYP6P9b) which explained high metabolic activity toward pyrethroids, especially the Type II 
class. These amino acid variants differ in their spatial positioning in the resistant allele compared with 
the corresponding residues in the allele from the susceptible strain, with different impact on 
specificity toward pyrethroids. One of these amino acids from resistant allele, a non-polar aliphatic 
residue (Val109) is a component of pw2a tunnel lining residue and involved in substrate-access 
channelling and enhanced specificity toward pyrethroid insecticides; the second residue, Asp335 is 
positioned away from the putative reductase interacting site 1 at the proximal face of the P450 from 
resistant strain reducing ionic repulsion with the negatively charged FMN residues involved in 
electrons transfer; the third residue Asn384 located within the loop joining β-1_4 with β-2_1 with 
Asn384-Arg385 position both Asn384 and Arg385 in closer proximity to the pyrethroid insecticide and heme 
catalytic centre, with the possibility of extensive hydrogen bonding, enhancing catalysis. Knocking 
down these amino acid variants into residues present in the susceptible strain (Ile109, Glu335 and Ser384) 
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resulted in drastic reduction in catalytic activity and affinity towards pyrethroids, especially Type II 
class, indicating that each of these mutations alone is important for efficient metabolism of 
pyrethroids. However, it’s thought that the presence of these three amino acids in the resistant allele 
harnessed several mechanisms to optimise catalytic efficiency, through substrate channelling, affinity, 
enhanced coupling to redox partners and maximal hydrogen bonding interactions.  
As this is the first marker of metabolic resistance to pyrethroids involving P450s in the An. 
funestus and/or even other mosquito species, DNA-based diagnostic test was sought to be created for 
these mutations to allow for tracking them in the field. However, unlike the case of  DDT-resistance 
gene  An. funestus GSTe2 (Leu119Phe substitution) recently described, and the Central and West 
African An. funestus Rdl mutation, CYP6P9a and CYP6P9b are duplicated genes; these makes it difficult 
to create a simple diagnostic test like RFLP based on polymorphic site(s).  
5.1.3 Pyrethroid Resistance is Multigenic in Field Populations of An. funestus 
Other candidate genes especially from CYP6 family (CYP6M7 and CYP6Z1) belonging to rp2 QTL, 
rp1 (CYP6AA4), rp3 (CYP9J11) and overexpressed in multiple resistant population of An. funestus from 
southern Africa were found to metabolise pyrethroids as well. This clearly established that pyrethroid 
resistance is more complex than previously thought. The finding of these pyrethroid metabolisers fits 
the presence of 3 QTLs described previously (Wondji et al., 2009). The impact of multiple genes 
involved in pyrethroid resistance added another twist to the already complex pattern and makes it 
difficult to implement resistance management based on straightforward evidences. Examples of these 
complexities include overexpression as in the case of all the genes from the three QTLs, duplication as 
in CYP6P9 and CYP6P4, allelic variation as established in CYP6P9a and CYP6P9b and yet to be 
investigated in other candidate P450s, and absence of allelic variation explaining resistance as in 
CYP6M7. Nevertheless, P450s from rp1 QTL occupy a central position in terms of pyrethroid resistance 
for two reasons: (i) the major resistance genes CYP6P9a and CYP6P9b, in addition to CYP6AA4 and 
other P450s yet to be validated are component of this QTL; (ii) CYP6P9a and CYP6P9b are the most 
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consistently overexpressed P450 genes in pyrethroid resistant populations of An. funestus across 
Africa, and (iii) The rp1 QTL (CYP6P9a and CYP6P9b) explained 87% of pyrethroid resistance in the 
FUMOZ lab strain. Thus, decisions on pyrethroid resistance management could be made based on the 
features of rp1 QTL genes than attribute of genes from the other two QTLs.  
Involvement of multiple P450s in pyrethroid metabolism is not unique to An. funestus; it has been 
described for other mosquito species including Ae. aegypti and An. gambiae (Stevenson et al., 2012, 
Edi et al., 2014). For An. funestus it remains to be known if these multiple genes are all part of the 
same pyrethroid resistance network and coordinated via the same mechanism or if they operate 
independent of one another. Future study notably metabolomics and fingerprinting can help sort this 
puzzle.  
5.1.4 CYP450 Genes Confer Cross Resistance to Bendiocarb and DDT in An. funestus 
Multiple resistances in An. funestus from southern Africa have been documented with CYPs 
involvement described through synergist assays, biochemical analysis and genome-wide transcription 
analysis. On the basis of this some of the top upregulated genes were functionally characterised to 
find out if they can metabolise non-pyrethroid insecticides. It was discovered that CYP6Z1, CYP9J11 
and to some extent CYP6AA4 are bendiocarb metabolisers, while CYP6Z1 metabolises DDT. These 
findings are of tremendous importance for it shows that the use of non-pyrethroid insecticides in 
malaria control as in IRS has great limitations. These P450s especially CYP6Z1 were found to adapt 
different mechanism of catalysis for different insecticide substrates in order to achieve optimal 
detoxification. For example, for bendiocarb and DDT the cross-resistance genes CYP6Z1 exhibited 
atypical, allosteric kinetics with distributive catalysis. This kind of allostery has also been described for 
several CYPs as a strategy to minimize the toxic effect of the toxophore like insecticides. However, the 
lower up-regulation of these cross-resistance genes (CYP6Z1, CYP9J11 and CYP6AA4) and the non-
involvement of the top upregulated candidates (CYP6P9a, CYP6P9b and CYP6M7) in metabolism of 
bendiocarb and DDT indicated that cross resistance is of secondary priority to the pyrethroid 
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resistance; at least in southern Africa. Cross-resistance P450s have been described for several insect 
species as well, including An. gambiae and D. melanogaster (Mitchell et al., 2012, Daborn et al., 2007).  
5.2 Conclusion 
Drawing from the findings accrued on the course of this study, the following conclusions could be 
made: (i) the duplicated P450s CYP6P9a and CYP6P9b are the major pyrethroid resistance genes in An. 
funestus across Africa; (ii) the two genes differ extensively in their active site topology and 
composition and these differences are responsible for the variation observed in their metabolic 
profiles; (iii) allelic variation in these genes is impacting their pyrethroid-metabolizing capability, with 
specific mutations selected and fixed in resistant populations, able to confer high activity towards 
pyrethroids; (iv) the genes CYP6P9a and CYP6P9b cannot metabolise representative carbamate 
(bendiocarb and propoxur), organochlorine (DDT) and organophosphate (malathion) insecticides; the 
genes are directionally selected specialist enzymes involvedin pyrethroid metabolism. This makes it 
possible to use non-pyrethroid insecticide as alternative insecticides, for IRS, even when CYP6P9a and 
CYP6P9b are overexpressed in An. funestus, although other P450s should be taken into consideration; 
(v) the highly polymorphic CYP6M7 gene, also a pyrethroid metabolizer, and suspected to sequester 
propoxur (though evidences are not conclusive) partners with CYP6P9a and CYP6P9b to confer 
pyrethroid resistance across southern Africa; (vi) other candidate genes, overexpressed in An. 
funestus, including CYP6Z1, CYP6AA4 and CYP9J11 metabolises pyrethroid insecticides as well, making 
the resistance multi-genic; (vii) these second group of genes especially CYP6Z1 confer cross-resistance 
to bendiocarb and DDT in the multiple resistant An. funestus populations from southern Africa, where 
other important non-monooxygenase mechanisms like Leu119Phe GSTe2 mutation is absent; (vii) the 
finding of cross-resistance genes make pyrethroid resistance phenomena in the major malaria vector, 
An. funestus more complex confounding the problem of resistance management.  
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5.3  Future Perspectives  
The results obtained on the course of this research are in no way exhaustive within the 
context of monooxygenase-mediated resistance mechanism. Overexpression of the protein of the 
detoxification gene can be due to changes at transcriptional level, e.g. higher constitutive production 
of transcripts, due to mutation in promoter sequences, higher inducible expression due to mutations 
in the trans-acting factors or greater responsiveness to transcriptional inducers. This is a frontier that 
needs to be explored in An. funestus detoxification genes, especially in CYP6P9a and CYP6P9b in order 
to elucidate what, why and how these genes are switched on and off in relation to the environmental 
response. Factors responsible for cis- or trans-regulation of P450s involved in detoxification may also 
be capable of regulating expression of other P450s that are not necessarily involved in the said 
resistance (this has been shown to be the case in housefly). Knowing which subsets of P450s are 
elevated by the same regulatory factors may help to elucidate cross-resistance phenomena.  
Herein, we studied mutations at the protein level which can impact on metabolism, e.g. 
mutations at the catalytic sites that may affect range (qualitative) or rate (quantitative) of substrate 
metabolism, and mutations in the proximal surface residues that may affect electron transfer from 
cytochrome P450 reductase and/or cytochrome b5.  
Throughout this research we adopted as surrogates electron transfer partners (cytochrome 
P450 reductase and cytochrome b5) from An. gambiae. It is possible that the interaction of An. 
funestus-specific electron transfer partners may affect the qualitative and quantitative activity of its 
CYP450s. Potential mutations in such partners may also possibly alter their coupling with the 
respective An. funestus CYP450s. 
The whole picture of the resistance phenomena can only be obtained using metabolomics 
studies. There is an overwhelming need to find out which subsets of genes are switched on and/or off 
in response to insecticide exposure, and which intermediates and products are generated from 
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insecticide metabolisms. These could be achieved using targeted transcriptomics, proteomics and 
MS/MS.  LC/MS could also be utilised to identify the metabolites generated by these P450s, and this 
could help in piecing together the pyrethroid resistance network.  
Modelling simulation has great shortcoming, there is an urgent need to create a crystal 
structure of the P450s involved in pyrethroids metabolism with the insecticides in its active site. This 
will greatly facilitate our understanding of the mechanism of action of these P450s, as well as help in 
design and production of potential synergists that could be used in combination with the insecticide to 
block the resistance P450s.  
Successful site-directed mutagenesis of resistant allele of CYP6P9a could potentially reveal the 
identity of the amino acids responsible for the ability of this gene to metabolize wide range of Type I 
and Type II pyrethroids. This is important, for the amino acid substitutions that could potentially 
impact on catalytic activity of CYP6P9a mapped to different domains of the P450 compared with those 
mutations characterised for CYP6P9b.  
CYP6P9a and CYP6P9b are duplicated genes, a phenomenon which makes it challenging to 
design an easy DNA-based diagnostics, such as PCR-RFLP. More efforts are needed to achieve this goal 
in order to track CYP6P9a and CYP6P9b mutations in the field population of An. funestus across Africa.  
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APPENDIX 2.1 
A: Maximum likelihood tree of An. funestus CYP6P9a and CYP6P9b; B: 
Python scripts used for model building. 
 
 
 A: Maximum likelihood tree of An.  funestus CYP6P9a (i) and CYP6P9b (ii) cDNA across Africa showing clades 
relationship. A number is given to each haplotype preceded by BEN, MAL, MOZ, UGA or FANG if it is unique to BENIN, MALAWI, 
MOZAMBIQUE, UGANDA or FANG  strains, respectively. 
 
(B) Python script used to build models using the MODELLER 9v2.0 
from modeller import *    # Load the automodel class 
from modeller.automodel import *  
log.verbose()    # request verbose output 
env = environ()  # create a new MODELLER environment to build this model in 
env.io.atom_files_directory = '/directory/folder/subfolder' 
env.io.hetatm = True 
a = automodel(env, 
              alnfile  = '/directory/folder/subfolder/alignment.ali',  
              knowns   = ( '1TQN' ), # codes of the templates 
              sequence = 'SEQUENCE NAME' 
       )              # code of the target 
a.starting_model= 1                 # index of the first model  
a.ending_model  = 50               # index of the last model 
a.make()                            # do the actual homology modelling  
220 
 
APPENDIX 2.2 
Errat profiles of CYP6P9a and CYP6P9b models and CYP3A4 (PDB:1TQN) 
Serial Number Model Name Overall Quality Factor (%) 
1 BENCYP6P9a.pdb 55.876 
2 FANGCYP6P9a.pdb 52.731 
3 MALCYP6P9a.pdb 51.527 
4 MOZCYP6P9a.pdb 51.527 
5 ZMBCYP6P9a.pdb 55.441 
6 UGANCYP6P9a.pdb 52.749 
7 BENCYP6P9b.pdb 55.072 
8 FANGCYP6P9b.pdb 59.175 
9 MALCYP6P9b.pdb 55.230 
10 MOZCYP6P9b.pdb 55.464 
11 ZMBCYP6P9b.pdb 53.992 
12 UGANCYP6P9b.pdb 62.134 
13 CYP3A4 (1TQN.pdb) 93.696 
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APPENDIX 2. 3 
Transmembrane domain prediction for CYP6P9a using DAS 
(a) Potential transmembrane segments of CYP6P9a protein sequence 
Start Stop Length ~ Cutoff 
6 20 15 ~ 2.2 
6 21 16 ~ 1.7 
80 89 10 ~ 1.7 
84 86 3 ~ 2.2 
186 187 2 ~ 1.7 
217 228 12 ~ 1.7 
219 226 8 ~ 2.2 
307 315 9 ~ 1.7 
309 313 5 ~ 2.2 
466 471 6 ~ 1.7 
495 498 4 ~ 1.7 
 
The 2.2 strict cut off is informative score in terms of matching segment while the loose score of 1.7 gives the 
actual location of the transmembrane segment. 
 
 
(b) DAS plot of transmembrane domains of CYP6P9a protein sequence 
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APPENDIX 2.4 
Transmembrane domain prediction for CYP6P9b using DAS 
(a) Potential transmembrane segments of CYP6P9b protein sequence 
Start Stop Length ~ Cutoff 
6 21 16 ~ 1.7 
7 20 14 ~ 2.2 
79 89 11 ~ 1.7 
81 86 6 ~ 2.2 
186 187 2 ~ 1.7 
218 228 11 ~ 1.7 
219 225 7 ~ 2.2 
305 315 11 ~ 1.7 
308 314 7 ~ 2.2 
466 471 6 ~ 1.7 
 
The 2.2 strict cut off is informative score in terms of matching segment while the loose score of 1.7 gives the 
actual location of the transmembrane segment. 
 
 
(b) DAS plot of transmembrane domains of CYP6P9b protein sequence 
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APPENDIX 2.5 
Binding modes of etofenprox in 1.0 CYP6P9a and 2.0 CYP6P9b models. 
 
 
 
 
 
1.0 Binding modes of etofenprox in (A) BENIN, (B) UGANDA, (C) FANG and (D) MALAWI 
CYP6P9a models. Etofenprox is in stick format and blue colour. Heme atoms are in stick and 
spectrum. Possible sites of metabolism are indicated with yellow arrows.  
 
2.0 Binding modes of etofenprox in (A) BENIN, (B) UGANDA, (C) FANG and (D) 
MOZAMBIQUE CYP6P9b models. Etofenprox is in stick format and green. Heme atoms 
are in stick format and spectrum.  
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APPENDIX 2.6 
 Binding modes of DDT in 1.0 CYP6P9a and 2.0 CYP6P9b models. 
 
 
 
 
 
 
 
1.0 Binding modes of DDT in (A) BENIN, (B) UGANDA, (C) FANG and (D) MALAWI 
CYP6P9a models. DDT is in line format and purple. Heme atoms are in green. C-2 is indicated 
with yellow arrow. 
 
2.0 Binding modes of DDT in (A) BENIN, (B) UGANDA, (C) FANG and (D) MOZAMBIQUE 
CYP6P9b models.  DDT is in line format and violet. Heme atoms are in green. C-2 is indicated 
with yellow arrow. 
 
225 
 
APPENDIX 2.7 
Binding modes of bendiocarb in 1.0 CYP6P9a and 2.0 CYP6P9b models. 
 
 
 
 
 
 
1.0 Binding modes of bendiocarb in (A) BENIN, (B) UGANDA, (C) FANG and (D) MALAWI 
CYP6P9a models.  Bendiocarb is in line format and purple. Heme atoms are in green. Probable 
sites of metabolism are indicated with yellow arrow. 
 
2.0 Binding modes of bendiocarb in (A) BENIN, (B) UGANDA, (C) FANG and (D) MOZAMBIQUE 
CYP6P9b models. Bendiocarb is in line format and purple. Heme atoms are in green. Probable sites 
of metabolism are indicated with yellow arrow. 
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APPENDIX 2.8 
Haplotype Diversity and Nucleotide Variations of CYP6P9a cDNA Sequences Across Africa. 
 
 
 
 
 
 
 
Schematic representation of CYP6P9a haplotypes for the coding region among resistant and 
susceptible mosquitoes. FANG is highlighted in red. Polymorphic positions are indicated by numbers 
above the nucleotides and the haplotypes identity reflected with a number in front of the country it belongs. 
MAL = MALAWI, MOZ = MOZAMBIQUE, ZMB = ZAMBIA, UGAN = UGANDA, BEN = BENIN. 
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APPENDIX 2.9  
Haplotype Diversity and Nucleotide Variations of CYP6P9b cDNA Sequences 
Across Africa. 
 
 
 
 
 
 
 
 
Schematic representation of CYP6P9b haplotypes for the coding region among resistant and 
susceptible mosquitoes. FANG is highlighted in red. Polymorphic positions are indicated by numbers 
above the nucleotides and the haplotypes identity with a number in front of the country it belongs.  
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APPENDIX 3.1 
Preparation of CYP450 Expressing Bacterial Membranes 
 
MATERIALS 
 50 mgl/ml ampicillin in water (filter-sterilized and stored in aliquots at -20ºC). 
 34 mg/ml chloramphenicol in ethanol (if expressing P450 reductase as well: co-
transformation). 
 2 X Tris-Sucrose –EDTA (TSE) buffer: 0.1M Tris-acetate at pH 7.6 with 0.5M sucrose and 0.5mM 
EDTA-filter-sterilize and store at 4ºC. 1X TSE is equivalent quantity of 2X TSE + equivalent 
quantity of distilled water. 
 Spheroplast Resuspension (SR) buffer: 0.1M potassium phosphate at pH 7.6, 6mM magnesium 
acetate and 20% (v/v) glycerol-filter-sterilized. Add dithiothreitol immediately before use for a 
final concentration of 0.1mM using a 100mM filter-sterilized stock solution stored in aliquots 
at -20ºC. 
CULTURES FOR P450 EXPRESSION 
1. Transform JM109 cells with the plasmid that express the P450 and the plasmid which express 
the P450 reductase. You need to have fresh LB+AMP+Chloramphenicol plates.  
2. Pick a single colony from the transformation and inoculate 3ml of LB with antibiotics (50μg/ml 
ampicillin and 34μg/ml chloramphenicol). 
3. Incubate this culture overnight (16 hours) at 37ºC with 150-200 rpm shaking. 
4. Use 2 ml of the overnight culture to inoculate 200ml of Terrific Broth in a 1L flask. The media 
should be pre-warmed to 37ºC, to avoid shocking cells, and include antibiotics as for the 
overnight culture.  
5. Incubate the culture at 37ºC with 200 rpm shaking. 
6. Monitor the absorption at of the culture at 595-600 nm (plate reader) and when this value has 
reached about 0.7-0.8, after ~4 hours, transfer the culture to a 21 or 25ºC incubator and 
continue with 150 rpm shaking. 
7. After 30 min at 21/25ºC (allowing for the culture to cool) add IPTG for a final concentration of 
1mM and ALA for 0.5mM (16,759 mg ALA and 47,66 mg IPTG). 
8. Continue incubating at 25ºC until the culture is ready for harvesting.  
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Note: several variables can be optimised for P450 expression: incubation time, incubation 
temperature, induction time (adding IPTG/ALA), and IPTG or ALA concentration. Cultures should be 
monitored daily for P450/P420 production using CO difference spectra. Some P450 require only 1 day 
at 25ºC whereas others need 3-4 days.  
SPHEROPLAST PREPARATION  
1. Pour the 200 ml bacterial culture into a 250 ml centrifuge bottle. Chill the bottles on ice for at 
least 10 minutes while checking and preparing the centrifuge and rotor. Centrifuge the 
cultures at 2800 x g for 20 minutes at 4ºC. 
2. Discard the supernatant and retain the pellet 
3. Re-suspend the cell pellets in 20 ml of 1x TSE with a 25ml transfer pipette while keeping the 
bottles on ice (use automatic machine for the pipetting). 
4. Add 10 ml dH20 and mix and mix again (on ice) 
5. Prepare a solution of 20mg/mL lysozyme in dH20 and store on ice. Add 250μl of this lysozyme 
solution to give 0.25 mg/mL lysozyme in 20 ml of cell suspension. 
6. Pipette the mix into 50ml Nalgene centrifuge tube (already chilled on ice) 
7. Keep the centrifuge bottles in a polystyrene container with ice, and place the container on a 
rocking platform to allow gentle mixing for 60 minutes while the cell walls are degraded to 
allow spheroplast to form.  
8. Load the 50mL bottles into the JA 25.50 rotor (Beckman) and centrifuge at 2800xg for 25 
minutes at 4ºC. Discard supernatant and retain pellet. 
9. Add 8mL of spheroplast re-suspension buffer and 8μl of 0.1M DTT. 
10. Proceed to the next step  or  store the spheroplast in -80 ºC 
FROM SPHEROPLASTS TO MEMBRANES 
1. Remove the spheroplast from -80ºC   and thaw it on ice. Add the following items to 8 mL of 
spheroplasts: 
a. 40 μl of 0.2 M PMSF (dissolved in ethanol and usually stored in the freezer) 
b. 0.8 μl of 10 mg/mL aprotinin (make aliquots and keep in freezer and use each aliquot 
only once.  
c. 0.8 μl of 10 mg/mL leupeptin ( usually stored in the freezer) 
2. Sonicate the suspension three times for 30 seconds with the sonicator (30 seconds on and 30 
seconds off/intervals) at about 70% power (this may need optimising) and tip should be kept 
submerged in the suspension to avoid frothing. Keep the sample on ice between the bursts of 
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sonication. The sample will initially become viscous during sonication as DNA is released, but 
this viscosity should drop as the DNA is sheared by the sonication.  
3. Dry and balance the weight of the tubes with dH20. 
4.  Load the 50 ml Nalgene tube with the sonicated sample into the JA 25.50 rotor (Beckman 
Avanti TM JM 25) along with a balance tube (+/-0.01g). Centrifuge at 30,000 x g for 20 minutes 
at 4ºC. 
5. Transfer the supernatant to a 26.3 ml ultracentrifuge bottles (transparent) on ice. Theses 
bottles must not be centrifuged when less than half full, can only be used up to 50000 rpm 
when over half full, and can only be centrifuged at their maximum rate, 60000 rpm, when full. 
Therefore, add 8 ml of ice-cold water to the 8 ml sample and make sure the bottles are not full 
to the neck. Prepare a balanced tube (+/-0.005 g) with ice-cold water. 
6. Dry and load the balanced ultracentrifuge bottles in the 70Ti rotor and centrifuge at 49600 
rpm (180000 x g), for 1 hour at 4ºC.   
7. Remove the tubes and discard the supernatant using a transfer pipette. The membranes 
should appear as a translucent red-brown pellet. Transfer the majority of this pellet to a 1mL 
Dounce homogeniser on ice using a glass Pasteur pipette to lightly scrape the pellet. Avoid 
blocking up the pipette with the membrane pellet by using the side of the tip to scrape and 
transfer bits of the pellet into the Dounce homogeniser. Once most of the pellet has been 
transferred, add 0.5 ml of ice-cold 1 X TSE buffer and 0.5ml of water and use the same Pasteur 
pipette to re-suspend the remaining pellet and transfer this to the Dounce homogeniser. Load 
the liquid from the bottom of the homogeniser to avoid bubbles.  Alternatively, 250uL of both 
1X TSE and 250uL of ddH20 should be used and then later the same amounts to wash the 
homogeniser and transfer the contents into the Eppendorf. 
8. Aliquot the homogenised membrane into small plastic tubes (100-200μl) and store at -80ºC. 
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APPENDIX 3.2 
CYP450s concentration, total protein and CPR activity of recombinant CYP6P9a 
and CYP6P9b 
  
n: Number of independent membranes expressed; P450 Yield: nmol/ml; CPR Activity: nmol of cytochrome c 
reduced/minutes/mg protein; Total protein: mg/ml.  
 
 
 
 
 
 
 
 
 
 
 
Recombinant Proteins n  P450 Yield Std Dev  CPR Activity Std Dev Total Protein Std Dev 
BENCYP6P9a 2 14.70 1.36 119.6 20.01 16.30 1.56 
UGANCYP6P9a 2 12.77 2.62 163.1 21.98 15.79 1.58 
FANGCYP6P9a 2 16.28 3.54 156.1 17.03 16.56 0.93 
MALCYP6P9a 2 13.79 1.41 151.0 18.88 19.49 1.74 
MOZCYP6P9a 3 7.24 0.59 157.0 20.65 17.62 0.70 
ZMBCYP6P9a 1 4.35 0.00 N.D. N.D. N.D. N.D. 
BENCYP6P9b 2 10.88 3.50 154.2 23.71 27.72 3.23 
UGANCYP6P9b 2 12.02 11.29 154.3 12.74 26.14 1.89 
FANGCYP6P9b 2 11.16 3.20 168.9 18.60 24.54 1.95 
MALCYP6P9b 2 7.40 2.13 161.5 16.48 21.08 1.69 
MOZCYP6P9b 4 7.59 2.13 205.3 19.19 21.17 3.17 
ZMBCYP6P9b 1 7.05 0 N.D. N.D. N.D. N.D. 
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APPENDIX 3.3 
Excitation and Emission wavelength of fluorescent probe substrates 
 
S/No Probe Substrate Excitation 
Wavelength (nm) 
Emission 
Wavelength (nm) 
1 7-ethoxyresorufin (ER) 544 590 
2 Benzyloxyresorufin (BR) 544 590 
3 Methoxyresorufin (MR) 544 590 
4 Pentoxyresorufin (PR)  544 590 
5 7-ethoxy-4-trifloromethyl-coumarin (EFC) 410 535 
6 7-methoxy-4-trifloromethyl-coumarin (MFC) 410 535 
7 Diethoxyfluorescein (DEF) 485 530 
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APPENDIX 3.4 
Time-course for CYP6P9a and CYP6P9b dealkylation of diethoxyfluorescein 
 
 
 
 
 
 
 
 
 
 
 
Time course for diethoxyfluorescein metabolism. Panel A: BENCYP6P9a; panel B: MALCYP6P9a; panel 
C: MOZCYP6P9b and panel D: UGANCY6P9b. Blue line: 90pmol; red line: 30pmol; yellow line: 10pmol and 
purple lines: 3.33pmol. 
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APPENDIX 3.5 
Summary of IC50 by time for insecticides with recombinant CYP6P9a and 
CYP6P9b 
      Time (min) 
 6.0 7.5 9.0 10.5 12.0 13.5 15.0 16.5 18.0 19.5 21.0 22.5 24.0 25.5 
MOZCYP6P9b 
Miconazole 0.028 0.025 0.023 0.022 0.022 0.021 0.021 0.020 0.020 0.021 0.022 0.021 0.023 0.024 
Cypermethrin 0.080 0.089 0.093 0.100 0.110 0.110 0.140 0.150 0.160 0.180 0.190 0.20 0.230 0.270 
Cyhalothrin 0.080 0.096 0.100 0.110 0.120 0.130 0.150 0.170 0.180 0.230 0.250 0.270 0.300 0.300 
Chlorpyrifos 0.690 0.810 0.920 0.970 0.950 1.100 1.200 1.300 1.400 1.500 1.600 1.600 1.800 1.800 
Bendiocarb >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 
Bifenthrin 1.800 2.200 2.400 2.400 2.300 2.400 2.500 2.500 2.700 2.900 2.900 2.800 3.000 3.000 
Etofenprox 0.360 0.460 0.560 0.600 0.670 0.720 0.750 0.760 0.830 0.920 0.970 1.000 1.100 1.100 
Propoxur >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 
Deltamethrin 0.065 0.079 0.090 0.100 0.120 0.130 0.150 0.170 0.190 0.210 0.230 0.240 0.280 0.300 
4,4ʹ-DDT 7.100 8.200 9.400 11.00 11.00 13.00 15.00 11.00 8.400 8.000 8.400 9.800 13.00 24.00 
Permethrin 2.400 2.500 2.500 2.500 2.400 2.300 2.500 2.60 2.600 2.800 2.800 2.600 2.700 3.000 
UGANCYP6P9b 
Miconazole 0.020 0.020 0.020 0.020 0.021 0.021 0.021 0.023 0.022 0.022 0.022 0.021 0.020 0.020 
Cypermethrin 0.110 0.120 0.130 0.140 0.160 0.180 0.200 0.230 0.250 0.280 0.280 0.280 0.310 0.310 
Cyhalothrin 0.120 0.130 0.140 0.160 0.170 0.180 0.200 0.220 0.220 0.240 0.250 0.250 0.260 0.260 
Chlorpyrifos 1.100 1.200 1.200 1.200 1.300 1.400 1.700 1.800 2.000 2.000 2.100 2.100 2.000 2.200 
Bendiocarb >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 
Bifenthrin 3.200 3.100 2.400 2.500 2.800 3.000 4.000 4.000 3.800 3.700 3.900 3.900 4.100 3.900 
Etofenprox 0.710 0.750 0.810 0.860 0.760 0.850 0.920 1.100 1.100 1.300 1.400 1.500 1.500 1.400 
Propoxur >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 
Deltamethrin 0.120 0.120 0.130 0.150 0.170 0.210 0.210 0.220 0.240 0.270 0.290 0.270 0.280 0.290 
4,4ʹ-DDT >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 
Permethrin 3.000 3.000 2.800 2.700 2.800 3.000 3.000 3.100 3.100 3.000 3.000 3.200 3.400 3.600 
MALCYP6P9a 
Miconazole 0.013 0.021 0.013 0.023 0.029 0.011 0.026 0.013 0.025 0.022 0.017 0.018 0.013 0.016 
Cypermethrin 0.024 0.066 0.140 0.110 0.140 0.150 0.190 0.160 0.091 0.160 0.170 0.130 0.280 0.330 
Cyhalothrin 0.087 0.140 0.160 0.097 0.130 0.360 0.550 0.460 0.270 0.170 0.150 0.240 0.350 0.410 
Chlorpyrifos 0.670 0.250 1.600 3.700 4.400 1.500 2.700 1.700 2.500 3.600 2.200 1.700 1.200 3.000 
Bendiocarb >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 
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Bifenthrin 0.230 0.320 0.820 1.500 2.100 1.300 2.000 1.300 1.800 1.200 1.700 0.490 1.000 1.600 
Etofenprox 0.330 0.420 0.660 1.400 1.200 1.700 2.300 2.500 3.000 2.700 2.000 1.600 0.800 2.500 
Propoxur >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 
Deltamethrin 0.05 0.040 0.063 0.099 0.140 0.380 0.520 0.880 1.000 1.100 0.680 0.400 0.310 0.210 
4,4ʹ-DDT 0.450 2.500 >25 >25 >25 >25 >25 >25 20.00 6.600 6.800 8.700 9.300 >25 
Permethrin 2.200 2.800 3.800 6.700 4.200 4.000 5.800 4.900 7.400 3.600 6.800 4.200 4.000 4.600 
BENCYP6P9a 
Miconazole 0.023 0.024 0.021 0.021 0.019 0.023 0.022 0.024 0.024 0.024 0.029 0.026 0.023 0.029 
Cypermethrin 0.064 0.099 0.130 0.140 0.150 0.160 0.160 0.130 0.180 0.210 0.230 0.260 0.270 0.330 
Cyhalothrin 0.097 0.110 0.150 0.160 0.160 0.150 0.160 0.230 0.280 0.320 0.320 0.290 0.220 0.230 
Chlorpyrifos 1.400 1.700 2.100 2.300 2.100 2.300 3.800 3.800 3.800 3.500 3.600 3.100 2.500 3.100 
Bendiocarb >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 
Bifenthrin 1.200 2.000 2.000 2.000 2.400 2.300 3.900 3.600 4.400 3.600 3.500 3.700 3.000 3.500 
Etofenprox 0.850 1.100 1.300 1.500 1.900 2.400 2.500 2.700 3.000 3.000 2.500 2.200 2.300 2.300 
Propoxur >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 >25 
Deltamethrin 0.085 0.130 0.180 0.230 0.290 0.380 0.470 0.530 0.670 0.530 0.360 0.460 0.380 0.430 
4,4ʹ-DDT 0.540 0.650 0.800 0.830 1.200 5.900 10.00 7.100 4.700 3.700 23.00 14.00 15.00 22.00 
Permethrin 3.100 4.200 4.700 4.100 3.500 3.400 3.600 3.400 3.700 5.000 4.500 3.800 4.500 4.900 
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APPENDIX 3.6 
Kinetic Parameters of CYP6P9b Mutants Recombinant Proteins With DEF and 
Pyrethroids 
 
(A): 
 
Table 1: Kinetic Constants for mutant CYP6P9b-mediated metabolism of DEF 
Recombinant Proteins Kcat (min
-1) KM  (µM) Kcat/KM  (min
-1 µM-1) 
Val109IleCYP6P9b 7.32±0.13*** 0.10±0.007 72.47±5.18$$ 
Asp335GluCYP6P9b 21.82±3.13** 0.23±0.10† 94.86±43.43$$ 
Asn384SerCYP6P9b 5.46±0.32*** 0.10±0.023 54.05±12.71$$ 
Pro401AlaCYP6P9b 88.32±7.57 0.25±0.07† 353.28±103.44$ 
MOZCYP6P9b 103.4±5.86 0.13±0.003 820.63±49.72 
Values are as mean ± S.E.M. of three independent replicates 
Apparent Kcat given as disappearance of pmol DEF/min/pmol P450. Catalytic efficiency was calculated as Kcat/KM 
** and *** statistically significant Kcat values at p<0.01 and p<0.001 respectively compared with MOZCYP6P9b 
$
 and 
$$
 statistically significant Kcat values at p<0.05 and p<0.01 respectively compared with MOZCYP6P9b 
 
 
(B): 
 
Table 2: Percentage depletion of pyrethroid insecticides by mutant CYP6P9b recombinant proteins 
Recombinant Proteins Deltamethrin Permethrin 
Val109IleCYP6P9b 17.88±1.00** 46.03±1.43* 
Asp335GluCYP6P9b 4.15±1.41*** 35.65±1.55* 
Asn384SerCYP6P9b 18.15±0.42** 18.33±0.63** 
Pro401AlaCYP6P9b 81.25±0.17 80.45±0.28 
MOZCYP6P9b 92.04±0.34 82.59±3.15 
Values are mean ± S.D. of three replicates compared with negative control (-NADPH);  
* and ** and ***Significantly different from FANGCYP6P9a or FANGCYP6Pb at p<0.05, p<0.01 or p<0.001, respectively.  
 
 
(C) Table 3: Kinetic constants for mutant CYP6P9b-mediated permethrin metabolism  
Recombinant Proteins Kcat (min
-1
) KM  (µM) Kcat/KM (min
-1
 µM
-1
) 
Val
109
Ile_CYP6P9b 1.35±0.57** 20.5±1.35
†
 0.06±0.03
$$$
 
Asp
335
Glu_CYP6P9b 0.98±0.12*** 5.19±1.89
†
 0.19±0.07
$$
 
Asn
384
Ser_CYP6P9b 0.87±0.08*** 17.85±0.87
†
 0.04±0.005
$$$
 
Pro
401
Ala_CYP6P9b 4.21±0.96* 15.38±6.50 0.27±0.13
$
 
MOZCYP6P9b(Wild Type) 7.902±0.83 10.33±2.38 0.76±0.19 
Values are as mean ± S.E.M. of three independent replicates. Significantly different from negative control  (-NADPH). 
 *, ** and *** Kcat significantly different  from MOZCYP6P9b at p<0.05, 0.01 and 0.001, respectively.  
†
KM significantly different  from MOZCYP6P9b at p<0.05. 
$
, 
$$
 and 
$$$
 Catalytic efficiency significantly different  from MOZCYP6P9b at p<0.05, 0.01 and 0.001, respectively. 
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APPENDIX 4.1 
Kinetic Constants of Recombinant P450s CYP6M7, CYP6Z1, CYP9J11 and 
CYP6AA4 With Pyrethroids, Bendiocarb and DDT 
 
A. Kinetic Constants for Recombinant CYP6M7, CYP6Z1, CYP9J11 and CYP6AA4 Metabolism of  
Permethrin and Deltamethrin 
Recombinant Proteins Kcat (min
-1
) KM  (µM) Kcat/KM (min
-1
 µM
-1
) 
  Permethrin  
CYP6M7 6.06±0.24
 
13.81±7.08
 
0.45±0.03 
CYP6Z1 1.90±0.08 4.37±0.62
 
0.44±0.06 
CYP9J11 5.39±0.69 31.04±5.79 0.17±0.04 
CYP6AA4 11.99±2.17 33.62±9.18
 
0.36±0.12 
  Deltamethrin  
CYP6M7 7.04±0.24
 
19.64±10.65 0.36±0.04 
CYP6Z1 1.74±0.07 2.89±0.52
 
0.60±0.11 
CYP9J11 1.94±0.45
 
6.08±2.01 0.32±0.13 
CYP6AA4 15.65±2.64
 
30.01±7.92 0.52±0.16 
Values are  mean ±S.D. of three  replicates 
Apparent Kcat was calculated as pmol/min/pmol P450; Catalytic efficiency was calculated as Kcat/KM 
 
B. Kinetic Constants for Recombinant CYP6Z1 and CYP9J11 Metabolism of  Bendiocarb and DDT 
Recombinant 
Proteins 
Vmax (min
-1
) Khalf  (µM) h Vmax/Khalf (min
-1
 µM
-1
) 
  Bendiocarb   
CYP6Z1 0.46±0.009
 
6.22±0.17
 
5.82 0.074±0.0025 
CYP9J11 0.53±0.044 8.30±0.83
 
2.29 0.06±0.0084 
  DDT   
CYP6Z1 101.7±25.5 13.38±2.99
 
2.60 7.60±2.55 
 
C. Kinetic Constants for Recombinant CYP6Z1 Metabolism of DEF, RBE and RME  
Recombinant Proteins Kcat (min
-1
) KM  (µM) Kcat/KM (min
-1
 µM
-1
) 
Diethoxyfluorescein (DEF) 390.3±21.21
 
0.13±0.03
 
2983.94±630.32 
Resorufin benzylether (RBE) 980.2±32.27 1.99±0.11
 
491.57±32.43 
Resorufin methylether (RME) 395.7±19.90 0.19±0.03 2056.65±367.63 
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APPENDIX 4.2 
Binding parameters of the productive mode of permethrin, deltamethrin and 
bendiocarb docked to the active sites of CYP6Z1 model 
 
 Rank ChemScore 
(kJ/mol) 
ΔG 
(kJ/mol) 
S(hbond) S(metal) S(lipo) ΔE(clash) 
Permethrin 2
nd
   39.19 -41.12 1.00 0.00 307.87 0.22 
Deltamethrin 3
rd
  36.14 -37.15 0.97 0.00 278.77 0.01 
Bendiocarb 1
st
  24.69 -24.32 1.93 0.00 135.46 0.07 
DDT 1
st
  36.81 -38.01 0.00 0.00 299.93 0.91 
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